<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="review-article" xml:lang="en" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Adv Drug Deliv Rev</journal-id><journal-id journal-id-type="iso-abbrev">Adv Drug Deliv Rev</journal-id><journal-id journal-id-type="pmc-domain-id">3815</journal-id><journal-id journal-id-type="pmc-domain">pheelsevier</journal-id><journal-title-group><journal-title>Advanced Drug Delivery Reviews</journal-title></journal-title-group><issn pub-type="ppub">0169-409X</issn><issn pub-type="epub">1872-8294</issn><custom-meta-group><custom-meta><meta-name>pmc-is-collection-domain</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-collection-title</meta-name><meta-value>Elsevier - PMC COVID-19 Collection</meta-value></custom-meta></custom-meta-group></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC7794055</article-id><article-id pub-id-type="pmcid-ver">PMC7794055.1</article-id><article-id pub-id-type="pmcaid">7794055</article-id><article-id pub-id-type="pmcaiid">7794055</article-id><article-id pub-id-type="pmid">33428995</article-id><article-id pub-id-type="doi">10.1016/j.addr.2021.01.002</article-id><article-id pub-id-type="pii">S0169-409X(21)00002-8</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>Nanocarrier vaccines for SARS-CoV-2</article-title></title-group><contrib-group><contrib contrib-type="author" id="au0005"><name name-style="western"><surname>Machhi</surname><given-names initials="J">Jatin</given-names></name><xref rid="af0005" ref-type="aff">a</xref></contrib><contrib contrib-type="author" id="au0010"><name name-style="western"><surname>Shahjin</surname><given-names initials="F">Farah</given-names></name><xref rid="af0005" ref-type="aff">a</xref></contrib><contrib contrib-type="author" id="au0015"><name name-style="western"><surname>Das</surname><given-names initials="S">Srijanee</given-names></name><xref rid="af0010" ref-type="aff">b</xref></contrib><contrib contrib-type="author" id="au0020"><name name-style="western"><surname>Patel</surname><given-names initials="M">Milankumar</given-names></name><xref rid="af0005" ref-type="aff">a</xref></contrib><contrib contrib-type="author" id="au0025"><name name-style="western"><surname>Abdelmoaty</surname><given-names initials="MM">Mai Mohamed</given-names></name><xref rid="af0015" ref-type="aff">c</xref><xref rid="af0020" ref-type="aff">d</xref></contrib><contrib contrib-type="author" id="au0030"><name name-style="western"><surname>Cohen</surname><given-names initials="JD">Jacob D.</given-names></name><xref rid="af0005" ref-type="aff">a</xref></contrib><contrib contrib-type="author" id="au0035"><name name-style="western"><surname>Singh</surname><given-names initials="PA">Preet Amol</given-names></name><xref rid="af0025" ref-type="aff">e</xref></contrib><contrib contrib-type="author" id="au0040"><name name-style="western"><surname>Baldi</surname><given-names initials="A">Ashish</given-names></name><xref rid="af0025" ref-type="aff">e</xref></contrib><contrib contrib-type="author" id="au0045"><name name-style="western"><surname>Bajwa</surname><given-names initials="N">Neha</given-names></name><xref rid="af0025" ref-type="aff">e</xref></contrib><contrib contrib-type="author" id="au0050"><name name-style="western"><surname>Kumar</surname><given-names initials="R">Raj</given-names></name><xref rid="af0030" ref-type="aff">f</xref></contrib><contrib contrib-type="author" id="au0055"><name name-style="western"><surname>Vora</surname><given-names initials="LK">Lalit K.</given-names></name><xref rid="af0035" ref-type="aff">g</xref></contrib><contrib contrib-type="author" id="au0060"><name name-style="western"><surname>Patel</surname><given-names initials="TA">Tapan A.</given-names></name><xref rid="af0040" ref-type="aff">h</xref></contrib><contrib contrib-type="author" id="au0065"><name name-style="western"><surname>Oleynikov</surname><given-names initials="MD">Maxim D.</given-names></name><xref rid="af0005" ref-type="aff">a</xref></contrib><contrib contrib-type="author" id="au0070"><name name-style="western"><surname>Soni</surname><given-names initials="D">Dhruvkumar</given-names></name><xref rid="af0015" ref-type="aff">c</xref></contrib><contrib contrib-type="author" id="au0075"><name name-style="western"><surname>Yeapuri</surname><given-names initials="P">Pravin</given-names></name><xref rid="af0005" ref-type="aff">a</xref></contrib><contrib contrib-type="author" id="au0080"><name name-style="western"><surname>Mukadam</surname><given-names initials="I">Insiya</given-names></name><xref rid="af0015" ref-type="aff">c</xref></contrib><contrib contrib-type="author" id="au0085"><name name-style="western"><surname>Chakraborty</surname><given-names initials="R">Rajashree</given-names></name><xref rid="af0005" ref-type="aff">a</xref></contrib><contrib contrib-type="author" id="au0090"><name name-style="western"><surname>Saksena</surname><given-names initials="CG">Caroline G.</given-names></name><xref rid="af0005" ref-type="aff">a</xref></contrib><contrib contrib-type="author" id="au0095"><name name-style="western"><surname>Herskovitz</surname><given-names initials="J">Jonathan</given-names></name><xref rid="af0010" ref-type="aff">b</xref></contrib><contrib contrib-type="author" id="au0100"><name name-style="western"><surname>Hasan</surname><given-names initials="M">Mahmudul</given-names></name><xref rid="af0015" ref-type="aff">c</xref></contrib><contrib contrib-type="author" id="au0105"><name name-style="western"><surname>Oupicky</surname><given-names initials="D">David</given-names></name><xref rid="af0030" ref-type="aff">f</xref></contrib><contrib contrib-type="author" id="au0110"><name name-style="western"><surname>Das</surname><given-names initials="S">Suvarthi</given-names></name><xref rid="af0045" ref-type="aff">i</xref></contrib><contrib contrib-type="author" id="au0115"><name name-style="western"><surname>Donnelly</surname><given-names initials="RF">Ryan F.</given-names></name><xref rid="af0035" ref-type="aff">g</xref></contrib><contrib contrib-type="author" id="au0120"><name name-style="western"><surname>Hettie</surname><given-names initials="KS">Kenneth S.</given-names></name><xref rid="af0050" ref-type="aff">j</xref></contrib><contrib contrib-type="author" id="au0125"><name name-style="western"><surname>Chang</surname><given-names initials="L">Linda</given-names></name><xref rid="af0055" ref-type="aff">k</xref></contrib><contrib contrib-type="author" id="au0130"><name name-style="western"><surname>Gendelman</surname><given-names initials="HE">Howard E.</given-names></name><xref rid="af0005" ref-type="aff">a</xref><xref rid="af0010" ref-type="aff">b</xref><xref rid="af0015" ref-type="aff">c</xref><xref rid="cr0005" ref-type="corresp">&#8270;</xref></contrib><contrib contrib-type="author" id="au0135"><name name-style="western"><surname>Kevadiya</surname><given-names initials="BD">Bhavesh D.</given-names></name><xref rid="af0005" ref-type="aff">a</xref></contrib><aff id="af0005"><label>a</label>Department of Pharmacology and Experimental Neuroscience, College of Medicine, University of Nebraska Medical Center, NE 68198, USA</aff><aff id="af0010"><label>b</label>Department of Pathology and Microbiology, College of Medicine, University of Nebraska Medical Center, NE 68198, USA</aff><aff id="af0015"><label>c</label>Department of Pharmaceutical Sciences, College of Pharmacy, University of Nebraska Medical Center, NE 68198, USA</aff><aff id="af0020"><label>d</label>Therapeutic Chemistry Department, Pharmaceutical and Drug Industries Research Division, National Research Centre, Giza, Egypt</aff><aff id="af0025"><label>e</label>Department of Pharmaceutical Sciences &amp; Technology, Maharaja Ranjit Singh Punjab Technical University, Bathinda, Punjab, India</aff><aff id="af0030"><label>f</label>Center for Drug Delivery and Nanomedicine, Department of Pharmaceutical Sciences, University of Nebraska Medical Center, Omaha, NE 68198, USA</aff><aff id="af0035"><label>g</label>School of Pharmacy, Queen's University Belfast, 97 Lisburn Road, Belfast BT9 7BL, United Kingdom.</aff><aff id="af0040"><label>h</label>Department of Biological Sciences, P. D. Patel Institute of Applied Sciences (PDPIAS), Charotar University of Science and Technology (CHARUSAT), Changa, Anand 388421, Gujarat, India</aff><aff id="af0045"><label>i</label>Department of Medicine, Stanford Medical School, Stanford University, Palo Alto, CA 94304, USA</aff><aff id="af0050"><label>j</label>Molecular Imaging Program at Stanford (MIPS), Department of Radiology, Department of Otolaryngology &#8211; Head &amp; Neck Surgery, Stanford University, Palo Alto, CA 94304, USA</aff><aff id="af0055"><label>k</label>Departments of Diagnostic Radiology &amp; Nuclear Medicine, and Neurology, University of Maryland, School of Medicine, Baltimore, MD 21201, USA</aff></contrib-group><author-notes><corresp id="cr0005"><label>&#8270;</label>Corresponding author at: Department of Pharmacology and Experimental Neuroscience, University of Nebraska Medical Center, Omaha, NE 68198-5880, USA.</corresp></author-notes><pub-date pub-type="ppub"><month>4</month><year>2021</year></pub-date><pub-date pub-type="epub"><day>9</day><month>1</month><year>2021</year></pub-date><volume>171</volume><issue-id pub-id-type="pmc-issue-id">372546</issue-id><fpage>215</fpage><lpage>239</lpage><history><date date-type="received"><day>10</day><month>10</month><year>2020</year></date><date date-type="rev-recd"><day>18</day><month>12</month><year>2020</year></date><date date-type="accepted"><day>1</day><month>1</month><year>2021</year></date></history><pub-history><event event-type="pmc-release"><date><day>09</day><month>01</month><year>2021</year></date></event><event event-type="pmc-live"><date><day>11</day><month>01</month><year>2021</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2024-09-21 16:25:26.393"><day>21</day><month>09</month><year>2024</year></date></event></pub-history><permissions><copyright-statement>Crown Copyright &#169; 2021 Published by Elsevier B.V. All rights reserved.</copyright-statement><copyright-year>2021</copyright-year><copyright-holder/><license><license-p>Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="main.pdf"/><abstract id="ab0005"><p>The SARS-CoV-2 global pandemic has seen rapid spread, disease morbidities and death associated with substantive social, economic and societal impacts. Treatments rely on re-purposed antivirals and immune modulatory agents focusing on attenuating the acute respiratory distress syndrome. No curative therapies exist. Vaccines remain the best hope for disease control and the principal global effort to end the pandemic. Herein, we summarize those developments with a focus on the role played by nanocarrier delivery.</p></abstract><abstract abstract-type="graphical" id="ab5005"><title>Graphical abstract</title><p><fig id="f5070" position="anchor" orientation="portrait"><alt-text id="al5095">Image 1</alt-text><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="ga1_lrg.jpg"/></fig></p></abstract><kwd-group id="ks0005"><title>Keywords</title><kwd>SARS-CoV-2</kwd><kwd>COVID-19 vaccine</kwd><kwd>Nanovaccine</kwd><kwd>mRNA vaccine</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="s0005"><label>1</label><title>Overview: pathways toward an effective COVID-19 vaccine</title><p id="p0005">In late 2019, the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) first emerged and on March 11, 2020 it was declared a pandemic [<xref rid="bb0005" ref-type="bibr">1</xref>]. Clinical outcomes ranged from asymptomatic infection to severe acute respiratory distress syndrome (ARDS) and death. The World Health Organization (WHO) named the resultant disease complex coronavirus disease 2019 (COVID-19) [<xref rid="bb0010" ref-type="bibr">2</xref>,<xref rid="bb0015" ref-type="bibr">3</xref>]. COVID-19 has negatively impacted the global socioeconomic well-being of the world's population. Global lack of health care, infrastructure, and preparedness has intensified the pandemic's impact [<xref rid="bb0020" ref-type="bibr">4</xref>].</p><p id="p0010">Viral detection, mobilization and control of person-to-person spread served as the primary means for containment. Induction of effective host antiviral immunity against SARS-CoV-2 comes secondary to infection [<xref rid="bb0025" ref-type="bibr">5</xref>,<xref rid="bb0030" ref-type="bibr">6</xref>]. An uncontrolled innate immune response is the signature of virus-induced pro-inflammatory responses for an ARDS. Alveolar macrophage inflammation disrupts cell and tissue homeostasis leading to end-organ lung disease [<xref rid="bb0035" ref-type="bibr">7</xref>,<xref rid="bb0040" ref-type="bibr">8</xref>]. In the absence of a vaccine, virus-induction of adaptive humoral immune responses can attenuate disease progression [<xref rid="bb0045" ref-type="bibr">9</xref>].</p><p id="p0015">A vaccine can elicit protective antiviral responses against SARS-CoV-2. Short of containment it is the most effective means to prevent infection in susceptible people [<xref rid="bb0050" ref-type="bibr">10</xref>]. To this end, there are more than 137 vaccine candidates in development and 23 in Phase 2 or 3 trials [<xref rid="bb0055" ref-type="bibr">11</xref>,<xref rid="bb0060" ref-type="bibr">12</xref>]. One promising candidate BNT162b2 is already approved while several others are soon to be approved for prevention in the United States of America (USA) [<xref rid="bb0065" ref-type="bibr">13</xref>,<xref rid="bb0070" ref-type="bibr">14</xref>]. However, how long an induced immune response remains effective is in question. Final outcomes will depend, in part, on the continuance of a neutralizing antibody response, the limitations seen on viral mutations and the long-term induction of antiviral memory T cell responses [<xref rid="bb0075" ref-type="bibr">15</xref>,<xref rid="bb0080" ref-type="bibr">16</xref>]. The long term efficacy of a SARS-CoV-2 vaccine requires limited boosting and divergent geographic, co-morbid and age-associated population efficacy [<xref rid="bb0085" ref-type="bibr">17</xref>]. Efficacy is defined as long-term prevention of viral infection and in halting transmission in broad populations [<xref rid="bb0090" ref-type="bibr">18</xref>].</p></sec><sec id="s0010"><label>2</label><title>SARS-CoV-2 pharmacological agents</title><p id="p0020">Currently, there are no potent effective antiviral therapies available for SARS-CoV-2 [<xref rid="bb0095" ref-type="bibr">19</xref>]. Nonetheless, the United States Food and Drug Administration (US FDA) approvals have sped drug repurposing [<xref rid="bb0100" ref-type="bibr">20</xref>]. Medications now availalbe were developed to treat other viral infections [<xref rid="bb0105" ref-type="bibr">21</xref>,<xref rid="bb0110" ref-type="bibr">22</xref>]. However, newer drugs or drug formulations remain under development. Ongoing efforts are in producing drugs that not only combat viral infection but modulate antiviral immunity [<xref rid="bb0075" ref-type="bibr">15</xref>,<xref rid="bb0115" ref-type="bibr">23</xref>]. Pharmacological agents target parts of the SARS-CoV-2 life cycle [<xref rid="bb0120" ref-type="bibr">24</xref>,<xref rid="bb0125" ref-type="bibr">25</xref>]. <italic toggle="yes">In silico</italic> viral gene profiles have uncovered prospective medicines that inhibit the viral protease, the hemagglutinin esterase (HE), the spike (S)/envelop (E) proteins, and RNA-dependent polymerases [<xref rid="bb0130" ref-type="bibr">26</xref>]. These and drug candidates that target the angiotensin-converting enzyme 2 (ACE2) receptor are major candidates for COVID-19 treatment.<list list-type="simple" id="l0005"><list-item id="li0005"><label>i.</label><p id="p0025"><italic toggle="yes">Broad-spectrum antiviral drugs: Hydroxychloroquine (HCQ)</italic> is an anti-malarial drug used successfully to treat systemic lupus erythematosus and rheumatoid disease [<xref rid="bb0135" ref-type="bibr">27</xref>]. It has anti-inflammatory activitiese with known control of interleukin 6, 17, and 22 (IL-6, IL-17, and IL-22) cytokines [<xref rid="bb0140" ref-type="bibr">28</xref>,<xref rid="bb0145" ref-type="bibr">29</xref>]. While HCQ received initial global attention based on symptom similarities between malaria and COVID-19, its use for COVI-19 remains controversial [<xref rid="bb0150" ref-type="bibr">30</xref>]. Its &#8220;putative&#8221; mechanisms of action include alkalization of intracellular pH, inhibition of lysosomal activity of antigen-presenting cells (APCs), and effects on cathepsins, mitogen-activated protein kinases, and autophagosomal functions which results in structural damage to SARS-CoV-2 S proteins [<xref rid="bb0155" ref-type="bibr">[31]</xref>, <xref rid="bb0160" ref-type="bibr">[32]</xref>, <xref rid="bb0165" ref-type="bibr">[33]</xref>, <xref rid="bb0170" ref-type="bibr">[34]</xref>, <xref rid="bb0175" ref-type="bibr">[35]</xref>, <xref rid="bb0180" ref-type="bibr">[36]</xref>, <xref rid="bb0185" ref-type="bibr">[37]</xref>, <xref rid="bb0190" ref-type="bibr">[38]</xref>]. HCQ can also attenuate cytokine production and autophagy [<xref rid="bb0195" ref-type="bibr">39</xref>,<xref rid="bb0200" ref-type="bibr">40</xref>]. However, based on variable clinical outcomes and toxicities, the US FDA revoked emergency-use authorization (EUA) for COVID-19 treatments on June 15th, 2020 [<xref rid="bb0205" ref-type="bibr">41</xref>,<xref rid="bb0210" ref-type="bibr">42</xref>].</p></list-item><list-item id="li0010"><label>ii.</label><p id="p0030"><italic toggle="yes">Protease inhibitors: Lopinavir/ritonavir and other human immunodeficiency virus type one (HIV) proteases</italic> were approved by the US FDA for HIV-1 infection. Promising results as an inhibitor of the 3-chymotrypsin-like protease of SARS-CoV-2 were reported [<xref rid="bb0215" ref-type="bibr">43</xref>]. However, use of the drugs for COVID-19 are limited [<xref rid="bb0220" ref-type="bibr">44</xref>]. Darunavir is an inhibitor of HIV-1 protease and cobicistat is a potent inhibitor of cytochrome P450 3A. All, regrettably, are limited against SARS-CoV-2 [<xref rid="bb0225" ref-type="bibr">45</xref>].</p></list-item><list-item id="li0015"><label>iii.</label><p id="p0035"><italic toggle="yes">Nucleoside analogs and inhibitors: Remdesivir:</italic> Remdesivir (GS-5734), a broad-spectrum antiviral drug, acts on the viral RNA-dependent RNA polymerases (RdRp) to suppress viral replication. It has activity against coronaviruses and was shown to be effective during the Ebola virus 2014&#8211;2016 outbreak and in some SARS-CoV-2 studies [<xref rid="bb0230" ref-type="bibr">46</xref>,<xref rid="bb0235" ref-type="bibr">47</xref>]. At the outset of the pandemic, remdesivir was used for COVID-19 treatments in late stage disease. Early successful reports were reinforced by a more extensive double-blind placebo-controlled study demonstrating shortened times on ventilator assistance precluding improvements in disease mortalities [<xref rid="bb0240" ref-type="bibr">48</xref>,<xref rid="bb0245" ref-type="bibr">49</xref>]. Soon remdesivir received a EUA by the US FDA for COVID-19 that included all age groups independent of disease severity [<xref rid="bb0240" ref-type="bibr">48</xref>,<xref rid="bb0250" ref-type="bibr">50</xref>]. However, on November 9, 2020, a follow on study concluded no clinical benefit for remdesivir in hospitalized patients [<xref rid="bb0255" ref-type="bibr">51</xref>]. <italic toggle="yes">Ribavirin:</italic> Ribavirin is a guanine nucleoside analog that prevents viral replication by acting on the viral RdRp. To date, there are no published reports on therapeutic efficacy for SARS-CoV-2 with only mild therapeutic benefit in MERS-CoV infections when used with interferon alpha (IFN-&#945;) [<xref rid="bb0260" ref-type="bibr">52</xref>]. <italic toggle="yes">Favipiravir (T-705):</italic> Favipiravir is known to undergo intracellular activation to favipiravir ribofuranosyl-5-triphosphate (RTP); a purine nucleotide that inhibits viral replication by control of RNA polymerase. Favipiravir has antiviral activity against a spectrum of RNA viruses such as influenza H1N1 and Ebola [<xref rid="bb0265" ref-type="bibr">53</xref>]. Laboratory studies demonstrate antiviral activity against SARS-CoV-2 [<xref rid="bb0270" ref-type="bibr">54</xref>]. In June 2020, the Drug Controller General of India (DGCI) approved the drug during ongoing clinical trials [<xref rid="bb0275" ref-type="bibr">55</xref>,<xref rid="bb0280" ref-type="bibr">56</xref>]. Other drug candidates under development for SARS-CoV-2 include <italic toggle="yes">umifenovir</italic> (<italic toggle="yes">arbidol)</italic>, an antiviral drug that interferes with the spike protein-ACE2 interactions. The drug acts by inhibiting cell membrane-SARS-CoV-2 envelope fusion [<xref rid="bb0285" ref-type="bibr">57</xref>].</p></list-item><list-item id="li0020"><label>iv.</label><p id="p0040"><italic toggle="yes">Immunotherapeutics:</italic> Impaired immunity with compromised lung functions and pro-inflammatory cytokine levels are COVID-19 features [<xref rid="bb0025" ref-type="bibr">5</xref>,<xref rid="bb0290" ref-type="bibr">58</xref>]. Adaptive immune dysfunctions include lymphopenia and activation, granulocyte and monocyte dysfunction, and elevated immunoglobulin G (IgG) and total antibody levels [<xref rid="bb0030" ref-type="bibr">6</xref>,<xref rid="bb0295" ref-type="bibr">59</xref>]. These are present in blood and convalescent plasma of infected people [<xref rid="bb0110" ref-type="bibr">22</xref>,<xref rid="bb0300" ref-type="bibr">60</xref>,<xref rid="bb0305" ref-type="bibr">61</xref>]. Control of inflammation is achieved by immune modulation [<xref rid="bb0110" ref-type="bibr">22</xref>,<xref rid="bb0310" ref-type="bibr">62</xref>,<xref rid="bb0315" ref-type="bibr">63</xref>]. <italic toggle="yes">Convalescent plasma:</italic> Convalescent plasma from recovered COVID-19 patients contains antibodies that can neutralize viral infection [<xref rid="bb0320" ref-type="bibr">64</xref>]. However, adverse events have been reported that include fever, allergic reactions, transfusion-related lung injury, life-threatening bronchospasm and circulatory overload. These are present in patients with cardiorespiratory disorders [<xref rid="bb0325" ref-type="bibr">65</xref>]. A cocktail of monoclonal antibodies was used successfully for USA President Donald J. Trump which now received an EUA [<xref rid="bb0330" ref-type="bibr">66</xref>]. <italic toggle="yes">Mesenchymal Stem Cells (MSC):</italic> MSC-based therapy is being developed for treatment of pneumonia [<xref rid="bb0335" ref-type="bibr">67</xref>]. Transplantation of MSCs possesses self-renewal and anti-inflammatory properties resulting in pulmonary epithelial cell repair and defense against a cytokine storm and promotion of alveolar fluid clearance [<xref rid="bb0340" ref-type="bibr">68</xref>]. <italic toggle="yes">Regulatory T cells</italic> (<italic toggle="yes">Treg</italic>)<italic toggle="yes">:</italic> The inflammatory processes seen during ARDS-asssociated COVID-19 may be linked to Treg dysfunction. Therefore, Treg therapy may serve to improve oxygenation and attenuate pro-inflammatory cytokines [<xref rid="bb0345" ref-type="bibr">69</xref>,<xref rid="bb0350" ref-type="bibr">70</xref>]. A novel allogeneic cell therapy (CK0802) developed by Cellenkos Inc. consists of Tregs administered to overcome immune dysfunction through resolving chronic inflammation in COVID-19 patients [<xref rid="bb0355" ref-type="bibr">71</xref>]. Such treatments serve to halt respiratory deterioration. <italic toggle="yes">IL-6 inhibitor:</italic> A key mediator in the COVID-19 cytokine storm is IL-6 [<xref rid="bb0360" ref-type="bibr">72</xref>], a driver of inflammatory responses. Targeting the IL-6/IL-6 receptor (IL-6R) signalling can halt inflammatory activities [<xref rid="bb0365" ref-type="bibr">73</xref>]. <italic toggle="yes">Tocilizumab</italic> and <italic toggle="yes">sarilumab</italic>, are humanized anti-IL-6R antibodies that inhibit IL-6 signalling [<xref rid="bb0370" ref-type="bibr">[74]</xref>, <xref rid="bb0375" ref-type="bibr">[75]</xref>, <xref rid="bb0380" ref-type="bibr">[76]</xref>]. Both are in Phase 3 clinical trials for COVID-19 [<xref rid="bb0060" ref-type="bibr">12</xref>]. <italic toggle="yes">Janus kinase (JAK) Inhibitors:</italic> Inhibition of the JAK signalling pathway together with IL-6 can ameliorate abnormal cytokine levels [<xref rid="bb0385" ref-type="bibr">77</xref>]. <italic toggle="yes">Baricitinib, fedratinib,</italic> and <italic toggle="yes">ruxolitinib</italic> are JAK inhibitors used for rheumatoid arthritis and myelofibrosis. COVID-19 patients treated with <italic toggle="yes">baricitinib</italic> in combination with lopinavir, ritonavir or remdesivir demonstrated reductions in viral and inflammatory activities [<xref rid="bb0390" ref-type="bibr">78</xref>,<xref rid="bb0395" ref-type="bibr">79</xref>]. <italic toggle="yes">Dihydroorotate dehydrogenase (DHODH) inhibitors:</italic> While DHODH inhibitors can suppress viral replication and modulate cytokines they have a low therapeutic index [<xref rid="bb0400" ref-type="bibr">80</xref>]. <italic toggle="yes">Others:</italic> NK cell-based immunotherapy is less defined for COVID-19 [<xref rid="bb0300" ref-type="bibr">60</xref>,<xref rid="bb0405" ref-type="bibr">81</xref>]. PEGylated IFN&#945;-2&#945; and 2&#946;, can stimulate innate antiviral responses for SARS-CoV-2 [<xref rid="bb0095" ref-type="bibr">19</xref>]. Clinical trial involving combination therapy of PEGylated IFN-&#945; with <italic toggle="yes">ribavirin</italic> has been reported (ChiCTR2000029387). <italic toggle="yes">Camostat mesylate</italic> inhibits host transmembrane proteases restricting viral host cell entry [<xref rid="bb0100" ref-type="bibr">20</xref>]. The anti-vascular endothelial factor <italic toggle="yes">bevacizumab</italic> (used in cancer), the monoclonal antibody <italic toggle="yes">eculizumab</italic> (used in autoimmune conditions), and a sphingosine-1-phosphate receptor modulator <italic toggle="yes">fingolimod</italic> which sequesters lymphocytes are under study [<xref rid="bb0100" ref-type="bibr">20</xref>,<xref rid="bb0290" ref-type="bibr">58</xref>,<xref rid="bb0410" ref-type="bibr">82</xref>].</p></list-item></list>
</p></sec><sec id="s0015"><label>3</label><title>Herd immunity</title><p id="p0045">Whether the elimination of COVID-19 is possible through herd immunity and vaccines is uncertain [<xref rid="bb0415" ref-type="bibr">83</xref>,<xref rid="bb0420" ref-type="bibr">84</xref>]. Previously, two human influenza viruses (H1N1 and H2N2) disappeared after pandemics explained by herd immunity [<xref rid="bb0425" ref-type="bibr">85</xref>]. The prior pandemics led to global immunity through the aid of highly-effective vaccination. These led to viral elimination. Two pathogenic avian influenza viruses also disappeared through herd immunity and vaccination. However, human person-to-person passage led to viral mutation and an epidemic [<xref rid="bb0430" ref-type="bibr">86</xref>,<xref rid="bb0435" ref-type="bibr">87</xref>]. These events support the idea that SARS-CoV-2 elimination can occur through herd immunity [<xref rid="bb0440" ref-type="bibr">88</xref>] defined as the point at which the proportion of infection in susceptible individuals falls below the threshold needed for viral transmission [<xref rid="bb0445" ref-type="bibr">89</xref>]. When herd immunity begins to take effect, susceptible individuals benefit from indirect protection of infection [<xref rid="bb0415" ref-type="bibr">83</xref>]. For SARS-CoV-2, herd immunity would be determined by: (i) the percentage of the population immune to infection (herd immunity threshold (HIT); (ii) the length and effectiveness of the SARS-CoV-2 immune response; and (iii) the stability of the virus epitopes to mutation [<xref rid="bb0450" ref-type="bibr">90</xref>]. The HIT depends upon the basic reproduction number (R<sub>0</sub>), the average number of people spawned by the one infected person in fully succeptible mixed populations. The HIT is calculated using formula 1-1/R<sub>0</sub> and different mathematical models predicted HIT for COVID-19 closer to 60 to 70% suggesting very high population need to be immune to the infection to achieve herd immunity [<xref rid="bb0420" ref-type="bibr">84</xref>,<xref rid="bb0455" ref-type="bibr">91</xref>]. As of December 10, 2020, 69 million people have been infected and 48 million people have recovered worldwide from the SARS-CoV-2 infection representing 0.90% and 0.62% of the world's population [<xref rid="bb0460" ref-type="bibr">92</xref>]. Therefore, it is far below a significant percentage of the world's population that could become immune to SARS-CoV-2 to confer herd immunity [<xref rid="bb0440" ref-type="bibr">88</xref>]. The Ferguson report estimated that with R<sub>0</sub> 2.4 the healthcare systems in the USA and the United Kingdom (UK) will incur more deaths then expected. The report suggested strict government interventions to prevent rapid viral spread which were soon implemented in different countries [<xref rid="bb0465" ref-type="bibr">93</xref>]. Sweden experienced rapid spread of COVID-19 without herd immunity and ten times greater number of deaths than neighboring Norway who implemented strict preventive measures. However, in a part of Sweden, Stockholm County, by April 11, 2020, the net hospital admissions decreased significantly when 17% of the population was infected, whether this was due to herd immunity is not clear [<xref rid="bb0470" ref-type="bibr">94</xref>]. To evaluate societal costs in achieving global SARS-CoV-2 herd immunity, the overall infection fatality rate (IFR) need be considered. Understandably, IFR will be lower than the reported case fatality rate (CFR) due to the numbers of asymptomatic individuals. If one combines infection fatality data with numbers of individuals needed to reach HIT, estimations of the expected number of deaths can be determined [<xref rid="bb0415" ref-type="bibr">83</xref>]. Achieving herd immunity remain theoretical [<xref rid="bb0440" ref-type="bibr">88</xref>,<xref rid="bb0475" ref-type="bibr">95</xref>].</p><p id="p0050">Effective antiviral immunity rests in its durability. SARS-CoV immunity can decline over time in levels of IgG, IgM, and IgA neutralizing antibodies [<xref rid="bb0480" ref-type="bibr">96</xref>]. While SARS-CoV antigen-specific memory B-cells decline, memory antiviral T cell responses require sustenance [<xref rid="bb0485" ref-type="bibr">97</xref>]. T cell responses persist &gt;10&#160;years in those who recovered from MERS-CoV and SARS-CoV infections. Whether these are protective is not known [<xref rid="bb0295" ref-type="bibr">59</xref>]. It was demonstrated by computer modeling that immunity against SARS-CoV-2 could be transient. If operative, there is a likelihood that, like influenza A and B viruses, SARS-CoV-2 may lead to biennial or annual outbreaks. Therefore, a need exists to determine the extent and duration of immunity against SARS-CoV-2 [<xref rid="bb0490" ref-type="bibr">98</xref>]. This need is further complicated because the antibody response that is mounted against SARS-CoV-2 is not always accompanied by viral clearance [<xref rid="bb0495" ref-type="bibr">99</xref>]. Antibody levels vary based on age [<xref rid="bb0500" ref-type="bibr">100</xref>], re-infection rates [<xref rid="bb0505" ref-type="bibr">101</xref>], and length of illness. Cases with SARS-CoV-2 re-infection have been reported and virus strains with different genome sequences in a single person [<xref rid="bb0510" ref-type="bibr">102</xref>]. Re-infection is distinguished from relapse and prolonged viral shedding [<xref rid="bb0515" ref-type="bibr">103</xref>]. Although the number of re-infection is limited compared to new infections, re-infection is linked to how long-term neutralizing antibody titers are sustained [<xref rid="bb0520" ref-type="bibr">104</xref>]. Emergence of mutant strains of SARS-CoV-2 and viral epitope stability affect re-infections [<xref rid="bb0525" ref-type="bibr">105</xref>]. COVID-19 has a lower fatality rate than SARS-CoV and MERS-CoV infections but higher than flu (~3% <italic toggle="yes">versus</italic> 0.1%) [<xref rid="bb0530" ref-type="bibr">106</xref>]. However, since SARS-CoV-2 is more contagious than the flu, and has spread rapidly across the globe, the 1.5 million deaths from COVID-19 in the past 10&#160;months has already exceeded the total number of deaths from the last five flu seasons [<xref rid="bb0460" ref-type="bibr">92</xref>,<xref rid="bb0535" ref-type="bibr">107</xref>,<xref rid="bb0540" ref-type="bibr">108</xref>]. Viral infections with low fatality rates enable the host to mount an immune response, that create selection pressure for the emergence of mutant virus strains [<xref rid="bb0545" ref-type="bibr">109</xref>]. Considering re-infection, limited immunity, virus mutations and need for herd immunity underlies the importance of vaccination.</p></sec><sec id="s0020"><label>4</label><title>Viral vaccines</title><p id="p0055">Bacteria and viruses are pathogens that commonly elicit disease [<xref rid="bb0550" ref-type="bibr">110</xref>]. For a successful pathogen to survive and grow, it must have ability to: (i) inhabit the host; (ii) avoid or circumvent host immune responses; (iii) grow by affecting host biological machineries to its benefit; and (iv) transmit itself from one host to another [<xref rid="bb0550" ref-type="bibr">110</xref>,<xref rid="bb0555" ref-type="bibr">111</xref>]. Viral infections possess nucleic acids surrounded by a protein shield. Viruses can also be classified based on various criterias including genetic material, number of nucleic acid strands, envelope, shape, and structure [<xref rid="bb0555" ref-type="bibr">111</xref>,<xref rid="bb0560" ref-type="bibr">112</xref>]. Some viruses contain an envelop whereas some do not. For example, adenoviruses and adeno-associated viruses (AAVs) are non-enveloped viruses, whereas herpesvirus and coronavirus are enveloped. The viral envelope-membrane, when present, consists of lipid and glycoproteins and it is acquired during detachment of virus from the host cell [<xref rid="bb0565" ref-type="bibr">113</xref>]. Upon exposure, body's immune system mount a specific response enabling the host to be protected upon re-exposure [<xref rid="bb0550" ref-type="bibr">110</xref>,<xref rid="bb0565" ref-type="bibr">113</xref>]. Vaccines harness the body's immune responses providing protective immune responses against infection. Vaccines are broadly available against tuberculosis, diphtheria, tetanus, pertussis, Haemophilus Influenzae Type b, <italic toggle="yes">Haemophilus Influenzae Type b</italic>, cholera, typhoid, <italic toggle="yes">Streptococcus pneumoniae</italic> and viral infections that include influenza, hepatitis, diphtheria, measles, mumps, and polio. Efforts are still under development for chikangunya, dengue, malaria, cytomegalovirus and leishmaniasis [<xref rid="bb0570" ref-type="bibr">114</xref>].</p><p id="p0060">SARS-CoV-2 vaccine development had now achieved US FDA approval [<xref rid="bb0060" ref-type="bibr">12</xref>]. What is now available is able to induce long-lasting viral neutralizing antibodies that prevent viral attachment (through a ACE2 receptor) to epithelial cells in the mucosal layers and type II pneumocytes [<xref rid="bb0080" ref-type="bibr">16</xref>,<xref rid="bb0575" ref-type="bibr">115</xref>]. Vaccine should also induce sustained humoral and cellular immune responses which would generate long-lasting memory T cell responses. Further features of an effective vaccine include ease of administration (single dose, mucosal), storage, production, and scale-up [<xref rid="bb0075" ref-type="bibr">15</xref>,<xref rid="bb0580" ref-type="bibr">116</xref>]. The spike (S), nucleocapsid (N), membrane (M), and envelope (E) glycoproteins are known immunogenic proteins for SARS-CoV-2. The spike S protein is the major target for vaccine development, as it is involved in the viral entry via ACE2 receptors [<xref rid="bb0575" ref-type="bibr">115</xref>,<xref rid="bb0585" ref-type="bibr">117</xref>]. Several COVID-19 vaccine candidates have or are being developed. Viral vaccines against SARS-CoV-2 include: (i) live and attenuated; (iii) inactivated; (iv) nucleic acids; (v) viral vectors (self- and non-replicating); and (vi) protein and subunits; (<xref rid="f0005" ref-type="fig">Fig. 1</xref>
). These can be propagated in animals, chicken embryos, and cell cultures and tissues [<xref rid="bb0590" ref-type="bibr">118</xref>,<xref rid="bb0595" ref-type="bibr">119</xref>]. Currently vaccines are approved for marketing in different countries to control more than 30 infectious diseases [<xref rid="bb0600" ref-type="bibr">120</xref>]. Vaccines are monovalent, effective against a single antigen or a pathogen (Rotarix) and polyvalent/multivalent, effective against strains of the same pathogen (RotaTeq) [<xref rid="bb0580" ref-type="bibr">116</xref>,<xref rid="bb0605" ref-type="bibr">121</xref>].<fig id="f0005" position="float" orientation="portrait"><label>Fig. 1</label><caption><p><bold>SARS-CoV-2 vaccine designs.</bold> Live-attenuated viruses are produced by serial passage in relevant tissue culture systems. Virus inactivation is produced by radiation, heat, or chemical treatments. Both live-attenuated and inactivated viruses are capable of inducing protective antiviral immune responses. Viral vectors are employed to deliver specific antigens through the genome of another virus. DNA vaccines, carried by recombinant bacterial vectors, are generated in relevant microorganisms or in cell cultures. When injected into a host they provide relevant virus-specific protein synthesis needed to generate an immune response. Recombinant subunits are antigenic determinants of SARS-CoV-2, obtained by recombinant DNA technology. VLPs contain no genetic materials but resemble the SARS-CoV-2 virus by virtue of specific surface antigenic proteins. Broadly neutralizing antibodies (bNAbs) are capable of binding to multiple conserved sites on viral spike proteins obtained from different viral strains, and thereby prevent virus neutralization escape. They may also function to attenuate virus evolution. Synthetic peptides can be designed to inhibit the receptor-binding domain (RBD) on the spike protein that is crucial for SARS-CoV-2 to gain host cell entry. Nanoparticles and extracellular vesicles (EVs) are the emerging technologies for the degevelopment of safer vaccines against SARS-CoV-2. Nanoparticles are decorated with antigenic molecules, while EVs serve as natural carrier of viral proteins, wherein both inducing antiviral immune responses.</p></caption><alt-text id="al0005">Fig. 1</alt-text><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="gr1_lrg.jpg"/></fig></p><sec id="s0025"><label>4.1</label><title>Live attenuated</title><p id="p0065">These use live viruses to elicit protective immune responses. India and China use a live virus vaccine to boost small pox immunization. They expose people to material obtained from patients infected with a mild virus form [<xref rid="bb0605" ref-type="bibr">121</xref>,<xref rid="bb0610" ref-type="bibr">122</xref>]. Live vaccine raises the possibility of viral virulence reversal [<xref rid="bb0615" ref-type="bibr">123</xref>]. Therefore, live virus vaccines need be developed by altering the viral genome and selecting non-pathogenic mutant strains incapable of causing disease [<xref rid="bb0620" ref-type="bibr">124</xref>]. Live virus vaccines can also be produced by viral attenuation. These are viruses weakened in their pathogenicity but can elicit antiviral immune responses without causing disease. One of the most widely used strategy is serial passages of virus in chick embryo fibroblasts and vero cells. This is a well accepted practice for the vaccine development [<xref rid="bb0625" ref-type="bibr">125</xref>,<xref rid="bb0630" ref-type="bibr">126</xref>].</p><p id="p0070">As the virus replicates through each passage, it loses virulence [<xref rid="bb0595" ref-type="bibr">119</xref>]. Attenuated viral vaccines against measles, mumps, and chickenpox were developed [<xref rid="bb0635" ref-type="bibr">127</xref>]. Another means used to generate live attenuated vaccines involves deletion or viral gene mutation essential for viral growth. These defective viruses cannot replicate in a human host [<xref rid="bb0640" ref-type="bibr">128</xref>] but can induce immune responses [<xref rid="bb0645" ref-type="bibr">129</xref>]. The first replication-defective live viral vaccine was developed against herpes simplex virus-1 (HSV-1) [<xref rid="bb0650" ref-type="bibr">130</xref>,<xref rid="bb0655" ref-type="bibr">131</xref>]. Replication-defective HSV-2 missing the genes essential for viral DNA synthesis was produced [<xref rid="bb0660" ref-type="bibr">132</xref>]. Another approach is to grow virus at reduced temperatures. Attenuated viruses can also be developed by inserting viral proteins into an attenuated cold-adapted virus [<xref rid="bb0665" ref-type="bibr">133</xref>]. Live attenuated virus induce no or limited infection [<xref rid="bb0670" ref-type="bibr">134</xref>]. However, these strains show an ability to induce herd immunity by shedding of viral particles and by host to host transmission. Live-attenuated vaccines are capable of eliciting illness in the immunosuppressed individuals [<xref rid="bb0615" ref-type="bibr">123</xref>]. To overcome this limitation, codon deoptimization is used. Codon deoptimization vaccines are completely safe due to substitution of several nucleotides from the virus coding sequence [<xref rid="bb0675" ref-type="bibr">135</xref>,<xref rid="bb0680" ref-type="bibr">136</xref>]. Recently, live attenuated vaccine was produced against Ebola and found to be &gt;97% effective in 90,000 individuals [<xref rid="bb0685" ref-type="bibr">137</xref>]. Currently, Griffith University in collaboration with Indian Immunologicals Ltd. developed codon deoptimized live attenuated vaccine for SARS-CoV-2. The vaccine can induce long lasting protective immunity after single dose without cross reactivity to MERS-CoV and SARS-CoV [<xref rid="bb0690" ref-type="bibr">138</xref>]. Existing vaccine manufacturing facilities are capable to develop live attenuated vaccine for large scale production [<xref rid="bb0695" ref-type="bibr">139</xref>].</p></sec><sec id="s0030"><label>4.2</label><title>Inactivated viruses</title><p id="p0075">These viruses are inactivated by radiation, heat, and chemicals such as binary ethyleneimine and formalin. This leads to an inability to cause illness. However, inactivated viruses maintain the ability to induce host immunity that recognize and destroy pathogens. This vaccine type contain viral particles from inactivated virus and hence do not develop pathogenicity [<xref rid="bb0580" ref-type="bibr">116</xref>,<xref rid="bb0700" ref-type="bibr">140</xref>]. The inactivated vaccine developed against poliovirus is an example, where virus is inactivated by formaldehyde treatment. Due to inactivated vaccine development, no new polio infection cases have been reported since 1999 and as a result disease eradication was declared in 2015 [<xref rid="bb0705" ref-type="bibr">141</xref>,<xref rid="bb0710" ref-type="bibr">142</xref>]. Another examples of an inactivated vaccine are those for typhoid, rabies, influenza and hepatitis A [<xref rid="bb0600" ref-type="bibr">120</xref>,<xref rid="bb0715" ref-type="bibr">143</xref>]. Such vaccines have set regulatory requirments for short-term protection as they, as a group, generate a weaker immune responses and require more frequent boosters for long-term immunity than other vaccine candidates. On balance, they are relatively stable and do not require refrigeration and can be freeze-dried and easily transported. Inactivated vaccines are boosted with adjuvants, such as saponins, alum, immune complexes and liposomes [<xref rid="bb0620" ref-type="bibr">124</xref>,<xref rid="bb0720" ref-type="bibr">144</xref>]. Currently, nine SARS-CoV-2 vaccines are being developed using this technology. Sinovac Biotech is developing inactivated vaccine PiCoVacc which is now known as CoronaVac against SARS-CoV-2 and this candidate induces broad neutralizing antibodies against ten different viral strains in multiple species that include primates. After three immunization of CoronaVac (6&#160;&#956;g per dose), complete protection was observed in macaques challenged with SARS-CoV-2 [<xref rid="bb0725" ref-type="bibr">145</xref>]. CoronaVac has already been tested in the human Phase 1/2 trials. 142 healthy volunteers were enrolled in Phase 1 while 600 healthy volunteers were enrolled in Phase 2 studies. CoronaVac was found safe and well tolerated in all studies. The neutralizing antibody titer rate was above 90%, confirming a robust protective immune response against SARS-CoV-2 [<xref rid="bb0730" ref-type="bibr">146</xref>]. Currently, Sinovac Biotech is studying CoronaVac in Brazil in collaboration with Instituto Butantan in a Phase 3 clinical trial where 90,000 healthy participants are or soon to be enrolled [<xref rid="bb0735" ref-type="bibr">147</xref>]. Another inactivated vaccine Covaxin is developed by the Indian Pharmaceutical company Bharat Biotech in collaboration with the Indian Council of Medical Research (ICMR) and National Institute of Virology (NIV). Preliminary results of a Phase 1/2 clinical trial showed that Covaxin is safe and effective. Currently, a Phase 3 trial with Covaxin is ongoing with 26,000 participants [<xref rid="bb0740" ref-type="bibr">148</xref>]. Other inactivated vaccine candidates are being developed by Beijing Institute of Biological Products in collaboration with Sinopharm and was found safe and able to generate a high antiviral antibody titer among participants as observed in a Phase 1/2 clinical trial [<xref rid="bb0745" ref-type="bibr">149</xref>]. Currently, a Phase 3 trial in the United Arab Emirates (UAE) in 15,000 participants is ongoing [<xref rid="bb0735" ref-type="bibr">147</xref>].</p></sec><sec id="s0035"><label>4.3</label><title>Nucleic acid &#8211; DNA</title><p id="p0080">DNA vaccines are a harmless complement to conventional live- and inactivated-virus vaccines [<xref rid="bb0600" ref-type="bibr">120</xref>]. DNA vaccines are generally safe and stable compared to conventional vaccines because the vectors used are non-replicating and express only the antigen of interest. Therefore, unlike viral vector vaccines, they are not able to revert to the disease-causing form. DNA vaccines also lack vector induced immunity which allow their use with other vaccines in the same individual [<xref rid="bb0750" ref-type="bibr">150</xref>]. In short time intervals, DNA vaccines are produced in bulk quantities. Additionally, such types of vaccines can provoke both humoral and cell-mediated immune responses but at lower levels when compared to conventional vaccines. Maintaining high-level protein expression is challenging with this platform (<xref rid="f0010" ref-type="fig">Fig. 2</xref>
) [<xref rid="bb0755" ref-type="bibr">151</xref>]. Under the transcriptional control of the CMV/R promoter, a West Nile virus DNA vaccine was shown to be safe and well tolerated [<xref rid="bb0760" ref-type="bibr">152</xref>]. A DNA vaccine against Rift Valley fever virus (RVFV) [<xref rid="bb0765" ref-type="bibr">153</xref>] and Chikungunya virus (CHIKV) elicited strong immune responses that protected mice and non-human primates after viral challenge [<xref rid="bb0770" ref-type="bibr">154</xref>]. Recently, the EBOV-GP DNA vaccine was shown to induce long-term immune responses and neutralizing antibodies in nonhuman primates [<xref rid="bb0775" ref-type="bibr">155</xref>]. A HIV-1 DNA vaccine DNA-4, which encodes the Pol(rt), gp140, Nef, and Gag proteins of HIV-1, was found to be safe, well-tolerated and capable to induce robust immune responses [<xref rid="bb0780" ref-type="bibr">156</xref>]. DNA vaccines from the envelope (E), ectodomain (domains I, II, and III), and the non-structural 1 (NS1) protein of dengue virus serotype 2 (DENV2) protected against lethal DENV2 challenges [<xref rid="bb0785" ref-type="bibr">157</xref>]. A DNA vaccine encoding the SARS-CoV S-protein induced T cell and neutralizing antibody responses in animals [<xref rid="bb0790" ref-type="bibr">158</xref>]. Despite the encouraging preclinical outcomes, no DNA vaccines yet are approved for human use based on their regulatory uncertainty. A vaccine candidate developed in this platform must have to go through vigorous regulatory process that could delay approval. Currently, three DNA vaccine candidates are under investigation for COVID-19. Inovio Pharmaceuticals with the International Vaccine Institute and Korea National Institute of Health are developing the SARS-CoV-2 vaccine INO-4800, using a DNA-based platform. In Phase 1 clinical trial with 40 healthy voluenteers, 94% participants showed protective immune responses six weeks after two doses (1 and 2&#160;mg) of INO-4800. After the early encouraging results, Inovio is now recruiting healthy participants for a Phase 2/3 trial [<xref rid="bb0795" ref-type="bibr">159</xref>]. The India-based pharmaceutical company Zydus Cadila is investigating a plasmid DNA vaccine candidate ZyCov-D for SARS-CoV-2. After seeing protective immmune responses in mice, rats, guinea pigs and rabbits, investigators are recruiting healthy voluenteers for a Phase 1/2 trial [<xref rid="bb0800" ref-type="bibr">160</xref>]. Genexine Inc. is developing DNA vaccine GX-19 for COVID-19 with the support of the Korean Government. Currently, recruitment of 120 healthy volunteers is under progress to initiate a Phase 1 clinical trial [<xref rid="bb0805" ref-type="bibr">161</xref>].<fig id="f0010" position="float" orientation="portrait"><label>Fig. 2</label><caption><p><bold>Schematics for vaccine-induced antiviral immunity.</bold> DNA vaccines carry viral genes, which are released inside the target APCs. The inserted genes are transcribed, then translated to antigenic viral proteins that are either presented through the APC to CD8 T cells through MHC-I TCR interactions. Alternatively, the viral protein of interest is presented to CD4 T cells by MHC-II TCR interactions. Cytotoxic CD8 T cells kill infected cells and B cells make antibodies by CD4 T cell dependent activation. These released antibodies are directed to target specific viral antigens. RNA vaccines incorporate mRNA into target APCs and undergo parallel pathway events once the immunogenic proteins are synthesized. Subunit vaccine consists of the antigenic determinants of the viral pathogen, which enters the target cells and subsequently releases the specific viral subunits. The subunits are engulfed into endosomes, which when fused with the membranes, present the viral antigens to the CD4 T cells for both T- and B- cell mediated antiviral immunity. Multivalent viral vaccines are also designed to display multiple antigens in order to enhance immunogenicity. <italic toggle="yes">Abbreviations; Antigen presenting cells, APCs; class I major histocompatibility complex, MHC-I; class II major histocompatibility complex, MHC-II, T-cell receptor,TCR; B-cell receptor, BCR.</italic> The illustration is prepared in-house and schematic ideas and technical details were followed as presented in previous published report [<xref rid="bb0085" ref-type="bibr">17</xref>].</p></caption><alt-text id="al0010">Fig. 2</alt-text><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="gr2_lrg.jpg"/></fig></p></sec><sec id="s0040"><label>4.4</label><title>Viral vectors</title><p id="p0085">Vector-based vaccines are kind of live attenuated vaccines which use available viral vectors with known safety profiles. Vectors deliver specific gene that encodes for a specific antigen. When viral vectors are injected, a gene of interest transcribes a specific antigenic protein, and thereby elicits immunity. Vectors do not require adjuvants and are capable of eliminating virus-infected cells by inducing a cytotoxic T cell (CTL) responses [<xref rid="bb0810" ref-type="bibr">[162]</xref>, <xref rid="bb0815" ref-type="bibr">[163]</xref>, <xref rid="bb0820" ref-type="bibr">[164]</xref>]. Existing viral vectros can be divided into two categories: replicating (replication-competent) and non-replicating (replication-deficient). The replicating viral vector produces infectious viruses capable of infecting target cells to produce viral antigens. The most widely used replicating vectors include the measles and the vesicular stomatitis virus, both are single-stranded, and antisense RNA viruses able to deliver heterologous antigens that can induce both cellular and humoral immune responses [<xref rid="bb0825" ref-type="bibr">165</xref>]. The major advantage of the measles virus vector (MVV) is that it elicits life-long cellular and humoral immunity. Due to helical structure of measles virus, vectors prepared from it can tolerate insertion of genes over a size of 6Kb and vectors are stable even after multiple passages [<xref rid="bb0830" ref-type="bibr">166</xref>].</p><p id="p0090">The recombinant versions of replicating viral vectors have better safety profile and superior infectivity over their native form. Recombinant MVV can elicite broad neutralizing antibodies against multiple conserved epitopes of viral spike proteins of divergent strains and therefore precluding virus escape [<xref rid="bb0835" ref-type="bibr">167</xref>,<xref rid="bb0840" ref-type="bibr">168</xref>]. Recombinant MVV is also known for more specific targeted antigen delivery to the macrophages and can be used as multivalent vector for HIV-1, West Nile virus, and others [<xref rid="bb0845" ref-type="bibr">169</xref>,<xref rid="bb0850" ref-type="bibr">170</xref>]. In contrast, non-replicating viral vectors include adenovirus, adeno-associated virus (AAV), herpes virus, and alpha virus. Originally, they were developed from simian adenoviruses and some other pathogens such as Ebola virus, RVFV, and Zika virus [<xref rid="bb0855" ref-type="bibr">171</xref>]. Adenovirus-based viral vectors are most commonly used. The E1A and E1B genomic regions of adenovirus are replaced by genes encoding target viral antigens [<xref rid="bb0860" ref-type="bibr">172</xref>]. Adenoviral vectors can express gene inserts of size over 8Kb, and hence can be used to generate multivalent vaccines [<xref rid="bb0865" ref-type="bibr">173</xref>]. Adenoviral vector Ad5 can provoke CD8 T cells and strong antiviral responses and provide ease of large scale production [<xref rid="bb0870" ref-type="bibr">174</xref>,<xref rid="bb0875" ref-type="bibr">175</xref>]. Other adenovirus-based vectors (Ad26 and Ad35) are candidates for HIV-1 vaccine due for their abilities to infect functional memory T cells [<xref rid="bb0880" ref-type="bibr">176</xref>,<xref rid="bb0885" ref-type="bibr">177</xref>]. The key advantages of non-replicating adenovirus vectors include ease of genetic alterations, stability, safety, higher growth rate, strong immune response, and thermostability [<xref rid="bb0890" ref-type="bibr">178</xref>].</p><p id="p0095">In spite of structural similarities, AAV display improved stability over adenoviruses. The protein coverings of a virus (capsid) and specific activating protein assembly facilitate their targeted delivery potential [<xref rid="bb0895" ref-type="bibr">179</xref>,<xref rid="bb0900" ref-type="bibr">180</xref>]. The recombinant AAV vectors (rAAV) are superior over native AVV where the Rep and Cap genes of AAV are replaced with the genes encoded for target antigens to elicit neutralizing antibodies [<xref rid="bb0905" ref-type="bibr">181</xref>]. AAV-based vectors are used as a tool in gene therapy for the treatment of various disorders like muscular atrophy, inherited blindness, and haemophilia [<xref rid="bb0910" ref-type="bibr">182</xref>]. Despite advantages, viral vectors have several limitations. Vector induced immunity is common with this technology that reduces the efficacy of the vaccine. Host genome integtation is another key limitation with viral vector leading to the risk of tumorigenesis. Also certain viral vectors like AAV have low titer production which become limiting step in bulk vaccine production. However, due to highly specific delivery and long lasting immune response after single administration, viral vector platform is still well accepted and in the past this technology has shown successful eradiation of smallpox [<xref rid="bb0810" ref-type="bibr">162</xref>]. Technological developments have increased host immune responses as well as the large-scale production of viral vectors that ease the regulatory requirements of this technology [<xref rid="bb0580" ref-type="bibr">116</xref>].</p><p id="p0100">Currently, many COVID-19 vaccines are under development with this technology. AD26 associated vaccine against SARS-CoV-2 showed complete protection in rhesus macaques after infection [<xref rid="bb0915" ref-type="bibr">183</xref>]. Thereafter, a series of AD26 vectors encoding different SARS-CoV-2 spike protein epitopes were developed with encouraging outcomes [<xref rid="bb0920" ref-type="bibr">184</xref>,<xref rid="bb0925" ref-type="bibr">185</xref>]. Recently, Russia approved a COVID-19 vaccine Sputnik V exhibiting two different adenovirus vectors (rAd26 and rAd5), both carrying the gene for SARS-CoV-2 S glycoprotein (rAd26-S and rAd5-S) (<xref rid="f0015" ref-type="fig">Fig. 3</xref>
).<fig id="f0015" position="float" orientation="portrait"><label>Fig. 3</label><caption><p><bold>Two-vector viral vaccines.</bold> Developed by Gamaleya Center in Russia, two-vector vaccine, as the name suggests, uses two different vectors (Ad5 and Ad26). Vector development involves the use of S-protein mRNA to generate the complementary DNA, followed by insertion of this S-protein encoding DNA into adenoviral vectors, Ad26 and Ad5. Ad26 vector encoding S-protein was administered as first vaccination followed by a booster dose of Ad5 vector encoding the same S-protein 21&#160;days later. Inside the recipient, these vectors generate the S-proteins, which upon entering the circulation induces protective immunity. The illustration is prepared in-house and schematic ideas and technical details were followed as presented in previous published report [<xref rid="bb0930" ref-type="bibr">186</xref>,<xref rid="bb0935" ref-type="bibr">187</xref>].</p></caption><alt-text id="al0015">Fig. 3</alt-text><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="gr3_lrg.jpg"/></fig></p><p id="p0105">The premature decision was made after the encouraging results of Sputnik V in Phase 1 and Phase 2 clinical trials, with just 38 participants in each study [<xref rid="bb0930" ref-type="bibr">186</xref>]. In Phase 1 study, both rAd5-S and rAd26-S vaccines were found safe and well tolerated for up to 28&#160;days. In Phase 2 study, rAd26 was administered on day 1 followed by a booster dose of rAd5 on day 21 where 100% of the participants showed seroconversion and high SARS-CoV-2 antibody titer than COVID-19 convalescent plasma. Both antigen-specific CD4 and CD8 T cells were observed in all the participants [<xref rid="bb0930" ref-type="bibr">186</xref>]. However, large-scale Phase 2 clinical trial results are needed for US FDA approval and to vaccinate the general population with Sputnik V [<xref rid="bb0935" ref-type="bibr">187</xref>]. Other COVID-19 vaccines developed using this technology include Ad5-nCoV, AZD1222, aAPC, and LV-SMENP-DC. Ad5-nCoV, developed by CanSino Biologics Inc., is the first vaccine to reach Phase 2 clinical trial. In Phase 1 clinical trial, Ad5-nCoV was found well tolerated and immunogenic in 108 participants 28&#160;days post vaccination [<xref rid="bb0940" ref-type="bibr">188</xref>]. In Phase 2 study, single immunization of Ad5-nCoV induced significant SARS-CoV-2 neutralizing antibodies and immunogenic response in all 508 participants [<xref rid="bb0945" ref-type="bibr">189</xref>]. Ad5-nCoV has already been approved for the military use in the China and currently it is under Phase 3 clinical trial investigation in russia [<xref rid="bb0950" ref-type="bibr">190</xref>]. AZD1222, formerly known as ChAdOx1-S is being developed by the University of Oxford with AstraZeneca. Currently, Phase 2/3 clinical trila is ongoing but the interim results of Phase 2 study showed better tolerance of AZD1222 in older adults compared to the young adults with equivalent immunogenicity across different age groups 28&#160;days after single booster immunization. To note, when tested in the animlas, no complete protection against SARS-CoV-2 infection was observed [<xref rid="bb0955" ref-type="bibr">191</xref>]. AZD1222 is the first vaccine candidate being investigated in the Phase 3 clinical trial. Previously, Phase 3 study of AZD1222 was put on hold after suspected serious adverse reactions in the UK trial participants which is now resumed after recommendations of the independent safety review committee and the United Kingdom Medicines and Healthcare Regulatory Agency [<xref rid="bb0960" ref-type="bibr">192</xref>]. AstraZeneca has agreement with Europe's Inclusive Vaccines Alliance to supply 400 million doses of AZD1222 by the end of 2020 [<xref rid="bb0965" ref-type="bibr">193</xref>]. Vaccines aAPC and LV-SMENP-DC are made by Shenzhen Geno-Immune Medical Institute which are currently in Phase 1/2 clinical trial (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="ClinicalTrials.gov" xlink:href="NCT04276896" id="ir0305">NCT04276896</ext-link>).</p></sec><sec id="s0045"><label>4.5</label><title>Protein and subunits</title><p id="p0110">These vaccines utilize viral proteins or protein fragments and able to elicit strong humoral and cellular CD4 and CD8 T cell antiviral responses (<xref rid="f0010" ref-type="fig">Fig. 2</xref>). Currently, many vaccines are under development which are based on the protein subunit technology. Such vaccines devoid of using infectious virus and instead use purified specific antigenic component, therefore eliminate isssues of virus attenuation/inactivation or virulence reversal to offer better safety profile compared to the other viral vaccines [<xref rid="bb0970" ref-type="bibr">194</xref>]. However, like other viral vaccines, protein subunit vaccines have limitations, major one is limited efficacy. In this technology, the isolated antigenic fragment of the pathogen likely denatured that conjugate with untargeted antibodies leading to the diminished efficacy [<xref rid="bb0975" ref-type="bibr">195</xref>]. Hovever, recombinant DNA technologies have successfully overcome such limitations as evidenced by the approval of first recombinant protein subunit vaccine against hepatitis B which has now controlled the disease to near elimination [<xref rid="bb0980" ref-type="bibr">196</xref>]. It has also open the way for regulatory relaxations for the vaccines developed by this technology [<xref rid="bb0985" ref-type="bibr">197</xref>]. Furhther advancements made in this vaccine technology make them more suitable for the immunocompromised individuals. For the production of recombinant proteins, <italic toggle="yes">E.coli</italic> [<xref rid="bb0990" ref-type="bibr">[198]</xref>, <xref rid="bb0995" ref-type="bibr">[199]</xref>, <xref rid="bb1000" ref-type="bibr">[200]</xref>] and yeasts are used [<xref rid="bb1000" ref-type="bibr">200</xref>,<xref rid="bb1005" ref-type="bibr">201</xref>].</p><p id="p0115">Several protein subunit vaccines are marketed against diseases including influenza, HPV, and hepatitis B [<xref rid="bb1010" ref-type="bibr">202</xref>]. To improve immunogenic action of such vaccines, diverse formulations of vaccines with potent adjuvants have been employed [<xref rid="bb0720" ref-type="bibr">144</xref>]. The subunit vaccine for hepatitis B is an example of a single antigen-containing subunit vaccines, whereas influenza vaccine is an example of a subunit vaccine that contains two antigens (haemagglutinin and neuraminidase) [<xref rid="bb0620" ref-type="bibr">124</xref>,<xref rid="bb0985" ref-type="bibr">197</xref>,<xref rid="bb0990" ref-type="bibr">198</xref>,<xref rid="bb1015" ref-type="bibr">203</xref>]. Large scale production of purified antigenic protein is also challenging which can be improved by various expression systems including plant-based [<xref rid="bb1020" ref-type="bibr">204</xref>]. Envelope glycoproteins E1 and E2 of Chikungunya virus (CHIKV) were expressed in insect cells as well as in bacterial expression systems to develop subunit vaccines effective against CHIKV [<xref rid="bb1025" ref-type="bibr">205</xref>]. The subunit vaccines developed from the capsid protein (CP) of astrovirus, protected mink litters against astrovirus infection better than the whole CP [<xref rid="bb1030" ref-type="bibr">206</xref>]. Recombinant subunit vaccines against herpes zoster showed significant reduction in the risk of post therapeutic neuralgia [<xref rid="bb1035" ref-type="bibr">207</xref>,<xref rid="bb1040" ref-type="bibr">208</xref>]. Currently, several vaccine candidates have been developed using this technology against COVID-19 focused on the SARS-CoV-2 S protein or specific domain within the S protein such as receptor binding domain (RBD). The University of Queensland in collaboration with GSK and Dynavax is developing stabilized pre-fusion recombinant protein subunit vaccine against SARS-CoV-2 using its Molecular Clamp technology that lock the SARS-CoV-2 specific protein in the three-dimentional shape with ability to develop humoral immune response against appropriate viral epitopes [<xref rid="bb0060" ref-type="bibr">12</xref>]. Novavax has developed a protein subunit vaccine, NVX-CoV2373 by combining its nanoparticle technology. The recombinant pre-fusion SARS-CoV-2 S protein is expressed in the Baculovirus system and uses Matrix-M adjuvant to enhance the protective immune response against SARS-CoV-2 S protein. Novavax is planning to initate Phase 1 clinical trial after encouraging observations in the animal studies where NVX-CoV2373 induced high levels of neutralizing antibodies against SARS-CoV-2 S protein [<xref rid="bb1045" ref-type="bibr">209</xref>]. MigVax Ltd. has developed oral subunit vaccine technology against poultry coronaviruses and now it is developing COVID-19 vaccine with this technology [<xref rid="bb1050" ref-type="bibr">210</xref>].</p></sec></sec><sec id="s0050"><label>5</label><title>Cell-based</title><p id="p0120">Deployment of CTL is a promising vaccine approach for different pathologies. T cell's unique T cell receptors (TCRs) recognize and activate against viral-specific antigens which drive immune responses [<xref rid="bb1055" ref-type="bibr">211</xref>,<xref rid="bb1060" ref-type="bibr">212</xref>]. Adoptive transfer of virus epitope-specific T cells showed protective immune responses against various viral infections including adenovirus [<xref rid="bb1065" ref-type="bibr">213</xref>], Epstein-Barr virus (EBV) [<xref rid="bb1070" ref-type="bibr">214</xref>], human cytomegalovirus (CMV), etc [<xref rid="bb1075" ref-type="bibr">215</xref>]. Antigen-targeted TCRs have limitations of cross-reactivity and induction of autoimmunity [<xref rid="bb1080" ref-type="bibr">216</xref>]. To overcome such limations, recently combination immunotherapy has been applied for the treatment of various cancers and chronic viral infections where antigen targeted cells are delivered along with other immunemodulators [<xref rid="bb1085" ref-type="bibr">217</xref>]. During viral infection, activated T cells express the programmed death (PD-1) and other inhibitory receptors that make T cells dysfunctional. To overcome such problems, antigen-targeted T cells should be administered alongside the anti-PD1 antibody, otherwise inhibitory receptors are genetically ablated to better control the viral infection [<xref rid="bb1090" ref-type="bibr">[218]</xref>, <xref rid="bb1095" ref-type="bibr">[219]</xref>, <xref rid="bb1100" ref-type="bibr">[220]</xref>, <xref rid="bb1105" ref-type="bibr">[221]</xref>, <xref rid="bb1110" ref-type="bibr">[222]</xref>]. Another cell-based vaccine approach uses whole cells or cell lysates as a source of antigen or as a platform to deliver antigens. Virus infected cells are irradiated or healthy cells are transfected with a virus to provoke humoral and cellular immune responses where endogenous dendritic cells (DCs) play a vital role in the development of neutralizing antibodies [<xref rid="bb1115" ref-type="bibr">223</xref>]. DCs are potential candidate for the cell-based vaccine. DCs play an intermediate role between the innate and adptive immunity. DCs sense foreign antigens, processs and represent them to the T cells to contribute protective immune responses [<xref rid="bb1055" ref-type="bibr">211</xref>]. Like T cells, DCs can be manipulated ex vivo to confirm antigen specificity. DCs can be modified by different technologies such as loading of DCs with the immunogenic viral protein, transfection with viral protein, or loading with viral mRNA, each strategy induce vaccine of different potency. DC-based vaccines can also be incorporated with the immunomodulatory agents or their gene to improve therapeutic outcomes [<xref rid="bb1120" ref-type="bibr">224</xref>,<xref rid="bb1125" ref-type="bibr">225</xref>]. DC-based vaccine PROVENGE (sipuleucel-T), loaded with a prostatic acid phosphatase (PAP)-granulocyte-macrophage colony-stimulating factor (GM-CSF) fusion protein has proven effective in patients with prostate cancer [<xref rid="bb1130" ref-type="bibr">226</xref>] and became the first US FDA approved DC-based vaccine for prostate cancer [<xref rid="bb1135" ref-type="bibr">227</xref>]. Because of such favourable immunotherapeutic activities, DCs have been targeted for the development of vaccines against a range of infectious diseases. However, cell-based vaccine development is complex, labor-intensive, and expensive. Large scale production is challenging compared to the traditional viral vaccines to fulfill the global demand in case of COVID-19. FLUCELVAX is the only cell-based vaccine approved by the US FDA for the influenza infection. The FLUCELVAX produces better protection in the people above 65&#160;years of age compared to the traditional flue vaccines. Effective cell banking ensures adequate supply of cells to scale-up FLUCELVAX in case of emergency [<xref rid="bb1140" ref-type="bibr">228</xref>]. University of Manitoba is developing DC-based vaccine for COVID-19 which is currently under preclinical development [<xref rid="bb1145" ref-type="bibr">229</xref>].</p></sec><sec id="s0055"><label>6</label><title>Adjuvants</title><p id="p0125">COVID-19 containment can only be achieved using effective vaccine strategy. Different technologies used for COVID-19 vaccine development have their own limitations. The inactivated and subunit vaccines often exhibit low immunogenicity therefore frequent booster dose administration is required. Also the effectiveness of the nucleic acid vaccines is questionable due to lack of any licensed vaccines for the human use [<xref rid="bb1150" ref-type="bibr">230</xref>,<xref rid="bb1155" ref-type="bibr">231</xref>]. The globally spread COVID-19 has affected a large population of all the ages due to lack of appropriate prophylactic measures. To fullfill the overwhelming demand in COVID-19 pandemic, a vaccine with high immuniogenicity, faster onset of action, low toxicity, and minimal dose injection is primary requiremet. All outcomes can be achieved by incorporating suitable adjuvants. [<xref rid="bb1160" ref-type="bibr">232</xref>]. A formulation or an immunostimulatory reagent which is designed to improve the performance of a vaccine is adjuvant. Adjuvants enhances antigen-specific protective immune responses and targeted antigen delivery of a vaccine and therefore reduce vaccine dose and associated toxicities [<xref rid="bb1165" ref-type="bibr">233</xref>,<xref rid="bb1170" ref-type="bibr">234</xref>]. An ideal adjuvant should offer heterologous antibody response, potential to kill or neutralize diverse pathogens, and effective T cell responses [<xref rid="bb1175" ref-type="bibr">235</xref>,<xref rid="bb1180" ref-type="bibr">236</xref>]. Moreover, adjuvants should be cheap and widely available with good biodegradable and biocompatible properties [<xref rid="bb1185" ref-type="bibr">237</xref>]. Strategies developed specifically for viral vaccine adjuvants are broadly classified based on formulation and composition which include Toll-like receptor (TLR) agonists, aluminium formulations, and emulsions, all have been tested preclinically in the coronavirus vaccines as discussed below.</p><sec id="s0060"><label>6.1</label><title>Toll-like receptor agonists</title><p id="p0130">APCs recognize viral antigenic peptide which serve as pathogen-associated molecular patterns (PAMPs) through various pattern recognition receptors (PRRs). Toll like receptors (TLRs) of different subtypes are known as PRRs. Activation of TLR lead to induction of robust humoral and cellular immune responses against invading pathogen. Therefore, use of small molecules that activate TCRs on the APCs are frequently incorporated in the vaccine to improve immune responses [<xref rid="bb1190" ref-type="bibr">238</xref>]. Due to ability to directly interact with the APCs and B cells, TLR agonists amplify the innate and adaptove immune responses [<xref rid="bb1195" ref-type="bibr">239</xref>]. Few examples of the TLR agonists are monophosphoryl lipid A (MPL, a derivative of Salmonella Minnesota R959) (TLR4), lipopolysaccharide (LPS) (TLR4), bacterial DNA (TLR7/8), and cysteine-phosphate-guanine (CpG) oligonucleotide (TLR9) which serve as PAMPs [<xref rid="bb1200" ref-type="bibr">240</xref>]. MPL is effective in eliciting both humoral and cell-based immunogenicity and capable of inducing Th1 and Th2 type responses, has been approved in the human vaccines for hepatitis (Fendrix&#174;), HPV (Cervarix&#8482;), and malaria (Mosquirix) [<xref rid="bb1205" ref-type="bibr">241</xref>]. SARS-CoV RBD subunit vaccine (S318-510) elicited immune responses were potentiated by incorporating adjuvant alum inducing Th2 cells mediated immune responses. Addition of CpG oligonucleotide in the alum adjuvanted vaccine added Th1 responses and offered dual immune arm activation [<xref rid="bb1210" ref-type="bibr">242</xref>]. Similar dual immune induction was observed with the MERS-CoV N terminal domain (NTD) vaccine upon incorporation of CpG oligonucleotide with aluminium [<xref rid="bb1215" ref-type="bibr">243</xref>]. UV-inactivated SARS-CoV vaccine has reported to induce systemic proinflammation leading to eosinophil infiltration in the animal lungs. Such limitations of inactivated vaccines can be successfully overcome by addition of TLR agnist LPS [<xref rid="bb1220" ref-type="bibr">244</xref>].</p></sec><sec id="s0065"><label>6.2</label><title>Aluminium</title><p id="p0135">Aluminium hydroxide or alum is the most commonly used adjuvant in the vaccine formulations. Alum adjuvant has been used in the licensed vaccines for the human use against diphtheria, tetanus, pertussis, and hepatitis [<xref rid="bb1225" ref-type="bibr">245</xref>]. Insoluble aluminium salts were the first generation of vaccine adjuvants founded on the discovery of an alum-precipitated diphtheria toxoid suspension. They show improved immunogenicity compared to soluble toxoid [<xref rid="bb1230" ref-type="bibr">246</xref>,<xref rid="bb1235" ref-type="bibr">247</xref>]. The performance of aluminium adjuvant, in part, depends on the composit concentration and absorption of the antigen on a preformed aluminium gel [<xref rid="bb1240" ref-type="bibr">248</xref>]. Alum adjuvants form depot at the injection site followed by slow release of the target antigen to enable its prolonged interactions with the APCs. Alum adjuvants also facilitate antigen uptake of the APCs to activate T cell responses [<xref rid="bb1245" ref-type="bibr">249</xref>]. A SARS-CoV viral vaccine sequencialy inactivated by formaldehyde and UV induced high antibody titer against S protein and neutralizing antibodies in the mice whereas the protective effects were improved by the adjuvant aluminium hydroxide [<xref rid="bb1250" ref-type="bibr">250</xref>]. A SARS-CoV inactivated vaccine induced dose dependent neutralizing antibody responses in the mice and protected them from the viral infection. Such protective effects of vaccine were further improved upon addition of alum adjuvant [<xref rid="bb1255" ref-type="bibr">251</xref>]. Alum in combination with CpG oligonucleotide had demonstrated enhanced humoral and cellular responses in the mice immunized with either inactived or S-based or RBD-based MERS-CoV vaccines [<xref rid="bb1260" ref-type="bibr">252</xref>,<xref rid="bb1265" ref-type="bibr">253</xref>].</p></sec><sec id="s0070"><label>6.3</label><title>Emulsions</title><p id="p0140">A decade after the discovery of alum-based formulations, emulsion adjuvants were developed by Freund [<xref rid="bb1270" ref-type="bibr">254</xref>]. Emulsions are a dispersion of two or more immiscible liquids composed of oil, emulsifiers, and excipients [<xref rid="bb1275" ref-type="bibr">255</xref>]. Emulsions are broadly categorized into two types: water-in-oil and oil-in-water. Both emulsion adjuvants are similar in physical structure, dimensions, follow an extended time of presence at the injection site and prolonged antigen release. Emulsion adjuvants have been demonstrated to activate APCs and improve their antigen uptake. They also promote APCs migration to the target tissue to induce robust CD4 and CD8 T cell responses [<xref rid="bb1280" ref-type="bibr">256</xref>]. MF59 is an oil-in-water emulsion adjuvant, consists squalene and Tween 80 and Span 85 surfactants. In 1997, the Fluad&#174; vaccine adjuvanted with MF59 was first approved for seasonal flu in Europe. Other marketed influenza vaccines consist MF59 as an adjuvant are Focetria&#174; and Celtura&#174; [<xref rid="bb1285" ref-type="bibr">257</xref>]. MF59 when used with the cationic lipid 1,2-dioleoyl-3-trimethylammonium-propane (DOTAP) has improved the antibody responses offered by different DNA vaccines compared to the unadjuvanted DNA vaccines [<xref rid="bb1290" ref-type="bibr">258</xref>,<xref rid="bb1295" ref-type="bibr">259</xref>]. SARS-CoV inactivated vaccine induced S protein specific antibodies and Th2 biased immune responsese were potentiated by the adjuvant MF59 leading to improved viral protection of mice [<xref rid="bb1300" ref-type="bibr">260</xref>]. A SARS-CoV inactivated vaccine induced neutralizing antibody and T cell responses were boosted by the MF59 but not CD8 T cell responses [<xref rid="bb1305" ref-type="bibr">261</xref>]. A MERS-CoV RBD subunit vaccine (S377-588-Fc, S377-588 protein fused with Fc of human IgG) induced detectable neutralizing antibodies and T cell responses in the mice. When vaccine efficacy assessed in the presence of different emulsion adjuvants, Freund's adjuvant, aluminium, montanide ISA51, MF59, and monophosphoryl lipid A; MF59 was found as the most potent adjuvant to substantially improve immune responses [<xref rid="bb1310" ref-type="bibr">262</xref>]. W805EC is an oil-in-water nanoemulsion which is formulated without squalene can substantially improve the protective spectrum of influenza vaccine [<xref rid="bb1315" ref-type="bibr">263</xref>]. Hemagglutinin influenza vaccine with glucopyranosyl lipid A (GLA) oil-in-water emulsion showed improved immune responses in mice [<xref rid="bb1320" ref-type="bibr">264</xref>]. AF03 is a squalene-based emulsion adjuvant present in the marketed influenza vaccine Humenza&#174; [<xref rid="bb1325" ref-type="bibr">265</xref>]. AS01 and AS03 are oil-in-water emulsions developed by GlaxoSmithKline. AS01 consists of MPL and a saponin-based molecule (QS-21) while AS03 consists of &#945;-tocopherol, squalene, and polysorbate 80. The influenza vaccine Pandemrix&#174; is adjuvanted with AS03 to induce antigen-specific immune responses [<xref rid="bb1330" ref-type="bibr">266</xref>]. An inactivated SARS-CoV whole virus vaccine induced high neutralizing antibody titer in the mice after two dose administration. However, vaccine adjuvanted with either AS01 or AS03 showed early and robust antiviral responses where AS01 performed slightly better compared to the AS03. Additionally adjuvanted vaccine offered complete protection of hamsters against wild-type SARS-CoV infection [<xref rid="bb1335" ref-type="bibr">267</xref>]. Montanide series emulsions (ISA-51, &#8722;206, &#8722;720, etc) are metabolizable squalene-based water-in-oil emulsions. Such adjuvants eliminate the cytotoxic effects of Freund's adjuvant due to their biodegradability [<xref rid="bb1340" ref-type="bibr">268</xref>,<xref rid="bb1345" ref-type="bibr">269</xref>]. A SARS-CoV DNA vaccine expressing recombinant NTD induced antigen-specific CD8 T cell responses and neutralizing antibodies in mice. Co-administration of adjuvants montanide and CpG further improved vaccine performance [<xref rid="bb1350" ref-type="bibr">270</xref>]. MERS-CoV RBD vaccine induced high neutralizing antibody titer and protcted mice against viral challenge when adjuvated with montanide ISA-51 [<xref rid="bb1355" ref-type="bibr">271</xref>].</p><p id="p0145">Few COVID-19 vaccine studies have discussed the adjuvant used in their formulation. NVX-CoV2373 is a recombinant (SARS-CoV-2) S protein nanoparticle vaccine uses Matrix-M, a saponin-based adjuvant, in the formulation. Matrix-M improved the recruitment of APCs at the site of injection and thereby increase T cell activation in the nearby lymph nodes [<xref rid="bb1360" ref-type="bibr">272</xref>]. A COVID-19 vaccine developed by the molecular modeling approaches, COVAX-19 is formulated with the Advax adjuvant which is a novel microcrystalline polysaccharide particle engineered from the delta inulin, potentiated the immunostimulatory potential of co-delivered antigen recombinant SARS-CoV-2 S protein [<xref rid="bb1365" ref-type="bibr">273</xref>]. In BNT162b1, an mRNA COVID-19 vaccine, mRNA itself serve as an adjuvant and therefore allow synchronized delivery of antigen and adjuvant [<xref rid="bb1370" ref-type="bibr">274</xref>]. The lipid nanocarriers used in the formulation of vaccines can also serve as adjuvant. The dicetyl phosphate when incorporated into the nonovaccine against diphtheria toxoid improved the protective immune responses by serving as an adjuvant [<xref rid="bb1375" ref-type="bibr">275</xref>]. Overall, the adjuvants with desired properties are critical for effective vaccine delivery.</p></sec></sec><sec id="s0075"><label>7</label><title>Nanovaccines</title><p id="p0150">Nanoparticles share size distribution with the viruses and therefore like viruses, nanoparticles can enter the virus targeted cells. Nanoparticles can be loaded with the antigen in the form of nucleic acids (DNA and mRNA) or the protein subunits and therefore allow targeted expression or direct delivey of viral antigen. Recently nanoparticles have gained significant attention for the development of effective vaccines against various pathogens including SARS-CoV-2. For effective vaccine responses both innate and adptive immune system should be activated synchronizely which has now successfully achieved with the help of innovative nanovaccine formulations such as solid-lipid nanoparticles, liposomes, polymeric nanoparticles, protein nanoparticles, and virus-like particles (VLP) [<xref rid="bb0085" ref-type="bibr">17</xref>,<xref rid="bb1380" ref-type="bibr">276</xref>]. Adjuvants pay a vital role in the nanovaccine mediated desired immune responses by assisting antigen delivery to the target APCs and reduce off-target side effects. Targeted antigen delivery reduces the dose of vaccine required to elicite effective immune response which is very essential consideration for the development of SARS-CoV-2 vaccines to achieve global demand [<xref rid="bb1380" ref-type="bibr">276</xref>,<xref rid="bb1385" ref-type="bibr">277</xref>,<xref rid="bb1390" ref-type="bibr">278</xref>]. Following approaches are used for antigens and adjuvants codelivery, (i) direct conjugation of antigen and adjuvant, (ii) encapsulation within or decorated onto the nanoparticle, and (iii) use of delivery vehicle as adjuvant. Nanovaccine formulations can enhance antigen stability by maintaining native confirmation and protect them from proteolytic degradation [<xref rid="bb1395" ref-type="bibr">279</xref>]. In the promising mRNA based COVID-19 nanovaccine BNT162b, the trimerized confirmation of SARS-CoV-2 RBD and pre-fused confirmation of S protein are maintained and secreted from the nanoformulation to allow induction of broadly neutralizing antibodies [<xref rid="bb1400" ref-type="bibr">280</xref>]. Nanovaccines further offer advantage of sustained release of target antigen due to their enhanced lipophilicity [<xref rid="bb1405" ref-type="bibr">281</xref>]. In addition to the unique physicochemical characteristics, nanoparticles allow flexibility of surface engineering by incorporating cell-targeting peptides, proteins or polymers on their surface (<xref rid="f0020" ref-type="fig">Fig. 4</xref>
) [<xref rid="bb1410" ref-type="bibr">282</xref>,<xref rid="bb1415" ref-type="bibr">283</xref>]. Delivery of the antigen to the lymphatic system is the frontmost requirement for vaccine efficacy. Nanovaccines have ability to cross the intestinal space and reach the lymphatic tissue. Intranasal delivery of nanovaccine can easilty target the lymph nodes nearby the lung which would be advantageous for fighting against COVID-19 [<xref rid="bb1415" ref-type="bibr">283</xref>,<xref rid="bb1420" ref-type="bibr">284</xref>]. Such properties make nanovaccines a versatile delivery vehicle for the treatment of COVID-19.<fig id="f0020" position="float" orientation="portrait"><label>Fig. 4</label><caption><p><bold>Targeted delivery of SARS-CoV-2 antigens.</bold> Nanoparticles are decorated on the surface to present SARS-CoV-2 antigens to efficiently enter APCs. Lymphatic drainage of the nanoparticles brings them in close proximity to the immune cells, particularly the APCs. Nanoparticles stimulate the APCs in different ways. APCs engulf the nanoparticles into endosomes and then presents the NP's surface engineered antigen to CD8 T lymphocytes via membrane-bound MHC-I and TCR interactions. Also, nanoparticles are ligands for the TLRs, which activates the APCs and induce secretion of pro-inflammatory cytokines. Following the interaction between MHC-I and TCR, in the presence of co-stimulatory molecules and cytokines, the activated CD8 T cells kill the infected cells by inducing cytotoxicity. Nanoparticles surface engineered antigens can also be presented to helper CD4 T cells via MHC-II. Subsequently, CD4 T cells activate the B cells to produce protective antibodies against the SARS-CoV-2 antigen. <italic toggle="yes">Abbreviations; Antigen presenting cells, APCs; class I major histocompatibility complex, MHC-I; class II major histocompatibility complex, MHC-II; T-cell receptor,TCR; Toll-like receptor, TLR.</italic></p></caption><alt-text id="al0020">Fig. 4</alt-text><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="gr4_lrg.jpg"/></fig></p><sec id="s0080"><label>7.1</label><title>mRNA nanovaccine</title><p id="p0155">The mRNA-based nanovaccines have benefits over other technologies which include short development time, simple manufacturing and purification processes regardless of the antigen, and most importantly, mimic natural infection to promote potent cellular and humoral immunity by eliciting CD4 and CD8 T cell responses (<xref rid="f0010" ref-type="fig">Fig. 2</xref>) [<xref rid="bb1425" ref-type="bibr">285</xref>,<xref rid="bb1430" ref-type="bibr">286</xref>]. Multiple mRNAs can be combined into a single vaccine to deliver mRNA transcripts of interest into the host cell cytosol, which allows the encoding of one or more antigen(s). Such favourable properties designate mRNA vaccine as a forefront runner for the development against COVID-19 [<xref rid="bb0105" ref-type="bibr">21</xref>]. To note, no commercial vaccine is available till date developed with this technology which mandate strict regulatory requirements to undergo the candidate before approval for the general public.</p><p id="p0160">Mainly two types of mRNA constructs have been evaluated: self-amplifying mRNA and non-replicating mRNA [<xref rid="bb1430" ref-type="bibr">286</xref>]. Both types of mRNAs are synthetically produced, encoding target antigens' 5&#8242; and 3&#8242; untranslated region, cap structure, and open-reading frame, through the use of a cell-free enzymatic transcription reaction. Self-amplifying mRNA vaccines possess genetically-engineered replication machinery that is obtained from the positive-stranded mRNA viruses [<xref rid="bb1430" ref-type="bibr">286</xref>]. Delivery of the intact mRNA vaccine from the injection site to the target cell cytosol for the initiation of protein translation is as important as manufacturing of the mRNA construct. mRNA is labile and prone to degradation primarily from nuclease activity within the cells; hence, efficient protection of the mRNA is critical during administration [<xref rid="bb1425" ref-type="bibr">285</xref>]. Lipid nanoparticles could serve as safe and compatible intracellular delivery platform for the development of successful mRNA vaccine. Lipid nanoparticles offer (i) sustained mRNA confirmation (iii) protection of mRNA cargos against nuclease degradation and; (ii) efficient cellular uptake for targeted mRNA delivery [<xref rid="bb0085" ref-type="bibr">17</xref>,<xref rid="bb1380" ref-type="bibr">276</xref>]. In the past, lipid nanocarrier system has delivered RNA for the therapeutic applications. In 2018, the first lipid nanoparticle formulated siRNA product Onpattro&#174; was approved by the US FDA for the treatment of polyneuropathy caused by hereditary transthyretin-mediated amyloidosis, which established the standard for the clinical safety of lipid nanoparticle-based siRNA formulations [<xref rid="bb1435" ref-type="bibr">287</xref>]. Lipid nanoparticles are generally composed of ionizable lipids, cholesterol, PEGylated lipids, and phospholipids to deliver an mRNA construct. The ionizable cationic lipids create a lipid bilayer shell that allow mRNA encapsulation within an aqueous core for endosomal escape [<xref rid="bb1440" ref-type="bibr">288</xref>]. New-generation cationic lipids and lipoids are developed that maintain neutral or mild cationic charge at physiological pH to reduce nonspecific lipid-protein interactions [<xref rid="bb1445" ref-type="bibr">289</xref>]. Cholesterol provides stability to the lipid bilayer membrane and facilitates cellular transfection. PEGylated lipids serve to sterically stabilize the nanoparticles and reduce nonspecific protein bindings. Decoration of the outer surface with targerting moieties and encapsulation of multiple antigens for tailor-made immunization are additional advantages with lipid nanoparticles [<xref rid="bb1450" ref-type="bibr">290</xref>]. Several companies have used nanovaccine technology for the development of SARS-CoV-2 vaccines. Moderna, an mRNA-based biotechnology company, initiated the first mRNA nanovaccine using their patented nanovaccine technology (WO2017070626 and WO2018115527). Moderna first developed an mRNA vaccines that encodes the MERS-CoV antigens: (i) S or its fragment (S1); (ii) E, (iii) membrane (M); or (iii) nucleocapsid (N) protein. These vaccines are effective in inducing antigen-specific immune responses. Moderna encapsulated the mRNA mixture into the cationic lipid nanoparticles and intradermally injected the vaccine into mice, which lead to the encoding MERS-CoV S proteins' translation <italic toggle="yes">in vivo</italic> for the subsequent induction of humoral immune responses. The MERS-CoV mRNA nanovaccine encoding the full-length S protein reduced more than 90% of the viral load in the lungs and induced a significant amount of neutralizing antibody against MERS-CoV in the New Zealand white rabbits [<xref rid="bb1455" ref-type="bibr">291</xref>]. Research on MERS-CoV vaccines led to funding from CEPI (Coalition for Epidemic Preparedness Innovations) to manufacture an mRNA nanovaccine against SARS-CoV-2 (mRNA-1273). This led to the first mRNA nanovaccine to enter clinical trial (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="ClinicalTrials.gov" xlink:href="NCT04283461" id="ir0310">NCT04283461</ext-link>) for SARS-CoV-2. In mRNA-1273 vaccine, two proline amino acids were substituted at 986 and 987 positions in the S2 cleavage site to maintain stability of the prefused S mRNA [<xref rid="bb1455" ref-type="bibr">291</xref>]. The findings from the Moderna SARS-CoV-2 vaccine trial raised optimism. In the preliminary Phase 1 clinical trial, Moderna investigated a dose-escalation study of mRNA-1273 in 45 healthy adults (18 to 55&#160;years of age), who were vaccinated at two time points, 28&#160;days apart, with three different doses (25&#160;&#956;g, 100&#160;&#956;g or 250&#160;&#956;g). Commensurately, antibody responses were highest with the higher dose after the first vaccination and titers were increased after the second vaccination. Serum-neutralizing activity was detected using pseudotyped lentivirus reporter single-round-of-infection neutralization assay (PsVNA) and live wild-type SARS-CoV-2 plaque-reduction neutralization testing (PRNT) assay. No participant had measurable neutralizing antibody responses before vaccination however all participants showed higher antibody responses after second vaccination in both PsVNA and PRNT assays. mRNA-1273 stimulated Th1-biased CD4 T cell responses in all participants. From the lower dose groups (50&#160;&#956;g and 100&#160;&#956;g), all the participants showed mild or moderate side effects. However, one or more adverse events were reported in few participants from the 250&#160;&#956;g dose group. Similar adverse events were presented in clinical trials with high dose of avian influenza mRNA vaccine (influenza A/H10N8 and influenza A/H7N9) manufactured by Moderna's lipid nanoparticle technology [<xref rid="bb1460" ref-type="bibr">292</xref>]. The Phase 1 clinical trial was expanded to included 40 older adults of 56 to 70&#160;years or&#160;&#8805;&#160;71&#160;years of age who received two doses of mRNA-1273 vaccine (50&#160;&#956;g and 100&#160;&#956;g). In this study, 100&#160;&#956;g dose induced higher antigen-binding and neutralizing antibodies in all the older participants while the associated side effects were mainly mild or moderate [<xref rid="bb1465" ref-type="bibr">293</xref>]. In Phase 2 clinical trial, Moderna is demonstrating safety and immunogenicity of mRNA-1273 in 600 healthy participants across all age groups (above 18&#160;years) where participants will receive either 50&#160;&#956;g or 100&#160;&#956;g dose twice at 28&#160;days interval with follow-up for 12&#160;months after the second vaccination (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="ClinicalTrials.gov" xlink:href="NCT04405076" id="ir0315">NCT04405076</ext-link>). Moderna has already initiated a Phase 3 clinical trial in collaboration with the National Institute of Allergy and Infectious Diseases (NIAID) in 30,000 young adult participants to test mRNA-1273 at 100&#160;&#956;g dosage. The primary endpoint of this study is prevention of symptomatic COVID-19 disease while the secondary endpoints include prevention of severe COVID-19 disease and infection by SARS-CoV-2 (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="ClinicalTrials.gov" xlink:href="NCT04470427" id="ir0320">NCT04470427</ext-link>) [<xref rid="bb1460" ref-type="bibr">292</xref>]. On November 15, 2020, the interim results of mRNA-1273 Phase 3 clinical trial were released that comprised 95 cases of symptomatic COVID-19 where 90 cases belongs to the placebo group and 5 cases from the vaccinated group. The vaccine was found safe and well-tolerated and showed 94.5% efficacy in studied candidates with statistical significance [<xref rid="bb1470" ref-type="bibr">294</xref>]. Based upon the promising interim results of Phase 3 trial, Moderna received the US FDA EUA of mRNA-1273 for COVID-19 treatment [<xref rid="bb1475" ref-type="bibr">295</xref>].</p><p id="p0165">BioNTech and Pfizer have jointly developed BNT162(b1,b2,b3) vaccines for COVID-19 (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="ClinicalTrials.gov" xlink:href="NCT04368728" id="ir0325">NCT04368728</ext-link>). BNT162b1 is a nucleoside-modified mRNA vaccine that encodes trimerized SARS-CoV-2 receptor-binding domain (RBD) which is a key target for viral neutralizing antibodies. BNT162b2 is mRNA vaccine that encodes a membrane-anchored SARS-CoV-2 full-length S protein stabilized in the prefusion confirmation. Nucleotide modifications in the RBD and S pretein sequences increase RNA stability from enzymatic degradation and protect RNA confirmations in the native form to improve immunogenicity. Both vaccines are encapsulated in lipid nanoparticles for more efficient mRNA delivery into the target cells after intramuscular injection. The Phase 1/2 clinical trial results of BNT162b1 were available in August 2020 from 45 healthy adults of 18&#8211;55&#160;years of age. Dose ascalation study was performed using 10&#160;&#956;g, 30&#160;&#956;g or 100&#160;&#956;g of BNT162b1. 10&#160;&#956;g and 30&#160;&#956;g doses were given twice at 21&#160;days interval while 100&#160;&#956;g dose was given once due to increased risk of reactogenicity. Dose dependant RBD-binding IgG levels and SARS-CoV-2 neutralizing titers in the sera were detected at 21&#160;days after the first dose that substantially increased after the second dose suggested robust immunogenicity in all participants. Geometric mean neutralizing titer levels were 1.8 to 2.8 fold higher than of COVID-19 convalescent human sera [<xref rid="bb1480" ref-type="bibr">296</xref>,<xref rid="bb1485" ref-type="bibr">297</xref>]. The extended results of the BNT162b1 Phase 1/2 clinical trial showed higer titers of broadly neutralizing antibodies in all participants with concurrent induction of RBD-specific CD4 and CD8 T cells. Surprisingly, all the participants showed Th1 biased SARS-CoV-2 immune responses after BNT162b1 immunization [<xref rid="bb1490" ref-type="bibr">298</xref>]. In a separate Phase 1 clinical trial, BNT162b2 was assessed with BNT162b1 in 195 healthy young (18 to 55&#160;years of age) and older adults (65 to 85&#160;years of age) at four dose levels (10&#160;&#956;g, 20&#160;&#956;g, 30&#160;&#956;g, and 100&#160;&#956;g), each injected twice 21&#160;days apart except the highest dose. Both, BNT162b1 and BNT162b2 elicited identical dose dependant SARS-CoV-2 nutralizing antibody titers higher than the COVID-19 convalescent serum. However, BNT162b2 was associated with lower incidences and severity of adverse reactions in both young and older adults compared to the BNT162b1. Therefore, BNT162b2 was selected for the advancement in the Phase 2/3 clinical safety and efficacy assessment trials [<xref rid="bb1400" ref-type="bibr">280</xref>]. Recently, BioNTech and Pfizer concluded the Phase 3 clinical trial results with BNT162b2. The study enrolled more than 43,000 young and older adult participants in approximately 150 clinical sites across different corners of the world. The results indicated 95% efficacy of the BNT162b2 vaccine in the study participant with or without prior SARS-CoV-2 infection including adults over 65&#160;years of age without any serious adverse reactions [<xref rid="bb1495" ref-type="bibr">299</xref>]. After the positive Phase 3 clinical trial conclusion, BNT162b2 vaccine recently received emergency approval from UK's healthcare regulator the Medicines and Healthcare Products Regulatory Agency (MHRA) for the treatment of COVID-19 [<xref rid="bb1500" ref-type="bibr">300</xref>]. BNT162b2 has also been approved for marketing in the Bahrain, Canada and USA for the COVID-19 treatment [<xref rid="bb0070" ref-type="bibr">14</xref>,<xref rid="bb1505" ref-type="bibr">301</xref>].</p><p id="p0170">Acuitas Therapeutics (Vancouver) and Imperial College (London) developed a self-amplifying RNA (saRNA) lipid nanoparticles encapsulated with the pre-fusion stabilized SARS-CoV-2 S protein. They characterized both the humoral and cellular immune response, as well as the neutralization capacity of a pseudo-typed SARS-CoV-2. The mice were immunized with two injections, one month apart, at doses ranging from 0.01&#160;&#956;g to 10&#160;&#956;g. After 6&#160;weeks, robust SARS-CoV-2 S protein specific IgG antibodies were seen in animals in a dose-dependent manner. Even at the lowest dose, saRNA nanovaccine induced higher neutralizing antibody teters in mice compared to the recovered COVID-19 patients or from other reported subunit vaccines for the MERS-CoV, SARS-CoV, and SARS-CoV-2. Higher viral neutralization, cellular responses, and antibody titers were demonstrated with saRNA nanovaccine in comparision to the electroporated plasmid DNA, the positive control, suggesting success of lipid nanoformulation for saRNA delivery [<xref rid="bb1510" ref-type="bibr">302</xref>].</p><p id="p0175">Vaccines must be stored in a narrow temperature range to maintain their stability and efficacy. Cold shipment chain for the vaccine, consumes almost 80% of the total vaccine development cost which limit vaccine access in the countries with low and emerging economies [<xref rid="bb1515" ref-type="bibr">303</xref>]. To overcone these challenges, a thermostable mRNA nanovaccine was developed by the Suzhou Abogen Biosciences in collaboration with Walvax Biotechnology and People's Liberation Army Academy of Military Sciences in China for COVID-19. The vaccine candidate ARCoV was developed by encapsulating an mRNA encoding the RBD of SARS-CoV-2 S glycoprotein in the lipid nanoparticles using a preformed vesicle method [<xref rid="bb1520" ref-type="bibr">304</xref>,<xref rid="bb1525" ref-type="bibr">305</xref>]. After intramuscular injection in mice, ARCoV (30&#160;&#956;g) readily biodistributed in the upper abdomen 6&#160;h post injection. At the injection site, expression of target SARS-CoV-2 RBD was colocalized with CD11b-positive monocytes, CD163-positive macrophages, and CD103-positive dendritic cells with no local inflammation, suggesting vaccine ability to recruit key APCs. ARCoV induced robust SARS-CoV-2 RBD specific IgG and neutralizing antibodies and antigen-specific T cell responses which were further elevated by ARCoV booster administration. Similar protective immune responses were also observed in non-human primates (cynomolgus monkeys) after ARCoV immunization [<xref rid="bb1530" ref-type="bibr">306</xref>,<xref rid="bb1535" ref-type="bibr">307</xref>]. ARCoV was found stable at different temperatures including 4&#160;&#176;C, 25&#160;&#176;C, and 37&#160;&#176;C upto a week confirming its thermostability [<xref rid="bb1540" ref-type="bibr">308</xref>].</p><p id="p0180">An alphavirus-derived replicating RNA vaccine encoding the SARS-CoV-2 S protein, repRNA-CoV2S, was developed using lipid inorganic nanoparticles to enhance vaccine stability, immunogenicity, and targeted delivery. After a single or multiple intramuscular injections, repRNA-CoV2S induced robust SARS-CoV-2 S protein IgG antibodies and antigen-specific T cell responses in rodents and monkeys. Additionally, the neutralizing antibody responses were comparable to the COVID-19 convalescent plasma. The repRNA-CoV2S also induced robust immune responses in aged mice suggesting its potential for the elderly population. repRNA-CoV2S should be further evaluated in clinical studies to confirm its immunogenicity in humans [<xref rid="bb1545" ref-type="bibr">309</xref>].</p></sec><sec id="s0085"><label>7.2</label><title>Protein and subunit nanovaccine</title><p id="p0185">Novavax Inc. is developing multiple nanoparticle vaccines for the COVID-19 treatment [<xref rid="bb1550" ref-type="bibr">310</xref>]. A promising candidate, recombinant SARS-CoV-2 full length S protein nanoparticle vaccine NVX-CoV2373 was generated by incorporating mutations at the S1 and S2 cleavage site to protect from proteolytic degradation and at the heptad repeat 1 site to maintain pre-fusion confugarations. NVX-CoV2373 was evaluated in Phase 1/2 clinical trials at two different dosages (5&#160;&#956;g and 25&#160;&#956;g) in 131 healthy participants, for each dose two intramuscular injections were administered 21&#160;days apart. NVX-CoV2373 was found to be safe and elicited strong immune responses, with SARS-CoV-2 S protein specific IgG and neutralizing antibodies that exceeded the levels of COVID-19 convalescent serum. The immunogenicity was improved by the sponin-based Matrix-M1 adjuvant, which induced Th1 biased immune responses [<xref rid="bb1360" ref-type="bibr">272</xref>]. A Phase 3 clinical trial of NVX-CoV2373 in combination with influenza nanoparticles vaccine NanoFlu&#8482;, initiated in the UK after enrolling 10,000 elderly participants from 18 to 84&#160;years of age. The study has now extended to include 30,000 participants from different parts of the world to reach better conclusions [<xref rid="bb1555" ref-type="bibr">311</xref>]. Novavax Inc. is collaborating with Takeda Pharmaceutical to establish the infrastructure and scale-up manufacturing with the aim of developing 250 million doses of the NVX-CoV2373 vaccine to fulfill global demand [<xref rid="bb1560" ref-type="bibr">312</xref>].</p><p id="p0190">During the past months, researchers have realized challenges in the development of therapeutics and preventive measures against SARS-CoV-2 mutations [<xref rid="bb1565" ref-type="bibr">313</xref>]. To overcome virus mutations associated complications, a novel cellular nanosponge concept was introduced as an active cellular entry-level neutralizing agent against SARS-CoV-2 [<xref rid="bb1570" ref-type="bibr">314</xref>]. In this technology, nanoparticle cores were synthesized (&lt;100&#160;nm size) using biodegradable polymer, poly(D,L-lactic-<italic toggle="yes">co</italic>-glycolic acid) (PLGA), followed by their coating with the plasma membrane derived from either human lung epithelial type II cells or human macrophages. Developed nanosponges (~100&#160;nm size) display the same protein RBD required by SARS-CoV-2 for cellular entry. Both epithelial-nanosponge and macrophage-nanosponge showed SARS-CoV-2 neutralization and protected Vero E6 cells against infection in a concentration-dependent manner. As long as the SARS-CoV-2 target remains the identified host cell, the nanosponge can neutralize the infection, thereby such platform offers (i) broad-acting countermeasures against SARS-CoV-2 mutations and (ii) protection against other emerging coronavirus species (<xref rid="f0025" ref-type="fig">Fig. 5</xref>
). Both nanosponges were found safe upon intratracheal administration (300&#160;&#956;g) which is very important to treat respiratory diseases including COVID-19. Overall, the nanosponge platform offers significant benefits over other therapies to fight against the rapidly mutating SARS-CoV-2 [<xref rid="bb1570" ref-type="bibr">314</xref>].<fig id="f0025" position="float" orientation="portrait"><label>Fig. 5</label><caption><p><bold>Schematic of nanoparticles used as a decoy to the SARS-CoV-2 virus</bold>. Polymeric nanoparticle cores are wrapped with cell membranes derived from SARS-CoV-2 target cells, human lung epithelial type II cells, or macrophages. The inheritance of the surface antigenic profiles of the target cells allows the nanosponges to act as decoys to the circulating viruses and be independent of the status of mutation and strain. They serve to prevent virus entry to the host's natural target cells. The illustration is prepared in-house and schematic ideas and technical details were followed as presented in previously published report [<xref rid="bb1570" ref-type="bibr">314</xref>].</p></caption><alt-text id="al0025">Fig. 5</alt-text><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="gr5_lrg.jpg"/></fig></p><p id="p0195">A recombinant SARS-CoV-2&#160;S1 subunit nanovaccine with two different adjuvants, amphiphilic adjuvant monophosphoryl lipid A (MPLA) and CpG oligiodeoxynucleotides (ODN) is developed. In mice, it induced robust humoral immune responses and strong CD4 and CD8 T cell activation compared to the free S1 subunit vaccine with traditional alum adjuvant.</p><p id="p9215">Further studies are required to assess safety and clinical translatability of this nanovaccine for the COVID-19 treatment [<xref rid="bb1575" ref-type="bibr">315</xref>]. University of Washington School of Medicine researchers are developing a novel nanovaccine platfrom where viral antigen(s) is fused on the surface of self-assembling <italic toggle="yes">de novo</italic> designed nanoparticles that allow unprecedented molecular configuration control of the resulting vaccine [<xref rid="bb1580" ref-type="bibr">316</xref>]. Researchers tailored self-assembling nanoparticles by presenting the ectodomains of influenza, HIV, and RSV viral glycoprotein trimers with the aim to induce better protective immune responses compared to direct antigen delivery [<xref rid="bb1580" ref-type="bibr">316</xref>]. Administration of HIV Env trimer-expressing nanoparticles in rhesus macaques showed accumulation of nanoparticles in the B cell follicles of the draining lymph nodes within two days after immunization, leading to enhanced protective immune responses [<xref rid="bb1585" ref-type="bibr">317</xref>]. As SARS-CoV-2 also exhibits trimeric S protein-like influenza, HIV, and RSV, researchers are developing a nanovaccine against COVID-19 using this technology [<xref rid="bb1580" ref-type="bibr">316</xref>].</p></sec></sec><sec id="s0090"><label>8</label><title>Virus like particles (VLPs)</title><p id="p0205">From various nanovaccine strategies, VLP is one of the preferred option with several advantages. VLPs are structurally identical to the virus particles, but lack viral genome. Therefore, VLPs are termed as non-replicating, and non-pathogenic viral capsid protein based vaccine [<xref rid="bb1590" ref-type="bibr">[318]</xref>, <xref rid="bb1595" ref-type="bibr">[319]</xref>, <xref rid="bb1600" ref-type="bibr">[320]</xref>]. VLPs can be either enveloped or non-enveloped. Enveloped VLPs contain viral proteins on their outer lipid membrane formed through budding from respective host cells, whereas non-enveloped VLPs lack lipid layers and are composed of one or more viral structural proteins [<xref rid="bb1605" ref-type="bibr">321</xref>]. VLPs can be decorated on their surface to display target antigen using recombinant fusion protein expression or chemical cross-linking with bifunctional linkers [<xref rid="bb1610" ref-type="bibr">322</xref>,<xref rid="bb1615" ref-type="bibr">323</xref>]. VLPs also allow encapsulation of target antigenic gene or peptide fragment for the immune cell presentation and activation. VLPs can be loaded with single or multiple capsid proteins and can be formulated in different diameters ranging from 20 to 200&#160;nm [<xref rid="bb1620" ref-type="bibr">324</xref>,<xref rid="bb1625" ref-type="bibr">325</xref>]. VLPs hold all the conformational epitopes to the native virus to allow repetitive antigen presentation. This multi-antigen nanoassembly allow recognization of VLPs by APCs through TLRs and PRRs. Upon recognition, APCs can transport VLPs to the target tissue and difficult to reach lymph nodes where VLPs can directly bind with the B cells and with the T cells through the route of the MHC-I and MHC-II, leading to the induction of strong humoral and cellular immune responses without need of adjuvants. However, adjuvants are frequenty employed in the VLP vaccines to improve immunogenicity in the older adults [<xref rid="bb1620" ref-type="bibr">[324]</xref>, <xref rid="bb1625" ref-type="bibr">[325]</xref>, <xref rid="bb1630" ref-type="bibr">[326]</xref>, <xref rid="bb1635" ref-type="bibr">[327]</xref>]. VLPs engineered with multiple viral antigens can provoke the immune response against multiple viral strains [<xref rid="bb1640" ref-type="bibr">328</xref>]. Recently, VLPs are developed using plug-and-play technologies such as AviTag [<xref rid="bb1645" ref-type="bibr">329</xref>] and SpyCatcher/SpyTag [<xref rid="bb1650" ref-type="bibr">330</xref>]. These technologies allow the conjugation of antigens through either reaction of biotin-streptavidin or the irreversible formation of an isopeptide. VLPs are potential vaccine candidates against diseases like malaria, dengue, and influenza [<xref rid="bb1655" ref-type="bibr">331</xref>,<xref rid="bb1660" ref-type="bibr">332</xref>]. Additionally, the recombinant VLP based nanovaccines are already commercially available to protect against hepatitis B, hepatitis E, HPV, and porcine circovirus type-2 (PCV2) [<xref rid="bb1665" ref-type="bibr">333</xref>]. Such commercialy available VLP vaccines have already set a platfrom for the future vaccine candidates developed with this technology and relaxations in their regulatory requirments are expected. VLP vaccines generally carry small size viral epitopes that accommodate within the particle and therefore loading of larget epitopes such as HIV and influenza haemagglutinin are always challenging [<xref rid="bb1670" ref-type="bibr">334</xref>].</p><p id="p0210">In the past, VLP vaccines were produced from the human serum. The antigen expressing VLPs were isolated from the asymptomatic individuals with chronic viral infection. Although, the isolated VLPs were inactivated and purified, their safety is always uncertain [<xref rid="bb1675" ref-type="bibr">335</xref>]. Therefore, the eukaryotic expression systems are employed for the safe VLPs production. Recombivax HB&#174; and Engerix-B&#174; are recombinant VLP vaccines against HBV produced by Merck and GlaxoSmithKline, respectively. These VLP vaccines are produced from the <italic toggle="yes">Saccharomyces cerevisiae</italic> system that stably express hepatitis B virus surface antigen (HBsAg). The vaccines are safe and consist 20&#160;nm size VLPs with octahedral symmetrical structure of the antigen [<xref rid="bb1680" ref-type="bibr">336</xref>]. The HPV prophylactic VLP vaccine Gardasil&#174; is synthesized by expressing HPV L1 capsid protein in <italic toggle="yes">Saccharomyces cerevisiae</italic> (yeast). The HPV L1 protein self-assembles into immunogenic non-infectious VLPs with the 40&#8211;60&#160;nm size, and can induce similar neutralizing antibody responses as the native virions [<xref rid="bb1685" ref-type="bibr">337</xref>]. Porcilis PCV&#174; is also a safe and effective prophylactic VLP vaccine against PCV associated diseases, and is formed by the ORF2 capsid protein of PCV2 using the baculovirus expression system [<xref rid="bb1690" ref-type="bibr">338</xref>,<xref rid="bb1695" ref-type="bibr">339</xref>]. The major disadvantages of the VLP vaccines produced from the a eukaryotic expression systems are that they offer low VLPs yield and expensive to scale-up and therefore such vaccine produce only partial immunity. As an alternative, mammalian expression systems are used for cost effective and large scale VLP vaccine development with the goal to incude better immune responses [<xref rid="bb1610" ref-type="bibr">322</xref>,<xref rid="bb1615" ref-type="bibr">323</xref>]. A VLP vaccine Sci-B-Vac&#174;, exhibiting three HBV surface antigens S, pre--S1, and pre--S2, is produced from the mammalian Chinese hamster ovary (CHO) cells produces higher antibody titers against HBV compared to the vaccines generated from the eukaryotic expression systems [<xref rid="bb1700" ref-type="bibr">340</xref>]. A hepatitis E virus (HEV) VLP vaccine Hecolin&#174; primarily consists of hepatitis E capsid protein that self assembles into 20&#8211;30&#160;nm particles is prepared using a cost effective recombinant <italic toggle="yes">Escherichia coli</italic> expression system [<xref rid="bb1705" ref-type="bibr">341</xref>]. A recombinant HPV vaccine Cecolin&#174; is recently approved for marketing in China is also developed from <italic toggle="yes">Escherichia coli</italic> expression system [<xref rid="bb1710" ref-type="bibr">342</xref>]. Novavax is currently developing a VLP nanovaccine tINV against influenza H3N2 virus. A recombinant hemagglutinin (HA) trivalent nanoparticle influenza vaccine (tNIV) adjuvanted with Matrix-M, is produced using the Sf9 insect cells and recombinant baculovirus platformt. In Phase 1/2 clinical trial with 330 adults (greater than 60&#160;years of age), tNIV induced robust neutralizing antibody response against three different influenza H3N2 virus strains [<xref rid="bb1715" ref-type="bibr">343</xref>].</p><p id="p0215">Several VLP nanovaccines have been tested preclinically against betacoronaviruses. MERS-CoV VLP vaccine was prepared by assembeling viral S protein on the surface of nanoparticles (100-200&#160;nm) secreted from the BM5 insect cells that co-express viral E and N proteins using mechanical extrusion. The resulting VLPs express all the viral components, S, E and N proteins, and able to bind human dipeptidyl peptidase 4 (DPP4) which is the target receptor for MERS-CoV host entry [<xref rid="bb1720" ref-type="bibr">344</xref>]. In another study, a chimeric VLP nanovaccine was produced by co-expressing MERS-CoV RBD and canine parvovirus (CPV) VP2 structural proteins on the surface of self-assembling spherical virus particles (~25&#160;nm) produced from recombinant baculoviruses expression system. The VLPs have structural morphology with CPV virions and their immunization in mice produced RBD-specifc neutralizing antibodes and elicited Th1 and Th2 mediated immune responses against MERS-CoV infection [<xref rid="bb1725" ref-type="bibr">345</xref>]. A recombinant SARS-CoV VLP nanovaccine containing both the SARS-CoV S and influenza M1 proteins produced using the baculovirus Sf6 insect cell expression system was shown to elicit an immune response in mice with a reduction in lung virus titers to below detectable levels when administered intramuscularly or intranasally [<xref rid="bb1730" ref-type="bibr">346</xref>]. A VLP vaccine co-expressing the SARS-CoV S protein along with E, M, and N proteins of the mouse hepatitis virus produced from the mammalian CHO cells was found to protect mice from the SARS-CoV challenge by triggering the release of neutralizing antibodies that are responsible for viral suppression in the lungs [<xref rid="bb1735" ref-type="bibr">347</xref>]. Several VLP vaccines are currently under development as a potential treatment of COVID-19. Medicago Inc. (Quebec, Canada) announced Phase 1 clinical trial of a recombinant coronavirus like particle COVID-19 vaccine (CoVLP) (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="ClinicalTrials.gov" xlink:href="NCT04450004" id="ir0330">NCT04450004</ext-link>). The company uses VLPs that are derived from an innovative plant-based production platform. They use plants as mini-factories, which produce proteins that self-assemble into the VLPs. The Phase 1 clinical study is intended to assess the safety, tolerability, and immunogenicity of CoVLP in 180 healthy adults of 18&#8211;55&#160;years of age. CoVLP vaccine will be administered at three dose levels (3.75&#160;&#956;g, 7.5&#160;&#956;g, and 15&#160;&#956;g), unadjuvanted or adjuvanted with either CpG 1018 or AS03 [<xref rid="bb1740" ref-type="bibr">348</xref>]. In preclinical testing, CoVLP vaccine induced high SARS-CoV-2 nutralizing antibody titers after a single adjuvanted dose [<xref rid="bb1745" ref-type="bibr">349</xref>,<xref rid="bb1750" ref-type="bibr">350</xref>]. Fudan University and Shanghai Jiao Tong University in china are developing COVID-19 VLP vaccine (RQ3013-VLP) that encodes mRNA of three SARS-CoV-2 structural proteins, S, M and E using the HEK293A cell platform. A single intramuscular dose of RQ3013-VLP in mice delivered 6&#160;&#956;g of S, 2.5&#160;&#956;g of M, and 1.5&#160;&#956;g of E mRNAs which induced higher S-protein specific binding antibodies and neutralizing antibodies and stronger CD4 and CD8 immune responses compared to the RQ3012-Spike vaccine which encodes SARS-CoV-2 S protein mRNA into the lipid nanoparticles. These results suggest VLP technology as a better platform for mRNA vaccine development compared to the traditional lipid nanoparticle formulation [<xref rid="bb1755" ref-type="bibr">351</xref>]. Although, the VLPs display repetative structures of the pathogen-derived epitopes, viral epitope sequences may not be sufficient immunogenic to elicit strong immune responses. Therefore, to increase the viral epitope density on the VLP surface, self-assembling protomers are employed during VLP production. University of Briston in collaboration with Imophoron Ltd. has developed ADDomer VLP platform which generates adenovirus-derived multimeric protein-based self-assembling VLPs to display multiple immunogenic epitopes from pathogens. First ADDomer VLP vaccine was developed against Chikungunya infectious disease and now researchers are developing COVID-19 vaccine using this technology [<xref rid="bb1760" ref-type="bibr">352</xref>,<xref rid="bb1765" ref-type="bibr">353</xref>].</p></sec><sec id="s0095"><label>9</label><title>Current SARS-CoV-2 vaccines</title><p id="p0220">A year has passed since the WHO declared a global pandemic for SARS-CoV-2. The pandemic has changed a normal way of life on an international scale. This is true in both developing and developed countries and sped by the lack of preparedness. The healthcare ramifications will persist beyond the period of infection. Clinical research into treating patients infected with COVID-19 and limiting the transmission of the disease is of immediate importance. Host immune response to SARS-CoV-2 determines the pathogenesis and subsequent clinical implications of the disease, and understanding such immune effects will be critical to intervention. Before a proficient vaccine or a targeted drug is approved for use, the management of host SARS-CoV-2 immune response serves as a only viable clinical option. One of the primary aspects of such a plan is to manage the inflammatory response of the infection, especially in regards to the release of proinflammatory cytokines. [<xref rid="bb0100" ref-type="bibr">20</xref>,<xref rid="bb1770" ref-type="bibr">354</xref>]. Currently, different antiviral agents and immunomodulatory therapies are used for COVID-19-associated complications but with limited efficacy. To induce passive immunity, convalescent plasma, neutralizing antibodies, and MSCs are employed in clinics. Radiation and gene-editing technologies are under development [<xref rid="bb0025" ref-type="bibr">5</xref>,<xref rid="bb0110" ref-type="bibr">22</xref>]. In order to achieve herd immunity and eliminate COVID-19, development of successful vaccines against SARS-CoV-2 using various technologies is highly desirable and certainly worth intensive consideration (<xref rid="f0030" ref-type="fig">Fig. 6</xref>
). Due to viral mutation frequencies and successive infection waves, multiple doses of SARS-CoV-2 vaccine may be necessary for prevention. Theoretically, the next two years could be vital for the elimination of SARS-CoV-2 through vaccination, as SARS-CoV-2 presumably would not have diversified into distinct lineages within this period. Thus, one vaccine strain or antigen can possibly match all lineages of SARS-CoV-2 that circulate worldwide within this timeline. Simultaneously, establishment of the natural herd immunity over the time would aid in eliminating COVID-19 disease [<xref rid="bb1775" ref-type="bibr">355</xref>].<fig id="f0030" position="float" orientation="portrait"><label>Fig. 6</label><caption><p><bold>Treatments for COVID-19</bold>. Currently, repurposed and recently approved antiviral agents are used to suppress COVID-19 disease complications that include the signs and symptoms of ARDS. A number of immunotherapies are being used and are currently being tested in randomized clinical trials of COVID-19. Vaccines are the principal challenge for SARS-CoV-2 to achieve herd immunity and eliminate SARS-CoV-2 infection and its consequences. Passive immunity can be achieved by convalescent plasma or neutralizing antibodies from recovered COVID-19 patients. Additionally, radiation and CRISPR based genome editing technologies are under development for the SARS-CoV-2 elimination.</p></caption><alt-text id="al0030">Fig. 6</alt-text><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="gr6_lrg.jpg"/></fig></p><p id="p0225">The use of a vaccine in at-risk populations is regarded as the safest option, though despite there being a plethora of vaccines in clinical development Phases, no vaccine has yet to achieve full US FDA approval [<xref rid="bb0060" ref-type="bibr">12</xref>]. Such a vaccine would protect at-risk individuals as well as curb the transmission of disease.</p><p id="p0230">Beyond the challenges of vaccine development and delivery, each vaccine requires rigorous testing to not only prove its' efficacy, but also to demonstrate its safety across mixed population. The WHO's criteria for vaccine prospects in Phase 2b/3 trials includes the vaccine's safety profile, potential for efficacy, stability, implementation, and availability. The specific criteria presented also revealed limitations and strengths of the different vaccines [<xref rid="bb0050" ref-type="bibr">10</xref>,<xref rid="bb0060" ref-type="bibr">12</xref>]. The global nature of the pandemic and the disease's transmission are pushing such criteria to a more rigorous standard including, if at all possible, a single booster dose vaccination. The dosage will be critical as it will need to be potent enough to provide immune system priming, and thus control any viral infection. Yet the vaccine's dosage must accommodate the global population with minimal-to-no deleterious effects. Finally, the stability of the vaccine must be robust to handle different environments and temperatures without losing efficacy. Different trials are ongoing using a broad array of vaccines, each with their respective strengths and weaknesses [<xref rid="bb0075" ref-type="bibr">15</xref>,<xref rid="bb0080" ref-type="bibr">16</xref>].</p><p id="p0235">Currently, approximately 120 candidates are under development using different technologies, some of which have not been used as a licensed-vaccine before. The approaches being used include the use of nucleic acids (DNA or RNA), inactivated or live attenuated virus, viral vectors, and recombinant proteins or VLPs [<xref rid="bb0080" ref-type="bibr">16</xref>,<xref rid="bb0580" ref-type="bibr">116</xref>]. Different vaccine candidates being developed using said technologies are summarized in <xref rid="t0005" ref-type="table">Table 1</xref>
. Challenges to develop an effective vaccine consist of technical barriers, such as the choice of proteins or domains that would provoke more protective antibodies, prior exposure to other viruses which impairs immunogenicity in the viral vector vaccine, need for an adjuvant, effectiveness in elderly patients, feasibility of large-scale production, regulation (e.g., ensuring safety and effectiveness), and legal barriers and issues (e.g., technology transfer and licensing agreements) including the potential duration of immunity as well as the number of vaccine doses needed to confer immunity. Other approaches for prevention are also emerging, which include hyperimmune globulin, monoclonal antibodies, and convalescent plasma. If they prove to be effective, these approaches could be used in high-risk individuals, including health care workers and older adults [<xref rid="bb0050" ref-type="bibr">10</xref>,<xref rid="bb0590" ref-type="bibr">118</xref>]. Regeneron's anti-SARS-CoV-2 antibody cocktail has already received EUA from the US FDA [<xref rid="bb0330" ref-type="bibr">66</xref>].<table-wrap position="float" id="t0005" orientation="portrait"><label>Table 1</label><caption><p>SARS-CoV-2 vaccine candidates [<xref rid="bb0055" ref-type="bibr">11</xref>,<xref rid="bb0060" ref-type="bibr">12</xref>].</p></caption><alt-text id="al0035">Table 1</alt-text><table frame="hsides" rules="groups"><thead><tr><th align="center" colspan="1" rowspan="1">#</th><th align="center" colspan="1" rowspan="1">Vector</th><th align="center" colspan="1" rowspan="1">Organizations</th><th align="center" colspan="1" rowspan="1">Formulation candidate</th><th align="center" colspan="1" rowspan="1">Trial phase</th></tr></thead><tbody><tr><td rowspan="16" colspan="1"><bold>1</bold></td><td rowspan="16" colspan="1"><bold>Viral</bold></td><td colspan="1" rowspan="1">Johnson &amp; Johnson, Janssen Pharmaceutical Companies + Beth Israel Deaconess Medical Center (Harvard Medical School), Emergent BioSolutions, Catalent<hr/></td><td colspan="1" rowspan="1">Ad26 (alone or with MVA boost)<hr/></td><td align="left" colspan="1" rowspan="1">Phase 1 (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="ClinicalTrials.gov" xlink:href="NCT04509947" id="ir0005">NCT04509947</ext-link>)<break/>Phase 1&#8211;2 (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="ClinicalTrials.gov" xlink:href="NCT04436276" id="ir0010">NCT04436276</ext-link>)<break/>Phase 2 (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="ClinicalTrials.gov" xlink:href="NCT04535453" id="ir0015">NCT04535453</ext-link>)<break/>Phase 3 (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="ClinicalTrials.gov" xlink:href="NCT04505722" id="ir0020">NCT04505722</ext-link>)<break/>Phase 3 (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="ClinicalTrials.gov" xlink:href="NCT04614948" id="ir0025">NCT04614948</ext-link>)<break/>Name: AdVac&#174;Ad26.COV2-S<hr/></td></tr><tr><td colspan="1" rowspan="1">Geovax Labs and BravoVax<hr/></td><td colspan="1" rowspan="1">MVA encoded<break/>VLP<hr/></td><td align="left" colspan="1" rowspan="1">Pre-Clinical<break/>Name: GV-MVA-VLP&#8482;<hr/></td></tr><tr><td colspan="1" rowspan="1">Jenner Institute (University of Oxford)&#160;+&#160;Cobra Biologics + Oxford Biomedica + Merck KGaA + Halix BV&#160;+&#160;Pall Corporation + SGS&#160;+&#160;India's Serum Institute + AstraZeneca + Catalent Biologics and CSL Limited<break/>[<xref rid="bb0090" ref-type="bibr">18</xref>]<hr/></td><td colspan="1" rowspan="1">AZD 1222<hr/></td><td align="left" colspan="1" rowspan="1">Phase 1/2 (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="ClinicalTrials.gov" xlink:href="NCT04324606" id="ir0030">NCT04324606</ext-link>, not yet recruiting)<break/>Phase 1&#8211;2 (UK) (2020&#8211;001072-15)<break/>Phase 1&#8211;2 (South Africa) (PACTR202006922165132)<break/>Phase 1&#8211;2 (Japan) (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="ClinicalTrials.gov" xlink:href="NCT04568031" id="ir0035">NCT04568031</ext-link>, Active, not recruiting)<break/>Phase 2b-3 (UK) (2020&#8211;001228-32)<break/>Phase 3 (Brazil) ISRCTN89951424<break/>Phase 3 (USA) <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="ClinicalTrials.gov" xlink:href="NCT04516746" id="ir0040">NCT04516746</ext-link><break/>Phase 3 (India) CTRI/2020/08/027170<hr/></td></tr><tr><td colspan="1" rowspan="1">Tonix Pharmaceuticals and Southern Research<hr/></td><td colspan="1" rowspan="1">Horsepox<break/>vector<break/>expressing S<break/>protein<hr/></td><td align="left" colspan="1" rowspan="1">Pre-Clinical<break/>Name: TNX-1800<hr/></td></tr><tr><td colspan="1" rowspan="1">Altimmune + University of Alabama + DynPort Vaccine Company<hr/></td><td colspan="1" rowspan="1">Adenovirus based NasoVAX expressing SARS2-CoV spike protein<hr/></td><td align="left" colspan="1" rowspan="1">Pre-Clinical<break/>Name: AdCOVID&#8482; and T-COVID&#8482;<hr/></td></tr><tr><td colspan="1" rowspan="1">Greffex<hr/></td><td colspan="1" rowspan="1">Ad5 S (GREVAX&#8482; platform)<hr/></td><td align="left" colspan="1" rowspan="1">Pre-Clinical<break/>Name: GreVac&#8482;<hr/></td></tr><tr><td colspan="1" rowspan="1">Vaxart + emergent BioSolutions + KindredBio<hr/></td><td colspan="1" rowspan="1">VAAST Oral Vaccine platform<hr/></td><td align="left" colspan="1" rowspan="1">Phase 1 <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="ClinicalTrials.gov" xlink:href="NCT04563702" id="ir0045">NCT04563702</ext-link><hr/></td></tr><tr><td colspan="1" rowspan="1">Gamaleya Research Institute<hr/></td><td colspan="1" rowspan="1">Adeno-based &#8211; sputnik V<hr/></td><td align="left" colspan="1" rowspan="1">Phase 1 (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="ClinicalTrials.gov" xlink:href="NCT04436471" id="ir0050">NCT04436471</ext-link>, <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="ClinicalTrials.gov" xlink:href="NCT04437875" id="ir0055">NCT04437875</ext-link>)<break/>Phase 2 <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="ClinicalTrials.gov" xlink:href="NCT04587219" id="ir0060">NCT04587219</ext-link><break/>Phase 2&#8211;3 <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="ClinicalTrials.gov" xlink:href="NCT04640233" id="ir0065">NCT04640233</ext-link> (Not yet recruiting)<break/>Phase 3 (Belarus) <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="ClinicalTrials.gov" xlink:href="NCT04564716" id="ir0070">NCT04564716</ext-link> (Not yet recruiting)<break/>Phase 3 (Russia) <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="ClinicalTrials.gov" xlink:href="NCT04530396" id="ir0075">NCT04530396</ext-link><break/>Phase 3 (Vnezuela) <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="ClinicalTrials.gov" xlink:href="NCT04642339" id="ir0080">NCT04642339</ext-link> (Not yet recruiting)<hr/></td></tr><tr><td colspan="1" rowspan="1">CanSino Biologics + Beijing Institute of BioTech + Canadian Center for Vaccinology at Dalhousie University + Precision NanoSystems + Petrovax<break/>[<xref rid="bb0940" ref-type="bibr">188</xref>,<xref rid="bb0945" ref-type="bibr">189</xref>]<hr/></td><td colspan="1" rowspan="1">Adenovirus Type 5 Vector<hr/></td><td colspan="1" rowspan="1">Phase 1 (ChiCTR2000030906)<break/>Phase 2 (ChiCTR2000031781)<break/>Phase 1 <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="ClinicalTrials.gov" xlink:href="NCT04568811" id="ir0085">NCT04568811</ext-link><break/>Phase 2 <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="ClinicalTrials.gov" xlink:href="NCT04566770" id="ir0090">NCT04566770</ext-link><break/>Phase 3 <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="ClinicalTrials.gov" xlink:href="NCT04526990" id="ir0095">NCT04526990</ext-link><break/>Phase 3 <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="ClinicalTrials.gov" xlink:href="NCT04540419" id="ir0100">NCT04540419</ext-link><hr/></td></tr><tr><td colspan="1" rowspan="1">Zydus Cadila Healthcare Ltd.<hr/></td><td colspan="1" rowspan="1">DNA plasmid vaccine + Adjuvant<hr/></td><td colspan="1" rowspan="1">Phase 1&#8211;2 (CTRI/2020/07/026352)<hr/></td></tr><tr><td colspan="1" rowspan="1">Institut Pasteur + Themis + University of Pittsburgh + Merck<hr/></td><td colspan="1" rowspan="1">Measles Vector<hr/></td><td colspan="1" rowspan="1">Phase 1 (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="ClinicalTrials.gov" xlink:href="NCT04497298" id="ir0105">NCT04497298</ext-link>)<hr/></td></tr><tr><td colspan="1" rowspan="1">ReiThera + Leukocare + Univercells<hr/></td><td colspan="1" rowspan="1">Replication defective Simian Adenovirus (GRAd) encoding SARSCoV-2&#160;S<hr/></td><td colspan="1" rowspan="1">Phase 1 <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="ClinicalTrials.gov" xlink:href="NCT04528641" id="ir0110">NCT04528641</ext-link><hr/></td></tr><tr><td colspan="1" rowspan="1">Centro Nacional Biotecnologia (CNB-CSIC), Spain<hr/></td><td colspan="1" rowspan="1">MVA expressing structural proteins<hr/></td><td colspan="1" rowspan="1">Pre-Clinical<hr/></td></tr><tr><td colspan="1" rowspan="1">University of Manitoba<hr/></td><td colspan="1" rowspan="1">Dendritic cellbased vaccine<hr/></td><td colspan="1" rowspan="1">Pre-Clinical<hr/></td></tr><tr><td colspan="1" rowspan="1">Bharat Biotech + Thomas Jefferson University<hr/></td><td colspan="1" rowspan="1">Recombinant deactivated rabies virus<hr/></td><td colspan="1" rowspan="1">Pre-Clinical<hr/></td></tr><tr><td colspan="1" rowspan="1">BiOCAD and IEM</td><td colspan="1" rowspan="1">Live viral vectored vaccine based on attenuated influenza virus backbone (intranasal)</td><td colspan="1" rowspan="1">Pre-Clinical</td></tr><tr><td rowspan="7" colspan="1"><bold>2</bold></td><td rowspan="7" colspan="1"><bold>DNA</bold><hr/></td><td colspan="1" rowspan="1">Inovio Pharmaceuticals + Beijing Advaccine Biotechnology + Ology Bioservices + VGXI + Richter-Helm + Thermo Fisher Scientific<hr/></td><td colspan="1" rowspan="1">INO-4800 DNA with electroporation<hr/></td><td colspan="1" rowspan="1">Phase 1 (USA) (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="ClinicalTrials.gov" xlink:href="NCT04336410" id="ir0115">NCT04336410</ext-link>)<break/>Phase 1&#8211;2 (South Korea) (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="ClinicalTrials.gov" xlink:href="NCT04447781" id="ir0120">NCT04447781</ext-link>)<break/>Phase 2&#8211;3 (USA) <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="ClinicalTrials.gov" xlink:href="NCT04642638" id="ir0125">NCT04642638</ext-link><hr/></td></tr><tr><td colspan="5" rowspan="1"><hr/></td></tr><tr><td colspan="1" rowspan="1">Osaka University + AnGes + Takara Bio&#160;+&#160;Cytiva + Brickell Biotech<hr/></td><td colspan="1" rowspan="1">DNA Plasmid<hr/></td><td colspan="1" rowspan="1">Phase 1&#8211;2 (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="ClinicalTrials.gov" xlink:href="NCT04463472" id="ir0130">NCT04463472</ext-link>)<break/>JapicCTI-205,328<break/>Title: AG0301-COVID19<break/>Phase 1&#8211;2 <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="ClinicalTrials.gov" xlink:href="NCT04527081" id="ir0135">NCT04527081</ext-link><hr/></td></tr><tr><td colspan="1" rowspan="1">Applied DNA Sciences + Takis Biotech + Evvivax<hr/></td><td colspan="1" rowspan="1">Linear DNA<hr/></td><td colspan="1" rowspan="1">Pre-Clinical<hr/></td></tr><tr><td colspan="1" rowspan="1">Zydus Cadila<hr/></td><td colspan="1" rowspan="1">DNA plasmid vaccine<hr/></td><td colspan="1" rowspan="1">Phase 1&#8211;2 (CTRI/2020/07/026352)<hr/></td></tr><tr><td colspan="1" rowspan="1">Genexine Inc. + Binex + GenNBio + International Vaccine Institute + Korea Advanced Institute of Science and Technology + Pohang University of Science and Technology + PT Kalbe Pharma<hr/></td><td colspan="1" rowspan="1">GX-19 DNA<hr/></td><td colspan="1" rowspan="1">Phase 1/2a (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="ClinicalTrials.gov" xlink:href="NCT04445389" id="ir0140">NCT04445389</ext-link>)<hr/></td></tr><tr><td colspan="1" rowspan="1">Symvivo + Nucleus Network<hr/></td><td colspan="1" rowspan="1">DNA BacTRL-Spike (oral)<hr/></td><td colspan="1" rowspan="1">Phase 1 (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="ClinicalTrials.gov" xlink:href="NCT04334980" id="ir0145">NCT04334980</ext-link>)<hr/></td></tr><tr><td colspan="1" rowspan="1">CureVac<hr/></td><td colspan="1" rowspan="1">mRNA<hr/></td><td colspan="1" rowspan="1">Phase 1 (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="ClinicalTrials.gov" xlink:href="NCT04449276" id="ir0150">NCT04449276</ext-link>)<break/>Phase 2 (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="ClinicalTrials.gov" xlink:href="NCT04515147" id="ir0155">NCT04515147</ext-link>)<hr/></td></tr><tr><td rowspan="8" colspan="1"><bold>3</bold><hr/></td><td rowspan="8" colspan="1"><bold>RNA</bold><hr/></td><td colspan="1" rowspan="1">Moderna + NIAID + Lonza + Catalent Inc. + BIOQUAL<break/>[<xref rid="bb1460" ref-type="bibr">292</xref>]<hr/></td><td colspan="1" rowspan="1">mRNA-1273 LNPencapsulated mRNA<hr/></td><td colspan="1" rowspan="1">Phase 1 (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="ClinicalTrials.gov" xlink:href="NCT04283461" id="ir0160">NCT04283461</ext-link>)<break/>Phase 2 (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="ClinicalTrials.gov" xlink:href="NCT04405076" id="ir0165">NCT04405076</ext-link>)<break/>Phase 3 (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="ClinicalTrials.gov" xlink:href="NCT04470427" id="ir0170">NCT04470427</ext-link>)<hr/></td></tr><tr><td colspan="1" rowspan="1">BioNTech + Pfizer + Fosun Pharma + University of Rochester Medical Center (URMC)&#160;+&#160;Rochester Regional Health (RRH)<break/>[<xref rid="bb1785" ref-type="bibr">357</xref>]<hr/></td><td colspan="1" rowspan="1">mRna BNT162b2<hr/></td><td colspan="1" rowspan="1">Phase 1&#8211;2 (UTRN U1111-1249-4220)<break/>Phase 1&#8211;2 (Germany) <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="ClinicalTrials.gov" xlink:href="NCT04537949" id="ir0175">NCT04537949</ext-link><break/>EudraCT Number (Germany) (2020&#8211;001038-36)<break/>Phase 2&#8211;3 (USA) (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="ClinicalTrials.gov" xlink:href="NCT04368728" id="ir0180">NCT04368728</ext-link>)<break/>Phase 1&#8211;2 (ChiCTR2000034825)<break/>Phase 1 (Japan) <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="ClinicalTrials.gov" xlink:href="NCT04588480" id="ir0185">NCT04588480</ext-link><hr/></td></tr><tr><td colspan="1" rowspan="1">Tongji University and Chinese Center for Disease Control and Prevention + Stemirna Therapeutics<hr/></td><td colspan="1" rowspan="1">mRNA<hr/></td><td colspan="1" rowspan="1">Pre-Clinical<hr/></td></tr><tr><td colspan="1" rowspan="1">Imperial College London<hr/></td><td colspan="1" rowspan="1">saRNA<hr/></td><td colspan="1" rowspan="1">Phase 1 (ISRCTN17072692)<hr/></td></tr><tr><td colspan="1" rowspan="1">Codagenix + Serum Institute of India<hr/></td><td colspan="1" rowspan="1">Codon deoptimized live attenuated<hr/></td><td colspan="1" rowspan="1">Phase 1 <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="ClinicalTrials.gov" xlink:href="NCT04619628" id="ir0190">NCT04619628</ext-link><hr/></td></tr><tr><td colspan="1" rowspan="1">Arcturus Therapeutics + Duke-NUS<hr/></td><td colspan="1" rowspan="1">mRNA Lunar-Cov19<hr/></td><td colspan="1" rowspan="1">Phase 1&#8211;2 (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="ClinicalTrials.gov" xlink:href="NCT04480957" id="ir0195">NCT04480957</ext-link>)<hr/></td></tr><tr><td colspan="1" rowspan="1">People's Liberation Army Academy of Military Sciences + Walvax Biotech<hr/></td><td colspan="1" rowspan="1">mRNA<hr/></td><td colspan="1" rowspan="1">Phase 1 (ChiCTR2000034112)<hr/></td></tr><tr><td colspan="1" rowspan="1">Sanofi Pasteur + Translate Bio<hr/></td><td colspan="1" rowspan="1">mRNA<hr/></td><td colspan="1" rowspan="1">Pre-Clinical<hr/></td></tr><tr><td rowspan="3" colspan="1"><bold>4</bold><hr/></td><td rowspan="3" colspan="1"><bold>Live</bold><hr/></td><td colspan="1" rowspan="1">German Center for Infection Research (DZIF)&#160;+&#160;CanVirex AG<hr/></td><td colspan="1" rowspan="1">Measles Virus (S, N targets)<hr/></td><td colspan="1" rowspan="1">Pre-Clinical<hr/></td></tr><tr><td colspan="1" rowspan="1">German Center for Infection Research (DZIF)&#160;+&#160;Ludwig-Maximilians University of Munich + IDT Biologika GmbH + Universit&#228;tsklinikum Hamburg-Eppendorf + Philipps University Marburg Medical Center<hr/></td><td colspan="1" rowspan="1">MVA-S-encoded<hr/></td><td colspan="1" rowspan="1">Phase 1 <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="ClinicalTrials.gov" xlink:href="NCT04569383" id="ir0200">NCT04569383</ext-link><hr/></td></tr><tr><td colspan="1" rowspan="1">Novavax + Emergent BioSolutions + FUJIFILM Diosynth Biotechnologies + Serum Institute of India<hr/></td><td colspan="1" rowspan="1">NVX-CoV2373 Recombinant glycopreotein<hr/></td><td colspan="1" rowspan="1">Phase 1 (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="ClinicalTrials.gov" xlink:href="NCT04368988" id="ir0205">NCT04368988</ext-link>)<break/>Phase 2 (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="ClinicalTrials.gov" xlink:href="NCT04533399" id="ir0210">NCT04533399</ext-link>)<break/>Phase 3 (UK) (2020&#8211;004123-16)<break/>Phase 3 (USA/Mexico) <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="ClinicalTrials.gov" xlink:href="NCT04611802" id="ir0215">NCT04611802</ext-link><hr/></td></tr><tr><td rowspan="7" colspan="1"><bold>5</bold></td><td rowspan="7" colspan="1"><bold>Protein</bold></td><td colspan="1" rowspan="1">Clover Biopharmaceuticals + GSK&#160;+&#160;Dynavax<hr/></td><td colspan="1" rowspan="1">Native like Trimeric subunit Spike Protein<hr/></td><td colspan="1" rowspan="1">Phase 1 (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="ClinicalTrials.gov" xlink:href="NCT04405908" id="ir0220">NCT04405908</ext-link>)<hr/></td></tr><tr><td colspan="1" rowspan="1">Baylor College of Medicine + Texa Children's Hospital + PATH<hr/></td><td colspan="1" rowspan="1">S1 or RBD protein<hr/></td><td colspan="1" rowspan="1">Pre-Clinical<hr/></td></tr><tr><td colspan="1" rowspan="1">Fudan University + Shanghai JiaoTong University + RNACure Biopharma<hr/></td><td colspan="1" rowspan="1">LNP encapsulated mRNA cocktail encoding RBD<hr/></td><td colspan="1" rowspan="1">Pre-Clinical<hr/></td></tr><tr><td colspan="1" rowspan="1">VIDO-InterVac + University of Saskatchewan, Canada<hr/></td><td colspan="1" rowspan="1">Adjuvanted microsphere peptide<hr/></td><td colspan="1" rowspan="1">Pre-Clinical<hr/></td></tr><tr><td colspan="1" rowspan="1">University of Queensland, Australia + Dynavax + GSK&#160;+&#160;Viroclinics Xplore + CSL Limited<hr/></td><td colspan="1" rowspan="1">Molecular clamp stabilized Spike protein<hr/></td><td colspan="1" rowspan="1">Phase 1 (ACTRN12620000674932)<break/>Phase 1 (ISRCTN51232965)<hr/></td></tr><tr><td colspan="1" rowspan="1">Vaxart + Emergent BioSolutions + KindredBio<hr/></td><td colspan="1" rowspan="1">VAAST Oral Vaccine platform<hr/></td><td colspan="1" rowspan="1">Phase 1 (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="ClinicalTrials.gov" xlink:href="NCT04563702" id="ir0225">NCT04563702</ext-link>)<hr/></td></tr><tr><td colspan="1" rowspan="1">Generex/ EpiVax</td><td colspan="1" rowspan="1">Ii-Key peptide</td><td colspan="1" rowspan="1">Pre-Clinical</td></tr><tr><td rowspan="6" colspan="1"><hr/></td><td rowspan="6" colspan="1"><hr/></td><td colspan="1" rowspan="1">ExpreS2ion<hr/></td><td colspan="1" rowspan="1">Drosophila S2 insect cell expression system VLPs<hr/></td><td colspan="1" rowspan="1">Pre-Clinical<hr/></td></tr><tr><td colspan="1" rowspan="1">Vaxil Bio<hr/></td><td colspan="1" rowspan="1">Peptide<hr/></td><td colspan="1" rowspan="1">Pre-Clinical<hr/></td></tr><tr><td colspan="1" rowspan="1">Sanofi Pasteur + GSK<hr/></td><td colspan="1" rowspan="1">S protein (baculovirus production)<hr/></td><td colspan="1" rowspan="1">Phase 1&#8211;2 (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="ClinicalTrials.gov" xlink:href="NCT04537208" id="ir0230">NCT04537208</ext-link>)<hr/></td></tr><tr><td colspan="1" rowspan="1">iBio/CC-Pharming<hr/></td><td colspan="1" rowspan="1">Subunit protein, plant produced<hr/></td><td colspan="1" rowspan="1">Pre-Clinical<hr/></td></tr><tr><td colspan="1" rowspan="1">Saiba + University of Bern<hr/></td><td colspan="1" rowspan="1">RBD displayed on virus-like particles<hr/></td><td colspan="1" rowspan="1">Pre-Clinical<hr/></td></tr><tr><td colspan="1" rowspan="1">Covaxx + university of Nebraska Medical Center (UNMC)&#160;+&#160;DASA<hr/></td><td colspan="1" rowspan="1">Multitope Peptide-Based Vaccine (MVP)<hr/></td><td colspan="1" rowspan="1">Phase 1 (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="ClinicalTrials.gov" xlink:href="NCT04545749" id="ir0235">NCT04545749</ext-link>)<hr/></td></tr><tr><td rowspan="3" colspan="1"><bold>6</bold><hr/></td><td rowspan="3" colspan="1"><bold>VLP</bold><hr/></td><td colspan="1" rowspan="1">Imophoron + Bristol University<hr/></td><td colspan="1" rowspan="1">VLP ADDomerTM multiepitope display<hr/></td><td colspan="1" rowspan="1">Pre-Clinical<hr/></td></tr><tr><td colspan="1" rowspan="1">Fundan University + Shanghai JiaoTong University + RNACure Biopharma<hr/></td><td colspan="1" rowspan="1">LNP encapsulated mRNA cocktail encoding VLP<hr/></td><td colspan="1" rowspan="1">Pre-Clinical<hr/></td></tr><tr><td colspan="1" rowspan="1">Medicago Inc.<hr/></td><td colspan="1" rowspan="1">Plant-derived VLP<hr/></td><td colspan="1" rowspan="1">Phase 1 (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="ClinicalTrials.gov" xlink:href="NCT04450004" id="ir0240">NCT04450004</ext-link>)<break/>Phase 2&#8211;3 (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="ClinicalTrials.gov" xlink:href="NCT04636697" id="ir0245">NCT04636697</ext-link>)<hr/></td></tr><tr><td rowspan="4" colspan="1"><bold>7</bold><hr/></td><td rowspan="4" colspan="1"><bold>Inactivated or Attenuated</bold><hr/></td><td colspan="1" rowspan="1">Beijing Institute of BioProducts (Sinopharm)&#160;+&#160;Chinese Center for Disease Control and Prevention<hr/></td><td colspan="1" rowspan="1">Inactivated<hr/></td><td colspan="1" rowspan="1">Phase 1&#8211;2 (ChiCTR2000032459) Phase 3 (ChiCTR2000034780)<hr/></td></tr><tr><td colspan="1" rowspan="1">Wuhan Institute of Biological Products/Sinopharm<break/>[<xref rid="bb0700" ref-type="bibr">140</xref>]<hr/></td><td colspan="1" rowspan="1">Inactivated<hr/></td><td colspan="1" rowspan="1">Phase 1&#8211;2 (ChiCTR2000031809)<break/>Phase 3 (ChiCTR2000034780)<break/>Phase 3 (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="ClinicalTrials.gov" xlink:href="NCT04560881" id="ir0250">NCT04560881</ext-link>)<hr/></td></tr><tr><td colspan="1" rowspan="1">Institute of Medical Biology + Chinese Academy of Medical Sciences<hr/></td><td colspan="1" rowspan="1">Inactivated<hr/></td><td colspan="1" rowspan="1">Phase 1 (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="ClinicalTrials.gov" xlink:href="NCT04412538" id="ir0255">NCT04412538</ext-link>)<break/>Phase 1&#8211;2 (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="ClinicalTrials.gov" xlink:href="NCT04470609" id="ir0260">NCT04470609</ext-link>)<hr/></td></tr><tr><td colspan="1" rowspan="1">Sinovac + Instituto Butatan<hr/></td><td colspan="1" rowspan="1">Inactivated + alum CoronaVac<hr/></td><td colspan="1" rowspan="1">Phase 1&#8211;2 (Jiangsu) (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="ClinicalTrials.gov" xlink:href="NCT04352608" id="ir0265">NCT04352608</ext-link>)<break/>Phase 1&#8211;2 (Hebei)<break/>(<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="ClinicalTrials.gov" xlink:href="NCT04383574" id="ir0270">NCT04383574</ext-link>)<break/>Phase 1&#8211;2 (Hebei children) (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="ClinicalTrials.gov" xlink:href="NCT04551547" id="ir0275">NCT04551547</ext-link>)<break/>Phase 3 (Brazil)<break/>(<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="ClinicalTrials.gov" xlink:href="NCT04456595" id="ir0280">NCT04456595</ext-link>)<break/>Phase 3 (Turkey) (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="ClinicalTrials.gov" xlink:href="NCT04582344" id="ir0285">NCT04582344</ext-link>)<break/>Phase 3 (Indonesia)<break/>(669/UN6.KEP/EC/2020)<break/>Phase 3 (China) (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="ClinicalTrials.gov" xlink:href="NCT04617483" id="ir0290">NCT04617483</ext-link>)<hr/></td></tr><tr><td rowspan="2" colspan="1"><bold>8</bold></td><td rowspan="2" colspan="1"><bold>Uncatorgized</bold></td><td colspan="1" rowspan="1">Shenzhen GenoImmune Medical Institute<hr/></td><td colspan="1" rowspan="1">Pathogen-specific aAPC<hr/></td><td colspan="1" rowspan="1">Phase 1 (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="ClinicalTrials.gov" xlink:href="NCT04299724" id="ir0295">NCT04299724</ext-link>)<hr/></td></tr><tr><td colspan="1" rowspan="1">Shenzhen GenoImmune Medical Institute</td><td colspan="1" rowspan="1">LV-SMENP-DC</td><td colspan="1" rowspan="1">Phase 1 (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="ClinicalTrials.gov" xlink:href="NCT04276896" id="ir0300">NCT04276896</ext-link>)</td></tr></tbody></table></table-wrap></p><p id="p0240">According to the WHO [<xref rid="bb0060" ref-type="bibr">12</xref>], more than thirty vaccine candidates are in Phase 2/3 clinical trials, two are approved in UK, USA, UAE, and Canada, as of December 15, 2020. From different clinical trial candidates, Sinovac, Wuhan Institute, and Beijing Institute are using the inactivated virus as their platforms. Moderna and Pfizer/BioNTech are using mRNA-based platforms, while Oxford University is using its proprietary nonreplicating chimpanzee adenovirus platform. CanSino Biologics Inc. is using a nonreplicating adenovirus type 5 vector platform, while Anhui Zhifel Longcom Biopharmaceutical is using a protein subunit platform. All of them intend to use intramuscular injection as the route of administration. Codiak BioSciences Inc. collaborated with Ragon Institute is investigating the exosome-based vaccine. With all the COVID-19 vaccine candidates, induction of robust neutralizing antibodies and antigen-specific T cell responses in the lung and other mucosal surfaces are expected for complete elimination of SARS-CoV-2 [<xref rid="bb1780" ref-type="bibr">356</xref>].</p></sec><sec id="s0100"><label>10</label><title>Summary</title><p id="p0245">Mass immunization through vaccination stands as the highest priority for control of the SARS-CoV-2 pandemic. Significant efforts are underway to complete this task and by the time of this publication, this goal will be on its ways toward a successful conclusion. Understandably, critical needs will remain and include how effective the chosen vaccine in the longer term and how to preclude adverse reactions. What underlies the immunological profiles for protective immunity and how long-lasting that immunity will be. Nonetheless, until these questions are addressed and a vaccine comes available parallel immune-based and pharmacological therapeutic options will be required to move forward with due diligence. While a many divergent vaccines and therapies are in the offering, full implementation is dependent on carefully-crafted clinical trial results and delivery. The bar to clear approvals for this task is high. Obstacles include product safety, efficacy, and robust sustained antiviral immune responses. The results of the ongoing vaccine efforts designed to eliminate SARS-CoV-2 infection will prove invaluable.</p></sec><sec sec-type="COI-statement"><title>Declaration of competing interest</title><p id="p5340">The authors declare no conflicts of interest.</p></sec></body><back><ref-list id="bi0005"><title>References</title><ref id="bb0005"><label>1</label><element-citation publication-type="journal" id="rf0005"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Guan</surname><given-names>X.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>P.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>X.</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>L.</given-names></name><etal/></person-group><article-title>Early transmission dynamics in Wuhan, China, of novel coronavirus-infected pneumonia</article-title><source>N. Engl. J. Med.</source><volume>382</volume><year>2020</year><fpage>1199</fpage><lpage>1207</lpage><pub-id pub-id-type="pmid">31995857</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1056/NEJMoa2001316</pub-id><pub-id pub-id-type="pmcid">PMC7121484</pub-id></element-citation></ref><ref id="bb0010"><label>2</label><element-citation publication-type="journal" id="rf0010"><issue-title>The species Severe acute respiratory syndrome-related coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2</issue-title><source>Nat. Microbiol.</source><volume>5</volume><year>2020</year><fpage>536</fpage><lpage>544</lpage><pub-id pub-id-type="pmid">32123347</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41564-020-0695-z</pub-id><pub-id pub-id-type="pmcid">PMC7095448</pub-id></element-citation></ref><ref id="bb0015"><label>3</label><element-citation publication-type="book" id="rf0015"><person-group person-group-type="author"><name name-style="western"><surname>World Health Organization</surname></name></person-group><part-title>Naming the coronavirus disease (COVID-19) and the virus that causes it</part-title><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.who.int/emergencies/diseases/novel-coronavirus-2019/technical-guidance/naming-the-coronavirus-disease-(covid-2019)-and-the-virus-that-causes-it" id="ir0335">https://www.who.int/emergencies/diseases/novel-coronavirus-2019/technical-guidance/naming-the-coronavirus-disease-(covid-2019)-and-the-virus-that-causes-it</ext-link><year>2020</year></element-citation></ref><ref id="bb0020"><label>4</label><element-citation publication-type="journal" id="rf0020"><person-group person-group-type="author"><name name-style="western"><surname>Lange</surname><given-names>S.J.</given-names></name><name name-style="western"><surname>Ritchey</surname><given-names>M.D.</given-names></name><name name-style="western"><surname>Goodman</surname><given-names>A.B.</given-names></name><name name-style="western"><surname>Dias</surname><given-names>T.</given-names></name><name name-style="western"><surname>Twentyman</surname><given-names>E.</given-names></name><etal/></person-group><article-title>Potential indirect effects of the COVID-19 pandemic on use of emergency departments for acute life-threatening conditions &#8212; United States</article-title><source>MMWR Morb. Mortal. Wkly Rep.</source><volume>69</volume><year>2020</year><fpage>795</fpage><lpage>800</lpage><pub-id pub-id-type="pmid">32584802</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.15585/mmwr.mm6925e2</pub-id><pub-id pub-id-type="pmcid">PMC7316316</pub-id></element-citation></ref><ref id="bb0025"><label>5</label><element-citation publication-type="journal" id="rf0025"><person-group person-group-type="author"><name name-style="western"><surname>Machhi</surname><given-names>J.</given-names></name><name name-style="western"><surname>Herskovitz</surname><given-names>J.</given-names></name><name name-style="western"><surname>Senan</surname><given-names>A.M.</given-names></name><name name-style="western"><surname>Dutta</surname><given-names>D.</given-names></name><name name-style="western"><surname>Nath</surname><given-names>B.</given-names></name><etal/></person-group><article-title>The natural history, pathobiology, and clinical manifestations of SARS-CoV-2 infections</article-title><source>J. NeuroImmune Pharmacol.</source><volume>15</volume><year>2020</year><fpage>359</fpage><lpage>386</lpage><pub-id pub-id-type="pmid">32696264</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s11481-020-09944-5</pub-id><pub-id pub-id-type="pmcid">PMC7373339</pub-id></element-citation></ref><ref id="bb0030"><label>6</label><element-citation publication-type="journal" id="rf0030"><person-group person-group-type="author"><name name-style="western"><surname>Sun</surname><given-names>X.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>T.</given-names></name><name name-style="western"><surname>Cai</surname><given-names>D.</given-names></name><name name-style="western"><surname>Hu</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>J.</given-names></name><name name-style="western"><surname>Liao</surname><given-names>H.</given-names></name><name name-style="western"><surname>Zhi</surname><given-names>L.</given-names></name><name name-style="western"><surname>Wei</surname><given-names>H.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Qiu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>J.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>A.</given-names></name></person-group><article-title>Cytokine storm intervention in the early stages of COVID-19 pneumonia</article-title><source>Cytokine Growth Factor Rev.</source><volume>53</volume><year>2020</year><fpage>38</fpage><lpage>42</lpage><pub-id pub-id-type="pmid">32360420</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.cytogfr.2020.04.002</pub-id><pub-id pub-id-type="pmcid">PMC7182527</pub-id></element-citation></ref><ref id="bb0035"><label>7</label><element-citation publication-type="journal" id="rf0035"><person-group person-group-type="author"><name name-style="western"><surname>Golonka</surname><given-names>R.M.</given-names></name><name name-style="western"><surname>Saha</surname><given-names>P.</given-names></name><name name-style="western"><surname>Yeoh</surname><given-names>B.S.</given-names></name><name name-style="western"><surname>Chattopadhyay</surname><given-names>S.</given-names></name><name name-style="western"><surname>Gewirtz</surname><given-names>A.T.</given-names></name><name name-style="western"><surname>Joe</surname><given-names>B.</given-names></name><name name-style="western"><surname>Vijay-Kumar</surname><given-names>M.</given-names></name></person-group><article-title>Harnessing innate immunity to eliminate SARS-CoV-2 and ameliorate COVID-19 disease</article-title><source>Physiol. Genomics</source><volume>52</volume><year>2020</year><fpage>217</fpage><lpage>221</lpage><pub-id pub-id-type="pmid">32275178</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1152/physiolgenomics.00033.2020</pub-id><pub-id pub-id-type="pmcid">PMC7200864</pub-id></element-citation></ref><ref id="bb0040"><label>8</label><element-citation publication-type="journal" id="rf0040"><person-group person-group-type="author"><name name-style="western"><surname>Blanco-Melo</surname><given-names>D.</given-names></name><name name-style="western"><surname>Nilsson-Payant</surname><given-names>B.E.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>W.C.</given-names></name><name name-style="western"><surname>Uhl</surname><given-names>S.</given-names></name><name name-style="western"><surname>Hoagland</surname><given-names>D.</given-names></name><etal/></person-group><article-title>Imbalanced host response to SARS-CoV-2 drives development of COVID-19</article-title><source>Cell</source><volume>181</volume><year>2020</year><fpage>1036</fpage><lpage>1045</lpage><comment>(e1039)</comment><pub-id pub-id-type="pmid">32416070</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.cell.2020.04.026</pub-id><pub-id pub-id-type="pmcid">PMC7227586</pub-id></element-citation></ref><ref id="bb0045"><label>9</label><element-citation publication-type="journal" id="rf0045"><person-group person-group-type="author"><name name-style="western"><surname>Yang</surname><given-names>L.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>S.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>J.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Wan</surname><given-names>X.</given-names></name><name name-style="western"><surname>Huang</surname><given-names>B.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Y.</given-names></name></person-group><article-title>COVID-19: immunopathogenesis and immunotherapeutics</article-title><source>Signal. Transduct. Target Ther.</source><volume>5</volume><year>2020</year><fpage>128</fpage><pub-id pub-id-type="pmid">32712629</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41392-020-00243-2</pub-id><pub-id pub-id-type="pmcid">PMC7381863</pub-id></element-citation></ref><ref id="bb0050"><label>10</label><element-citation publication-type="journal" id="rf0050"><person-group person-group-type="author"><name name-style="western"><surname>Amanat</surname><given-names>F.</given-names></name><name name-style="western"><surname>Krammer</surname><given-names>F.</given-names></name></person-group><article-title>SARS-CoV-2 vaccines: status report</article-title><source>Immunity</source><volume>52</volume><year>2020</year><fpage>583</fpage><lpage>589</lpage><pub-id pub-id-type="pmid">32259480</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.immuni.2020.03.007</pub-id><pub-id pub-id-type="pmcid">PMC7136867</pub-id></element-citation></ref><ref id="bb0055"><label>11</label><element-citation publication-type="other" id="rf0055"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://covidvax.org/" id="ir0340">https://covidvax.org/</ext-link></element-citation></ref><ref id="bb0060"><label>12</label><element-citation publication-type="book" id="rf0060"><person-group person-group-type="author"><name name-style="western"><surname>World Health Organization</surname></name></person-group><part-title>Draft landscape of COVID-19 candidate vaccines</part-title><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.who.int/publications/m/item/draft-landscape-of-covid-19-candidate-vaccines" id="ir0345">https://www.who.int/publications/m/item/draft-landscape-of-covid-19-candidate-vaccines</ext-link><year>2020</year></element-citation></ref><ref id="bb0065"><label>13</label><element-citation publication-type="other" id="rf0065"><person-group person-group-type="author"><name name-style="western"><surname>McKinsey &amp; Company</surname></name></person-group><article-title>On Pins and Needles: Will COVID-19 Vaccines &#8216;Save the World&#8217;?</article-title><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.mckinsey.com/industries/pharmaceuticals-and-medical-products/our-insights/on-pins-and-needles-will-covid-19-vaccines-save-the-world" id="ir0350">https://www.mckinsey.com/industries/pharmaceuticals-and-medical-products/our-insights/on-pins-and-needles-will-covid-19-vaccines-save-the-world</ext-link><year>2020</year></element-citation></ref><ref id="bb0070"><label>14</label><element-citation publication-type="other" id="rf0070"><person-group person-group-type="author"><name name-style="western"><surname>U.S. Food and Drug Administration</surname></name></person-group><article-title>FDA Takes Key Action in Fight Against COVID-19 By Issuing Emergency Use Authorization for First COVID-19 Vaccine</article-title><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.fda.gov/news-events/press-announcements/fda-takes-key-action-fight-against-covid-19-issuing-emergency-use-authorization-first-covid-19" id="ir0355">https://www.fda.gov/news-events/press-announcements/fda-takes-key-action-fight-against-covid-19-issuing-emergency-use-authorization-first-covid-19</ext-link><year>2020</year></element-citation></ref><ref id="bb0075"><label>15</label><element-citation publication-type="journal" id="rf0075"><person-group person-group-type="author"><name name-style="western"><surname>Corey</surname><given-names>L.</given-names></name><name name-style="western"><surname>Mascola</surname><given-names>J.R.</given-names></name><name name-style="western"><surname>Fauci</surname><given-names>A.S.</given-names></name><name name-style="western"><surname>Collins</surname><given-names>F.S.</given-names></name></person-group><article-title>A strategic approach to COVID-19 vaccine R&amp;D</article-title><source>Science</source><volume>368</volume><year>2020</year><fpage>948</fpage><lpage>950</lpage><pub-id pub-id-type="pmid">32393526</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1126/science.abc5312</pub-id></element-citation></ref><ref id="bb0080"><label>16</label><element-citation publication-type="journal" id="rf0080"><person-group person-group-type="author"><name name-style="western"><surname>Lurie</surname><given-names>N.</given-names></name><name name-style="western"><surname>Saville</surname><given-names>M.</given-names></name><name name-style="western"><surname>Hatchett</surname><given-names>R.</given-names></name><name name-style="western"><surname>Halton</surname><given-names>J.</given-names></name></person-group><article-title>Developing Covid-19 vaccines at pandemic speed</article-title><source>N. Engl. J. Med.</source><volume>382</volume><year>2020</year><fpage>1969</fpage><lpage>1973</lpage><pub-id pub-id-type="pmid">32227757</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1056/NEJMp2005630</pub-id></element-citation></ref><ref id="bb0085"><label>17</label><element-citation publication-type="journal" id="rf0085"><person-group person-group-type="author"><name name-style="western"><surname>Shin</surname><given-names>M.D.</given-names></name><name name-style="western"><surname>Shukla</surname><given-names>S.</given-names></name><name name-style="western"><surname>Chung</surname><given-names>Y.H.</given-names></name><name name-style="western"><surname>Beiss</surname><given-names>V.</given-names></name><name name-style="western"><surname>Chan</surname><given-names>S.K.</given-names></name><name name-style="western"><surname>Ortega-Rivera</surname><given-names>O.A.</given-names></name><name name-style="western"><surname>Wirth</surname><given-names>D.M.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>A.</given-names></name><name name-style="western"><surname>Sack</surname><given-names>M.</given-names></name><name name-style="western"><surname>Pokorski</surname><given-names>J.K.</given-names></name><name name-style="western"><surname>Steinmetz</surname><given-names>N.F.</given-names></name></person-group><article-title>COVID-19 vaccine development and a potential nanomaterial path forward</article-title><source>Nat. Nanotechnol.</source><volume>15</volume><year>2020</year><fpage>646</fpage><lpage>655</lpage><pub-id pub-id-type="pmid">32669664</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41565-020-0737-y</pub-id></element-citation></ref><ref id="bb0090"><label>18</label><element-citation publication-type="journal" id="rf0090"><person-group person-group-type="author"><name name-style="western"><surname>Folegatti</surname><given-names>P.M.</given-names></name><name name-style="western"><surname>Ewer</surname><given-names>K.J.</given-names></name><name name-style="western"><surname>Aley</surname><given-names>P.K.</given-names></name><name name-style="western"><surname>Angus</surname><given-names>B.</given-names></name><name name-style="western"><surname>Becker</surname><given-names>S.</given-names></name><etal/></person-group><article-title>Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomized controlled trial</article-title><source>Lancet</source><volume>396</volume><year>2020</year><fpage>467</fpage><lpage>478</lpage><pub-id pub-id-type="pmid">32702298</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S0140-6736(20)31604-4</pub-id><pub-id pub-id-type="pmcid">PMC7445431</pub-id></element-citation></ref><ref id="bb0095"><label>19</label><element-citation publication-type="journal" id="rf0095"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>G.</given-names></name><name name-style="western"><surname>De Clercq</surname><given-names>E.</given-names></name></person-group><article-title>Therapeutic options for the 2019 novel coronavirus (2019-nCoV), Nat</article-title><source>Rev. Drug Discov</source><volume>19</volume><year>2020</year><fpage>149</fpage><lpage>150</lpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/d41573-020-00016-0</pub-id><pub-id pub-id-type="pmid">32127666</pub-id></element-citation></ref><ref id="bb0100"><label>20</label><element-citation publication-type="journal" id="rf0100"><person-group person-group-type="author"><name name-style="western"><surname>Sanders</surname><given-names>J.M.</given-names></name><name name-style="western"><surname>Monogue</surname><given-names>M.L.</given-names></name><name name-style="western"><surname>Jodlowski</surname><given-names>T.Z.</given-names></name><name name-style="western"><surname>Cutrell</surname><given-names>J.B.</given-names></name></person-group><article-title>Pharmacologic treatments for coronavirus disease 2019 (COVID-19): a review</article-title><source>JAMA</source><volume>323</volume><year>2020</year><fpage>1824</fpage><lpage>1836</lpage><pub-id pub-id-type="pmid">32282022</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1001/jama.2020.6019</pub-id></element-citation></ref><ref id="bb0105"><label>21</label><element-citation publication-type="journal" id="rf0105"><person-group person-group-type="author"><name name-style="western"><surname>Liu</surname><given-names>C.</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Li</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Garner</surname><given-names>L.V.</given-names></name><name name-style="western"><surname>Watkins</surname><given-names>S.P.</given-names></name><name name-style="western"><surname>Carter</surname><given-names>L.J.</given-names></name><name name-style="western"><surname>Smoot</surname><given-names>J.</given-names></name><name name-style="western"><surname>Gregg</surname><given-names>A.C.</given-names></name><name name-style="western"><surname>Daniels</surname><given-names>A.D.</given-names></name><name name-style="western"><surname>Jervey</surname><given-names>S.</given-names></name><name name-style="western"><surname>Albaiu</surname><given-names>D.</given-names></name></person-group><article-title>Research and development on therapeutic agents and vaccines for COVID-19 and related human coronavirus diseases</article-title><source>ACS Cent. Sci.</source><volume>6</volume><year>2020</year><fpage>315</fpage><lpage>331</lpage><pub-id pub-id-type="pmid">32226821</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1021/acscentsci.0c00272</pub-id><pub-id pub-id-type="pmcid">PMC10467574</pub-id></element-citation></ref><ref id="bb0110"><label>22</label><element-citation publication-type="journal" id="rf0110"><person-group person-group-type="author"><name name-style="western"><surname>Owji</surname><given-names>H.</given-names></name><name name-style="western"><surname>Negahdaripour</surname><given-names>M.</given-names></name><name name-style="western"><surname>Hajighahramani</surname><given-names>N.</given-names></name></person-group><article-title>Immunotherapeutic approaches to curtail COVID-19</article-title><source>Int. Immunopharmacol.</source><volume>88</volume><year>2020</year><fpage>106924</fpage><pub-id pub-id-type="pmid">32877828</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.intimp.2020.106924</pub-id><pub-id pub-id-type="pmcid">PMC7441891</pub-id></element-citation></ref><ref id="bb0115"><label>23</label><element-citation publication-type="journal" id="rf0115"><person-group person-group-type="author"><name name-style="western"><surname>Farrugia</surname><given-names>G.</given-names></name><name name-style="western"><surname>Plutowski</surname><given-names>R.W.</given-names></name></person-group><article-title>Innovation lessons from the COVID-19 pandemic</article-title><source>Mayo Clin. Proc.</source><volume>95</volume><year>2020</year><fpage>1574</fpage><lpage>1577</lpage><pub-id pub-id-type="pmid">32753130</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.mayocp.2020.05.024</pub-id><pub-id pub-id-type="pmcid">PMC7275154</pub-id></element-citation></ref><ref id="bb0120"><label>24</label><element-citation publication-type="journal" id="rf0120"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>F.</given-names></name><name name-style="western"><surname>Li</surname><given-names>W.</given-names></name><name name-style="western"><surname>Farzan</surname><given-names>M.</given-names></name><name name-style="western"><surname>Harrison</surname><given-names>S.C.</given-names></name></person-group><article-title>Structure of SARS coronavirus spike receptor-binding domain complexed with receptor</article-title><source>Science</source><volume>309</volume><year>2005</year><fpage>1864</fpage><lpage>1868</lpage><pub-id pub-id-type="pmid">16166518</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1126/science.1116480</pub-id></element-citation></ref><ref id="bb0125"><label>25</label><element-citation publication-type="journal" id="rf0125"><person-group person-group-type="author"><name name-style="western"><surname>Wrapp</surname><given-names>D.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>N.</given-names></name><name name-style="western"><surname>Corbett</surname><given-names>K.S.</given-names></name><name name-style="western"><surname>Goldsmith</surname><given-names>J.A.</given-names></name><name name-style="western"><surname>Hsieh</surname><given-names>C.L.</given-names></name><name name-style="western"><surname>Abiona</surname><given-names>O.</given-names></name><name name-style="western"><surname>Graham</surname><given-names>B.S.</given-names></name><name name-style="western"><surname>McLellan</surname><given-names>J.S.</given-names></name></person-group><article-title>Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation</article-title><source>Science</source><volume>367</volume><year>2020</year><fpage>1260</fpage><lpage>1263</lpage><pub-id pub-id-type="pmid">32075877</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1126/science.abb2507</pub-id><pub-id pub-id-type="pmcid">PMC7164637</pub-id></element-citation></ref><ref id="bb0130"><label>26</label><element-citation publication-type="journal" id="rf0130"><person-group person-group-type="author"><name name-style="western"><surname>Theerawatanasirikul</surname><given-names>S.</given-names></name><name name-style="western"><surname>Kuo</surname><given-names>C.J.</given-names></name><name name-style="western"><surname>Phetcharat</surname><given-names>N.</given-names></name><name name-style="western"><surname>Lekcharoensuk</surname><given-names>P.</given-names></name></person-group><article-title>In silico and in vitro analysis of small molecules and natural compounds targeting the 3CL protease of feline infectious peritonitis virus</article-title><source>Antivir. Res.</source><volume>174</volume><year>2020</year><fpage>104697</fpage><pub-id pub-id-type="pmid">31863793</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.antiviral.2019.104697</pub-id><pub-id pub-id-type="pmcid">PMC7114316</pub-id></element-citation></ref><ref id="bb0135"><label>27</label><element-citation publication-type="journal" id="rf0135"><person-group person-group-type="author"><name name-style="western"><surname>Cohen</surname><given-names>M.S.</given-names></name></person-group><article-title>Hydroxychloroquine for the prevention of Covid-19 - searching for evidence</article-title><source>N. Engl. J. Med.</source><volume>383</volume><year>2020</year><fpage>585</fpage><lpage>586</lpage><pub-id pub-id-type="pmid">32492298</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1056/NEJMe2020388</pub-id><pub-id pub-id-type="pmcid">PMC7289275</pub-id></element-citation></ref><ref id="bb0140"><label>28</label><element-citation publication-type="journal" id="rf0140"><person-group person-group-type="author"><name name-style="western"><surname>Khuroo</surname><given-names>M.S.</given-names></name></person-group><article-title>Chloroquine and hydroxychloroquine in coronavirus disease 2019 (COVID-19). Facts, fiction and the hype: a critical appraisal</article-title><source>Int. J. Antimicrob. Agents</source><volume>56</volume><year>2020</year><fpage>106101</fpage><pub-id pub-id-type="pmid">32687949</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ijantimicag.2020.106101</pub-id><pub-id pub-id-type="pmcid">PMC7366996</pub-id></element-citation></ref><ref id="bb0145"><label>29</label><element-citation publication-type="journal" id="rf0145"><person-group person-group-type="author"><name name-style="western"><surname>Liu</surname><given-names>J.</given-names></name><name name-style="western"><surname>Cao</surname><given-names>R.</given-names></name><name name-style="western"><surname>Xu</surname><given-names>M.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>X.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>H.</given-names></name><name name-style="western"><surname>Hu</surname><given-names>H.</given-names></name><name name-style="western"><surname>Li</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Hu</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Zhong</surname><given-names>W.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>M.</given-names></name></person-group><article-title>Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro</article-title><source>Cell Discov.</source><volume>6</volume><year>2020</year><fpage>16</fpage><pub-id pub-id-type="pmid">32194981</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41421-020-0156-0</pub-id><pub-id pub-id-type="pmcid">PMC7078228</pub-id></element-citation></ref><ref id="bb0150"><label>30</label><element-citation publication-type="journal" id="rf0150"><person-group person-group-type="author"><name name-style="western"><surname>Yazdany</surname><given-names>J.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>A.H.J.</given-names></name></person-group><article-title>Use of hydroxychloroquine and chloroquine during the COVID-19 pandemic: what every clinician should know</article-title><source>Ann. Intern. Med.</source><volume>172</volume><year>2020</year><fpage>754</fpage><lpage>755</lpage><pub-id pub-id-type="pmid">32232419</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.7326/M20-1334</pub-id><pub-id pub-id-type="pmcid">PMC7138336</pub-id></element-citation></ref><ref id="bb0155"><label>31</label><element-citation publication-type="journal" id="rf0155"><person-group person-group-type="author"><name name-style="western"><surname>Lotteau</surname><given-names>V.</given-names></name><name name-style="western"><surname>Teyton</surname><given-names>L.</given-names></name><name name-style="western"><surname>Peleraux</surname><given-names>A.</given-names></name><name name-style="western"><surname>Nilsson</surname><given-names>T.</given-names></name><name name-style="western"><surname>Karlsson</surname><given-names>L.</given-names></name><name name-style="western"><surname>Schmid</surname><given-names>S.L.</given-names></name><name name-style="western"><surname>Quaranta</surname><given-names>V.</given-names></name><name name-style="western"><surname>Peterson</surname><given-names>P.A.</given-names></name></person-group><article-title>Intracellular transport of class II MHC molecules directed by invariant chain</article-title><source>Nature</source><volume>348</volume><year>1990</year><fpage>600</fpage><lpage>605</lpage><pub-id pub-id-type="pmid">2250716</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/348600a0</pub-id></element-citation></ref><ref id="bb0160"><label>32</label><element-citation publication-type="journal" id="rf0160"><person-group person-group-type="author"><name name-style="western"><surname>Wu</surname><given-names>S.F.</given-names></name><name name-style="western"><surname>Chang</surname><given-names>C.B.</given-names></name><name name-style="western"><surname>Hsu</surname><given-names>J.M.</given-names></name><name name-style="western"><surname>Lu</surname><given-names>M.C.</given-names></name><name name-style="western"><surname>Lai</surname><given-names>N.S.</given-names></name><name name-style="western"><surname>Li</surname><given-names>C.</given-names></name><name name-style="western"><surname>Tung</surname><given-names>C.H.</given-names></name></person-group><article-title>Hydroxychloroquine inhibits CD154 expression in CD4(+) T lymphocytes of systemic lupus erythematosus through NFAT, but not STAT5, signalling</article-title><source>Arthritis Res. Ther.</source><volume>19</volume><year>2017</year><fpage>183</fpage><pub-id pub-id-type="pmid">28793932</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s13075-017-1393-y</pub-id><pub-id pub-id-type="pmcid">PMC5550984</pub-id></element-citation></ref><ref id="bb0165"><label>33</label><element-citation publication-type="journal" id="rf0165"><person-group person-group-type="author"><name name-style="western"><surname>van den Borne</surname><given-names>B.E.</given-names></name><name name-style="western"><surname>Dijkmans</surname><given-names>B.A.</given-names></name><name name-style="western"><surname>de Rooij</surname><given-names>H.H.</given-names></name><name name-style="western"><surname>le Cessie</surname><given-names>S.</given-names></name><name name-style="western"><surname>Verweij</surname><given-names>C.L.</given-names></name></person-group><article-title>Chloroquine and hydroxychloroquine equally affect tumor necrosis factor-alpha, interleukin 6, and interferon-gamma production by peripheral blood mononuclear cells</article-title><source>J. Rheumatol.</source><volume>24</volume><year>1997</year><fpage>55</fpage><lpage>60</lpage><pub-id pub-id-type="pmid">9002011</pub-id></element-citation></ref><ref id="bb0170"><label>34</label><element-citation publication-type="journal" id="rf0170"><person-group person-group-type="author"><name name-style="western"><surname>Kuznik</surname><given-names>A.</given-names></name><name name-style="western"><surname>Bencina</surname><given-names>M.</given-names></name><name name-style="western"><surname>Svajger</surname><given-names>U.</given-names></name><name name-style="western"><surname>Jeras</surname><given-names>M.</given-names></name><name name-style="western"><surname>Rozman</surname><given-names>B.</given-names></name><name name-style="western"><surname>Jerala</surname><given-names>R.</given-names></name></person-group><article-title>Mechanism of endosomal TLR inhibition by antimalarial drugs and imidazoquinolines</article-title><source>J. Immunol.</source><volume>186</volume><year>2011</year><fpage>4794</fpage><lpage>4804</lpage><pub-id pub-id-type="pmid">21398612</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.4049/jimmunol.1000702</pub-id></element-citation></ref><ref id="bb0175"><label>35</label><element-citation publication-type="journal" id="rf0175"><person-group person-group-type="author"><name name-style="western"><surname>Ewald</surname><given-names>S.E.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>B.L.</given-names></name><name name-style="western"><surname>Lau</surname><given-names>L.</given-names></name><name name-style="western"><surname>Wickliffe</surname><given-names>K.E.</given-names></name><name name-style="western"><surname>Shi</surname><given-names>G.P.</given-names></name><name name-style="western"><surname>Chapman</surname><given-names>H.A.</given-names></name><name name-style="western"><surname>Barton</surname><given-names>G.M.</given-names></name></person-group><article-title>The ectodomain of Toll-like receptor 9 is cleaved to generate a functional receptor</article-title><source>Nature</source><volume>456</volume><year>2008</year><fpage>658</fpage><lpage>662</lpage><pub-id pub-id-type="pmid">18820679</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/nature07405</pub-id><pub-id pub-id-type="pmcid">PMC2596276</pub-id></element-citation></ref><ref id="bb0180"><label>36</label><element-citation publication-type="journal" id="rf0180"><person-group person-group-type="author"><name name-style="western"><surname>Hacker</surname><given-names>H.</given-names></name><name name-style="western"><surname>Mischak</surname><given-names>H.</given-names></name><name name-style="western"><surname>Miethke</surname><given-names>T.</given-names></name><name name-style="western"><surname>Liptay</surname><given-names>S.</given-names></name><name name-style="western"><surname>Schmid</surname><given-names>R.</given-names></name><name name-style="western"><surname>Sparwasser</surname><given-names>T.</given-names></name><name name-style="western"><surname>Heeg</surname><given-names>K.</given-names></name><name name-style="western"><surname>Lipford</surname><given-names>G.B.</given-names></name><name name-style="western"><surname>Wagner</surname><given-names>H.</given-names></name></person-group><article-title>CpG-DNA-specific activation of antigen-presenting cells requires stress kinase activity and is preceded by non-specific endocytosis and endosomal maturation</article-title><source>EMBO J.</source><volume>17</volume><year>1998</year><fpage>6230</fpage><lpage>6240</lpage><pub-id pub-id-type="pmid">9799232</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/emboj/17.21.6230</pub-id><pub-id pub-id-type="pmcid">PMC1170949</pub-id></element-citation></ref><ref id="bb0185"><label>37</label><element-citation publication-type="journal" id="rf0185"><person-group person-group-type="author"><name name-style="western"><surname>Vollmer</surname><given-names>J.</given-names></name><name name-style="western"><surname>Tluk</surname><given-names>S.</given-names></name><name name-style="western"><surname>Schmitz</surname><given-names>C.</given-names></name><name name-style="western"><surname>Hamm</surname><given-names>S.</given-names></name><name name-style="western"><surname>Jurk</surname><given-names>M.</given-names></name><name name-style="western"><surname>Forsbach</surname><given-names>A.</given-names></name><name name-style="western"><surname>Akira</surname><given-names>S.</given-names></name><name name-style="western"><surname>Kelly</surname><given-names>K.M.</given-names></name><name name-style="western"><surname>Reeves</surname><given-names>W.H.</given-names></name><name name-style="western"><surname>Bauer</surname><given-names>S.</given-names></name><name name-style="western"><surname>Krieg</surname><given-names>A.M.</given-names></name></person-group><article-title>Immune stimulation mediated by autoantigen binding sites within small nuclear RNAs involves Toll-like receptors 7 and 8</article-title><source>J. Exp. Med.</source><volume>202</volume><year>2005</year><fpage>1575</fpage><lpage>1585</lpage><pub-id pub-id-type="pmid">16330816</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1084/jem.20051696</pub-id><pub-id pub-id-type="pmcid">PMC2213330</pub-id></element-citation></ref><ref id="bb0190"><label>38</label><element-citation publication-type="journal" id="rf0190"><person-group person-group-type="author"><name name-style="western"><surname>An</surname><given-names>J.</given-names></name><name name-style="western"><surname>Woodward</surname><given-names>J.J.</given-names></name><name name-style="western"><surname>Sasaki</surname><given-names>T.</given-names></name><name name-style="western"><surname>Minie</surname><given-names>M.</given-names></name><name name-style="western"><surname>Elkon</surname><given-names>K.B.</given-names></name></person-group><article-title>Cutting edge: antimalarial drugs inhibit IFN-beta production through blockade of cyclic GMP-AMP synthase-DNA interaction</article-title><source>J. Immunol.</source><volume>194</volume><year>2015</year><fpage>4089</fpage><lpage>4093</lpage><pub-id pub-id-type="pmid">25821216</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.4049/jimmunol.1402793</pub-id></element-citation></ref><ref id="bb0195"><label>39</label><element-citation publication-type="journal" id="rf0195"><person-group person-group-type="author"><name name-style="western"><surname>Cook</surname><given-names>K.L.</given-names></name><name name-style="western"><surname>Warri</surname><given-names>A.</given-names></name><name name-style="western"><surname>Soto-Pantoja</surname><given-names>D.R.</given-names></name><name name-style="western"><surname>Clarke</surname><given-names>P.A.</given-names></name><name name-style="western"><surname>Cruz</surname><given-names>M.I.</given-names></name><name name-style="western"><surname>Zwart</surname><given-names>A.</given-names></name><name name-style="western"><surname>Clarke</surname><given-names>R.</given-names></name></person-group><article-title>Hydroxychloroquine inhibits autophagy to potentiate antiestrogen responsiveness in ER+ breast cancer</article-title><source>Clin. Cancer Res.</source><volume>20</volume><year>2014</year><fpage>3222</fpage><lpage>3232</lpage><pub-id pub-id-type="pmid">24928945</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1158/1078-0432.CCR-13-3227</pub-id><pub-id pub-id-type="pmcid">PMC4073207</pub-id></element-citation></ref><ref id="bb0200"><label>40</label><element-citation publication-type="journal" id="rf0200"><person-group person-group-type="author"><name name-style="western"><surname>Mocholi</surname><given-names>E.</given-names></name><name name-style="western"><surname>Dowling</surname><given-names>S.D.</given-names></name><name name-style="western"><surname>Botbol</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Gruber</surname><given-names>R.C.</given-names></name><name name-style="western"><surname>Ray</surname><given-names>A.K.</given-names></name><name name-style="western"><surname>Vastert</surname><given-names>S.</given-names></name><name name-style="western"><surname>Shafit-Zagardo</surname><given-names>B.</given-names></name><name name-style="western"><surname>Coffer</surname><given-names>P.J.</given-names></name><name name-style="western"><surname>Macian</surname><given-names>F.</given-names></name></person-group><article-title>Autophagy is a tolerance-avoidance mechanism that modulates TCR-mediated signalling and cell metabolism to prevent induction of T cell anergy</article-title><source>Cell Rep.</source><volume>24</volume><year>2018</year><fpage>1136</fpage><lpage>1150</lpage><pub-id pub-id-type="pmid">30067971</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.celrep.2018.06.065</pub-id><pub-id pub-id-type="pmcid">PMC6109966</pub-id></element-citation></ref><ref id="bb0205"><label>41</label><element-citation publication-type="other" id="rf0205"><person-group person-group-type="author"><name name-style="western"><surname>U.S. Food and Drug Administration</surname></name></person-group><article-title>Coronavirus (COVID-19) Update: FDA Revokes Emergency Use Authorization for Chloroquine and Hydroxychloroquine</article-title><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-revokes-emergency-use-authorization-chloroquine-and" id="ir0360">https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-revokes-emergency-use-authorization-chloroquine-and</ext-link><year>2020</year></element-citation></ref><ref id="bb0210"><label>42</label><element-citation publication-type="journal" id="rf0210"><person-group person-group-type="author"><name name-style="western"><surname>Boulware</surname><given-names>D.R.</given-names></name><name name-style="western"><surname>Pullen</surname><given-names>M.F.</given-names></name><name name-style="western"><surname>Bangdiwala</surname><given-names>A.S.</given-names></name><name name-style="western"><surname>Pastick</surname><given-names>K.A.</given-names></name><name name-style="western"><surname>Lofgren</surname><given-names>S.M.</given-names></name><etal/></person-group><article-title>A randomized trial of hydroxychloroquine as postexposure prophylaxis for Covid-19</article-title><source>N. Engl. J. Med.</source><volume>383</volume><year>2020</year><fpage>517</fpage><lpage>525</lpage><pub-id pub-id-type="pmid">32492293</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1056/NEJMoa2016638</pub-id><pub-id pub-id-type="pmcid">PMC7289276</pub-id></element-citation></ref><ref id="bb0215"><label>43</label><element-citation publication-type="journal" id="rf0215"><person-group person-group-type="author"><name name-style="western"><surname>Cao</surname><given-names>B.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Wen</surname><given-names>D.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>W.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>J.</given-names></name><etal/></person-group><article-title>A Trial of lopinavir-ritonavir in adults hospitalized with severe Covid-19</article-title><source>N. Engl. J. Med.</source><volume>382</volume><year>2020</year><fpage>1787</fpage><lpage>1799</lpage><pub-id pub-id-type="pmid">32187464</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1056/NEJMoa2001282</pub-id><pub-id pub-id-type="pmcid">PMC7121492</pub-id></element-citation></ref><ref id="bb0220"><label>44</label><element-citation publication-type="journal" id="rf0220"><person-group person-group-type="author"><name name-style="western"><surname>Yao</surname><given-names>T.T.</given-names></name><name name-style="western"><surname>Qian</surname><given-names>J.D.</given-names></name><name name-style="western"><surname>Zhu</surname><given-names>W.Y.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>G.Q.</given-names></name></person-group><article-title>A systematic review of lopinavir therapy for SARS coronavirus and MERS coronavirus-A possible reference for coronavirus disease-19 treatment option</article-title><source>J. Med. Virol.</source><volume>92</volume><year>2020</year><fpage>556</fpage><lpage>563</lpage><pub-id pub-id-type="pmid">32104907</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/jmv.25729</pub-id><pub-id pub-id-type="pmcid">PMC7217143</pub-id></element-citation></ref><ref id="bb0225"><label>45</label><element-citation publication-type="journal" id="rf0225"><person-group person-group-type="author"><name name-style="western"><surname>De Meyer</surname><given-names>S.</given-names></name><name name-style="western"><surname>Bojkova</surname><given-names>D.</given-names></name><name name-style="western"><surname>Cinatl</surname><given-names>J.</given-names></name><name name-style="western"><surname>Van Damme</surname><given-names>E.</given-names></name><name name-style="western"><surname>Buyck</surname><given-names>C.</given-names></name><name name-style="western"><surname>Van Loock</surname><given-names>M.</given-names></name><name name-style="western"><surname>Woodfall</surname><given-names>B.</given-names></name><name name-style="western"><surname>Ciesek</surname><given-names>S.</given-names></name></person-group><article-title>Lack of antiviral activity of darunavir against SARS-CoV-2</article-title><source>Int. J. Infect. Dis.</source><volume>97</volume><year>2020</year><fpage>7</fpage><lpage>10</lpage><pub-id pub-id-type="pmid">32479865</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ijid.2020.05.085</pub-id><pub-id pub-id-type="pmcid">PMC7258847</pub-id></element-citation></ref><ref id="bb0230"><label>46</label><element-citation publication-type="journal" id="rf0230"><person-group person-group-type="author"><name name-style="western"><surname>Siegel</surname><given-names>D.</given-names></name><name name-style="western"><surname>Hui</surname><given-names>H.C.</given-names></name><name name-style="western"><surname>Doerffler</surname><given-names>E.</given-names></name><name name-style="western"><surname>Clarke</surname><given-names>M.O.</given-names></name><name name-style="western"><surname>Chun</surname><given-names>K.</given-names></name><etal/></person-group><article-title>Discovery and synthesis of a phosphoramidate prodrug of a pyrrolo[2,1-f][triazin-4-amino] adenine C-nucleoside (GS-5734) for the treatment of ebola and emerging viruses</article-title><source>J. Med. Chem.</source><volume>60</volume><year>2017</year><fpage>1648</fpage><lpage>1661</lpage><pub-id pub-id-type="pmid">28124907</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1021/acs.jmedchem.6b01594</pub-id></element-citation></ref><ref id="bb0235"><label>47</label><element-citation publication-type="journal" id="rf0235"><person-group person-group-type="author"><name name-style="western"><surname>Al-Tawfiq</surname><given-names>J.A.</given-names></name><name name-style="western"><surname>Al-Homoud</surname><given-names>A.H.</given-names></name><name name-style="western"><surname>Memish</surname><given-names>Z.A.</given-names></name></person-group><article-title>Remdesivir as a possible therapeutic option for the COVID-19</article-title><source>Travel Med. Infect. Dis.</source><volume>34</volume><year>2020</year><fpage>101615</fpage><pub-id pub-id-type="pmid">32145386</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.tmaid.2020.101615</pub-id><pub-id pub-id-type="pmcid">PMC7129391</pub-id></element-citation></ref><ref id="bb0240"><label>48</label><element-citation publication-type="journal" id="rf0240"><person-group person-group-type="author"><name name-style="western"><surname>Beigel</surname><given-names>J.H.</given-names></name><name name-style="western"><surname>Tomashek</surname><given-names>K.M.</given-names></name><name name-style="western"><surname>Dodd</surname><given-names>L.E.</given-names></name><name name-style="western"><surname>Mehta</surname><given-names>A.K.</given-names></name><name name-style="western"><surname>Zingman</surname><given-names>B.S.</given-names></name><etal/></person-group><article-title>Remdesivir for the treatment of Covid-19 - preliminary report</article-title><source>N. Engl. J. Med.</source><volume>383</volume><year>2020</year><fpage>1813</fpage><lpage>1826</lpage><pub-id pub-id-type="pmid">32649078</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1056/NEJMc2022236</pub-id></element-citation></ref><ref id="bb0245"><label>49</label><element-citation publication-type="journal" id="rf0245"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>D.</given-names></name><name name-style="western"><surname>Du</surname><given-names>G.</given-names></name><name name-style="western"><surname>Du</surname><given-names>R.</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>J.</given-names></name><etal/></person-group><article-title>Remdesivir in adults with severe COVID-19: a randomized, double-blind, placebo-controlled, multicentre trial</article-title><source>Lancet</source><volume>395</volume><year>2020</year><fpage>1569</fpage><lpage>1578</lpage><pub-id pub-id-type="pmid">32423584</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S0140-6736(20)31022-9</pub-id><pub-id pub-id-type="pmcid">PMC7190303</pub-id></element-citation></ref><ref id="bb0250"><label>50</label><element-citation publication-type="journal" id="rf0250"><person-group person-group-type="author"><name name-style="western"><surname>Grein</surname><given-names>J.</given-names></name><name name-style="western"><surname>Ohmagari</surname><given-names>N.</given-names></name><name name-style="western"><surname>Shin</surname><given-names>D.</given-names></name><name name-style="western"><surname>Diaz</surname><given-names>G.</given-names></name><name name-style="western"><surname>Asperges</surname><given-names>E.</given-names></name><etal/></person-group><article-title>Compassionate use of remdesivir for patients with severe Covid-19</article-title><source>N. Engl. J. Med.</source><volume>382</volume><year>2020</year><fpage>2327</fpage><lpage>2336</lpage><pub-id pub-id-type="pmid">32275812</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1056/NEJMoa2007016</pub-id><pub-id pub-id-type="pmcid">PMC7169476</pub-id></element-citation></ref><ref id="bb0255"><label>51</label><element-citation publication-type="journal" id="rf0255"><person-group person-group-type="author"><name name-style="western"><surname>Self</surname><given-names>W.H.</given-names></name><name name-style="western"><surname>Semler</surname><given-names>M.W.</given-names></name><name name-style="western"><surname>Leither</surname><given-names>L.M.</given-names></name><name name-style="western"><surname>Casey</surname><given-names>J.D.</given-names></name><name name-style="western"><surname>Angus</surname><given-names>D.C.</given-names></name><etal/></person-group><article-title>Effect of hydroxychloroquine on clinical status at 14&#160;days in hospitalized patients with COVID-19: a randomized clinical trial</article-title><source>JAMA</source><volume>324</volume><year>2020</year><fpage>2165</fpage><lpage>2176</lpage><pub-id pub-id-type="pmid">33165621</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1001/jama.2020.22240</pub-id><pub-id pub-id-type="pmcid">PMC7653542</pub-id></element-citation></ref><ref id="bb0260"><label>52</label><element-citation publication-type="journal" id="rf0260"><person-group person-group-type="author"><name name-style="western"><surname>Stockman</surname><given-names>L.J.</given-names></name><name name-style="western"><surname>Bellamy</surname><given-names>R.</given-names></name><name name-style="western"><surname>Garner</surname><given-names>P.</given-names></name></person-group><article-title>SARS: systematic review of treatment effects</article-title><source>PLoS Med.</source><volume>3</volume><year>2006</year><object-id pub-id-type="publisher-id">e343</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1371/journal.pmed.0030343</pub-id><pub-id pub-id-type="pmcid">PMC1564166</pub-id><pub-id pub-id-type="pmid">16968120</pub-id></element-citation></ref><ref id="bb0265"><label>53</label><element-citation publication-type="journal" id="rf0265"><person-group person-group-type="author"><name name-style="western"><surname>Furuta</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Komeno</surname><given-names>T.</given-names></name><name name-style="western"><surname>Nakamura</surname><given-names>T.</given-names></name></person-group><article-title>Favipiravir (T-705), a broad spectrum inhibitor of viral RNA polymerase</article-title><source>Proc. Jpn. Acad. Ser. B Phys. Biol. Sci.</source><volume>93</volume><year>2017</year><fpage>449</fpage><lpage>463</lpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.2183/pjab.93.027</pub-id><pub-id pub-id-type="pmcid">PMC5713175</pub-id><pub-id pub-id-type="pmid">28769016</pub-id></element-citation></ref><ref id="bb0270"><label>54</label><element-citation publication-type="journal" id="rf0270"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>M.</given-names></name><name name-style="western"><surname>Cao</surname><given-names>R.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>L.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>X.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>J.</given-names></name><name name-style="western"><surname>Xu</surname><given-names>M.</given-names></name><name name-style="western"><surname>Shi</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Hu</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Zhong</surname><given-names>W.</given-names></name><name name-style="western"><surname>Xiao</surname><given-names>G.</given-names></name></person-group><article-title>Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro</article-title><source>Cell Res.</source><volume>30</volume><year>2020</year><fpage>269</fpage><lpage>271</lpage><pub-id pub-id-type="pmid">32020029</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41422-020-0282-0</pub-id><pub-id pub-id-type="pmcid">PMC7054408</pub-id></element-citation></ref><ref id="bb0275"><label>55</label><element-citation publication-type="journal" id="rf0275"><person-group person-group-type="author"><name name-style="western"><surname>Shannon</surname><given-names>A.</given-names></name><name name-style="western"><surname>Selisko</surname><given-names>B.</given-names></name><name name-style="western"><surname>Le</surname><given-names>N.T.</given-names></name><name name-style="western"><surname>Huchting</surname><given-names>J.</given-names></name><name name-style="western"><surname>Touret</surname><given-names>F.</given-names></name><name name-style="western"><surname>Piorkowski</surname><given-names>G.</given-names></name><name name-style="western"><surname>Fattorini</surname><given-names>V.</given-names></name><name name-style="western"><surname>Ferron</surname><given-names>F.</given-names></name><name name-style="western"><surname>Decroly</surname><given-names>E.</given-names></name><name name-style="western"><surname>Meier</surname><given-names>C.</given-names></name><name name-style="western"><surname>Coutard</surname><given-names>B.</given-names></name><name name-style="western"><surname>Peersen</surname><given-names>O.</given-names></name><name name-style="western"><surname>Canard</surname><given-names>B.</given-names></name></person-group><article-title>Rapid incorporation of Favipiravir by the fast and permissive viral RNA polymerase complex results in SARS-CoV-2 lethal mutagenesis</article-title><source>Nat. Commun.</source><volume>11</volume><year>2020</year><fpage>4682</fpage><pub-id pub-id-type="pmid">32943628</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41467-020-18463-z</pub-id><pub-id pub-id-type="pmcid">PMC7499305</pub-id></element-citation></ref><ref id="bb0280"><label>56</label><element-citation publication-type="journal" id="rf0280"><person-group person-group-type="author"><name name-style="western"><surname>Agrawal</surname><given-names>U.</given-names></name><name name-style="western"><surname>Raju</surname><given-names>R.</given-names></name><name name-style="western"><surname>Udwadia</surname><given-names>Z.F.</given-names></name></person-group><article-title>Favipiravir: A new and emerging antiviral option in COVID-19</article-title><source>Med. J. Armed Forces India</source><volume>76</volume><year>2020</year><fpage>370</fpage><lpage>376</lpage><pub-id pub-id-type="pmid">32895599</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.mjafi.2020.08.004</pub-id><pub-id pub-id-type="pmcid">PMC7467067</pub-id></element-citation></ref><ref id="bb0285"><label>57</label><element-citation publication-type="journal" id="rf0285"><person-group person-group-type="author"><name name-style="western"><surname>Chen</surname><given-names>C.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Huang</surname><given-names>J.</given-names></name><name name-style="western"><surname>Yin</surname><given-names>P.</given-names></name><name name-style="western"><surname>Cheng</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>J.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>S.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>B.</given-names></name><name name-style="western"><surname>Lu</surname><given-names>M.</given-names></name><name name-style="western"><surname>Luo</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Ju</surname><given-names>L.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>J.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>X.</given-names></name></person-group><article-title>Favipiravir versus arbidol for COVID-19: a randomized clinical trial</article-title><source>medRxiv</source><year>2020</year><pub-id pub-id-type="doi">10.1101/2020.03.17.20037432</pub-id></element-citation></ref><ref id="bb0290"><label>58</label><element-citation publication-type="journal" id="rf0290"><person-group person-group-type="author"><name name-style="western"><surname>Shi</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Shao</surname><given-names>C.</given-names></name><name name-style="western"><surname>Huang</surname><given-names>J.</given-names></name><name name-style="western"><surname>Gan</surname><given-names>J.</given-names></name><name name-style="western"><surname>Huang</surname><given-names>X.</given-names></name><name name-style="western"><surname>Bucci</surname><given-names>E.</given-names></name><name name-style="western"><surname>Piacentini</surname><given-names>M.</given-names></name><name name-style="western"><surname>Ippolito</surname><given-names>G.</given-names></name><name name-style="western"><surname>Melino</surname><given-names>G.</given-names></name></person-group><article-title>COVID-19 infection: the perspectives on immune responses</article-title><source>Cell Death Differ.</source><volume>27</volume><year>2020</year><fpage>1451</fpage><lpage>1454</lpage><pub-id pub-id-type="pmid">32205856</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41418-020-0530-3</pub-id><pub-id pub-id-type="pmcid">PMC7091918</pub-id></element-citation></ref><ref id="bb0295"><label>59</label><element-citation publication-type="journal" id="rf0295"><person-group person-group-type="author"><name name-style="western"><surname>Rokni</surname><given-names>M.</given-names></name><name name-style="western"><surname>Ghasemi</surname><given-names>V.</given-names></name><name name-style="western"><surname>Tavakoli</surname><given-names>Z.</given-names></name></person-group><article-title>Immune responses and pathogenesis of SARS-CoV-2 during an outbreak in Iran: Comparison with SARS and MERS</article-title><source>Rev. Med. Virol.</source><volume>30</volume><year>2020</year><object-id pub-id-type="publisher-id">e2107</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/rmv.2107</pub-id><pub-id pub-id-type="pmcid">PMC7235481</pub-id><pub-id pub-id-type="pmid">32267987</pub-id></element-citation></ref><ref id="bb0300"><label>60</label><element-citation publication-type="journal" id="rf0300"><person-group person-group-type="author"><name name-style="western"><surname>Market</surname><given-names>M.</given-names></name><name name-style="western"><surname>Angka</surname><given-names>L.</given-names></name><name name-style="western"><surname>Martel</surname><given-names>A.B.</given-names></name><name name-style="western"><surname>Bastin</surname><given-names>D.</given-names></name><name name-style="western"><surname>Olanubi</surname><given-names>O.</given-names></name><name name-style="western"><surname>Tennakoon</surname><given-names>G.</given-names></name><name name-style="western"><surname>Boucher</surname><given-names>D.M.</given-names></name><name name-style="western"><surname>Ng</surname><given-names>J.</given-names></name><name name-style="western"><surname>Ardolino</surname><given-names>M.</given-names></name><name name-style="western"><surname>Auer</surname><given-names>R.C.</given-names></name></person-group><article-title>Flattening the COVID-19 curve with natural killer cell based immunotherapies</article-title><source>Front. Immunol.</source><volume>11</volume><year>2020</year><fpage>1512</fpage><pub-id pub-id-type="pmid">32655581</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fimmu.2020.01512</pub-id><pub-id pub-id-type="pmcid">PMC7324763</pub-id></element-citation></ref><ref id="bb0305"><label>61</label><element-citation publication-type="journal" id="rf0305"><person-group person-group-type="author"><name name-style="western"><surname>Chen</surname><given-names>L.</given-names></name><name name-style="western"><surname>Xiong</surname><given-names>J.</given-names></name><name name-style="western"><surname>Bao</surname><given-names>L.</given-names></name><name name-style="western"><surname>Shi</surname><given-names>Y.</given-names></name></person-group><article-title>Convalescent plasma as a potential therapy for COVID-19</article-title><source>Lancet Infect. Dis.</source><volume>20</volume><year>2020</year><fpage>398</fpage><lpage>400</lpage><pub-id pub-id-type="pmid">32113510</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S1473-3099(20)30141-9</pub-id><pub-id pub-id-type="pmcid">PMC7128218</pub-id></element-citation></ref><ref id="bb0310"><label>62</label><element-citation publication-type="journal" id="rf0310"><person-group person-group-type="author"><name name-style="western"><surname>Suvakov</surname><given-names>S.</given-names></name><name name-style="western"><surname>Richards</surname><given-names>C.</given-names></name><name name-style="western"><surname>Nikolic</surname><given-names>V.</given-names></name><name name-style="western"><surname>Simic</surname><given-names>T.</given-names></name><name name-style="western"><surname>McGrath</surname><given-names>K.</given-names></name><name name-style="western"><surname>Krasnodembskaya</surname><given-names>A.</given-names></name><name name-style="western"><surname>McClements</surname><given-names>L.</given-names></name></person-group><article-title>Emerging therapeutic potential of mesenchymal stem/stromal cells in preeclampsia</article-title><source>Curr. Hypertens. Rep.</source><volume>22</volume><year>2020</year><fpage>37</fpage><pub-id pub-id-type="pmid">32291521</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s11906-020-1034-8</pub-id></element-citation></ref><ref id="bb0315"><label>63</label><element-citation publication-type="journal" id="rf0315"><person-group person-group-type="author"><name name-style="western"><surname>Bari</surname><given-names>E.</given-names></name><name name-style="western"><surname>Ferrarotti</surname><given-names>I.</given-names></name><name name-style="western"><surname>Saracino</surname><given-names>L.</given-names></name><name name-style="western"><surname>Perteghella</surname><given-names>S.</given-names></name><name name-style="western"><surname>Torre</surname><given-names>M.L.</given-names></name><name name-style="western"><surname>Corsico</surname><given-names>A.G.</given-names></name></person-group><article-title>Mesenchymal stromal cell secretome for severe COVID-19 infections: premises for the therapeutic use</article-title><source>Cells</source><volume>9</volume><year>2020</year><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/cells9040924</pub-id><pub-id pub-id-type="pmcid">PMC7226831</pub-id><pub-id pub-id-type="pmid">32283815</pub-id></element-citation></ref><ref id="bb0320"><label>64</label><element-citation publication-type="journal" id="rf0320"><person-group person-group-type="author"><name name-style="western"><surname>Liu</surname><given-names>S.T.H.</given-names></name><name name-style="western"><surname>Lin</surname><given-names>H.M.</given-names></name><name name-style="western"><surname>Baine</surname><given-names>I.</given-names></name><name name-style="western"><surname>Wajnberg</surname><given-names>A.</given-names></name><name name-style="western"><surname>Gumprecht</surname><given-names>J.P.</given-names></name><etal/></person-group><article-title>Convalescent plasma treatment of severe COVID-19: a propensity score-matched control study</article-title><source>Nat. Med.</source><volume>26</volume><year>2020</year><fpage>1708</fpage><lpage>1713</lpage><pub-id pub-id-type="pmid">32934372</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41591-020-1088-9</pub-id></element-citation></ref><ref id="bb0325"><label>65</label><element-citation publication-type="journal" id="rf0325"><person-group person-group-type="author"><name name-style="western"><surname>Roback</surname><given-names>J.D.</given-names></name><name name-style="western"><surname>Guarner</surname><given-names>J.</given-names></name></person-group><article-title>Convalescent plasma to treat COVID-19: possibilities and challenges</article-title><source>JAMA</source><volume>323</volume><year>2020</year><fpage>1561</fpage><lpage>1562</lpage><pub-id pub-id-type="pmid">32219429</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1001/jama.2020.4940</pub-id></element-citation></ref><ref id="bb0330"><label>66</label><element-citation publication-type="other" id="rf0330"><person-group person-group-type="author"><name name-style="western"><surname>BioPharma-Reporter</surname></name></person-group><article-title>Regeneron's COVID-19 Antibody Cocktail Receives EUA from FDA</article-title><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.biopharma-reporter.com/Article/2020/11/23/Regeneron-s-COVID-19-antibody-cocktail-receives-EUA-from-FDA" id="ir0365">https://www.biopharma-reporter.com/Article/2020/11/23/Regeneron-s-COVID-19-antibody-cocktail-receives-EUA-from-FDA</ext-link><year>2020</year></element-citation></ref><ref id="bb0335"><label>67</label><element-citation publication-type="journal" id="rf0335"><person-group person-group-type="author"><name name-style="western"><surname>Soo</surname><given-names>Y.O.</given-names></name><name name-style="western"><surname>Cheng</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Wong</surname><given-names>R.</given-names></name><name name-style="western"><surname>Hui</surname><given-names>D.S.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>C.K.</given-names></name><etal/></person-group><article-title>Retrospective comparison of convalescent plasma with continuing high-dose methylprednisolone treatment in SARS patients</article-title><source>Clin. Microbiol. Infect.</source><volume>10</volume><year>2004</year><fpage>676</fpage><lpage>678</lpage><pub-id pub-id-type="pmid">15214887</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/j.1469-0691.2004.00956.x</pub-id><pub-id pub-id-type="pmcid">PMC7129386</pub-id></element-citation></ref><ref id="bb0340"><label>68</label><element-citation publication-type="journal" id="rf0340"><person-group person-group-type="author"><name name-style="western"><surname>Chen</surname><given-names>J.</given-names></name><name name-style="western"><surname>Hu</surname><given-names>C.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>L.</given-names></name><name name-style="western"><surname>Tang</surname><given-names>L.</given-names></name><name name-style="western"><surname>Zhu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Xu</surname><given-names>X.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>L.</given-names></name><name name-style="western"><surname>Gao</surname><given-names>H.</given-names></name><name name-style="western"><surname>Lu</surname><given-names>X.</given-names></name><name name-style="western"><surname>Yu</surname><given-names>L.</given-names></name><name name-style="western"><surname>Dai</surname><given-names>X.</given-names></name><name name-style="western"><surname>Xiang</surname><given-names>C.</given-names></name><name name-style="western"><surname>Li</surname><given-names>L.</given-names></name></person-group><article-title>Clinical study of mesenchymal stem cell treating acute respiratory distress syndrome induced by epidemic Influenza A (H7N9) infection, a hint for COVID-19 treatment</article-title><source>Engineering (Beijing)</source><volume>6</volume><year>2020</year><fpage>1153</fpage><lpage>1161</lpage><pub-id pub-id-type="pmid">32292627</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.eng.2020.02.006</pub-id><pub-id pub-id-type="pmcid">PMC7102606</pub-id></element-citation></ref><ref id="bb0345"><label>69</label><element-citation publication-type="journal" id="rf0345"><person-group person-group-type="author"><name name-style="western"><surname>Gladstone</surname><given-names>D.E.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>B.S.</given-names></name><name name-style="western"><surname>Mooney</surname><given-names>K.</given-names></name><name name-style="western"><surname>Karaba</surname><given-names>A.H.</given-names></name><name name-style="western"><surname>D'Alessio</surname><given-names>F.R.</given-names></name></person-group><article-title>Regulatory T cells for treating patients with COVID-19 and acute respiratory distress syndrome: two case reports</article-title><source>Ann. Intern. Med.</source><volume>173</volume><year>2020</year><fpage>852</fpage><lpage>853</lpage><pub-id pub-id-type="pmid">32628535</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.7326/L20-0681</pub-id><pub-id pub-id-type="pmcid">PMC7370819</pub-id></element-citation></ref><ref id="bb0350"><label>70</label><element-citation publication-type="journal" id="rf0350"><person-group person-group-type="author"><name name-style="western"><surname>Abbasi</surname><given-names>J.</given-names></name></person-group><article-title>Regulatory T cells tested in patients with COVID-19 ARDS</article-title><source>JAMA</source><volume>324</volume><year>2020</year><fpage>539</fpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1001/jama.2020.13765</pub-id><pub-id pub-id-type="pmid">32780125</pub-id></element-citation></ref><ref id="bb0355"><label>71</label><element-citation publication-type="other" id="rf0355"><person-group person-group-type="author"><name name-style="western"><surname>PR Newswire, Cellenkos Inc</surname></name></person-group><article-title>Focuses on the Development of Cell-Therapy for Treatment of COVID-19 Mediated Acute Respiratory Distress Syndrome (CoV-ARDS)</article-title><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.prnewswire.com/news-releases/cellenkos-inc-focuses-on-the-development-of-cell-therapy-for-treatment-of-covid-19-mediated-acute-respiratory-distress-syndrome-cov-ards-301025278.html" id="ir0370">https://www.prnewswire.com/news-releases/cellenkos-inc-focuses-on-the-development-of-cell-therapy-for-treatment-of-covid-19-mediated-acute-respiratory-distress-syndrome-cov-ards-301025278.html</ext-link><year>2020</year></element-citation></ref><ref id="bb0360"><label>72</label><element-citation publication-type="journal" id="rf0360"><person-group person-group-type="author"><name name-style="western"><surname>Yip</surname><given-names>M.S.</given-names></name><name name-style="western"><surname>Leung</surname><given-names>H.L.</given-names></name><name name-style="western"><surname>Li</surname><given-names>P.H.</given-names></name><name name-style="western"><surname>Cheung</surname><given-names>C.Y.</given-names></name><name name-style="western"><surname>Dutry</surname><given-names>I.</given-names></name><name name-style="western"><surname>Li</surname><given-names>D.</given-names></name><name name-style="western"><surname>Daeron</surname><given-names>M.</given-names></name><name name-style="western"><surname>Bruzzone</surname><given-names>R.</given-names></name><name name-style="western"><surname>Peiris</surname><given-names>J.S.</given-names></name><name name-style="western"><surname>Jaume</surname><given-names>M.</given-names></name></person-group><article-title>Antibody-dependent enhancement of SARS coronavirus infection and its role in the pathogenesis of SARS</article-title><source>Hong Kong Med. J.</source><volume>22</volume><year>2016</year><fpage>25</fpage><lpage>31</lpage><pub-id pub-id-type="pmid">27390007</pub-id></element-citation></ref><ref id="bb0365"><label>73</label><element-citation publication-type="journal" id="rf0365"><person-group person-group-type="author"><name name-style="western"><surname>Salome</surname><given-names>B.</given-names></name><name name-style="western"><surname>Magen</surname><given-names>A.</given-names></name></person-group><article-title>Dysregulation of lung myeloid cells in COVID-19</article-title><source>Nat. Rev. Immunol.</source><volume>20</volume><year>2020</year><fpage>277</fpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41577-020-0303-8</pub-id><pub-id pub-id-type="pmcid">PMC7132548</pub-id><pub-id pub-id-type="pmid">32249846</pub-id></element-citation></ref><ref id="bb0370"><label>74</label><element-citation publication-type="journal" id="rf0370"><person-group person-group-type="author"><name name-style="western"><surname>Burmester</surname><given-names>G.R.</given-names></name><name name-style="western"><surname>Rigby</surname><given-names>W.F.</given-names></name><name name-style="western"><surname>van Vollenhoven</surname><given-names>R.F.</given-names></name><name name-style="western"><surname>Kay</surname><given-names>J.</given-names></name><name name-style="western"><surname>Rubbert-Roth</surname><given-names>A.</given-names></name><name name-style="western"><surname>Kelman</surname><given-names>A.</given-names></name><name name-style="western"><surname>Dimonaco</surname><given-names>S.</given-names></name><name name-style="western"><surname>Mitchell</surname><given-names>N.</given-names></name></person-group><article-title>Tocilizumab in early progressive rheumatoid arthritis: FUNCTION, a randomized controlled trial</article-title><source>Ann. Rheum. Dis.</source><volume>75</volume><year>2016</year><fpage>1081</fpage><lpage>1091</lpage><pub-id pub-id-type="pmid">26511996</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1136/annrheumdis-2015-207628</pub-id><pub-id pub-id-type="pmcid">PMC4893095</pub-id></element-citation></ref><ref id="bb0375"><label>75</label><element-citation publication-type="journal" id="rf0375"><person-group person-group-type="author"><name name-style="western"><surname>Yokota</surname><given-names>S.</given-names></name><name name-style="western"><surname>Itoh</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Morio</surname><given-names>T.</given-names></name><name name-style="western"><surname>Origasa</surname><given-names>H.</given-names></name><name name-style="western"><surname>Sumitomo</surname><given-names>N.</given-names></name><name name-style="western"><surname>Tomobe</surname><given-names>M.</given-names></name><name name-style="western"><surname>Tanaka</surname><given-names>K.</given-names></name><name name-style="western"><surname>Minota</surname><given-names>S.</given-names></name></person-group><article-title>Tocilizumab in systemic juvenile idiopathic arthritis in a real-world clinical setting: results from 1&#160;year of postmarketing surveillance follow-up of 417 patients in Japan</article-title><source>Ann. Rheum. Dis.</source><volume>75</volume><year>2016</year><fpage>1654</fpage><lpage>1660</lpage><pub-id pub-id-type="pmid">26644233</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1136/annrheumdis-2015-207818</pub-id><pub-id pub-id-type="pmcid">PMC5013079</pub-id></element-citation></ref><ref id="bb0380"><label>76</label><element-citation publication-type="journal" id="rf0380"><person-group person-group-type="author"><name name-style="western"><surname>Khan</surname><given-names>F.</given-names></name><name name-style="western"><surname>Fabbri</surname><given-names>L.</given-names></name><name name-style="western"><surname>Stewart</surname><given-names>I.</given-names></name><name name-style="western"><surname>Robinson</surname><given-names>K.</given-names></name><name name-style="western"><surname>Smyth</surname><given-names>A.R.</given-names></name><name name-style="western"><surname>Jenkins</surname><given-names>G.</given-names></name></person-group><article-title>A systematic review of Anakinra, Tocilizumab, Sarilumab and Siltuximab for coronavirus-related infections</article-title><source>medRxiv</source><year>2020</year><pub-id pub-id-type="doi">10.1101/2020.04.23.20076612</pub-id></element-citation></ref><ref id="bb0385"><label>77</label><element-citation publication-type="journal" id="rf0385"><person-group person-group-type="author"><name name-style="western"><surname>Luo</surname><given-names>W.</given-names></name><name name-style="western"><surname>Li</surname><given-names>Y.X.</given-names></name><name name-style="western"><surname>Jiang</surname><given-names>L.J.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>T.</given-names></name><name name-style="western"><surname>Ye</surname><given-names>D.W.</given-names></name></person-group><article-title>Targeting JAK-STAT signalling to control cytokine release syndrome in COVID-19</article-title><source>Trends Pharmacol. Sci.</source><volume>41</volume><year>2020</year><fpage>531</fpage><lpage>543</lpage><pub-id pub-id-type="pmid">32580895</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.tips.2020.06.007</pub-id><pub-id pub-id-type="pmcid">PMC7298494</pub-id></element-citation></ref><ref id="bb0390"><label>78</label><element-citation publication-type="journal" id="rf0390"><person-group person-group-type="author"><name name-style="western"><surname>Wu</surname><given-names>D.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>X.O.</given-names></name></person-group><article-title>TH17 responses in cytokine storm of COVID-19: An emerging target of JAK2 inhibitor Fedratinib</article-title><source>J. Microbiol. Immunol. Infect.</source><volume>53</volume><year>2020</year><fpage>368</fpage><lpage>370</lpage><pub-id pub-id-type="pmid">32205092</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jmii.2020.03.005</pub-id><pub-id pub-id-type="pmcid">PMC7156211</pub-id></element-citation></ref><ref id="bb0395"><label>79</label><element-citation publication-type="journal" id="rf0395"><person-group person-group-type="author"><name name-style="western"><surname>Stebbing</surname><given-names>J.</given-names></name><name name-style="western"><surname>Phelan</surname><given-names>A.</given-names></name><name name-style="western"><surname>Griffin</surname><given-names>I.</given-names></name><name name-style="western"><surname>Tucker</surname><given-names>C.</given-names></name><name name-style="western"><surname>Oechsle</surname><given-names>O.</given-names></name><name name-style="western"><surname>Smith</surname><given-names>D.</given-names></name><name name-style="western"><surname>Richardson</surname><given-names>P.</given-names></name></person-group><article-title>COVID-19: combining antiviral and anti-inflammatory treatments</article-title><source>Lancet Infect. Dis.</source><volume>20</volume><year>2020</year><fpage>400</fpage><lpage>402</lpage><pub-id pub-id-type="pmid">32113509</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S1473-3099(20)30132-8</pub-id><pub-id pub-id-type="pmcid">PMC7158903</pub-id></element-citation></ref><ref id="bb0400"><label>80</label><element-citation publication-type="journal" id="rf0400"><person-group person-group-type="author"><name name-style="western"><surname>Schett</surname><given-names>G.</given-names></name><name name-style="western"><surname>Sticherling</surname><given-names>M.</given-names></name><name name-style="western"><surname>Neurath</surname><given-names>M.F.</given-names></name></person-group><article-title>COVID-19: risk for cytokine targeting in chronic inflammatory diseases?</article-title><source>Nat. Rev. Immunol.</source><volume>20</volume><year>2020</year><fpage>271</fpage><lpage>272</lpage><pub-id pub-id-type="pmid">32296135</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41577-020-0312-7</pub-id><pub-id pub-id-type="pmcid">PMC7186927</pub-id></element-citation></ref><ref id="bb0405"><label>81</label><element-citation publication-type="other" id="rf0405"><person-group person-group-type="author"><name name-style="western"><surname>Kleo Pharmaceuticals</surname></name></person-group><article-title>Kleo Pharmaceuticals Enters into Research Collaboration with Green Cross LabCell (GCLC) To Rapidly Develop COVID-19-Targeting Allogeneic NK Cell Combination Therapy</article-title><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.kleopharmaceuticals.com/kleo-pharmaceuticals-enters-into-research-collaboration-with-green-cross-labcell-gclc-to-rapidly-develop-covid-19-targeting-allogeneic-nk-cell-combination-therapy/" id="ir0375">https://www.kleopharmaceuticals.com/kleo-pharmaceuticals-enters-into-research-collaboration-with-green-cross-labcell-gclc-to-rapidly-develop-covid-19-targeting-allogeneic-nk-cell-combination-therapy/</ext-link><year>2020</year></element-citation></ref><ref id="bb0410"><label>82</label><element-citation publication-type="journal" id="rf0410"><person-group person-group-type="author"><name name-style="western"><surname>Korsukewitz</surname><given-names>C.</given-names></name><name name-style="western"><surname>Reddel</surname><given-names>S.W.</given-names></name><name name-style="western"><surname>Bar-Or</surname><given-names>A.</given-names></name><name name-style="western"><surname>Wiendl</surname><given-names>H.</given-names></name></person-group><article-title>Neurological immunotherapy in the era of COVID-19 - looking for consensus in the literature</article-title><source>Nat. Rev. Neurol.</source><volume>16</volume><year>2020</year><fpage>493</fpage><lpage>505</lpage><pub-id pub-id-type="pmid">32641860</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41582-020-0385-8</pub-id><pub-id pub-id-type="pmcid">PMC7341707</pub-id></element-citation></ref><ref id="bb0415"><label>83</label><element-citation publication-type="journal" id="rf0415"><person-group person-group-type="author"><name name-style="western"><surname>Randolph</surname><given-names>H.E.</given-names></name><name name-style="western"><surname>Barreiro</surname><given-names>L.B.</given-names></name></person-group><article-title>Herd immunity: understanding COVID-19</article-title><source>Immunity</source><volume>52</volume><year>2020</year><fpage>737</fpage><lpage>741</lpage><pub-id pub-id-type="pmid">32433946</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.immuni.2020.04.012</pub-id><pub-id pub-id-type="pmcid">PMC7236739</pub-id></element-citation></ref><ref id="bb0420"><label>84</label><element-citation publication-type="journal" id="rf0420"><person-group person-group-type="author"><name name-style="western"><surname>Kwok</surname><given-names>K.O.</given-names></name><name name-style="western"><surname>Lai</surname><given-names>F.</given-names></name><name name-style="western"><surname>Wei</surname><given-names>W.I.</given-names></name><name name-style="western"><surname>Wong</surname><given-names>S.Y.S.</given-names></name><name name-style="western"><surname>Tang</surname><given-names>J.W.T.</given-names></name></person-group><article-title>Herd immunity - estimating the level required to halt the COVID-19 epidemics in affected countries</article-title><source>J. Inf. Secur.</source><volume>80</volume><year>2020</year><fpage>e32</fpage><lpage>e33</lpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jinf.2020.03.027</pub-id><pub-id pub-id-type="pmcid">PMC7151357</pub-id><pub-id pub-id-type="pmid">32209383</pub-id></element-citation></ref><ref id="bb0425"><label>85</label><element-citation publication-type="journal" id="rf0425"><person-group person-group-type="author"><name name-style="western"><surname>Palese</surname><given-names>P.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>T.T.</given-names></name></person-group><article-title>Why do influenza virus subtypes die out? A hypothesis</article-title><source>mBio</source><volume>2</volume><year>2011</year><pub-id pub-id-type="doi" assigning-authority="pmc">10.1128/mBio.00150-11</pub-id><pub-id pub-id-type="pmcid">PMC3163940</pub-id><pub-id pub-id-type="pmid">21878571</pub-id></element-citation></ref><ref id="bb0430"><label>86</label><element-citation publication-type="journal" id="rf0430"><person-group person-group-type="author"><name name-style="western"><surname>Liu</surname><given-names>S.</given-names></name><name name-style="western"><surname>Zhuang</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>S.</given-names></name><name name-style="western"><surname>Jiang</surname><given-names>W.</given-names></name><name name-style="western"><surname>Jin</surname><given-names>J.</given-names></name><name name-style="western"><surname>Peng</surname><given-names>C.</given-names></name><name name-style="western"><surname>Hou</surname><given-names>G.</given-names></name><name name-style="western"><surname>Li</surname><given-names>J.</given-names></name><name name-style="western"><surname>Yu</surname><given-names>J.</given-names></name><name name-style="western"><surname>Yu</surname><given-names>X.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>H.</given-names></name><name name-style="western"><surname>Sun</surname><given-names>S.</given-names></name><name name-style="western"><surname>Yuan</surname><given-names>L.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>J.</given-names></name></person-group><article-title>Control of avian influenza in China: Strategies and lessons</article-title><source>Transbound. Emerg. Dis.</source><volume>67</volume><year>2020</year><fpage>1463</fpage><lpage>1471</lpage><pub-id pub-id-type="pmid">32065513</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/tbed.13515</pub-id></element-citation></ref><ref id="bb0435"><label>87</label><element-citation publication-type="journal" id="rf0435"><person-group person-group-type="author"><name name-style="western"><surname>Zeng</surname><given-names>X.</given-names></name><name name-style="western"><surname>Tian</surname><given-names>G.</given-names></name><name name-style="western"><surname>Shi</surname><given-names>J.</given-names></name><name name-style="western"><surname>Deng</surname><given-names>G.</given-names></name><name name-style="western"><surname>Li</surname><given-names>C.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>H.</given-names></name></person-group><article-title>Vaccination of poultry successfully eliminated human infection with H7N9 virus in China</article-title><source>Sci. China Life Sci.</source><volume>61</volume><year>2018</year><fpage>1465</fpage><lpage>1473</lpage><pub-id pub-id-type="pmid">30414008</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s11427-018-9420-1</pub-id></element-citation></ref><ref id="bb0440"><label>88</label><element-citation publication-type="journal" id="rf0440"><person-group person-group-type="author"><name name-style="western"><surname>Aschwanden</surname><given-names>C.</given-names></name></person-group><article-title>The false promise of herd immunity for COVID-19</article-title><source>Nature</source><volume>587</volume><year>2020</year><fpage>26</fpage><lpage>28</lpage><pub-id pub-id-type="pmid">33087872</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/d41586-020-02948-4</pub-id></element-citation></ref><ref id="bb0445"><label>89</label><element-citation publication-type="journal" id="rf0445"><person-group person-group-type="author"><name name-style="western"><surname>Anderson</surname><given-names>R.M.</given-names></name><name name-style="western"><surname>May</surname><given-names>R.M.</given-names></name></person-group><article-title>Vaccination and herd immunity to infectious diseases</article-title><source>Nature</source><volume>318</volume><year>1985</year><fpage>323</fpage><lpage>329</lpage><pub-id pub-id-type="pmid">3906406</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/318323a0</pub-id></element-citation></ref><ref id="bb0450"><label>90</label><element-citation publication-type="journal" id="rf0450"><person-group person-group-type="author"><name name-style="western"><surname>Mallory</surname><given-names>M.L.</given-names></name><name name-style="western"><surname>Lindesmith</surname><given-names>L.C.</given-names></name><name name-style="western"><surname>Baric</surname><given-names>R.S.</given-names></name></person-group><article-title>Vaccination-induced herd immunity: Successes and challenges</article-title><source>J. Allergy Clin. Immunol.</source><volume>142</volume><year>2018</year><fpage>64</fpage><lpage>66</lpage><pub-id pub-id-type="pmid">29803799</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jaci.2018.05.007</pub-id><pub-id pub-id-type="pmcid">PMC6433118</pub-id></element-citation></ref><ref id="bb0455"><label>91</label><element-citation publication-type="journal" id="rf0455"><person-group person-group-type="author"><name name-style="western"><surname>Syal</surname><given-names>K.</given-names></name></person-group><article-title>COVID-19: Herd immunity and convalescent plasma transfer therapy</article-title><source>J. Med. Virol.</source><volume>92</volume><year>2020</year><fpage>1380</fpage><lpage>1382</lpage><pub-id pub-id-type="pmid">32281679</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/jmv.25870</pub-id><pub-id pub-id-type="pmcid">PMC7262166</pub-id></element-citation></ref><ref id="bb0460"><label>92</label><element-citation publication-type="journal" id="rf0460"><person-group person-group-type="author"><name name-style="western"><surname>Dong</surname><given-names>E.</given-names></name><name name-style="western"><surname>Du</surname><given-names>H.</given-names></name><name name-style="western"><surname>Gardner</surname><given-names>L.</given-names></name></person-group><article-title>An interactive web-based dashboard to track COVID-19 in real time</article-title><source>Lancet Infect. Dis.</source><volume>20</volume><year>2020</year><fpage>533</fpage><lpage>534</lpage><pub-id pub-id-type="pmid">32087114</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S1473-3099(20)30120-1</pub-id><pub-id pub-id-type="pmcid">PMC7159018</pub-id></element-citation></ref><ref id="bb0465"><label>93</label><element-citation publication-type="journal" id="rf0465"><person-group person-group-type="author"><name name-style="western"><surname>Ferguson</surname><given-names>N.</given-names></name><name name-style="western"><surname>Laydon</surname><given-names>D.</given-names></name><name name-style="western"><surname>Nedjati Gilani</surname><given-names>G.</given-names></name><name name-style="western"><surname>Imai</surname><given-names>N.</given-names></name><name name-style="western"><surname>Ainslie</surname><given-names>K.</given-names></name><etal/></person-group><article-title>Report 9: Impact of non-pharmaceutical interventions (NPIs) to reduce COVID19 mortality and healthcare demand</article-title><source>Imperical College London</source><year>2020</year><fpage>1</fpage><lpage>20</lpage></element-citation></ref><ref id="bb0470"><label>94</label><element-citation publication-type="journal" id="rf0470"><person-group person-group-type="author"><name name-style="western"><surname>Kavaliunas</surname><given-names>A.</given-names></name><name name-style="western"><surname>Ocaya</surname><given-names>P.</given-names></name><name name-style="western"><surname>Mumper</surname><given-names>J.</given-names></name><name name-style="western"><surname>Lindfeldt</surname><given-names>I.</given-names></name><name name-style="western"><surname>Kyhlstedt</surname><given-names>M.</given-names></name></person-group><article-title>Swedish policy analysis for Covid-19</article-title><source>Health Policy Technol.</source><volume>9</volume><year>2020</year><fpage>598</fpage><lpage>612</lpage><pub-id pub-id-type="pmid">32904437</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.hlpt.2020.08.009</pub-id><pub-id pub-id-type="pmcid">PMC7455549</pub-id></element-citation></ref><ref id="bb0475"><label>95</label><element-citation publication-type="journal" id="rf0475"><person-group person-group-type="author"><name name-style="western"><surname>Rubin</surname><given-names>R.</given-names></name></person-group><article-title>Difficult to determine herd immunity threshold for COVID-19</article-title><source>JAMA</source><volume>324</volume><year>2020</year><fpage>732</fpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1001/jama.2020.14778</pub-id><pub-id pub-id-type="pmid">32840583</pub-id></element-citation></ref><ref id="bb0480"><label>96</label><element-citation publication-type="journal" id="rf0480"><person-group person-group-type="author"><name name-style="western"><surname>Mo</surname><given-names>H.</given-names></name><name name-style="western"><surname>Zeng</surname><given-names>G.</given-names></name><name name-style="western"><surname>Ren</surname><given-names>X.</given-names></name><name name-style="western"><surname>Li</surname><given-names>H.</given-names></name><name name-style="western"><surname>Ke</surname><given-names>C.</given-names></name><name name-style="western"><surname>Tan</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Cai</surname><given-names>C.</given-names></name><name name-style="western"><surname>Lai</surname><given-names>K.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>R.</given-names></name><name name-style="western"><surname>Chan-Yeung</surname><given-names>M.</given-names></name><name name-style="western"><surname>Zhong</surname><given-names>N.</given-names></name></person-group><article-title>Longitudinal profile of antibodies against SARS-coronavirus in SARS patients and their clinical significance</article-title><source>Respirology</source><volume>11</volume><year>2006</year><fpage>49</fpage><lpage>53</lpage><pub-id pub-id-type="pmid">16423201</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/j.1440-1843.2006.00783.x</pub-id><pub-id pub-id-type="pmcid">PMC7192223</pub-id></element-citation></ref><ref id="bb0485"><label>97</label><element-citation publication-type="journal" id="rf0485"><person-group person-group-type="author"><name name-style="western"><surname>Tang</surname><given-names>F.</given-names></name><name name-style="western"><surname>Quan</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Xin</surname><given-names>Z.T.</given-names></name><name name-style="western"><surname>Wrammert</surname><given-names>J.</given-names></name><name name-style="western"><surname>Ma</surname><given-names>M.J.</given-names></name><name name-style="western"><surname>Lv</surname><given-names>H.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>T.B.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>H.</given-names></name><name name-style="western"><surname>Richardus</surname><given-names>J.H.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>W.</given-names></name><name name-style="western"><surname>Cao</surname><given-names>W.C.</given-names></name></person-group><article-title>Lack of peripheral memory B cell responses in recovered patients with severe acute respiratory syndrome: a six-year follow-up study</article-title><source>J. Immunol.</source><volume>186</volume><year>2011</year><fpage>7264</fpage><lpage>7268</lpage><pub-id pub-id-type="pmid">21576510</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.4049/jimmunol.0903490</pub-id></element-citation></ref><ref id="bb0490"><label>98</label><element-citation publication-type="journal" id="rf0490"><person-group person-group-type="author"><name name-style="western"><surname>Kissler</surname><given-names>S.M.</given-names></name><name name-style="western"><surname>Tedijanto</surname><given-names>C.</given-names></name><name name-style="western"><surname>Goldstein</surname><given-names>E.</given-names></name><name name-style="western"><surname>Grad</surname><given-names>Y.H.</given-names></name><name name-style="western"><surname>Lipsitch</surname><given-names>M.</given-names></name></person-group><article-title>Projecting the transmission dynamics of SARS-CoV-2 through the postpandemic period</article-title><source>Science</source><volume>368</volume><year>2020</year><fpage>860</fpage><lpage>868</lpage><pub-id pub-id-type="pmid">32291278</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1126/science.abb5793</pub-id><pub-id pub-id-type="pmcid">PMC7164482</pub-id></element-citation></ref><ref id="bb0495"><label>99</label><element-citation publication-type="journal" id="rf0495"><person-group person-group-type="author"><name name-style="western"><surname>Zhao</surname><given-names>J.</given-names></name><name name-style="western"><surname>Yuan</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>H.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>W.</given-names></name><name name-style="western"><surname>Liao</surname><given-names>X.</given-names></name><etal/></person-group><article-title>Antibody responses to SARS-CoV-2 in patients of novel coronavirus disease 2019</article-title><source>Clin. Infect. Dis.</source><volume>71</volume><year>2020</year><fpage>2027</fpage><lpage>2034</lpage><pub-id pub-id-type="pmid">32221519</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/cid/ciaa344</pub-id><pub-id pub-id-type="pmcid">PMC7184337</pub-id></element-citation></ref><ref id="bb0500"><label>100</label><element-citation publication-type="journal" id="rf0500"><person-group person-group-type="author"><name name-style="western"><surname>Wu</surname><given-names>F.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>A.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>M.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>J.</given-names></name><etal/></person-group><article-title>Neutralizing antibody responses to SARS-CoV-2 in a COVID-19 recovered patient cohort and their implications</article-title><source>medRxiv</source><year>2020</year><pub-id pub-id-type="doi">10.1101/2020.03.30.20047365</pub-id></element-citation></ref><ref id="bb0505"><label>101</label><element-citation publication-type="journal" id="rf0505"><person-group person-group-type="author"><name name-style="western"><surname>Lan</surname><given-names>L.</given-names></name><name name-style="western"><surname>Xu</surname><given-names>D.</given-names></name><name name-style="western"><surname>Ye</surname><given-names>G.</given-names></name><name name-style="western"><surname>Xia</surname><given-names>C.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>S.</given-names></name><name name-style="western"><surname>Li</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Xu</surname><given-names>H.</given-names></name></person-group><article-title>Positive RT-PCR test results in patients recovered from COVID-19</article-title><source>JAMA</source><volume>323</volume><year>2020</year><fpage>1502</fpage><lpage>1503</lpage><pub-id pub-id-type="pmid">32105304</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1001/jama.2020.2783</pub-id><pub-id pub-id-type="pmcid">PMC7047852</pub-id></element-citation></ref><ref id="bb0510"><label>102</label><element-citation publication-type="journal" id="rf0510"><person-group person-group-type="author"><name name-style="western"><surname>Moore</surname><given-names>J.L.</given-names></name><name name-style="western"><surname>Ganapathiraju</surname><given-names>P.V.</given-names></name><name name-style="western"><surname>Kurtz</surname><given-names>C.P.</given-names></name><name name-style="western"><surname>Wainscoat</surname><given-names>B.</given-names></name></person-group><article-title>A 63-year-old woman with a history of non-hodgkin lymphoma with persistent SARS-CoV-2 infection who was seronegative and treated with convalescent plasma</article-title><source>Am. J. Case Rep.</source><volume>21</volume><year>2020</year><object-id pub-id-type="publisher-id">e927812</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.12659/AJCR.927812</pub-id><pub-id pub-id-type="pmcid">PMC7542548</pub-id><pub-id pub-id-type="pmid">33009361</pub-id></element-citation></ref><ref id="bb0515"><label>103</label><element-citation publication-type="journal" id="rf0515"><person-group person-group-type="author"><name name-style="western"><surname>Madan</surname><given-names>M.</given-names></name><name name-style="western"><surname>Kunal</surname><given-names>S.</given-names></name></person-group><article-title>COVID-19 reinfection or relapse: an intriguing dilemma</article-title><source>Clin. Rheumatol.</source><volume>39</volume><year>2020</year><fpage>3189</fpage><pub-id pub-id-type="pmid">32980985</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s10067-020-05427-3</pub-id><pub-id pub-id-type="pmcid">PMC7519850</pub-id></element-citation></ref><ref id="bb0520"><label>104</label><element-citation publication-type="journal" id="rf0520"><person-group person-group-type="author"><name name-style="western"><surname>Seow</surname><given-names>J.</given-names></name><name name-style="western"><surname>Graham</surname><given-names>C.</given-names></name><name name-style="western"><surname>Merrick</surname><given-names>B.</given-names></name><name name-style="western"><surname>Acors</surname><given-names>S.</given-names></name><name name-style="western"><surname>Pickering</surname><given-names>S.</given-names></name><etal/></person-group><article-title>Longitudinal observation and decline of neutralizing antibody responses in the three months following SARS-CoV-2 infection in humans</article-title><source>Nat. Microbiol.</source><volume>5</volume><year>2020</year><fpage>1598</fpage><lpage>1607</lpage><pub-id pub-id-type="pmid">33106674</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41564-020-00813-8</pub-id><pub-id pub-id-type="pmcid">PMC7610833</pub-id></element-citation></ref><ref id="bb0525"><label>105</label><element-citation publication-type="journal" id="rf0525"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>M.</given-names></name><name name-style="western"><surname>Li</surname><given-names>M.</given-names></name><name name-style="western"><surname>Ren</surname><given-names>R.</given-names></name><name name-style="western"><surname>Li</surname><given-names>L.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>E.Q.</given-names></name><name name-style="western"><surname>Li</surname><given-names>W.</given-names></name><name name-style="western"><surname>Ying</surname><given-names>B.</given-names></name></person-group><article-title>International expansion of a novel SARS-CoV-2 mutant</article-title><source>J. Virol.</source><volume>94</volume><year>2020</year><pub-id pub-id-type="doi" assigning-authority="pmc">10.1128/JVI.00567-20</pub-id><pub-id pub-id-type="pmcid">PMC7307084</pub-id><pub-id pub-id-type="pmid">32269121</pub-id></element-citation></ref><ref id="bb0530"><label>106</label><element-citation publication-type="other" id="rf0530"><person-group person-group-type="author"><name name-style="western"><surname>World Health Organization</surname></name></person-group><article-title>Q&amp;A: Influenza and COVID-19 - Similarities and Differences</article-title><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.who.int/westernpacific/news/q-a-detail/q-a-similarities-and-differences-covid-19-and-influenza" id="ir0380">https://www.who.int/westernpacific/news/q-a-detail/q-a-similarities-and-differences-covid-19-and-influenza</ext-link><year>2020</year></element-citation></ref><ref id="bb0535"><label>107</label><element-citation publication-type="other" id="rf0535"><person-group person-group-type="author"><name name-style="western"><surname>Centers for Disease Control &amp; Prevention</surname></name></person-group><article-title>Estimated Influenza Illnesses, Medical visits, Hospitalizations, and Deaths in the United States &#8212; 2019&#8211;2020 Influenza Season</article-title><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.cdc.gov/flu/about/burden/2019-2020.html" id="ir0385">https://www.cdc.gov/flu/about/burden/2019-2020.html</ext-link><year>2020</year></element-citation></ref><ref id="bb0540"><label>108</label><element-citation publication-type="other" id="rf0540"><person-group person-group-type="author"><name name-style="western"><surname>CNN</surname></name></person-group><article-title>More People Have Died from Covid-19 than in the Past 5 Flu Seasons Combined. And Coronavirus is Much More Contagious</article-title><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.cnn.com/2020/10/06/health/flu-covid-19-deaths-comparison-trnd/index.html" id="ir0390">https://www.cnn.com/2020/10/06/health/flu-covid-19-deaths-comparison-trnd/index.html</ext-link><year>2020</year></element-citation></ref><ref id="bb0545"><label>109</label><element-citation publication-type="journal" id="rf0545"><person-group person-group-type="author"><name name-style="western"><surname>Biswas</surname><given-names>A.</given-names></name><name name-style="western"><surname>Bhattacharjee</surname><given-names>U.</given-names></name><name name-style="western"><surname>Chakrabarti</surname><given-names>A.K.</given-names></name><name name-style="western"><surname>Tewari</surname><given-names>D.N.</given-names></name><name name-style="western"><surname>Banu</surname><given-names>H.</given-names></name><name name-style="western"><surname>Dutta</surname><given-names>S.</given-names></name></person-group><article-title>Emergence of novel coronavirus and COVID-19: whether to stay or die out?</article-title><source>Crit. Rev. Microbiol.</source><volume>46</volume><year>2020</year><fpage>182</fpage><lpage>193</lpage><pub-id pub-id-type="pmid">32282268</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1080/1040841X.2020.1739001</pub-id><pub-id pub-id-type="pmcid">PMC7157960</pub-id></element-citation></ref><ref id="bb0550"><label>110</label><element-citation publication-type="book" id="rf0550"><person-group person-group-type="author"><name name-style="western"><surname>Janeway</surname><given-names>C.A.</given-names><suffix>Jr.</suffix></name><name name-style="western"><surname>Travers</surname><given-names>P.</given-names></name><name name-style="western"><surname>Walport</surname><given-names>M.</given-names></name></person-group><part-title>Immunobiology: the immune system in health and disease</part-title><source>Infectious Agents and How They Cause Disease</source><edition>5th ed.</edition><year>2001</year><publisher-name>Garland Science</publisher-name><publisher-loc>New York</publisher-loc><fpage>455</fpage><lpage>465</lpage></element-citation></ref><ref id="bb0555"><label>111</label><element-citation publication-type="book" id="rf0555"><person-group person-group-type="author"><name name-style="western"><surname>Alberts</surname><given-names>B.</given-names></name><name name-style="western"><surname>Johnson</surname><given-names>A.</given-names></name><name name-style="western"><surname>Lewis</surname><given-names>J.</given-names></name></person-group><part-title>Molecular Biology of the Cell. Pathogens and Infection</part-title><edition>4th ed.</edition><year>2002</year><publisher-name>Garland Science</publisher-name><publisher-loc>New York</publisher-loc><fpage>1263</fpage><lpage>1268</lpage></element-citation></ref><ref id="bb0560"><label>112</label><element-citation publication-type="book" id="rf0560"><person-group person-group-type="author"><name name-style="western"><surname>Louten</surname><given-names>J.</given-names></name></person-group><part-title>Chapter 2 - virus structure and classification</part-title><person-group person-group-type="editor"><name name-style="western"><surname>Louten</surname><given-names>J.</given-names></name></person-group><source>Essential Human Virology</source><year>2016</year><publisher-name>Academic Press</publisher-name><publisher-loc>Boston</publisher-loc><fpage>19</fpage><lpage>29</lpage></element-citation></ref><ref id="bb0565"><label>113</label><element-citation publication-type="journal" id="rf0565"><person-group person-group-type="author"><name name-style="western"><surname>Afrough</surname><given-names>B.</given-names></name><name name-style="western"><surname>Dowall</surname><given-names>S.</given-names></name><name name-style="western"><surname>Hewson</surname><given-names>R.</given-names></name></person-group><article-title>Emerging viruses and current strategies for vaccine intervention</article-title><source>Clin. Exp. Immunol.</source><volume>196</volume><year>2019</year><fpage>157</fpage><lpage>166</lpage><pub-id pub-id-type="pmid">30993690</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/cei.13295</pub-id><pub-id pub-id-type="pmcid">PMC6468171</pub-id></element-citation></ref><ref id="bb0570"><label>114</label><element-citation publication-type="journal" id="rf0570"><person-group person-group-type="author"><name name-style="western"><surname>Fauci</surname><given-names>A.S.</given-names></name><name name-style="western"><surname>Marston</surname><given-names>H.D.</given-names></name></person-group><article-title>PUBLIC HEALTH. Toward an HIV vaccine: a scientific journey</article-title><source>Science</source><volume>349</volume><year>2015</year><fpage>386</fpage><lpage>387</lpage><pub-id pub-id-type="pmid">26206922</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1126/science.aac6300</pub-id></element-citation></ref><ref id="bb0575"><label>115</label><element-citation publication-type="journal" id="rf0575"><person-group person-group-type="author"><name name-style="western"><surname>Peeples</surname><given-names>L.</given-names></name><name name-style="western"><surname>Feature</surname><given-names>News</given-names></name></person-group><article-title>Avoiding pitfalls in the pursuit of a COVID-19 vaccine</article-title><source>Proc. Natl. Acad. Sci. U. S. A.</source><volume>117</volume><year>2020</year><fpage>8218</fpage><lpage>8221</lpage><pub-id pub-id-type="pmid">32229574</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1073/pnas.2005456117</pub-id><pub-id pub-id-type="pmcid">PMC7165470</pub-id></element-citation></ref><ref id="bb0580"><label>116</label><element-citation publication-type="journal" id="rf0580"><person-group person-group-type="author"><name name-style="western"><surname>Thanh Le</surname><given-names>T.</given-names></name><name name-style="western"><surname>Andreadakis</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Kumar</surname><given-names>A.</given-names></name><name name-style="western"><surname>Gomez Roman</surname><given-names>R.</given-names></name><name name-style="western"><surname>Tollefsen</surname><given-names>S.</given-names></name><name name-style="western"><surname>Saville</surname><given-names>M.</given-names></name><name name-style="western"><surname>Mayhew</surname><given-names>S.</given-names></name></person-group><article-title>The COVID-19 vaccine development landscape</article-title><source>Nat. Rev. Drug Discov.</source><volume>19</volume><year>2020</year><fpage>305</fpage><lpage>306</lpage><pub-id pub-id-type="pmid">32273591</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/d41573-020-00073-5</pub-id></element-citation></ref><ref id="bb0585"><label>117</label><element-citation publication-type="journal" id="rf0585"><person-group person-group-type="author"><name name-style="western"><surname>Pandey</surname><given-names>S.C.</given-names></name><name name-style="western"><surname>Pande</surname><given-names>V.</given-names></name><name name-style="western"><surname>Sati</surname><given-names>D.</given-names></name><name name-style="western"><surname>Upreti</surname><given-names>S.</given-names></name><name name-style="western"><surname>Samant</surname><given-names>M.</given-names></name></person-group><article-title>Vaccination strategies to combat novel corona virus SARS-CoV-2</article-title><source>Life Sci.</source><volume>256</volume><year>2020</year><fpage>117956</fpage><pub-id pub-id-type="pmid">32535078</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.lfs.2020.117956</pub-id><pub-id pub-id-type="pmcid">PMC7289747</pub-id></element-citation></ref><ref id="bb0590"><label>118</label><element-citation publication-type="journal" id="rf0590"><person-group person-group-type="author"><name name-style="western"><surname>Buckland</surname><given-names>B.C.</given-names></name></person-group><article-title>The process development challenge for a new vaccine</article-title><source>Nat. Med.</source><volume>11</volume><year>2005</year><fpage>S16</fpage><lpage>S19</lpage><pub-id pub-id-type="pmid">15812483</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/nm1218</pub-id></element-citation></ref><ref id="bb0595"><label>119</label><element-citation publication-type="journal" id="rf0595"><person-group person-group-type="author"><name name-style="western"><surname>Hajj Hussein</surname><given-names>I.</given-names></name><name name-style="western"><surname>Chams</surname><given-names>N.</given-names></name><name name-style="western"><surname>Chams</surname><given-names>S.</given-names></name><name name-style="western"><surname>El Sayegh</surname><given-names>S.</given-names></name><name name-style="western"><surname>Badran</surname><given-names>R.</given-names></name><name name-style="western"><surname>Raad</surname><given-names>M.</given-names></name><name name-style="western"><surname>Gerges-Geagea</surname><given-names>A.</given-names></name><name name-style="western"><surname>Leone</surname><given-names>A.</given-names></name><name name-style="western"><surname>Jurjus</surname><given-names>A.</given-names></name></person-group><article-title>Vaccines through centuries: major cornerstones of global health</article-title><source>Front. Public Health</source><volume>3</volume><year>2015</year><fpage>269</fpage><pub-id pub-id-type="pmid">26636066</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fpubh.2015.00269</pub-id><pub-id pub-id-type="pmcid">PMC4659912</pub-id></element-citation></ref><ref id="bb0600"><label>120</label><element-citation publication-type="journal" id="rf0600"><person-group person-group-type="author"><name name-style="western"><surname>Delany</surname><given-names>I.</given-names></name><name name-style="western"><surname>Rappuoli</surname><given-names>R.</given-names></name><name name-style="western"><surname>De Gregorio</surname><given-names>E.</given-names></name></person-group><article-title>Vaccines for the 21st century</article-title><source>EMBO Mol. Med.</source><volume>6</volume><year>2014</year><fpage>708</fpage><lpage>720</lpage><pub-id pub-id-type="pmid">24803000</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/emmm.201403876</pub-id><pub-id pub-id-type="pmcid">PMC4203350</pub-id></element-citation></ref><ref id="bb0605"><label>121</label><element-citation publication-type="book" id="rf0605"><person-group person-group-type="editor"><name name-style="western"><surname>Levine</surname><given-names>M.M.</given-names></name><name name-style="western"><surname>Woodrow</surname><given-names>G.C.</given-names></name><name name-style="western"><surname>Kaper</surname><given-names>J.B.</given-names></name><name name-style="western"><surname>Cobon</surname><given-names>G.S.</given-names></name></person-group><source>New Generation Vaccines</source><edition>2nd ed.</edition><year>1997</year><publisher-name>Marcel Dekker</publisher-name><publisher-loc>New York</publisher-loc></element-citation></ref><ref id="bb0610"><label>122</label><element-citation publication-type="book" id="rf0610"><person-group person-group-type="editor"><name name-style="western"><surname>Salisbury</surname><given-names>D.</given-names></name><name name-style="western"><surname>Ramsay</surname><given-names>M.</given-names></name><name name-style="western"><surname>Noakes</surname><given-names>K.</given-names></name></person-group><source>Immunization Against Infectious Disease</source><year>2006</year><publisher-name>Green Book</publisher-name></element-citation></ref><ref id="bb0615"><label>123</label><element-citation publication-type="journal" id="rf0615"><person-group person-group-type="author"><name name-style="western"><surname>Jang</surname><given-names>Y.H.</given-names></name><name name-style="western"><surname>Seong</surname><given-names>B.L.</given-names></name></person-group><article-title>Principles underlying rational design of live attenuated influenza vaccines</article-title><source>Clin. Exp. Vaccine Res.</source><volume>1</volume><year>2012</year><fpage>35</fpage><lpage>49</lpage><pub-id pub-id-type="pmid">23596576</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.7774/cevr.2012.1.1.35</pub-id><pub-id pub-id-type="pmcid">PMC3623510</pub-id></element-citation></ref><ref id="bb0620"><label>124</label><element-citation publication-type="journal" id="rf0620"><person-group person-group-type="author"><name name-style="western"><surname>Lee</surname><given-names>N.H.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>J.A.</given-names></name><name name-style="western"><surname>Park</surname><given-names>S.Y.</given-names></name><name name-style="western"><surname>Song</surname><given-names>C.S.</given-names></name><name name-style="western"><surname>Choi</surname><given-names>I.S.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>J.B.</given-names></name></person-group><article-title>A review of vaccine development and research for industry animals in Korea</article-title><source>Clin. Exp. Vaccine Res.</source><volume>1</volume><year>2012</year><fpage>18</fpage><lpage>34</lpage><pub-id pub-id-type="pmid">23596575</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.7774/cevr.2012.1.1.18</pub-id><pub-id pub-id-type="pmcid">PMC3623508</pub-id></element-citation></ref><ref id="bb0625"><label>125</label><element-citation publication-type="journal" id="rf0625"><person-group person-group-type="author"><name name-style="western"><surname>Hanley</surname><given-names>K.A.</given-names></name></person-group><article-title>The double-edged sword: How evolution can make or break a live-attenuated virus vaccine</article-title><source>Evolution</source><volume>4</volume><year>2011</year><fpage>635</fpage><lpage>643</lpage><pub-id pub-id-type="pmid">22468165</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s12052-011-0365-y</pub-id><pub-id pub-id-type="pmcid">PMC3314307</pub-id></element-citation></ref><ref id="bb0630"><label>126</label><element-citation publication-type="journal" id="rf0630"><person-group person-group-type="author"><name name-style="western"><surname>Minor</surname><given-names>P.D.</given-names></name><name name-style="western"><surname>vaccines</surname><given-names>Live attenuated</given-names></name></person-group><article-title>Historical successes and current challenges</article-title><source>Virology</source><volume>479&#8211;480</volume><year>2015</year><fpage>379</fpage><lpage>392</lpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.virol.2015.03.032</pub-id><pub-id pub-id-type="pmid">25864107</pub-id></element-citation></ref><ref id="bb0635"><label>127</label><element-citation publication-type="journal" id="rf0635"><person-group person-group-type="author"><name name-style="western"><surname>Clem</surname><given-names>A.S.</given-names></name></person-group><article-title>Fundamentals of vaccine immunology</article-title><source>J. Global Infect. Dis.</source><volume>3</volume><year>2011</year><fpage>73</fpage><lpage>78</lpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.4103/0974-777X.77299</pub-id><pub-id pub-id-type="pmcid">PMC3068582</pub-id><pub-id pub-id-type="pmid">21572612</pub-id></element-citation></ref><ref id="bb0640"><label>128</label><element-citation publication-type="journal" id="rf0640"><person-group person-group-type="author"><name name-style="western"><surname>Dudek</surname><given-names>T.</given-names></name><name name-style="western"><surname>Knipe</surname><given-names>D.M.</given-names></name></person-group><article-title>Replication-defective viruses as vaccines and vaccine vectors</article-title><source>Virology</source><volume>344</volume><year>2006</year><fpage>230</fpage><lpage>239</lpage><pub-id pub-id-type="pmid">16364753</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.virol.2005.09.020</pub-id></element-citation></ref><ref id="bb0645"><label>129</label><element-citation publication-type="journal" id="rf0645"><person-group person-group-type="author"><name name-style="western"><surname>Loudon</surname><given-names>P.T.</given-names></name><name name-style="western"><surname>Blakeley</surname><given-names>D.M.</given-names></name><name name-style="western"><surname>Boursnell</surname><given-names>M.E.</given-names></name><name name-style="western"><surname>Day</surname><given-names>D.A.</given-names></name><name name-style="western"><surname>Duncan</surname><given-names>I.A.</given-names></name><name name-style="western"><surname>Lowden</surname><given-names>R.C.</given-names></name><name name-style="western"><surname>McLean</surname><given-names>C.S.</given-names></name><name name-style="western"><surname>Martin</surname><given-names>G.</given-names></name><name name-style="western"><surname>Miller</surname><given-names>J.C.</given-names></name><name name-style="western"><surname>Shaw</surname><given-names>M.L.</given-names></name></person-group><article-title>Preclinical safety testing of DISC-hGMCSF to support phase I clinical trials in cancer patients</article-title><source>J. Gene Med.</source><volume>3</volume><year>2001</year><fpage>458</fpage><lpage>467</lpage><pub-id pub-id-type="pmid">11601759</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/jgm.206</pub-id></element-citation></ref><ref id="bb0650"><label>130</label><element-citation publication-type="journal" id="rf0650"><person-group person-group-type="author"><name name-style="western"><surname>Nguyen</surname><given-names>L.H.</given-names></name><name name-style="western"><surname>Knipe</surname><given-names>D.M.</given-names></name><name name-style="western"><surname>Finberg</surname><given-names>R.W.</given-names></name></person-group><article-title>Replication-defective mutants of herpes simplex virus (HSV) induce cellular immunity and protect against lethal HSV infection</article-title><source>J. Virol.</source><volume>66</volume><year>1992</year><fpage>7067</fpage><lpage>7072</lpage><pub-id pub-id-type="pmid">1331509</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1128/jvi.66.12.7067-7072.1992</pub-id><pub-id pub-id-type="pmcid">PMC240374</pub-id></element-citation></ref><ref id="bb0655"><label>131</label><element-citation publication-type="journal" id="rf0655"><person-group person-group-type="author"><name name-style="western"><surname>Morrison</surname><given-names>L.A.</given-names></name><name name-style="western"><surname>Knipe</surname><given-names>D.M.</given-names></name></person-group><article-title>Mechanisms of immunization with a replication-defective mutant of herpes simplex virus 1</article-title><source>Virology</source><volume>220</volume><year>1996</year><fpage>402</fpage><lpage>413</lpage><pub-id pub-id-type="pmid">8661391</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1006/viro.1996.0328</pub-id></element-citation></ref><ref id="bb0660"><label>132</label><element-citation publication-type="journal" id="rf0660"><person-group person-group-type="author"><name name-style="western"><surname>Da Costa</surname><given-names>X.</given-names></name><name name-style="western"><surname>Kramer</surname><given-names>M.F.</given-names></name><name name-style="western"><surname>Zhu</surname><given-names>J.</given-names></name><name name-style="western"><surname>Brockman</surname><given-names>M.A.</given-names></name><name name-style="western"><surname>Knipe</surname><given-names>D.M.</given-names></name></person-group><article-title>Construction, phenotypic analysis, and immunogenicity of a UL5/UL29 double deletion mutant of herpes simplex virus 2</article-title><source>J. Virol.</source><volume>74</volume><year>2000</year><fpage>7963</fpage><lpage>7971</lpage><pub-id pub-id-type="pmid">10933704</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1128/jvi.74.17.7963-7971.2000</pub-id><pub-id pub-id-type="pmcid">PMC112327</pub-id></element-citation></ref><ref id="bb0665"><label>133</label><element-citation publication-type="journal" id="rf0665"><person-group person-group-type="author"><name name-style="western"><surname>Gomez Lorenzo</surname><given-names>M.M.</given-names></name><name name-style="western"><surname>Fenton</surname><given-names>M.J.</given-names></name></person-group><article-title>Immunobiology of influenza vaccines</article-title><source>Chest</source><volume>143</volume><year>2013</year><fpage>502</fpage><lpage>510</lpage><pub-id pub-id-type="pmid">23381315</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1378/chest.12-1711</pub-id><pub-id pub-id-type="pmcid">PMC3619640</pub-id></element-citation></ref><ref id="bb0670"><label>134</label><element-citation publication-type="journal" id="rf0670"><person-group person-group-type="author"><name name-style="western"><surname>Pulendran</surname><given-names>B.</given-names></name><name name-style="western"><surname>Ahmed</surname><given-names>R.</given-names></name></person-group><article-title>Immunological mechanisms of vaccination</article-title><source>Nat. Immunol.</source><volume>12</volume><year>2011</year><fpage>509</fpage><lpage>517</lpage><pub-id pub-id-type="pmid">21739679</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/ni.2039</pub-id><pub-id pub-id-type="pmcid">PMC3253344</pub-id></element-citation></ref><ref id="bb0675"><label>135</label><element-citation publication-type="journal" id="rf0675"><person-group person-group-type="author"><name name-style="western"><surname>Le Nouen</surname><given-names>C.</given-names></name><name name-style="western"><surname>Collins</surname><given-names>P.L.</given-names></name><name name-style="western"><surname>Buchholz</surname><given-names>U.J.</given-names></name></person-group><article-title>Attenuation of human respiratory viruses by synonymous genome recoding</article-title><source>Front. Immunol.</source><volume>10</volume><year>2019</year><fpage>1250</fpage><pub-id pub-id-type="pmid">31231383</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fimmu.2019.01250</pub-id><pub-id pub-id-type="pmcid">PMC6558635</pub-id></element-citation></ref><ref id="bb0680"><label>136</label><element-citation publication-type="journal" id="rf0680"><person-group person-group-type="author"><name name-style="western"><surname>Meng</surname><given-names>J.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>S.</given-names></name><name name-style="western"><surname>Hotard</surname><given-names>A.L.</given-names></name><name name-style="western"><surname>Moore</surname><given-names>M.L.</given-names></name></person-group><article-title>Refining the balance of attenuation and immunogenicity of respiratory syncytial virus by targeted codon deoptimization of virulence genes</article-title><source>mBio</source><volume>5</volume><year>2014</year><object-id pub-id-type="publisher-id">e01704-01714</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1128/mBio.01704-14</pub-id><pub-id pub-id-type="pmcid">PMC4173764</pub-id><pub-id pub-id-type="pmid">25249281</pub-id></element-citation></ref><ref id="bb0685"><label>137</label><element-citation publication-type="journal" id="rf0685"><issue-title>First Ebola vaccine approved</issue-title><source>Nat. Biotechnol.</source><volume>38</volume><year>2020</year><fpage>6</fpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41587-019-0385-7</pub-id><pub-id pub-id-type="pmid">31919440</pub-id></element-citation></ref><ref id="bb0690"><label>138</label><element-citation publication-type="other" id="rf0690"><person-group person-group-type="author"><name name-style="western"><surname>Pharmaceutical Technology</surname></name></person-group><article-title>Indian Immunologicals, Griffith University to Develop Covid-19 Vaccine</article-title><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.pharmaceutical-technology.com/news/indian-immunologicals-covid-19-vaccine/" id="ir0395">https://www.pharmaceutical-technology.com/news/indian-immunologicals-covid-19-vaccine/</ext-link><year>2020</year></element-citation></ref><ref id="bb0695"><label>139</label><element-citation publication-type="journal" id="rf0695"><person-group person-group-type="author"><name name-style="western"><surname>Ulmer</surname><given-names>J.B.</given-names></name><name name-style="western"><surname>Valley</surname><given-names>U.</given-names></name><name name-style="western"><surname>Rappuoli</surname><given-names>R.</given-names></name></person-group><article-title>Vaccine manufacturing: challenges and solutions</article-title><source>Nat. Biotechnol.</source><volume>24</volume><year>2006</year><fpage>1377</fpage><lpage>1383</lpage><pub-id pub-id-type="pmid">17093488</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/nbt1261</pub-id></element-citation></ref><ref id="bb0700"><label>140</label><element-citation publication-type="journal" id="rf0700"><person-group person-group-type="author"><name name-style="western"><surname>Xia</surname><given-names>S.</given-names></name><name name-style="western"><surname>Duan</surname><given-names>K.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>D.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>H.</given-names></name><etal/></person-group><article-title>Effect of an inactivated vaccine against SARS-CoV-2 on safety and immunogenicity outcomes: interim analysis of 2 randomized clinical trials</article-title><source>JAMA</source><volume>324</volume><year>2020</year><fpage>951</fpage><lpage>960</lpage><pub-id pub-id-type="pmid">32789505</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1001/jama.2020.15543</pub-id><pub-id pub-id-type="pmcid">PMC7426884</pub-id></element-citation></ref><ref id="bb0705"><label>141</label><element-citation publication-type="journal" id="rf0705"><person-group person-group-type="author"><name name-style="western"><surname>Salk</surname><given-names>J.E.</given-names></name><name name-style="western"><surname>Krech</surname><given-names>U.</given-names></name><name name-style="western"><surname>Youngner</surname><given-names>J.S.</given-names></name><name name-style="western"><surname>Bennett</surname><given-names>B.L.</given-names></name><name name-style="western"><surname>Lewis</surname><given-names>L.J.</given-names></name><name name-style="western"><surname>Bazeley</surname><given-names>P.L.</given-names></name></person-group><article-title>Formaldehyde treatment and safety testing of experimental poliomyelitis vaccines</article-title><source>Am. J. Public Health Nations Health</source><volume>44</volume><year>1954</year><fpage>563</fpage><lpage>570</lpage><pub-id pub-id-type="pmid">13148396</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2105/ajph.44.5.563</pub-id><pub-id pub-id-type="pmcid">PMC1620937</pub-id></element-citation></ref><ref id="bb0710"><label>142</label><element-citation publication-type="journal" id="rf0710"><person-group person-group-type="author"><name name-style="western"><surname>Morales</surname><given-names>M.</given-names></name><name name-style="western"><surname>Tangermann</surname><given-names>R.H.</given-names></name><name name-style="western"><surname>Wassilak</surname><given-names>S.G.</given-names></name></person-group><article-title>Progress toward polio eradication - worldwide, 2015&#8211;2016</article-title><source>MMWR Morb. Mortal. Wkly Rep.</source><volume>65</volume><year>2016</year><fpage>470</fpage><lpage>473</lpage><pub-id pub-id-type="pmid">27171208</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.15585/mmwr.mm6518a4</pub-id></element-citation></ref><ref id="bb0715"><label>143</label><element-citation publication-type="journal" id="rf0715"><person-group person-group-type="author"><name name-style="western"><surname>Cunningham</surname><given-names>A.L.</given-names></name><name name-style="western"><surname>Garcon</surname><given-names>N.</given-names></name><name name-style="western"><surname>Leo</surname><given-names>O.</given-names></name><name name-style="western"><surname>Friedland</surname><given-names>L.R.</given-names></name><name name-style="western"><surname>Strugnell</surname><given-names>R.</given-names></name><name name-style="western"><surname>Laupeze</surname><given-names>B.</given-names></name><name name-style="western"><surname>Doherty</surname><given-names>M.</given-names></name><name name-style="western"><surname>Stern</surname><given-names>P.</given-names></name></person-group><article-title>Vaccine development: from concept to early clinical testing</article-title><source>Vaccine</source><volume>34</volume><year>2016</year><fpage>6655</fpage><lpage>6664</lpage><pub-id pub-id-type="pmid">27769596</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.vaccine.2016.10.016</pub-id></element-citation></ref><ref id="bb0720"><label>144</label><element-citation publication-type="journal" id="rf0720"><person-group person-group-type="author"><name name-style="western"><surname>Vogel</surname><given-names>F.R.</given-names></name></person-group><article-title>Improving vaccine performance with adjuvants</article-title><source>Clin. Infect. Dis.</source><volume>30</volume><issue>Suppl. 3</issue><year>2000</year><fpage>S266</fpage><lpage>S270</lpage><pub-id pub-id-type="pmid">10875797</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1086/313883</pub-id></element-citation></ref><ref id="bb0725"><label>145</label><element-citation publication-type="journal" id="rf0725"><person-group person-group-type="author"><name name-style="western"><surname>Gao</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Bao</surname><given-names>L.</given-names></name><name name-style="western"><surname>Mao</surname><given-names>H.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>L.</given-names></name><name name-style="western"><surname>Xu</surname><given-names>K.</given-names></name><etal/></person-group><article-title>Development of an inactivated vaccine candidate for SARS-CoV-2</article-title><source>Science</source><volume>369</volume><year>2020</year><fpage>77</fpage><lpage>81</lpage><pub-id pub-id-type="pmid">32376603</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1126/science.abc1932</pub-id><pub-id pub-id-type="pmcid">PMC7202686</pub-id></element-citation></ref><ref id="bb0730"><label>146</label><element-citation publication-type="other" id="rf0730"><person-group person-group-type="author"><name name-style="western"><surname>SINOVAC</surname></name></person-group><article-title>Sinovac Announces Positive Preliminary Results of Phase I/II Clinical Trials for Inactivated Vaccine Candidate Against COVID-19</article-title><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.sinovac.com/?optionid=754&amp;auto_id=904" id="ir0400">http://www.sinovac.com/?optionid=754&amp;auto_id=904</ext-link><year>2020</year></element-citation></ref><ref id="bb0735"><label>147</label><element-citation publication-type="other" id="rf0735"><person-group person-group-type="author"><name name-style="western"><surname>ContagionLive</surname></name></person-group><article-title>The COVID-19 Live Vaccine Tracker</article-title><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.contagionlive.com/view/the-covid19-live-vaccine-tracker" id="ir0405">https://www.contagionlive.com/view/the-covid19-live-vaccine-tracker</ext-link><year>2020</year></element-citation></ref><ref id="bb0740"><label>148</label><element-citation publication-type="other" id="rf0740"><person-group person-group-type="author"><name name-style="western"><surname>Wire</surname><given-names>T.</given-names></name></person-group><article-title>COVID-19: Bharat Biotech's Covaxin Expected To Be 60% Effective, Company Says</article-title><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://science.thewire.in/health/covid-19-bharat-biotechs-covaxin-expected-to-be-60-effective-company-says/" id="ir0410">https://science.thewire.in/health/covid-19-bharat-biotechs-covaxin-expected-to-be-60-effective-company-says/</ext-link><year>2020</year></element-citation></ref><ref id="bb0745"><label>149</label><element-citation publication-type="book" id="rf0745"><person-group person-group-type="author"><name name-style="western"><surname>Isakova-Sivak</surname><given-names>I.</given-names></name><name name-style="western"><surname>Rudenko</surname><given-names>L.</given-names></name></person-group><part-title>A promising inactivated whole-virion SARS-CoV-2 vaccine</part-title><source>Lancet Infect Dis</source><year>2020</year><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S1473-3099(20)30832-X</pub-id><pub-id pub-id-type="pmcid">PMC7561316</pub-id><pub-id pub-id-type="pmid">33069282</pub-id></element-citation></ref><ref id="bb0750"><label>150</label><element-citation publication-type="journal" id="rf0750"><person-group person-group-type="author"><name name-style="western"><surname>Liu</surname><given-names>M.A.</given-names></name><name name-style="western"><surname>Wahren</surname><given-names>B.</given-names></name><name name-style="western"><surname>Karlsson Hedestam</surname><given-names>G.B.</given-names></name></person-group><article-title>DNA vaccines: recent developments and future possibilities</article-title><source>Hum. Gene Ther.</source><volume>17</volume><year>2006</year><fpage>1051</fpage><lpage>1061</lpage><pub-id pub-id-type="pmid">17032152</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1089/hum.2006.17.1051</pub-id></element-citation></ref><ref id="bb0755"><label>151</label><element-citation publication-type="journal" id="rf0755"><person-group person-group-type="author"><name name-style="western"><surname>Restifo</surname><given-names>N.P.</given-names></name><name name-style="western"><surname>Ying</surname><given-names>H.</given-names></name><name name-style="western"><surname>Hwang</surname><given-names>L.</given-names></name><name name-style="western"><surname>Leitner</surname><given-names>W.W.</given-names></name></person-group><article-title>The promise of nucleic acid vaccines</article-title><source>Gene Ther.</source><volume>7</volume><year>2000</year><fpage>89</fpage><lpage>92</lpage><pub-id pub-id-type="pmid">10673713</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/sj.gt.3301117</pub-id><pub-id pub-id-type="pmcid">PMC2241736</pub-id></element-citation></ref><ref id="bb0760"><label>152</label><element-citation publication-type="journal" id="rf0760"><person-group person-group-type="author"><name name-style="western"><surname>Ledgerwood</surname><given-names>J.E.</given-names></name><name name-style="western"><surname>Pierson</surname><given-names>T.C.</given-names></name><name name-style="western"><surname>Hubka</surname><given-names>S.A.</given-names></name><name name-style="western"><surname>Desai</surname><given-names>N.</given-names></name><name name-style="western"><surname>Rucker</surname><given-names>S.</given-names></name><etal/></person-group><article-title>A West Nile virus DNA vaccine utilizing a modified promoter induces neutralizing antibody in younger and older healthy adults in a phase I clinical trial</article-title><source>J. Infect. Dis.</source><volume>203</volume><year>2011</year><fpage>1396</fpage><lpage>1404</lpage><pub-id pub-id-type="pmid">21398392</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/infdis/jir054</pub-id><pub-id pub-id-type="pmcid">PMC3080891</pub-id></element-citation></ref><ref id="bb0765"><label>153</label><element-citation publication-type="journal" id="rf0765"><person-group person-group-type="author"><name name-style="western"><surname>Boshra</surname><given-names>H.</given-names></name><name name-style="western"><surname>Lorenzo</surname><given-names>G.</given-names></name><name name-style="western"><surname>Rodriguez</surname><given-names>F.</given-names></name><name name-style="western"><surname>Brun</surname><given-names>A.</given-names></name></person-group><article-title>A DNA vaccine encoding ubiquitinated Rift Valley fever virus nucleoprotein provides consistent immunity and protects IFNAR(&#8722;/&#8722;) mice upon lethal virus challenge</article-title><source>Vaccine</source><volume>29</volume><year>2011</year><fpage>4469</fpage><lpage>4475</lpage><pub-id pub-id-type="pmid">21549790</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.vaccine.2011.04.043</pub-id></element-citation></ref><ref id="bb0770"><label>154</label><element-citation publication-type="journal" id="rf0770"><person-group person-group-type="author"><name name-style="western"><surname>Mallilankaraman</surname><given-names>K.</given-names></name><name name-style="western"><surname>Shedlock</surname><given-names>D.J.</given-names></name><name name-style="western"><surname>Bao</surname><given-names>H.</given-names></name><name name-style="western"><surname>Kawalekar</surname><given-names>O.U.</given-names></name><name name-style="western"><surname>Fagone</surname><given-names>P.</given-names></name><etal/></person-group><article-title>A DNA vaccine against chikungunya virus is protective in mice and induces neutralizing antibodies in mice and nonhuman primates</article-title><source>PLoS Negl. Trop. Dis.</source><volume>5</volume><year>2011</year><object-id pub-id-type="publisher-id">e928</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1371/journal.pntd.0000928</pub-id><pub-id pub-id-type="pmcid">PMC3019110</pub-id><pub-id pub-id-type="pmid">21264351</pub-id></element-citation></ref><ref id="bb0775"><label>155</label><element-citation publication-type="journal" id="rf0775"><person-group person-group-type="author"><name name-style="western"><surname>Patel</surname><given-names>A.</given-names></name><name name-style="western"><surname>Reuschel</surname><given-names>E.L.</given-names></name><name name-style="western"><surname>Kraynyak</surname><given-names>K.A.</given-names></name><name name-style="western"><surname>Racine</surname><given-names>T.</given-names></name><name name-style="western"><surname>Park</surname><given-names>D.H.</given-names></name><etal/></person-group><article-title>Protective efficacy and long-term immunogenicity in cynomolgus macaques by Ebola virus glycoprotein synthetic DNA vaccines</article-title><source>J. Infect. Dis.</source><volume>219</volume><year>2019</year><fpage>544</fpage><lpage>555</lpage><pub-id pub-id-type="pmid">30304515</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/infdis/jiy537</pub-id></element-citation></ref><ref id="bb0780"><label>156</label><element-citation publication-type="journal" id="rf0780"><person-group person-group-type="author"><name name-style="western"><surname>Akulova</surname><given-names>E.</given-names></name><name name-style="western"><surname>Murashev</surname><given-names>B.</given-names></name><name name-style="western"><surname>Verevochkin</surname><given-names>S.</given-names></name><name name-style="western"><surname>Masharsky</surname><given-names>A.</given-names></name><name name-style="western"><surname>Al-Shekhadat</surname><given-names>R.</given-names></name><etal/></person-group><article-title>The increase of the magnitude of spontaneous viral blips in some participants of phase II clinical trial of therapeutic optimized HIV DNA vaccine candidate</article-title><source>Vaccines (Basel)</source><volume>7</volume><year>2019</year><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/vaccines7030092</pub-id><pub-id pub-id-type="pmcid">PMC6789887</pub-id><pub-id pub-id-type="pmid">31434305</pub-id></element-citation></ref><ref id="bb0785"><label>157</label><element-citation publication-type="journal" id="rf0785"><person-group person-group-type="author"><name name-style="western"><surname>Pinto</surname><given-names>P.B.A.</given-names></name><name name-style="western"><surname>Assis</surname><given-names>M.L.</given-names></name><name name-style="western"><surname>Vallochi</surname><given-names>A.L.</given-names></name><name name-style="western"><surname>Pacheco</surname><given-names>A.R.</given-names></name><name name-style="western"><surname>Lima</surname><given-names>L.M.</given-names></name><etal/></person-group><article-title>T cell responses induced by DNA vaccines based on the DENV2 E and NS1 proteins in mice: importance in protection and immunodominant epitope identification</article-title><source>Front. Immunol.</source><volume>10</volume><year>2019</year><fpage>1522</fpage><pub-id pub-id-type="pmid">31333657</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fimmu.2019.01522</pub-id><pub-id pub-id-type="pmcid">PMC6617960</pub-id></element-citation></ref><ref id="bb0790"><label>158</label><element-citation publication-type="journal" id="rf0790"><person-group person-group-type="author"><name name-style="western"><surname>Yang</surname><given-names>Z.Y.</given-names></name><name name-style="western"><surname>Kong</surname><given-names>W.P.</given-names></name><name name-style="western"><surname>Huang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Roberts</surname><given-names>A.</given-names></name><name name-style="western"><surname>Murphy</surname><given-names>B.R.</given-names></name><name name-style="western"><surname>Subbarao</surname><given-names>K.</given-names></name><name name-style="western"><surname>Nabel</surname><given-names>G.J.</given-names></name></person-group><article-title>A DNA vaccine induces SARS coronavirus neutralization and protective immunity in mice</article-title><source>Nature</source><volume>428</volume><year>2004</year><fpage>561</fpage><lpage>564</lpage><pub-id pub-id-type="pmid">15024391</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/nature02463</pub-id><pub-id pub-id-type="pmcid">PMC7095382</pub-id></element-citation></ref><ref id="bb0795"><label>159</label><element-citation publication-type="book" id="rf0795"><person-group person-group-type="author"><name name-style="western"><surname>PipelineReview</surname></name></person-group><part-title>INOVIO announces initiation of Phase 2 segment of Phase 2/3 clinical trial for COVID-19 DNA vaccine candidate INO-4800</part-title><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://pipelinereview.com/index.php/2020111776561/Vaccines/INOVIO-announces-initiation-of-Phase-2-segment-of-Phase-2/3-clinical-trial-for-COVID-19-DNA-vaccine-candidate-INO-4800.html" id="ir0415">https://pipelinereview.com/index.php/2020111776561/Vaccines/INOVIO-announces-initiation-of-Phase-2-segment-of-Phase-2/3-clinical-trial-for-COVID-19-DNA-vaccine-candidate-INO-4800.html</ext-link><year>2020</year></element-citation></ref><ref id="bb0800"><label>160</label><element-citation publication-type="other" id="rf0800"><person-group person-group-type="author"><name name-style="western"><surname>BusinessLine</surname></name></person-group><article-title>Zydus Cadila Gets DCGI Nod for Human Trials of Covid-19 Vaccine</article-title><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.thehindubusinessline.com/companies/zydus-cadila-gets-dcgi-nod-for-human-trials-of-covid-19-vaccine/article31977182.ece" id="ir0420">https://www.thehindubusinessline.com/companies/zydus-cadila-gets-dcgi-nod-for-human-trials-of-covid-19-vaccine/article31977182.ece</ext-link><year>2020</year></element-citation></ref><ref id="bb0805"><label>161</label><element-citation publication-type="other" id="rf0805"><person-group person-group-type="author"><name name-style="western"><surname>BioWorld</surname></name></person-group><article-title>South Korea's Genexine begins phase I/IIa trials for COVID-19 vaccine</article-title><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.bioworld.com/articles/435995-south-koreas-genexine-begins-phase-iiia-trials-for-covid-19-vaccine" id="ir0425">https://www.bioworld.com/articles/435995-south-koreas-genexine-begins-phase-iiia-trials-for-covid-19-vaccine</ext-link><year>2020</year></element-citation></ref><ref id="bb0810"><label>162</label><element-citation publication-type="journal" id="rf0810"><person-group person-group-type="author"><name name-style="western"><surname>Ura</surname><given-names>T.</given-names></name><name name-style="western"><surname>Okuda</surname><given-names>K.</given-names></name><name name-style="western"><surname>Shimada</surname><given-names>M.</given-names></name></person-group><article-title>Developments in viral vector-based vaccines</article-title><source>Vaccines (Basel)</source><volume>2</volume><year>2014</year><fpage>624</fpage><lpage>641</lpage><pub-id pub-id-type="pmid">26344749</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/vaccines2030624</pub-id><pub-id pub-id-type="pmcid">PMC4494222</pub-id></element-citation></ref><ref id="bb0815"><label>163</label><element-citation publication-type="journal" id="rf0815"><person-group person-group-type="author"><name name-style="western"><surname>Small</surname><given-names>J.C.</given-names></name><name name-style="western"><surname>Ertl</surname><given-names>H.C.</given-names></name></person-group><article-title>Viruses - from pathogens to vaccine carriers</article-title><source>Curr. Opin. Virol.</source><volume>1</volume><year>2011</year><fpage>241</fpage><lpage>245</lpage><pub-id pub-id-type="pmid">22003377</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.coviro.2011.07.009</pub-id><pub-id pub-id-type="pmcid">PMC3190199</pub-id></element-citation></ref><ref id="bb0820"><label>164</label><element-citation publication-type="journal" id="rf0820"><person-group person-group-type="author"><name name-style="western"><surname>Rollier</surname><given-names>C.S.</given-names></name><name name-style="western"><surname>Reyes-Sandoval</surname><given-names>A.</given-names></name><name name-style="western"><surname>Cottingham</surname><given-names>M.G.</given-names></name><name name-style="western"><surname>Ewer</surname><given-names>K.</given-names></name><name name-style="western"><surname>Hill</surname><given-names>A.V.</given-names></name></person-group><article-title>Viral vectors as vaccine platforms: deployment in sight</article-title><source>Curr. Opin. Immunol.</source><volume>23</volume><year>2011</year><fpage>377</fpage><lpage>382</lpage><pub-id pub-id-type="pmid">21514130</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.coi.2011.03.006</pub-id></element-citation></ref><ref id="bb0825"><label>165</label><element-citation publication-type="journal" id="rf0825"><person-group person-group-type="author"><name name-style="western"><surname>Lundstrom</surname><given-names>K.</given-names></name></person-group><article-title>Self-replicating RNA viruses for RNA therapeutics</article-title><source>Molecules</source><volume>23</volume><year>2018</year><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/molecules23123310</pub-id><pub-id pub-id-type="pmcid">PMC6321401</pub-id><pub-id pub-id-type="pmid">30551668</pub-id></element-citation></ref><ref id="bb0830"><label>166</label><element-citation publication-type="journal" id="rf0830"><person-group person-group-type="author"><name name-style="western"><surname>Zuniga</surname><given-names>A.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Liniger</surname><given-names>M.</given-names></name><name name-style="western"><surname>Hangartner</surname><given-names>L.</given-names></name><name name-style="western"><surname>Caballero</surname><given-names>M.</given-names></name><name name-style="western"><surname>Pavlovic</surname><given-names>J.</given-names></name><name name-style="western"><surname>Wild</surname><given-names>P.</given-names></name><name name-style="western"><surname>Viret</surname><given-names>J.F.</given-names></name><name name-style="western"><surname>Glueck</surname><given-names>R.</given-names></name><name name-style="western"><surname>Billeter</surname><given-names>M.A.</given-names></name><name name-style="western"><surname>Naim</surname><given-names>H.Y.</given-names></name></person-group><article-title>Attenuated measles virus as a vaccine vector</article-title><source>Vaccine</source><volume>25</volume><year>2007</year><fpage>2974</fpage><lpage>2983</lpage><pub-id pub-id-type="pmid">17303293</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.vaccine.2007.01.064</pub-id><pub-id pub-id-type="pmcid">PMC3707277</pub-id></element-citation></ref><ref id="bb0835"><label>167</label><element-citation publication-type="journal" id="rf0835"><person-group person-group-type="author"><name name-style="western"><surname>Lorin</surname><given-names>C.</given-names></name><name name-style="western"><surname>Delebecque</surname><given-names>F.</given-names></name><name name-style="western"><surname>Labrousse</surname><given-names>V.</given-names></name><name name-style="western"><surname>Da Silva</surname><given-names>L.</given-names></name><name name-style="western"><surname>Lemonnier</surname><given-names>F.</given-names></name><name name-style="western"><surname>Brahic</surname><given-names>M.</given-names></name><name name-style="western"><surname>Tangy</surname><given-names>F.</given-names></name></person-group><article-title>A recombinant live attenuated measles vaccine vector primes effective HLA-A0201-restricted cytotoxic T lymphocytes and broadly neutralizing antibodies against HIV-1 conserved epitopes</article-title><source>Vaccine</source><volume>23</volume><year>2005</year><fpage>4463</fpage><lpage>4472</lpage><pub-id pub-id-type="pmid">15993518</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.vaccine.2005.04.024</pub-id></element-citation></ref><ref id="bb0840"><label>168</label><element-citation publication-type="journal" id="rf0840"><person-group person-group-type="author"><name name-style="western"><surname>Lorin</surname><given-names>C.</given-names></name><name name-style="western"><surname>Mollet</surname><given-names>L.</given-names></name><name name-style="western"><surname>Delebecque</surname><given-names>F.</given-names></name><name name-style="western"><surname>Combredet</surname><given-names>C.</given-names></name><name name-style="western"><surname>Hurtrel</surname><given-names>B.</given-names></name><name name-style="western"><surname>Charneau</surname><given-names>P.</given-names></name><name name-style="western"><surname>Brahic</surname><given-names>M.</given-names></name><name name-style="western"><surname>Tangy</surname><given-names>F.</given-names></name></person-group><article-title>A single injection of recombinant measles virus vaccines expressing human immunodeficiency virus (HIV) type 1 clade B envelope glycoproteins induces neutralizing antibodies and cellular immune responses to HIV</article-title><source>J. Virol.</source><volume>78</volume><year>2004</year><fpage>146</fpage><lpage>157</lpage><pub-id pub-id-type="pmid">14671096</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1128/JVI.78.1.146-157.2004</pub-id><pub-id pub-id-type="pmcid">PMC303376</pub-id></element-citation></ref><ref id="bb0845"><label>169</label><element-citation publication-type="journal" id="rf0845"><person-group person-group-type="author"><name name-style="western"><surname>Baldo</surname><given-names>A.</given-names></name><name name-style="western"><surname>Galanis</surname><given-names>E.</given-names></name><name name-style="western"><surname>Tangy</surname><given-names>F.</given-names></name><name name-style="western"><surname>Herman</surname><given-names>P.</given-names></name></person-group><article-title>Biosafety considerations for attenuated measles virus vectors used in virotherapy and vaccination</article-title><source>Hum. Vaccin Immunother.</source><volume>12</volume><year>2016</year><fpage>1102</fpage><lpage>1116</lpage><pub-id pub-id-type="pmid">26631840</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1080/21645515.2015.1122146</pub-id><pub-id pub-id-type="pmcid">PMC4963060</pub-id></element-citation></ref><ref id="bb0850"><label>170</label><element-citation publication-type="journal" id="rf0850"><person-group person-group-type="author"><name name-style="western"><surname>Brandler</surname><given-names>S.</given-names></name><name name-style="western"><surname>Tangy</surname><given-names>F.</given-names></name></person-group><article-title>Recombinant vector derived from live attenuated measles virus: potential for flavivirus vaccines</article-title><source>Comp. Immunol. Microbiol. Infect. Dis.</source><volume>31</volume><year>2008</year><fpage>271</fpage><lpage>291</lpage><pub-id pub-id-type="pmid">17869338</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.cimid.2007.07.012</pub-id></element-citation></ref><ref id="bb0855"><label>171</label><element-citation publication-type="journal" id="rf0855"><person-group person-group-type="author"><name name-style="western"><surname>Dicks</surname><given-names>M.D.</given-names></name><name name-style="western"><surname>Spencer</surname><given-names>A.J.</given-names></name><name name-style="western"><surname>Edwards</surname><given-names>N.J.</given-names></name><name name-style="western"><surname>Wadell</surname><given-names>G.</given-names></name><name name-style="western"><surname>Bojang</surname><given-names>K.</given-names></name><name name-style="western"><surname>Gilbert</surname><given-names>S.C.</given-names></name><name name-style="western"><surname>Hill</surname><given-names>A.V.</given-names></name><name name-style="western"><surname>Cottingham</surname><given-names>M.G.</given-names></name></person-group><article-title>A novel chimpanzee adenovirus vector with low human seroprevalence: improved systems for vector derivation and comparative immunogenicity</article-title><source>PLoS One</source><volume>7</volume><year>2012</year><object-id pub-id-type="publisher-id">e40385</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1371/journal.pone.0040385</pub-id><pub-id pub-id-type="pmcid">PMC3396660</pub-id><pub-id pub-id-type="pmid">22808149</pub-id></element-citation></ref><ref id="bb0860"><label>172</label><element-citation publication-type="journal" id="rf0860"><person-group person-group-type="author"><name name-style="western"><surname>Wold</surname><given-names>W.S.</given-names></name><name name-style="western"><surname>Toth</surname><given-names>K.</given-names></name></person-group><article-title>Adenovirus vectors for gene therapy, vaccination and cancer gene therapy</article-title><source>Curr. Gene Ther.</source><volume>13</volume><year>2013</year><fpage>421</fpage><lpage>433</lpage><pub-id pub-id-type="pmid">24279313</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2174/1566523213666131125095046</pub-id><pub-id pub-id-type="pmcid">PMC4507798</pub-id></element-citation></ref><ref id="bb0865"><label>173</label><element-citation publication-type="journal" id="rf0865"><person-group person-group-type="author"><name name-style="western"><surname>Lauer</surname><given-names>K.B.</given-names></name><name name-style="western"><surname>Borrow</surname><given-names>R.</given-names></name><name name-style="western"><surname>Blanchard</surname><given-names>T.J.</given-names></name></person-group><article-title>Multivalent and multipathogen viral vector vaccines</article-title><source>Clin. Vaccine Immunol.</source><volume>24</volume><year>2017</year><pub-id pub-id-type="doi" assigning-authority="pmc">10.1128/CVI.00298-16</pub-id><pub-id pub-id-type="pmcid">PMC5216423</pub-id><pub-id pub-id-type="pmid">27535837</pub-id></element-citation></ref><ref id="bb0870"><label>174</label><element-citation publication-type="journal" id="rf0870"><person-group person-group-type="author"><name name-style="western"><surname>Humphreys</surname><given-names>I.R.</given-names></name><name name-style="western"><surname>Sebastian</surname><given-names>S.</given-names></name></person-group><article-title>Novel viral vectors in infectious diseases</article-title><source>Immunology</source><volume>153</volume><year>2018</year><fpage>1</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">28869761</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/imm.12829</pub-id><pub-id pub-id-type="pmcid">PMC5721250</pub-id></element-citation></ref><ref id="bb0875"><label>175</label><element-citation publication-type="journal" id="rf0875"><person-group person-group-type="author"><name name-style="western"><surname>Tatsis</surname><given-names>N.</given-names></name><name name-style="western"><surname>Ertl</surname><given-names>H.C.</given-names></name></person-group><article-title>Adenoviruses as vaccine vectors</article-title><source>Mol. Ther.</source><volume>10</volume><year>2004</year><fpage>616</fpage><lpage>629</lpage><pub-id pub-id-type="pmid">15451446</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ymthe.2004.07.013</pub-id><pub-id pub-id-type="pmcid">PMC7106330</pub-id></element-citation></ref><ref id="bb0880"><label>176</label><element-citation publication-type="journal" id="rf0880"><person-group person-group-type="author"><name name-style="western"><surname>Tan</surname><given-names>W.G.</given-names></name><name name-style="western"><surname>Jin</surname><given-names>H.T.</given-names></name><name name-style="western"><surname>West</surname><given-names>E.E.</given-names></name><name name-style="western"><surname>Penaloza-MacMaster</surname><given-names>P.</given-names></name><name name-style="western"><surname>Wieland</surname><given-names>A.</given-names></name><etal/></person-group><article-title>Comparative analysis of simian immunodeficiency virus gag-specific effector and memory CD8+ T cells induced by different adenovirus vectors</article-title><source>J. Virol.</source><volume>87</volume><year>2013</year><fpage>1359</fpage><lpage>1372</lpage><pub-id pub-id-type="pmid">23175355</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1128/JVI.02055-12</pub-id><pub-id pub-id-type="pmcid">PMC3554140</pub-id></element-citation></ref><ref id="bb0885"><label>177</label><element-citation publication-type="journal" id="rf0885"><person-group person-group-type="author"><name name-style="western"><surname>Baden</surname><given-names>L.R.</given-names></name><name name-style="western"><surname>Karita</surname><given-names>E.</given-names></name><name name-style="western"><surname>Mutua</surname><given-names>G.</given-names></name><name name-style="western"><surname>Bekker</surname><given-names>L.G.</given-names></name><name name-style="western"><surname>Gray</surname><given-names>G.</given-names></name><etal/></person-group><article-title>Assessment of the safety and immunogenicity of 2 novel vaccine platforms for HIV-1 prevention: a randomized trial</article-title><source>Ann. Intern. Med.</source><volume>164</volume><year>2016</year><fpage>313</fpage><lpage>322</lpage><pub-id pub-id-type="pmid">26833336</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.7326/M15-0880</pub-id><pub-id pub-id-type="pmcid">PMC5034222</pub-id></element-citation></ref><ref id="bb0890"><label>178</label><element-citation publication-type="journal" id="rf0890"><person-group person-group-type="author"><name name-style="western"><surname>Coughlan</surname><given-names>L.</given-names></name></person-group><article-title>Factors which contribute to the immunogenicity of non-replicating adenoviral vectored vaccines</article-title><source>Front. Immunol.</source><volume>11</volume><year>2020</year><fpage>909</fpage><pub-id pub-id-type="pmid">32508823</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fimmu.2020.00909</pub-id><pub-id pub-id-type="pmcid">PMC7248264</pub-id></element-citation></ref><ref id="bb0895"><label>179</label><element-citation publication-type="journal" id="rf0895"><person-group person-group-type="author"><name name-style="western"><surname>Balakrishnan</surname><given-names>B.</given-names></name><name name-style="western"><surname>Jayandharan</surname><given-names>G.R.</given-names></name></person-group><article-title>Basic biology of adeno-associated virus (AAV) vectors used in gene therapy</article-title><source>Curr. Gene Ther.</source><volume>14</volume><year>2014</year><fpage>86</fpage><lpage>100</lpage><pub-id pub-id-type="pmid">24588706</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2174/1566523214666140302193709</pub-id></element-citation></ref><ref id="bb0900"><label>180</label><element-citation publication-type="journal" id="rf0900"><person-group person-group-type="author"><name name-style="western"><surname>Ogden</surname><given-names>P.J.</given-names></name><name name-style="western"><surname>Kelsic</surname><given-names>E.D.</given-names></name><name name-style="western"><surname>Sinai</surname><given-names>S.</given-names></name><name name-style="western"><surname>Church</surname><given-names>G.M.</given-names></name></person-group><article-title>Comprehensive AAV capsid fitness landscape reveals a viral gene and enables machine-guided design</article-title><source>Science</source><volume>366</volume><year>2019</year><fpage>1139</fpage><lpage>1143</lpage><pub-id pub-id-type="pmid">31780559</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1126/science.aaw2900</pub-id><pub-id pub-id-type="pmcid">PMC7197022</pub-id></element-citation></ref><ref id="bb0905"><label>181</label><element-citation publication-type="journal" id="rf0905"><person-group person-group-type="author"><name name-style="western"><surname>Johnson</surname><given-names>P.R.</given-names></name><name name-style="western"><surname>Schnepp</surname><given-names>B.C.</given-names></name><name name-style="western"><surname>Connell</surname><given-names>M.J.</given-names></name><name name-style="western"><surname>Rohne</surname><given-names>D.</given-names></name><name name-style="western"><surname>Robinson</surname><given-names>S.</given-names></name><name name-style="western"><surname>Krivulka</surname><given-names>G.R.</given-names></name><name name-style="western"><surname>Lord</surname><given-names>C.I.</given-names></name><name name-style="western"><surname>Zinn</surname><given-names>R.</given-names></name><name name-style="western"><surname>Montefiori</surname><given-names>D.C.</given-names></name><name name-style="western"><surname>Letvin</surname><given-names>N.L.</given-names></name><name name-style="western"><surname>Clark</surname><given-names>K.R.</given-names></name></person-group><article-title>Novel adeno-associated virus vector vaccine restricts replication of simian immunodeficiency virus in macaques</article-title><source>J. Virol.</source><volume>79</volume><year>2005</year><fpage>955</fpage><lpage>965</lpage><pub-id pub-id-type="pmid">15613324</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1128/JVI.79.2.955-965.2005</pub-id><pub-id pub-id-type="pmcid">PMC538580</pub-id></element-citation></ref><ref id="bb0910"><label>182</label><element-citation publication-type="journal" id="rf0910"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>C.</given-names></name><name name-style="western"><surname>Samulski</surname><given-names>R.J.</given-names></name></person-group><article-title>Engineering adeno-associated virus vectors for gene therapy, Nat</article-title><source>Rev. Gen. Therm.</source><volume>21</volume><year>2020</year><fpage>255</fpage><lpage>272</lpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41576-019-0205-4</pub-id><pub-id pub-id-type="pmid">32042148</pub-id></element-citation></ref><ref id="bb0915"><label>183</label><element-citation publication-type="journal" id="rf0915"><person-group person-group-type="author"><name name-style="western"><surname>Mercado</surname><given-names>N.B.</given-names></name><name name-style="western"><surname>Zahn</surname><given-names>R.</given-names></name><name name-style="western"><surname>Wegmann</surname><given-names>F.</given-names></name><name name-style="western"><surname>Loos</surname><given-names>C.</given-names></name><name name-style="western"><surname>Chandrashekar</surname><given-names>A.</given-names></name><etal/></person-group><article-title>Single-shot Ad26 vaccine protects against SARS-CoV-2 in rhesus macaques</article-title><source>Nature</source><volume>586</volume><year>2020</year><fpage>583</fpage><lpage>588</lpage><pub-id pub-id-type="pmid">32731257</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41586-020-2607-z</pub-id><pub-id pub-id-type="pmcid">PMC7581548</pub-id></element-citation></ref><ref id="bb0920"><label>184</label><element-citation publication-type="journal" id="rf0920"><person-group person-group-type="author"><name name-style="western"><surname>Yu</surname><given-names>J.</given-names></name><name name-style="western"><surname>Tostanoski</surname><given-names>L.H.</given-names></name><name name-style="western"><surname>Peter</surname><given-names>L.</given-names></name><name name-style="western"><surname>Mercado</surname><given-names>N.B.</given-names></name><name name-style="western"><surname>McMahan</surname><given-names>K.</given-names></name><etal/></person-group><article-title>DNA vaccine protection against SARS-CoV-2 in rhesus macaques</article-title><source>Science</source><volume>369</volume><year>2020</year><fpage>806</fpage><lpage>811</lpage><pub-id pub-id-type="pmid">32434945</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1126/science.abc6284</pub-id><pub-id pub-id-type="pmcid">PMC7243363</pub-id></element-citation></ref><ref id="bb0925"><label>185</label><element-citation publication-type="journal" id="rf0925"><person-group person-group-type="author"><name name-style="western"><surname>Chandrashekar</surname><given-names>A.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>J.</given-names></name><name name-style="western"><surname>Martinot</surname><given-names>A.J.</given-names></name><name name-style="western"><surname>McMahan</surname><given-names>K.</given-names></name><name name-style="western"><surname>Mercado</surname><given-names>N.B.</given-names></name><etal/></person-group><article-title>SARS-CoV-2 infection protects against rechallenge in rhesus macaques</article-title><source>Science</source><volume>369</volume><year>2020</year><fpage>812</fpage><lpage>817</lpage><pub-id pub-id-type="pmid">32434946</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1126/science.abc4776</pub-id><pub-id pub-id-type="pmcid">PMC7243369</pub-id></element-citation></ref><ref id="bb0930"><label>186</label><element-citation publication-type="journal" id="rf0930"><person-group person-group-type="author"><name name-style="western"><surname>Logunov</surname><given-names>D.Y.</given-names></name><name name-style="western"><surname>Dolzhikova</surname><given-names>I.V.</given-names></name><name name-style="western"><surname>Zubkova</surname><given-names>O.V.</given-names></name><name name-style="western"><surname>Tukhvatullin</surname><given-names>A.I.</given-names></name><name name-style="western"><surname>Shcheblyakov</surname><given-names>D.V.</given-names></name><etal/></person-group><article-title>Safety and immunogenicity of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine in two formulations: two open, non-randomized phase 1/2 studies from Russia</article-title><source>Lancet</source><volume>396</volume><year>2020</year><fpage>887</fpage><lpage>897</lpage><pub-id pub-id-type="pmid">32896291</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S0140-6736(20)31866-3</pub-id><pub-id pub-id-type="pmcid">PMC7471804</pub-id></element-citation></ref><ref id="bb0935"><label>187</label><element-citation publication-type="journal" id="rf0935"><person-group person-group-type="author"><name name-style="western"><surname>Burki</surname><given-names>T.K.</given-names></name></person-group><article-title>The Russian vaccine for COVID-19</article-title><source>Lancet Respir. Med.</source><volume>8</volume><year>2020</year><fpage>e85</fpage><lpage>e86</lpage><pub-id pub-id-type="pmid">32896274</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S2213-2600(20)30402-1</pub-id><pub-id pub-id-type="pmcid">PMC7837053</pub-id></element-citation></ref><ref id="bb0940"><label>188</label><element-citation publication-type="journal" id="rf0940"><person-group person-group-type="author"><name name-style="western"><surname>Zhu</surname><given-names>F.C.</given-names></name><name name-style="western"><surname>Li</surname><given-names>Y.H.</given-names></name><name name-style="western"><surname>Guan</surname><given-names>X.H.</given-names></name><name name-style="western"><surname>Hou</surname><given-names>L.H.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>W.J.</given-names></name><etal/></person-group><article-title>Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomized, first-in-human trial</article-title><source>Lancet</source><volume>395</volume><year>2020</year><fpage>1845</fpage><lpage>1854</lpage><pub-id pub-id-type="pmid">32450106</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S0140-6736(20)31208-3</pub-id><pub-id pub-id-type="pmcid">PMC7255193</pub-id></element-citation></ref><ref id="bb0945"><label>189</label><element-citation publication-type="journal" id="rf0945"><person-group person-group-type="author"><name name-style="western"><surname>Zhu</surname><given-names>F.C.</given-names></name><name name-style="western"><surname>Guan</surname><given-names>X.H.</given-names></name><name name-style="western"><surname>Li</surname><given-names>Y.H.</given-names></name><name name-style="western"><surname>Huang</surname><given-names>J.Y.</given-names></name><name name-style="western"><surname>Jiang</surname><given-names>T.</given-names></name><etal/></person-group><article-title>Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18&#160;years or older: a randomized, double-blind, placebo-controlled, phase 2 trial</article-title><source>Lancet</source><volume>396</volume><year>2020</year><fpage>479</fpage><lpage>488</lpage><pub-id pub-id-type="pmid">32702299</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S0140-6736(20)31605-6</pub-id><pub-id pub-id-type="pmcid">PMC7836858</pub-id></element-citation></ref><ref id="bb0950"><label>190</label><element-citation publication-type="other" id="rf0950"><person-group person-group-type="author"><name name-style="western"><surname>News18</surname></name></person-group><article-title>CanSino's Covid-19 Vaccine Candidate Approved for Military Use in China</article-title><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.news18.com/news/world/cansinos-covid-19-vaccine-candidate-approved-for-military-use-in-china-2692251.html" id="ir0430">https://www.news18.com/news/world/cansinos-covid-19-vaccine-candidate-approved-for-military-use-in-china-2692251.html</ext-link><year>2020</year></element-citation></ref><ref id="bb0955"><label>191</label><element-citation publication-type="journal" id="rf0955"><person-group person-group-type="author"><name name-style="western"><surname>van Doremalen</surname><given-names>N.</given-names></name><name name-style="western"><surname>Lambe</surname><given-names>T.</given-names></name><name name-style="western"><surname>Spencer</surname><given-names>A.</given-names></name><name name-style="western"><surname>Belij-Rammerstorfer</surname><given-names>S.</given-names></name><name name-style="western"><surname>Purushotham</surname><given-names>J.N.</given-names></name><etal/></person-group><article-title>ChAdOx1 nCoV-19 vaccine prevents SARS-CoV-2 pneumonia in rhesus macaques</article-title><source>Nature</source><volume>586</volume><year>2020</year><fpage>578</fpage><lpage>582</lpage><pub-id pub-id-type="pmid">32731258</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41586-020-2608-y</pub-id><pub-id pub-id-type="pmcid">PMC8436420</pub-id></element-citation></ref><ref id="bb0960"><label>192</label><element-citation publication-type="journal" id="rf0960"><person-group person-group-type="author"><name name-style="western"><surname>Ramasamy</surname><given-names>M.N.</given-names></name><name name-style="western"><surname>Minassian</surname><given-names>A.M.</given-names></name><name name-style="western"><surname>Ewer</surname><given-names>K.J.</given-names></name><name name-style="western"><surname>Flaxman</surname><given-names>A.L.</given-names></name><name name-style="western"><surname>Folegatti</surname><given-names>P.M.</given-names></name><etal/></person-group><article-title>Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomized, controlled, phase 2/3 trial</article-title><source>Lancet</source><volume>396</volume><year>2020</year><fpage>1979</fpage><lpage>1993</lpage><pub-id pub-id-type="pmid">33220855</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S0140-6736(20)32466-1</pub-id><pub-id pub-id-type="pmcid">PMC7674972</pub-id></element-citation></ref><ref id="bb0965"><label>193</label><element-citation publication-type="other" id="rf0965"><person-group person-group-type="author"><name name-style="western"><surname>AstraZeneca</surname></name></person-group><article-title>AstraZeneca to supply Europe with up to 400 million doses of Oxford University's vaccine at no profit</article-title><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.astrazeneca.com/media-centre/articles/2020/astrazeneca-to-supply-europe-with-up-to-400-million-doses-of-oxford-universitys-potential-covid-19-vaccine.html" id="ir0435">https://www.astrazeneca.com/media-centre/articles/2020/astrazeneca-to-supply-europe-with-up-to-400-million-doses-of-oxford-universitys-potential-covid-19-vaccine.html</ext-link></element-citation></ref><ref id="bb0970"><label>194</label><element-citation publication-type="journal" id="rf0970"><person-group person-group-type="author"><name name-style="western"><surname>Liljeqvist</surname><given-names>S.</given-names></name><name name-style="western"><surname>Stahl</surname><given-names>S.</given-names></name></person-group><article-title>Production of recombinant subunit vaccines: protein immunogens, live delivery systems and nucleic acid vaccines</article-title><source>J. Biotechnol.</source><volume>73</volume><year>1999</year><fpage>1</fpage><lpage>33</lpage><pub-id pub-id-type="pmid">10483112</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/s0168-1656(99)00107-8</pub-id></element-citation></ref><ref id="bb0975"><label>195</label><element-citation publication-type="journal" id="rf0975"><person-group person-group-type="author"><name name-style="western"><surname>Vartak</surname><given-names>A.</given-names></name><name name-style="western"><surname>Sucheck</surname><given-names>S.J.</given-names></name></person-group><article-title>Recent advances in subunit vaccine carriers</article-title><source>Vaccines (Basel)</source><volume>4</volume><year>2016</year><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/vaccines4020012</pub-id><pub-id pub-id-type="pmcid">PMC4931629</pub-id><pub-id pub-id-type="pmid">27104575</pub-id></element-citation></ref><ref id="bb0980"><label>196</label><element-citation publication-type="journal" id="rf0980"><person-group person-group-type="author"><name name-style="western"><surname>Degos</surname><given-names>F.</given-names></name></person-group><article-title>Protein subunit vaccines: example of vaccination against hepatitis B virus</article-title><source>Rev. Prat.</source><volume>45</volume><year>1995</year><fpage>1488</fpage><lpage>1491</lpage><pub-id pub-id-type="pmid">7660001</pub-id></element-citation></ref><ref id="bb0985"><label>197</label><element-citation publication-type="journal" id="rf0985"><person-group person-group-type="author"><name name-style="western"><surname>Huzair</surname><given-names>F.</given-names></name><name name-style="western"><surname>Sturdy</surname><given-names>S.</given-names></name></person-group><article-title>Biotechnology and the transformation of vaccine innovation: the case of the hepatitis B vaccines 1968&#8211;2000</article-title><source>Stud. Hist. Phil. Biol. Biomed. Sci.</source><volume>64</volume><year>2017</year><fpage>11</fpage><lpage>21</lpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.shpsc.2017.05.004</pub-id><pub-id pub-id-type="pmcid">PMC5541201</pub-id><pub-id pub-id-type="pmid">28511068</pub-id></element-citation></ref><ref id="bb0990"><label>198</label><element-citation publication-type="journal" id="rf0990"><person-group person-group-type="author"><name name-style="western"><surname>Tripathi</surname><given-names>N.K.</given-names></name></person-group><article-title>Production and purification of recombinant proteins from <italic toggle="yes">Escherichia coli</italic></article-title><source>ChemBioEng Rev.</source><volume>3</volume><year>2016</year><fpage>116</fpage><lpage>133</lpage></element-citation></ref><ref id="bb0995"><label>199</label><element-citation publication-type="journal" id="rf0995"><person-group person-group-type="author"><name name-style="western"><surname>Baeshen</surname><given-names>M.N.</given-names></name><name name-style="western"><surname>Al-Hejin</surname><given-names>A.M.</given-names></name><name name-style="western"><surname>Bora</surname><given-names>R.S.</given-names></name><name name-style="western"><surname>Ahmed</surname><given-names>M.M.</given-names></name><name name-style="western"><surname>Ramadan</surname><given-names>H.A.</given-names></name><name name-style="western"><surname>Saini</surname><given-names>K.S.</given-names></name><name name-style="western"><surname>Baeshen</surname><given-names>N.A.</given-names></name><name name-style="western"><surname>Redwan</surname><given-names>E.M.</given-names></name></person-group><article-title>Production of biopharmaceuticals in <italic toggle="yes">E. coli</italic>: current scenario and future perspectives</article-title><source>J. Microbiol. Biotechnol.</source><volume>25</volume><year>2015</year><fpage>953</fpage><lpage>962</lpage><pub-id pub-id-type="pmid">25737124</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.4014/jmb.1412.12079</pub-id></element-citation></ref><ref id="bb1000"><label>200</label><element-citation publication-type="journal" id="rf1000"><person-group person-group-type="author"><name name-style="western"><surname>Berlec</surname><given-names>A.</given-names></name><name name-style="western"><surname>Strukelj</surname><given-names>B.</given-names></name></person-group><article-title>Current state and recent advances in biopharmaceutical production in <italic toggle="yes">Escherichia coli,</italic> yeasts and mammalian cells</article-title><source>J. Ind. Microbiol. Biotechnol.</source><volume>40</volume><year>2013</year><fpage>257</fpage><lpage>274</lpage><pub-id pub-id-type="pmid">23385853</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s10295-013-1235-0</pub-id></element-citation></ref><ref id="bb1005"><label>201</label><element-citation publication-type="journal" id="rf1005"><person-group person-group-type="author"><name name-style="western"><surname>Porro</surname><given-names>D.</given-names></name><name name-style="western"><surname>Gasser</surname><given-names>B.</given-names></name><name name-style="western"><surname>Fossati</surname><given-names>T.</given-names></name><name name-style="western"><surname>Maurer</surname><given-names>M.</given-names></name><name name-style="western"><surname>Branduardi</surname><given-names>P.</given-names></name><name name-style="western"><surname>Sauer</surname><given-names>M.</given-names></name><name name-style="western"><surname>Mattanovich</surname><given-names>D.</given-names></name></person-group><article-title>Production of recombinant proteins and metabolites in yeasts: when are these systems better than bacterial production systems?</article-title><source>Appl. Microbiol. Biotechnol.</source><volume>89</volume><year>2011</year><fpage>939</fpage><lpage>948</lpage><pub-id pub-id-type="pmid">21125266</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s00253-010-3019-z</pub-id></element-citation></ref><ref id="bb1010"><label>202</label><element-citation publication-type="journal" id="rf1010"><person-group person-group-type="author"><name name-style="western"><surname>Arvin</surname><given-names>A.M.</given-names></name><name name-style="western"><surname>Greenberg</surname><given-names>H.B.</given-names></name></person-group><article-title>New viral vaccines</article-title><source>Virology</source><volume>344</volume><year>2006</year><fpage>240</fpage><lpage>249</lpage><pub-id pub-id-type="pmid">16364754</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.virol.2005.09.057</pub-id></element-citation></ref><ref id="bb1015"><label>203</label><element-citation publication-type="journal" id="rf1015"><person-group person-group-type="author"><name name-style="western"><surname>Baxter</surname><given-names>D.</given-names></name></person-group><article-title>Active and passive immunity, vaccine types, excipients and licensing</article-title><source>Occup. Med. (Lond.)</source><volume>57</volume><year>2007</year><fpage>552</fpage><lpage>556</lpage><pub-id pub-id-type="pmid">18045976</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/occmed/kqm110</pub-id></element-citation></ref><ref id="bb1020"><label>204</label><element-citation publication-type="journal" id="rf1020"><person-group person-group-type="author"><name name-style="western"><surname>Tison</surname><given-names>E.</given-names></name><name name-style="western"><surname>Marpeau</surname><given-names>L.</given-names></name><name name-style="western"><surname>Pigne</surname><given-names>A.</given-names></name><name name-style="western"><surname>Tessier</surname><given-names>F.</given-names></name><name name-style="western"><surname>Barrat</surname><given-names>J.</given-names></name></person-group><article-title>Treatment of acute non-chlamydial salpingitis. Study of the efficacy and tolerance of a single-therapy antibiotic: augmentin</article-title><source>J. Gynecol. Obstet. Biol. Reprod. (Paris)</source><volume>17</volume><year>1988</year><fpage>513</fpage><lpage>519</lpage><pub-id pub-id-type="pmid">3209830</pub-id></element-citation></ref><ref id="bb1025"><label>205</label><element-citation publication-type="journal" id="rf1025"><person-group person-group-type="author"><name name-style="western"><surname>Gao</surname><given-names>S.</given-names></name><name name-style="western"><surname>Song</surname><given-names>S.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>L.</given-names></name></person-group><article-title>Recent progress in vaccine development against chikungunya virus</article-title><source>Front. Microbiol.</source><volume>10</volume><year>2019</year><fpage>2881</fpage><pub-id pub-id-type="pmid">31921059</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fmicb.2019.02881</pub-id><pub-id pub-id-type="pmcid">PMC6930866</pub-id></element-citation></ref><ref id="bb1030"><label>206</label><element-citation publication-type="journal" id="rf1030"><person-group person-group-type="author"><name name-style="western"><surname>Bidokhti</surname><given-names>M.R.M.</given-names></name><name name-style="western"><surname>Ullman</surname><given-names>K.</given-names></name><name name-style="western"><surname>Hammer</surname><given-names>A.S.</given-names></name><name name-style="western"><surname>Jensen</surname><given-names>T.H.</given-names></name><name name-style="western"><surname>Chriel</surname><given-names>M.</given-names></name><name name-style="western"><surname>Byrareddy</surname><given-names>S.N.</given-names></name><name name-style="western"><surname>Baule</surname><given-names>C.</given-names></name></person-group><article-title>Immunogenicity and efficacy evaluation of subunit astrovirus vaccines</article-title><source>Vaccines (Basel)</source><volume>7</volume><year>2019</year><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/vaccines7030079</pub-id><pub-id pub-id-type="pmcid">PMC6789684</pub-id><pub-id pub-id-type="pmid">31382451</pub-id></element-citation></ref><ref id="bb1035"><label>207</label><element-citation publication-type="journal" id="rf1035"><person-group person-group-type="author"><name name-style="western"><surname>Yancey</surname><given-names>K.B.</given-names></name></person-group><article-title>Commentary regarding: efficacy of an adjuvanted herpes zoster subunit vaccine in older adults. H Lal, AL Cunningham, O Godeaux et al., N. Engl. J. Med. 372:2087&#8211;2096, 2015</article-title><source>Dermatol. Ther.</source><volume>29</volume><year>2016</year><fpage>300</fpage><lpage>301</lpage><pub-id pub-id-type="pmid">26798973</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/dth.12330</pub-id></element-citation></ref><ref id="bb1040"><label>208</label><element-citation publication-type="journal" id="rf1040"><person-group person-group-type="author"><name name-style="western"><surname>Cunningham</surname><given-names>A.L.</given-names></name><name name-style="western"><surname>Lal</surname><given-names>H.</given-names></name><name name-style="western"><surname>Kovac</surname><given-names>M.</given-names></name><name name-style="western"><surname>Chlibek</surname><given-names>R.</given-names></name><name name-style="western"><surname>Hwang</surname><given-names>S.J.</given-names></name><etal/></person-group><article-title>Efficacy of the herpes zoster subunit vaccine in adults 70&#160;years of age or older</article-title><source>N. Engl. J. Med.</source><volume>375</volume><year>2016</year><fpage>1019</fpage><lpage>1032</lpage><pub-id pub-id-type="pmid">27626517</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1056/NEJMoa1603800</pub-id></element-citation></ref><ref id="bb1045"><label>209</label><element-citation publication-type="journal" id="rf1045"><person-group person-group-type="author"><name name-style="western"><surname>Coleman</surname><given-names>C.M.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>Y.V.</given-names></name><name name-style="western"><surname>Mu</surname><given-names>H.</given-names></name><name name-style="western"><surname>Taylor</surname><given-names>J.K.</given-names></name><name name-style="western"><surname>Massare</surname><given-names>M.</given-names></name><name name-style="western"><surname>Flyer</surname><given-names>D.C.</given-names></name><name name-style="western"><surname>Smith</surname><given-names>G.E.</given-names></name><name name-style="western"><surname>Frieman</surname><given-names>M.B.</given-names></name></person-group><article-title>Purified coronavirus spike protein nanoparticles induce coronavirus neutralizing antibodies in mice</article-title><source>Vaccine</source><volume>32</volume><year>2014</year><fpage>3169</fpage><lpage>3174</lpage><pub-id pub-id-type="pmid">24736006</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.vaccine.2014.04.016</pub-id><pub-id pub-id-type="pmcid">PMC4058772</pub-id></element-citation></ref><ref id="bb1050"><label>210</label><element-citation publication-type="book" id="rf1050"><person-group person-group-type="author"><name name-style="western"><surname>MigVax</surname></name></person-group><part-title>MigVax is developing an oral COVID-19 sub-unit vaccine</part-title><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.migvax.com/" id="ir0440">https://www.migvax.com/</ext-link><year>2020</year></element-citation></ref><ref id="bb1055"><label>211</label><element-citation publication-type="journal" id="rf1055"><person-group person-group-type="author"><name name-style="western"><surname>Machhi</surname><given-names>J.</given-names></name><name name-style="western"><surname>Kevadiya</surname><given-names>B.D.</given-names></name><name name-style="western"><surname>Muhammad</surname><given-names>I.K.</given-names></name><name name-style="western"><surname>Herskovitz</surname><given-names>J.</given-names></name><name name-style="western"><surname>Olson</surname><given-names>K.E.</given-names></name><name name-style="western"><surname>Mosley</surname><given-names>R.L.</given-names></name><name name-style="western"><surname>Gendelman</surname><given-names>H.E.</given-names></name></person-group><article-title>Harnessing regulatory T cell neuroprotective activities for treatment of neurodegenerative disorders</article-title><source>Mol. Neurodegener.</source><volume>15</volume><year>2020</year><fpage>32</fpage><pub-id pub-id-type="pmid">32503641</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s13024-020-00375-7</pub-id><pub-id pub-id-type="pmcid">PMC7275301</pub-id></element-citation></ref><ref id="bb1060"><label>212</label><element-citation publication-type="journal" id="rf1060"><person-group person-group-type="author"><name name-style="western"><surname>Chen</surname><given-names>Z.</given-names></name><name name-style="western"><surname>John Wherry</surname><given-names>E.</given-names></name></person-group><article-title>T cell responses in patients with COVID-19</article-title><source>Nat. Rev. Immunol.</source><volume>20</volume><year>2020</year><fpage>529</fpage><lpage>536</lpage><pub-id pub-id-type="pmid">32728222</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41577-020-0402-6</pub-id><pub-id pub-id-type="pmcid">PMC7389156</pub-id></element-citation></ref><ref id="bb1065"><label>213</label><element-citation publication-type="journal" id="rf1065"><person-group person-group-type="author"><name name-style="western"><surname>Qian</surname><given-names>C.</given-names></name><name name-style="western"><surname>Campidelli</surname><given-names>A.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Cai</surname><given-names>H.</given-names></name><name name-style="western"><surname>Venard</surname><given-names>V.</given-names></name><etal/></person-group><article-title>Curative or pre-emptive adenovirus-specific T cell transfer from matched unrelated or third party haploidentical donors after HSCT, including UCB transplantations: a successful phase I/II multicenter clinical trial</article-title><source>J. Hematol. Oncol.</source><volume>10</volume><year>2017</year><fpage>102</fpage><pub-id pub-id-type="pmid">28482908</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s13045-017-0469-0</pub-id><pub-id pub-id-type="pmcid">PMC5421327</pub-id></element-citation></ref><ref id="bb1070"><label>214</label><element-citation publication-type="journal" id="rf1070"><person-group person-group-type="author"><name name-style="western"><surname>Icheva</surname><given-names>V.</given-names></name><name name-style="western"><surname>Kayser</surname><given-names>S.</given-names></name><name name-style="western"><surname>Wolff</surname><given-names>D.</given-names></name><name name-style="western"><surname>Tuve</surname><given-names>S.</given-names></name><name name-style="western"><surname>Kyzirakos</surname><given-names>C.</given-names></name><etal/></person-group><article-title>Adoptive transfer of epstein-barr virus (EBV) nuclear antigen 1-specific t cells as treatment for EBV reactivation and lymphoproliferative disorders after allogeneic stem-cell transplantation</article-title><source>J. Clin. Oncol.</source><volume>31</volume><year>2013</year><fpage>39</fpage><lpage>48</lpage><pub-id pub-id-type="pmid">23169501</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1200/JCO.2011.39.8495</pub-id></element-citation></ref><ref id="bb1075"><label>215</label><element-citation publication-type="journal" id="rf1075"><person-group person-group-type="author"><name name-style="western"><surname>Feuchtinger</surname><given-names>T.</given-names></name><name name-style="western"><surname>Opherk</surname><given-names>K.</given-names></name><name name-style="western"><surname>Bethge</surname><given-names>W.A.</given-names></name><name name-style="western"><surname>Topp</surname><given-names>M.S.</given-names></name><name name-style="western"><surname>Schuster</surname><given-names>F.R.</given-names></name><etal/></person-group><article-title>Adoptive transfer of pp65-specific T cells for the treatment of chemorefractory cytomegalovirus disease or reactivation after haploidentical and matched unrelated stem cell transplantation</article-title><source>Blood</source><volume>116</volume><year>2010</year><fpage>4360</fpage><lpage>4367</lpage><pub-id pub-id-type="pmid">20625005</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1182/blood-2010-01-262089</pub-id></element-citation></ref><ref id="bb1080"><label>216</label><element-citation publication-type="journal" id="rf1080"><person-group person-group-type="author"><name name-style="western"><surname>Soon</surname><given-names>C.F.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>S.</given-names></name><name name-style="western"><surname>Suneetha</surname><given-names>P.V.</given-names></name><name name-style="western"><surname>Antunes</surname><given-names>D.A.</given-names></name><name name-style="western"><surname>Manns</surname><given-names>M.P.</given-names></name><name name-style="western"><surname>Raha</surname><given-names>S.</given-names></name><name name-style="western"><surname>Schultze-Florey</surname><given-names>C.</given-names></name><name name-style="western"><surname>Prinz</surname><given-names>I.</given-names></name><name name-style="western"><surname>Wedemeyer</surname><given-names>H.</given-names></name><name name-style="western"><surname>Sallberg Chen</surname><given-names>M.</given-names></name><name name-style="western"><surname>Cornberg</surname><given-names>M.</given-names></name><name name-style="western"><surname>Hepatitis</surname><given-names>E.</given-names></name></person-group><article-title>Virus (HEV)-specific T cell receptor cross-recognition: implications for immunotherapy</article-title><source>Front. Immunol.</source><volume>10</volume><year>2019</year><fpage>2076</fpage><pub-id pub-id-type="pmid">31552033</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fimmu.2019.02076</pub-id><pub-id pub-id-type="pmcid">PMC6738269</pub-id></element-citation></ref><ref id="bb1085"><label>217</label><element-citation publication-type="journal" id="rf1085"><person-group person-group-type="author"><name name-style="western"><surname>David</surname><given-names>P.</given-names></name><name name-style="western"><surname>Drabczyk-Pluta</surname><given-names>M.</given-names></name><name name-style="western"><surname>Pastille</surname><given-names>E.</given-names></name><name name-style="western"><surname>Knuschke</surname><given-names>T.</given-names></name><name name-style="western"><surname>Werner</surname><given-names>T.</given-names></name><etal/></person-group><article-title>Combination immunotherapy with anti-PD-L1 antibody and depletion of regulatory T cells during acute viral infections results in improved virus control but lethal immunopathology</article-title><source>PLoS Pathog.</source><volume>16</volume><year>2020</year><object-id pub-id-type="publisher-id">e1008340</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1371/journal.ppat.1008340</pub-id><pub-id pub-id-type="pmcid">PMC7105110</pub-id><pub-id pub-id-type="pmid">32226027</pub-id></element-citation></ref><ref id="bb1090"><label>218</label><element-citation publication-type="journal" id="rf1090"><person-group person-group-type="author"><name name-style="western"><surname>Attanasio</surname><given-names>J.</given-names></name><name name-style="western"><surname>Wherry</surname><given-names>E.J.</given-names></name></person-group><article-title>Costimulatory and coinhibitory receptor pathways in infectious disease</article-title><source>Immunity</source><volume>44</volume><year>2016</year><fpage>1052</fpage><lpage>1068</lpage><pub-id pub-id-type="pmid">27192569</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.immuni.2016.04.022</pub-id><pub-id pub-id-type="pmcid">PMC4873956</pub-id></element-citation></ref><ref id="bb1095"><label>219</label><element-citation publication-type="journal" id="rf1095"><person-group person-group-type="author"><name name-style="western"><surname>Zelinskyy</surname><given-names>G.</given-names></name><name name-style="western"><surname>Myers</surname><given-names>L.</given-names></name><name name-style="western"><surname>Dietze</surname><given-names>K.K.</given-names></name><name name-style="western"><surname>Gibbert</surname><given-names>K.</given-names></name><name name-style="western"><surname>Roggendorf</surname><given-names>M.</given-names></name><etal/></person-group><article-title>Virus-specific CD8+ T cells upregulate programmed death-1 expression during acute friend retrovirus infection but are highly cytotoxic and control virus replication</article-title><source>J. Immunol.</source><volume>187</volume><year>2011</year><fpage>3730</fpage><lpage>3737</lpage><pub-id pub-id-type="pmid">21873525</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.4049/jimmunol.1101612</pub-id><pub-id pub-id-type="pmcid">PMC3402334</pub-id></element-citation></ref><ref id="bb1100"><label>220</label><element-citation publication-type="journal" id="rf1100"><person-group person-group-type="author"><name name-style="western"><surname>Urbani</surname><given-names>S.</given-names></name><name name-style="western"><surname>Amadei</surname><given-names>B.</given-names></name><name name-style="western"><surname>Tola</surname><given-names>D.</given-names></name><name name-style="western"><surname>Pedrazzi</surname><given-names>G.</given-names></name><name name-style="western"><surname>Sacchelli</surname><given-names>L.</given-names></name><name name-style="western"><surname>Cavallo</surname><given-names>M.C.</given-names></name><name name-style="western"><surname>Orlandini</surname><given-names>A.</given-names></name><name name-style="western"><surname>Missale</surname><given-names>G.</given-names></name><name name-style="western"><surname>Ferrari</surname><given-names>C.</given-names></name></person-group><article-title>Restoration of HCV-specific T cell functions by PD-1/PD-L1 blockade in HCV infection: effect of viremia levels and antiviral treatment</article-title><source>J. Hepatol.</source><volume>48</volume><year>2008</year><fpage>548</fpage><lpage>558</lpage><pub-id pub-id-type="pmid">18280607</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jhep.2007.12.014</pub-id></element-citation></ref><ref id="bb1105"><label>221</label><element-citation publication-type="journal" id="rf1105"><person-group person-group-type="author"><name name-style="western"><surname>Akhmetzyanova</surname><given-names>I.</given-names></name><name name-style="western"><surname>Drabczyk</surname><given-names>M.</given-names></name><name name-style="western"><surname>Neff</surname><given-names>C.P.</given-names></name><name name-style="western"><surname>Gibbert</surname><given-names>K.</given-names></name><name name-style="western"><surname>Dietze</surname><given-names>K.K.</given-names></name><name name-style="western"><surname>Werner</surname><given-names>T.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>J.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>L.</given-names></name><name name-style="western"><surname>Lang</surname><given-names>K.S.</given-names></name><name name-style="western"><surname>Palmer</surname><given-names>B.E.</given-names></name><name name-style="western"><surname>Dittmer</surname><given-names>U.</given-names></name><name name-style="western"><surname>Zelinskyy</surname><given-names>G.</given-names></name></person-group><article-title>PD-L1 expression on retrovirus-infected cells mediates immune escape from CD8+ T cell killing</article-title><source>PLoS Pathog.</source><volume>11</volume><year>2015</year><object-id pub-id-type="publisher-id">e1005224</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1371/journal.ppat.1005224</pub-id><pub-id pub-id-type="pmcid">PMC4617866</pub-id><pub-id pub-id-type="pmid">26484769</pub-id></element-citation></ref><ref id="bb1110"><label>222</label><element-citation publication-type="journal" id="rf1110"><person-group person-group-type="author"><name name-style="western"><surname>Stadtmauer</surname><given-names>E.A.</given-names></name><name name-style="western"><surname>Fraietta</surname><given-names>J.A.</given-names></name><name name-style="western"><surname>Davis</surname><given-names>M.M.</given-names></name><name name-style="western"><surname>Cohen</surname><given-names>A.D.</given-names></name><name name-style="western"><surname>Weber</surname><given-names>K.L.</given-names></name><etal/></person-group><article-title>CRISPR-engineered T cells in patients with refractory cancer</article-title><source>Science</source><volume>367</volume><year>2020</year><pub-id pub-id-type="doi" assigning-authority="pmc">10.1126/science.aba7365</pub-id><pub-id pub-id-type="pmcid">PMC11249135</pub-id><pub-id pub-id-type="pmid">32029687</pub-id></element-citation></ref><ref id="bb1115"><label>223</label><element-citation publication-type="journal" id="rf1115"><person-group person-group-type="author"><name name-style="western"><surname>Zhou</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Yao</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Moorman</surname><given-names>J.P.</given-names></name><name name-style="western"><surname>Jia</surname><given-names>Z.</given-names></name></person-group><article-title>Dendritic cell-based immunity and vaccination against hepatitis C virus infection</article-title><source>Immunology</source><volume>136</volume><year>2012</year><fpage>385</fpage><lpage>396</lpage><pub-id pub-id-type="pmid">22486354</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/j.1365-2567.2012.03590.x</pub-id><pub-id pub-id-type="pmcid">PMC3401977</pub-id></element-citation></ref><ref id="bb1120"><label>224</label><element-citation publication-type="journal" id="rf1120"><person-group person-group-type="author"><name name-style="western"><surname>Cintolo</surname><given-names>J.A.</given-names></name><name name-style="western"><surname>Datta</surname><given-names>J.</given-names></name><name name-style="western"><surname>Mathew</surname><given-names>S.J.</given-names></name><name name-style="western"><surname>Czerniecki</surname><given-names>B.J.</given-names></name></person-group><article-title>Dendritic cell-based vaccines: barriers and opportunities</article-title><source>Future Oncol.</source><volume>8</volume><year>2012</year><fpage>1273</fpage><lpage>1299</lpage><pub-id pub-id-type="pmid">23130928</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2217/fon.12.125</pub-id><pub-id pub-id-type="pmcid">PMC4260651</pub-id></element-citation></ref><ref id="bb1125"><label>225</label><element-citation publication-type="journal" id="rf1125"><person-group person-group-type="author"><name name-style="western"><surname>Golchin</surname><given-names>A.</given-names></name></person-group><article-title>Cell-based therapy for severe COVID-19 patients: clinical trials and cost-utility</article-title><source>Stem Cell Rev. Rep.</source><year>2020</year><comment>(Online ahead of print)</comment><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s12015-020-10046-1</pub-id><pub-id pub-id-type="pmcid">PMC7532742</pub-id><pub-id pub-id-type="pmid">33009982</pub-id></element-citation></ref><ref id="bb1130"><label>226</label><element-citation publication-type="journal" id="rf1130"><person-group person-group-type="author"><name name-style="western"><surname>Le</surname><given-names>D.T.</given-names></name><name name-style="western"><surname>Pardoll</surname><given-names>D.M.</given-names></name><name name-style="western"><surname>Jaffee</surname><given-names>E.M.</given-names></name></person-group><article-title>Cellular vaccine approaches</article-title><source>Cancer J.</source><volume>16</volume><year>2010</year><fpage>304</fpage><lpage>310</lpage><pub-id pub-id-type="pmid">20693840</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/PPO.0b013e3181eb33d7</pub-id><pub-id pub-id-type="pmcid">PMC3086689</pub-id></element-citation></ref><ref id="bb1135"><label>227</label><element-citation publication-type="journal" id="rf1135"><person-group person-group-type="author"><name name-style="western"><surname>Anassi</surname><given-names>E.</given-names></name><name name-style="western"><surname>Ndefo</surname><given-names>U.A.</given-names></name></person-group><article-title>Sipuleucel-T (provenge) injection: the first immunotherapy agent (vaccine) for hormone-refractory prostate cancer</article-title><source>P T</source><volume>36</volume><year>2011</year><fpage>197</fpage><lpage>202</lpage><pub-id pub-id-type="pmid">21572775</pub-id><pub-id pub-id-type="pmcid">PMC3086121</pub-id></element-citation></ref><ref id="bb1140"><label>228</label><element-citation publication-type="other" id="rf1140"><person-group person-group-type="author"><name name-style="western"><surname>Centers for Drug Control anf Prevention</surname></name></person-group><article-title>Cell-Based Flu Vaccines</article-title><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.cdc.gov/flu/prevent/cell-based.htm" id="ir0445">https://www.cdc.gov/flu/prevent/cell-based.htm</ext-link><year>2020</year></element-citation></ref><ref id="bb1145"><label>229</label><element-citation publication-type="other" id="rf1145"><person-group person-group-type="author"><name name-style="western"><surname>University of Manitoba</surname></name></person-group><article-title>A treatment for COVID-19 will be found, reassures UM virologist</article-title><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://news.umanitoba.ca/a-treatment-for-covid-19-will-be-found-reassures-um-virologist/" id="ir0450">https://news.umanitoba.ca/a-treatment-for-covid-19-will-be-found-reassures-um-virologist/</ext-link><year>2020</year></element-citation></ref><ref id="bb1150"><label>230</label><element-citation publication-type="journal" id="rf1150"><person-group person-group-type="author"><name name-style="western"><surname>Liang</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Zhu</surname><given-names>H.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>X.</given-names></name><name name-style="western"><surname>Jing</surname><given-names>B.</given-names></name><name name-style="western"><surname>Li</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Xia</surname><given-names>X.</given-names></name><name name-style="western"><surname>Sun</surname><given-names>H.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>W.</given-names></name><name name-style="western"><surname>Shi</surname><given-names>L.</given-names></name><name name-style="western"><surname>Zeng</surname><given-names>H.</given-names></name><name name-style="western"><surname>Sun</surname><given-names>B.</given-names></name></person-group><article-title>Adjuvants for coronavirus vaccines</article-title><source>Front. Immunol.</source><volume>11</volume><year>2020</year><fpage>589833</fpage><pub-id pub-id-type="pmid">33240278</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fimmu.2020.589833</pub-id><pub-id pub-id-type="pmcid">PMC7677582</pub-id></element-citation></ref><ref id="bb1155"><label>231</label><element-citation publication-type="journal" id="rf1155"><person-group person-group-type="author"><name name-style="western"><surname>Gupta</surname><given-names>T.</given-names></name><name name-style="western"><surname>Gupta</surname><given-names>S.K.</given-names></name></person-group><article-title>Potential adjuvants for the development of a SARS-CoV-2 vaccine based on experimental results from similar coronaviruses</article-title><source>Int. Immunopharmacol.</source><volume>86</volume><year>2020</year><fpage>106717</fpage><pub-id pub-id-type="pmid">32585611</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.intimp.2020.106717</pub-id><pub-id pub-id-type="pmcid">PMC7301105</pub-id></element-citation></ref><ref id="bb1160"><label>232</label><element-citation publication-type="journal" id="rf1160"><person-group person-group-type="author"><name name-style="western"><surname>Nalwa</surname><given-names>H.S.</given-names></name></person-group><article-title>A special issue on reviews in nanomedicine, drug delivery and vaccine development</article-title><source>J. Biomed. Nanotechnol.</source><volume>10</volume><year>2014</year><fpage>1635</fpage><lpage>1640</lpage><pub-id pub-id-type="pmid">25992435</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1166/jbn.2014.2033</pub-id></element-citation></ref><ref id="bb1165"><label>233</label><element-citation publication-type="journal" id="rf1165"><person-group person-group-type="author"><name name-style="western"><surname>Pashine</surname><given-names>A.</given-names></name><name name-style="western"><surname>Valiante</surname><given-names>N.M.</given-names></name><name name-style="western"><surname>Ulmer</surname><given-names>J.B.</given-names></name></person-group><article-title>Targeting the innate immune response with improved vaccine adjuvants</article-title><source>Nat. Med.</source><volume>11</volume><year>2005</year><fpage>S63</fpage><lpage>S68</lpage><pub-id pub-id-type="pmid">15812492</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/nm1210</pub-id></element-citation></ref><ref id="bb1170"><label>234</label><element-citation publication-type="journal" id="rf1170"><person-group person-group-type="author"><name name-style="western"><surname>Caetano</surname><given-names>L.A.</given-names></name><name name-style="western"><surname>Almeida</surname><given-names>A.J.</given-names></name><name name-style="western"><surname>Goncalves</surname><given-names>L.M.</given-names></name></person-group><article-title>Approaches to tuberculosis mucosal vaccine development using nanoparticles and microparticles: a review</article-title><source>J. Biomed. Nanotechnol.</source><volume>10</volume><year>2014</year><fpage>2295</fpage><lpage>2316</lpage><pub-id pub-id-type="pmid">25992458</pub-id></element-citation></ref><ref id="bb1175"><label>235</label><element-citation publication-type="journal" id="rf1175"><person-group person-group-type="author"><name name-style="western"><surname>Petrovsky</surname><given-names>N.</given-names></name><name name-style="western"><surname>Aguilar</surname><given-names>J.C.</given-names></name></person-group><article-title>Vaccine adjuvants: current state and future trends</article-title><source>Immunol. Cell Biol.</source><volume>82</volume><year>2004</year><fpage>488</fpage><lpage>496</lpage><pub-id pub-id-type="pmid">15479434</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/j.0818-9641.2004.01272.x</pub-id></element-citation></ref><ref id="bb1180"><label>236</label><element-citation publication-type="journal" id="rf1180"><person-group person-group-type="author"><name name-style="western"><surname>Singh</surname><given-names>M.</given-names></name></person-group><article-title>D. O'Hagan, Advances in vaccine adjuvants</article-title><source>Nat. Biotechnol.</source><volume>17</volume><year>1999</year><fpage>1075</fpage><lpage>1081</lpage><pub-id pub-id-type="pmid">10545912</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/15058</pub-id></element-citation></ref><ref id="bb1185"><label>237</label><element-citation publication-type="journal" id="rf1185"><person-group person-group-type="author"><name name-style="western"><surname>Bowen</surname><given-names>W.S.</given-names></name><name name-style="western"><surname>Svrivastava</surname><given-names>A.K.</given-names></name><name name-style="western"><surname>Batra</surname><given-names>L.</given-names></name><name name-style="western"><surname>Barsoumian</surname><given-names>H.</given-names></name><name name-style="western"><surname>Shirwan</surname><given-names>H.</given-names></name></person-group><article-title>Current challenges for cancer vaccine adjuvant development</article-title><source>Expert Rev. Vaccines</source><volume>17</volume><year>2018</year><fpage>207</fpage><lpage>215</lpage><pub-id pub-id-type="pmid">29372660</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1080/14760584.2018.1434000</pub-id><pub-id pub-id-type="pmcid">PMC6093214</pub-id></element-citation></ref><ref id="bb1190"><label>238</label><element-citation publication-type="journal" id="rf1190"><person-group person-group-type="author"><name name-style="western"><surname>Schijns</surname><given-names>V.E.</given-names></name><name name-style="western"><surname>Degen</surname><given-names>W.G.</given-names></name></person-group><article-title>Vaccine immunopotentiators of the future</article-title><source>Clin. Pharmacol. Ther.</source><volume>82</volume><year>2007</year><fpage>750</fpage><lpage>755</lpage><pub-id pub-id-type="pmid">17914440</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/sj.clpt.6100394</pub-id></element-citation></ref><ref id="bb1195"><label>239</label><element-citation publication-type="journal" id="rf1195"><person-group person-group-type="author"><name name-style="western"><surname>Akira</surname><given-names>S.</given-names></name><name name-style="western"><surname>Takeda</surname><given-names>K.</given-names></name></person-group><article-title>Toll-like receptor signalling</article-title><source>Nat. Rev. Immunol.</source><volume>4</volume><year>2004</year><fpage>499</fpage><lpage>511</lpage><pub-id pub-id-type="pmid">15229469</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/nri1391</pub-id></element-citation></ref><ref id="bb1200"><label>240</label><element-citation publication-type="journal" id="rf1200"><person-group person-group-type="author"><name name-style="western"><surname>Singh</surname><given-names>M.</given-names></name><name name-style="western"><surname>Kazzaz</surname><given-names>J.</given-names></name><name name-style="western"><surname>Ugozzoli</surname><given-names>M.</given-names></name><name name-style="western"><surname>Baudner</surname><given-names>B.</given-names></name><name name-style="western"><surname>Pizza</surname><given-names>M.</given-names></name><etal/></person-group><article-title>MF59 oil-in-water emulsion in combination with a synthetic TLR4 agonist (E6020) is a potent adjuvant for a combination Meningococcus vaccine</article-title><source>Hum. Vaccin Immunother.</source><volume>8</volume><year>2012</year><fpage>486</fpage><lpage>490</lpage><pub-id pub-id-type="pmid">22832252</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.4161/hv.19229</pub-id></element-citation></ref><ref id="bb1205"><label>241</label><element-citation publication-type="journal" id="rf1205"><person-group person-group-type="author"><name name-style="western"><surname>Kazzaz</surname><given-names>J.</given-names></name><name name-style="western"><surname>Singh</surname><given-names>M.</given-names></name><name name-style="western"><surname>Ugozzoli</surname><given-names>M.</given-names></name><name name-style="western"><surname>Chesko</surname><given-names>J.</given-names></name><name name-style="western"><surname>Soenawan</surname><given-names>E.</given-names></name></person-group><article-title>D.T. O'Hagan, Encapsulation of the immune potentiators MPL and RC529 in PLG microparticles enhances their potency</article-title><source>J. Control. Release</source><volume>110</volume><year>2006</year><fpage>566</fpage><lpage>573</lpage><pub-id pub-id-type="pmid">16360956</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jconrel.2005.10.010</pub-id></element-citation></ref><ref id="bb1210"><label>242</label><element-citation publication-type="journal" id="rf1210"><person-group person-group-type="author"><name name-style="western"><surname>Zakhartchouk</surname><given-names>A.N.</given-names></name><name name-style="western"><surname>Sharon</surname><given-names>C.</given-names></name><name name-style="western"><surname>Satkunarajah</surname><given-names>M.</given-names></name><name name-style="western"><surname>Auperin</surname><given-names>T.</given-names></name><name name-style="western"><surname>Viswanathan</surname><given-names>S.</given-names></name><etal/></person-group><article-title>Immunogenicity of a receptor-binding domain of SARS coronavirus spike protein in mice: implications for a subunit vaccine</article-title><source>Vaccine</source><volume>25</volume><year>2007</year><fpage>136</fpage><lpage>143</lpage><pub-id pub-id-type="pmid">16919855</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.vaccine.2006.06.084</pub-id><pub-id pub-id-type="pmcid">PMC7115608</pub-id></element-citation></ref><ref id="bb1215"><label>243</label><element-citation publication-type="journal" id="rf1215"><person-group person-group-type="author"><name name-style="western"><surname>Jiaming</surname><given-names>L.</given-names></name><name name-style="western"><surname>Yanfeng</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Yao</surname><given-names>D.</given-names></name><name name-style="western"><surname>Yawei</surname><given-names>H.</given-names></name><name name-style="western"><surname>Linlin</surname><given-names>B.</given-names></name><etal/></person-group><article-title>The recombinant N-terminal domain of spike proteins is a potential vaccine against Middle East respiratory syndrome coronavirus (MERS-CoV) infection</article-title><source>Vaccine</source><volume>35</volume><year>2017</year><fpage>10</fpage><lpage>18</lpage><pub-id pub-id-type="pmid">27899228</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.vaccine.2016.11.064</pub-id><pub-id pub-id-type="pmcid">PMC7115548</pub-id></element-citation></ref><ref id="bb1220"><label>244</label><element-citation publication-type="journal" id="rf1220"><person-group person-group-type="author"><name name-style="western"><surname>Iwata-Yoshikawa</surname><given-names>N.</given-names></name><name name-style="western"><surname>Uda</surname><given-names>A.</given-names></name><name name-style="western"><surname>Suzuki</surname><given-names>T.</given-names></name><name name-style="western"><surname>Tsunetsugu-Yokota</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Sato</surname><given-names>Y.</given-names></name><etal/></person-group><article-title>Effects of Toll-like receptor stimulation on eosinophilic infiltration in lungs of BALB/c mice immunized with UV-inactivated severe acute respiratory syndrome-related coronavirus vaccine</article-title><source>J. Virol.</source><volume>88</volume><year>2014</year><fpage>8597</fpage><lpage>8614</lpage><pub-id pub-id-type="pmid">24850731</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1128/JVI.00983-14</pub-id><pub-id pub-id-type="pmcid">PMC4135953</pub-id></element-citation></ref><ref id="bb1225"><label>245</label><element-citation publication-type="journal" id="rf1225"><person-group person-group-type="author"><name name-style="western"><surname>Tomljenovic</surname><given-names>L.</given-names></name><name name-style="western"><surname>Shaw</surname><given-names>C.A.</given-names></name></person-group><article-title>Aluminium vaccine adjuvants: are they safe?</article-title><source>Curr. Med. Chem.</source><volume>18</volume><year>2011</year><fpage>2630</fpage><lpage>2637</lpage><pub-id pub-id-type="pmid">21568886</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2174/092986711795933740</pub-id></element-citation></ref><ref id="bb1230"><label>246</label><element-citation publication-type="journal" id="rf1230"><person-group person-group-type="author"><name name-style="western"><surname>Oleszycka</surname><given-names>E.</given-names></name><name name-style="western"><surname>Lavelle</surname><given-names>E.C.</given-names></name></person-group><article-title>Immunomodulatory properties of the vaccine adjuvant alum</article-title><source>Curr. Opin. Immunol.</source><volume>28</volume><year>2014</year><fpage>1</fpage><lpage>5</lpage><pub-id pub-id-type="pmid">24463269</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.coi.2013.12.007</pub-id></element-citation></ref><ref id="bb1235"><label>247</label><element-citation publication-type="journal" id="rf1235"><person-group person-group-type="author"><name name-style="western"><surname>Gupta</surname><given-names>R.K.</given-names></name></person-group><article-title>Aluminium compounds as vaccine adjuvants</article-title><source>Adv. Drug Deliv. Rev.</source><volume>32</volume><year>1998</year><fpage>155</fpage><lpage>172</lpage><pub-id pub-id-type="pmid">10837642</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/s0169-409x(98)00008-8</pub-id></element-citation></ref><ref id="bb1240"><label>248</label><element-citation publication-type="journal" id="rf1240"><person-group person-group-type="author"><name name-style="western"><surname>Brito</surname><given-names>L.A.</given-names></name><name name-style="western"><surname>Malyala</surname><given-names>P.</given-names></name></person-group><article-title>D.T. O'Hagan, Vaccine adjuvant formulations: a pharmaceutical perspective</article-title><source>Semin. Immunol.</source><volume>25</volume><year>2013</year><fpage>130</fpage><lpage>145</lpage><pub-id pub-id-type="pmid">23850011</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.smim.2013.05.007</pub-id></element-citation></ref><ref id="bb1245"><label>249</label><element-citation publication-type="journal" id="rf1245"><person-group person-group-type="author"><name name-style="western"><surname>Hogenesch</surname><given-names>H.</given-names></name></person-group><article-title>Mechanism of immunopotentiation and safety of aluminium adjuvants</article-title><source>Front. Immunol.</source><volume>3</volume><year>2012</year><fpage>406</fpage><pub-id pub-id-type="pmid">23335921</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fimmu.2012.00406</pub-id><pub-id pub-id-type="pmcid">PMC3541479</pub-id></element-citation></ref><ref id="bb1250"><label>250</label><element-citation publication-type="journal" id="rf1250"><person-group person-group-type="author"><name name-style="western"><surname>Spruth</surname><given-names>M.</given-names></name><name name-style="western"><surname>Kistner</surname><given-names>O.</given-names></name><name name-style="western"><surname>Savidis-Dacho</surname><given-names>H.</given-names></name><name name-style="western"><surname>Hitter</surname><given-names>E.</given-names></name><name name-style="western"><surname>Crowe</surname><given-names>B.</given-names></name><etal/></person-group><article-title>A double-inactivated whole virus candidate SARS coronavirus vaccine stimulates neutralizing and protective antibody responses</article-title><source>Vaccine</source><volume>24</volume><year>2006</year><fpage>652</fpage><lpage>661</lpage><pub-id pub-id-type="pmid">16214268</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.vaccine.2005.08.055</pub-id><pub-id pub-id-type="pmcid">PMC7115667</pub-id></element-citation></ref><ref id="bb1255"><label>251</label><element-citation publication-type="journal" id="rf1255"><person-group person-group-type="author"><name name-style="western"><surname>Tang</surname><given-names>L.</given-names></name><name name-style="western"><surname>Zhu</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Qin</surname><given-names>E.</given-names></name><name name-style="western"><surname>Yu</surname><given-names>M.</given-names></name><name name-style="western"><surname>Ding</surname><given-names>Z.</given-names></name><etal/></person-group><article-title>Inactivated SARS-CoV vaccine prepared from whole virus induces a high level of neutralizing antibodies in BALB/c mice</article-title><source>DNA Cell Biol.</source><volume>23</volume><year>2004</year><fpage>391</fpage><lpage>394</lpage><pub-id pub-id-type="pmid">15231072</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1089/104454904323145272</pub-id></element-citation></ref><ref id="bb1260"><label>252</label><element-citation publication-type="journal" id="rf1260"><person-group person-group-type="author"><name name-style="western"><surname>Deng</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Lan</surname><given-names>J.</given-names></name><name name-style="western"><surname>Bao</surname><given-names>L.</given-names></name><name name-style="western"><surname>Huang</surname><given-names>B.</given-names></name><name name-style="western"><surname>Ye</surname><given-names>F.</given-names></name><etal/></person-group><article-title>Enhanced protection in mice induced by immunization with inactivated whole viruses compare to spike protein of middle east respiratory syndrome coronavirus</article-title><source>Emerg. Microbes Infect.</source><volume>7</volume><year>2018</year><fpage>60</fpage><pub-id pub-id-type="pmid">29618723</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41426-018-0056-7</pub-id><pub-id pub-id-type="pmcid">PMC5884803</pub-id></element-citation></ref><ref id="bb1265"><label>253</label><element-citation publication-type="journal" id="rf1265"><person-group person-group-type="author"><name name-style="western"><surname>Lan</surname><given-names>J.</given-names></name><name name-style="western"><surname>Deng</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>H.</given-names></name><name name-style="western"><surname>Lu</surname><given-names>G.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>W.</given-names></name><etal/></person-group><article-title>Tailoring subunit vaccine immunity with adjuvant combinations and delivery routes using the Middle East respiratory coronavirus (MERS-CoV) receptor-binding domain as an antigen</article-title><source>PLoS One</source><volume>9</volume><year>2014</year><object-id pub-id-type="publisher-id">e112602</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1371/journal.pone.0112602</pub-id><pub-id pub-id-type="pmcid">PMC4236105</pub-id><pub-id pub-id-type="pmid">25405618</pub-id></element-citation></ref><ref id="bb1270"><label>254</label><element-citation publication-type="journal" id="rf1270"><person-group person-group-type="author"><name name-style="western"><surname>Stills</surname><given-names>H.F.</given-names><suffix>Jr.</suffix></name></person-group><article-title>Adjuvants and antibody production: dispelling the myths associated with Freund's complete and other adjuvants</article-title><source>ILAR J.</source><volume>46</volume><year>2005</year><fpage>280</fpage><lpage>293</lpage><pub-id pub-id-type="pmid">15953835</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/ilar.46.3.280</pub-id></element-citation></ref><ref id="bb1275"><label>255</label><element-citation publication-type="journal" id="rf1275"><person-group person-group-type="author"><name name-style="western"><surname>Jansen</surname><given-names>T.</given-names></name><name name-style="western"><surname>Hofmans</surname><given-names>M.P.</given-names></name><name name-style="western"><surname>Theelen</surname><given-names>M.J.</given-names></name><name name-style="western"><surname>Manders</surname><given-names>F.</given-names></name><name name-style="western"><surname>Schijns</surname><given-names>V.E.</given-names></name></person-group><article-title>Structure- and oil type-based efficacy of emulsion adjuvants</article-title><source>Vaccine</source><volume>24</volume><year>2006</year><fpage>5400</fpage><lpage>5405</lpage><pub-id pub-id-type="pmid">16675072</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.vaccine.2006.03.074</pub-id></element-citation></ref><ref id="bb1280"><label>256</label><element-citation publication-type="journal" id="rf1280"><person-group person-group-type="author"><name name-style="western"><surname>Morel</surname><given-names>S.</given-names></name><name name-style="western"><surname>Didierlaurent</surname><given-names>A.</given-names></name><name name-style="western"><surname>Bourguignon</surname><given-names>P.</given-names></name><name name-style="western"><surname>Delhaye</surname><given-names>S.</given-names></name><name name-style="western"><surname>Baras</surname><given-names>B.</given-names></name><etal/></person-group><article-title>Adjuvant System AS03 containing alpha-tocopherol modulates innate immune response and leads to improved adaptive immunity</article-title><source>Vaccine</source><volume>29</volume><year>2011</year><fpage>2461</fpage><lpage>2473</lpage><pub-id pub-id-type="pmid">21256188</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.vaccine.2011.01.011</pub-id></element-citation></ref><ref id="bb1285"><label>257</label><element-citation publication-type="journal" id="rf1285"><person-group person-group-type="author"><name name-style="western"><surname>Vesikari</surname><given-names>T.</given-names></name><name name-style="western"><surname>Groth</surname><given-names>N.</given-names></name><name name-style="western"><surname>Karvonen</surname><given-names>A.</given-names></name><name name-style="western"><surname>Borkowski</surname><given-names>A.</given-names></name><name name-style="western"><surname>Pellegrini</surname><given-names>M.</given-names></name></person-group><article-title>MF59-adjuvanted influenza vaccine (FLUAD) in children: safety and immunogenicity following a second year seasonal vaccination</article-title><source>Vaccine</source><volume>27</volume><year>2009</year><fpage>6291</fpage><lpage>6295</lpage><pub-id pub-id-type="pmid">19840662</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.vaccine.2009.02.004</pub-id></element-citation></ref><ref id="bb1290"><label>258</label><element-citation publication-type="journal" id="rf1290"><person-group person-group-type="author"><name name-style="western"><surname>Ott</surname><given-names>G.</given-names></name><name name-style="western"><surname>Barchfeld</surname><given-names>G.L.</given-names></name><name name-style="western"><surname>Van Nest</surname><given-names>G.</given-names></name></person-group><article-title>Enhancement of humoral response against human influenza vaccine with the simple submicron oil/water emulsion adjuvant MF59</article-title><source>Vaccine</source><volume>13</volume><year>1995</year><fpage>1557</fpage><lpage>1562</lpage><pub-id pub-id-type="pmid">8578842</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/0264-410x(95)00089-j</pub-id></element-citation></ref><ref id="bb1295"><label>259</label><element-citation publication-type="journal" id="rf1295"><person-group person-group-type="author"><name name-style="western"><surname>Ott</surname><given-names>G.</given-names></name></person-group><article-title>The adjuvant MF59: the 1998 perspective, clinical performance and mechanism of action</article-title><source>Res. Immunol.</source><volume>149</volume><year>1998</year><fpage>25</fpage><lpage>27</lpage></element-citation></ref><ref id="bb1300"><label>260</label><element-citation publication-type="journal" id="rf1300"><person-group person-group-type="author"><name name-style="western"><surname>Stadler</surname><given-names>K.</given-names></name><name name-style="western"><surname>Roberts</surname><given-names>A.</given-names></name><name name-style="western"><surname>Becker</surname><given-names>S.</given-names></name><name name-style="western"><surname>Vogel</surname><given-names>L.</given-names></name><name name-style="western"><surname>Eickmann</surname><given-names>M.</given-names></name><name name-style="western"><surname>Kolesnikova</surname><given-names>L.</given-names></name><name name-style="western"><surname>Klenk</surname><given-names>H.D.</given-names></name><name name-style="western"><surname>Murphy</surname><given-names>B.</given-names></name><name name-style="western"><surname>Rappuoli</surname><given-names>R.</given-names></name><name name-style="western"><surname>Abrignani</surname><given-names>S.</given-names></name><name name-style="western"><surname>Subbarao</surname><given-names>K.</given-names></name></person-group><article-title>SARS vaccine protective in mice</article-title><source>Emerg. Infect. Dis.</source><volume>11</volume><year>2005</year><fpage>1312</fpage><lpage>1314</lpage><pub-id pub-id-type="pmid">16110580</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3201/eid1108.041003</pub-id><pub-id pub-id-type="pmcid">PMC3320494</pub-id></element-citation></ref><ref id="bb1305"><label>261</label><element-citation publication-type="journal" id="rf1305"><person-group person-group-type="author"><name name-style="western"><surname>Kong</surname><given-names>W.P.</given-names></name><name name-style="western"><surname>Xu</surname><given-names>L.</given-names></name><name name-style="western"><surname>Stadler</surname><given-names>K.</given-names></name><name name-style="western"><surname>Ulmer</surname><given-names>J.B.</given-names></name><name name-style="western"><surname>Abrignani</surname><given-names>S.</given-names></name><name name-style="western"><surname>Rappuoli</surname><given-names>R.</given-names></name><name name-style="western"><surname>Nabel</surname><given-names>G.J.</given-names></name></person-group><article-title>Modulation of the immune response to the severe acute respiratory syndrome spike glycoprotein by gene-based and inactivated virus immunization</article-title><source>J. Virol.</source><volume>79</volume><year>2005</year><fpage>13915</fpage><lpage>13923</lpage><pub-id pub-id-type="pmid">16254327</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1128/JVI.79.22.13915-13923.2005</pub-id><pub-id pub-id-type="pmcid">PMC1280202</pub-id></element-citation></ref><ref id="bb1310"><label>262</label><element-citation publication-type="journal" id="rf1310"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>N.</given-names></name><name name-style="western"><surname>Channappanavar</surname><given-names>R.</given-names></name><name name-style="western"><surname>Ma</surname><given-names>C.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>L.</given-names></name><name name-style="western"><surname>Tang</surname><given-names>J.</given-names></name><etal/></person-group><article-title>Identification of an ideal adjuvant for receptor-binding domain-based subunit vaccines against Middle East respiratory syndrome coronavirus</article-title><source>Cell. Mol. Immunol.</source><volume>13</volume><year>2016</year><fpage>180</fpage><lpage>190</lpage><pub-id pub-id-type="pmid">25640653</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/cmi.2015.03</pub-id><pub-id pub-id-type="pmcid">PMC4786625</pub-id></element-citation></ref><ref id="bb1315"><label>263</label><element-citation publication-type="journal" id="rf1315"><person-group person-group-type="author"><name name-style="western"><surname>Das</surname><given-names>S.C.</given-names></name><name name-style="western"><surname>Hatta</surname><given-names>M.</given-names></name><name name-style="western"><surname>Wilker</surname><given-names>P.R.</given-names></name><name name-style="western"><surname>Myc</surname><given-names>A.</given-names></name><name name-style="western"><surname>Hamouda</surname><given-names>T.</given-names></name><name name-style="western"><surname>Neumann</surname><given-names>G.</given-names></name><name name-style="western"><surname>Baker</surname><given-names>J.R.</given-names><suffix>Jr.</suffix></name><name name-style="western"><surname>Kawaoka</surname><given-names>Y.</given-names></name></person-group><article-title>Nanoemulsion W805EC improves immune responses upon intranasal delivery of an inactivated pandemic H1N1 influenza vaccine</article-title><source>Vaccine</source><volume>30</volume><year>2012</year><fpage>6871</fpage><lpage>6877</lpage><pub-id pub-id-type="pmid">22989689</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.vaccine.2012.09.007</pub-id><pub-id pub-id-type="pmcid">PMC3488283</pub-id></element-citation></ref><ref id="bb1320"><label>264</label><element-citation publication-type="journal" id="rf1320"><person-group person-group-type="author"><name name-style="western"><surname>Treanor</surname><given-names>J.J.</given-names></name><name name-style="western"><surname>Essink</surname><given-names>B.</given-names></name><name name-style="western"><surname>Hull</surname><given-names>S.</given-names></name><name name-style="western"><surname>Reed</surname><given-names>S.</given-names></name><name name-style="western"><surname>Izikson</surname><given-names>R.</given-names></name><etal/></person-group><article-title>Evaluation of safety and immunogenicity of recombinant influenza hemagglutinin (H5/Indonesia/05/2005) formulated with and without a stable oil-in-water emulsion containing glucopyranosyl-lipid A (SE&#160;+&#160;GLA) adjuvant</article-title><source>Vaccine</source><volume>31</volume><year>2013</year><fpage>5760</fpage><lpage>5765</lpage><pub-id pub-id-type="pmid">24075920</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.vaccine.2013.08.064</pub-id></element-citation></ref><ref id="bb1325"><label>265</label><element-citation publication-type="journal" id="rf1325"><person-group person-group-type="author"><name name-style="western"><surname>Klucker</surname><given-names>M.F.</given-names></name><name name-style="western"><surname>Dalencon</surname><given-names>F.</given-names></name><name name-style="western"><surname>Probeck</surname><given-names>P.</given-names></name><name name-style="western"><surname>Haensler</surname><given-names>J.</given-names></name></person-group><article-title>AF03, an alternative squalene emulsion-based vaccine adjuvant prepared by a phase inversion temperature method</article-title><source>J. Pharm. Sci.</source><volume>101</volume><year>2012</year><fpage>4490</fpage><lpage>4500</lpage><pub-id pub-id-type="pmid">22941944</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/jps.23311</pub-id></element-citation></ref><ref id="bb1330"><label>266</label><element-citation publication-type="journal" id="rf1330"><person-group person-group-type="author"><name name-style="western"><surname>Garcon</surname><given-names>N.</given-names></name><name name-style="western"><surname>Vaughn</surname><given-names>D.W.</given-names></name><name name-style="western"><surname>Didierlaurent</surname><given-names>A.M.</given-names></name></person-group><article-title>Development and evaluation of AS03, an Adjuvant System containing alpha-tocopherol and squalene in an oil-in-water emulsion</article-title><source>Expert Rev. Vaccines</source><volume>11</volume><year>2012</year><fpage>349</fpage><lpage>366</lpage><pub-id pub-id-type="pmid">22380826</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1586/erv.11.192</pub-id></element-citation></ref><ref id="bb1335"><label>267</label><element-citation publication-type="journal" id="rf1335"><person-group person-group-type="author"><name name-style="western"><surname>Roberts</surname><given-names>A.</given-names></name><name name-style="western"><surname>Lamirande</surname><given-names>E.W.</given-names></name><name name-style="western"><surname>Vogel</surname><given-names>L.</given-names></name><name name-style="western"><surname>Baras</surname><given-names>B.</given-names></name><name name-style="western"><surname>Goossens</surname><given-names>G.</given-names></name><etal/></person-group><article-title>Immunogenicity and protective efficacy in mice and hamsters of a beta-propiolactone inactivated whole virus SARS-CoV vaccine</article-title><source>Viral Immunol.</source><volume>23</volume><year>2010</year><fpage>509</fpage><lpage>519</lpage><pub-id pub-id-type="pmid">20883165</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1089/vim.2010.0028</pub-id><pub-id pub-id-type="pmcid">PMC2967819</pub-id></element-citation></ref><ref id="bb1340"><label>268</label><element-citation publication-type="journal" id="rf1340"><person-group person-group-type="author"><name name-style="western"><surname>Geale</surname><given-names>P.F.</given-names></name><name name-style="western"><surname>Sheehy</surname><given-names>P.A.</given-names></name><name name-style="western"><surname>Giles</surname><given-names>C.</given-names></name><name name-style="western"><surname>Thomson</surname><given-names>P.C.</given-names></name><name name-style="western"><surname>Wynn</surname><given-names>P.C.</given-names></name></person-group><article-title>Efficacy of two adjuvant systems to promote humoral immunity to the pre-proghrelin peptide obestatin in pigs: consequences for the growth of piglets to weaning</article-title><source>Anim. Prod. Sci.</source><volume>60</volume><year>2020</year><fpage>356</fpage><lpage>362</lpage></element-citation></ref><ref id="bb1345"><label>269</label><element-citation publication-type="journal" id="rf1345"><person-group person-group-type="author"><name name-style="western"><surname>Nordly</surname><given-names>P.</given-names></name><name name-style="western"><surname>Madsen</surname><given-names>H.B.</given-names></name><name name-style="western"><surname>Nielsen</surname><given-names>H.M.</given-names></name><name name-style="western"><surname>Foged</surname><given-names>C.</given-names></name></person-group><article-title>Status and future prospects of lipid-based particulate delivery systems as vaccine adjuvants and their combination with immunostimulators</article-title><source>Expert Opi.n Drug Deliv.</source><volume>6</volume><year>2009</year><fpage>657</fpage><lpage>672</lpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1517/17425240903018863</pub-id><pub-id pub-id-type="pmid">19538037</pub-id></element-citation></ref><ref id="bb1350"><label>270</label><element-citation publication-type="journal" id="rf1350"><person-group person-group-type="author"><name name-style="western"><surname>Azizi</surname><given-names>A.</given-names></name><name name-style="western"><surname>Aucoin</surname><given-names>S.</given-names></name><name name-style="western"><surname>Tadesse</surname><given-names>H.</given-names></name><name name-style="western"><surname>Frost</surname><given-names>R.</given-names></name><name name-style="western"><surname>Ghorbani</surname><given-names>M.</given-names></name><name name-style="western"><surname>Soare</surname><given-names>C.</given-names></name><name name-style="western"><surname>Naas</surname><given-names>T.</given-names></name><name name-style="western"><surname>Diaz-Mitoma</surname><given-names>F.</given-names></name></person-group><article-title>A combined nucleocapsid vaccine induces vigorous SARS-CD8+ T-cell immune responses</article-title><source>Genet. Vaccines Ther.</source><volume>3</volume><year>2005</year><fpage>7</fpage><pub-id pub-id-type="pmid">16115319</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/1479-0556-3-7</pub-id><pub-id pub-id-type="pmcid">PMC1249587</pub-id></element-citation></ref><ref id="bb1355"><label>271</label><element-citation publication-type="journal" id="rf1355"><person-group person-group-type="author"><name name-style="western"><surname>Du</surname><given-names>L.</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>G.</given-names></name><name name-style="western"><surname>Kou</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Ma</surname><given-names>C.</given-names></name><name name-style="western"><surname>Sun</surname><given-names>S.</given-names></name><name name-style="western"><surname>Poon</surname><given-names>V.K.</given-names></name><name name-style="western"><surname>Lu</surname><given-names>L.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>L.</given-names></name><name name-style="western"><surname>Debnath</surname><given-names>A.K.</given-names></name><name name-style="western"><surname>Zheng</surname><given-names>B.J.</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Jiang</surname><given-names>S.</given-names></name></person-group><article-title>Identification of a receptor-binding domain in the S protein of the novel human coronavirus Middle East respiratory syndrome coronavirus as an essential target for vaccine development</article-title><source>J. Virol.</source><volume>87</volume><year>2013</year><fpage>9939</fpage><lpage>9942</lpage><pub-id pub-id-type="pmid">23824801</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1128/JVI.01048-13</pub-id><pub-id pub-id-type="pmcid">PMC3754113</pub-id></element-citation></ref><ref id="bb1360"><label>272</label><element-citation publication-type="journal" id="rf1360"><person-group person-group-type="author"><name name-style="western"><surname>Keech</surname><given-names>C.</given-names></name><name name-style="western"><surname>Albert</surname><given-names>G.</given-names></name><name name-style="western"><surname>Cho</surname><given-names>I.</given-names></name><name name-style="western"><surname>Robertson</surname><given-names>A.</given-names></name><name name-style="western"><surname>Reed</surname><given-names>P.</given-names></name><etal/></person-group><article-title>Phase 1&#8211;2 Trial of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine</article-title><source>N. Engl. J. Med.</source><volume>383</volume><year>2020</year><fpage>2320</fpage><lpage>2332</lpage><pub-id pub-id-type="pmid">32877576</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1056/NEJMoa2026920</pub-id><pub-id pub-id-type="pmcid">PMC7494251</pub-id></element-citation></ref><ref id="bb1365"><label>273</label><element-citation publication-type="other" id="rf1365"><person-group person-group-type="author"><name name-style="western"><surname>Vaxine</surname></name></person-group><article-title>COVID-19</article-title><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://vaxine.net/covid-19/" id="ir0455">https://vaxine.net/covid-19/</ext-link><year>2020</year></element-citation></ref><ref id="bb1370"><label>274</label><element-citation publication-type="journal" id="rf1370"><person-group person-group-type="author"><name name-style="western"><surname>Mulligan</surname><given-names>M.J.</given-names></name><name name-style="western"><surname>Lyke</surname><given-names>K.E.</given-names></name><name name-style="western"><surname>Kitchin</surname><given-names>N.</given-names></name><name name-style="western"><surname>Absalon</surname><given-names>J.</given-names></name><name name-style="western"><surname>Gurtman</surname><given-names>A.</given-names></name><etal/></person-group><article-title>Phase I/II study of COVID-19 RNA vaccine BNT162b1 in adults</article-title><source>Nature</source><volume>586</volume><year>2020</year><fpage>589</fpage><lpage>593</lpage><pub-id pub-id-type="pmid">32785213</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41586-020-2639-4</pub-id></element-citation></ref><ref id="bb1375"><label>275</label><element-citation publication-type="journal" id="rf1375"><person-group person-group-type="author"><name name-style="western"><surname>Perrie</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Crofts</surname><given-names>F.</given-names></name><name name-style="western"><surname>Devitt</surname><given-names>A.</given-names></name><name name-style="western"><surname>Griffiths</surname><given-names>H.R.</given-names></name><name name-style="western"><surname>Kastner</surname><given-names>E.</given-names></name><name name-style="western"><surname>Nadella</surname><given-names>V.</given-names></name></person-group><article-title>Designing liposomal adjuvants for the next generation of vaccines</article-title><source>Adv. Drug Deliv. Rev.</source><volume>99</volume><year>2016</year><fpage>85</fpage><lpage>96</lpage><pub-id pub-id-type="pmid">26576719</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.addr.2015.11.005</pub-id></element-citation></ref><ref id="bb1380"><label>276</label><element-citation publication-type="journal" id="rf1380"><person-group person-group-type="author"><name name-style="western"><surname>Chung</surname><given-names>Y.H.</given-names></name><name name-style="western"><surname>Beiss</surname><given-names>V.</given-names></name><name name-style="western"><surname>Fiering</surname><given-names>S.N.</given-names></name><name name-style="western"><surname>Steinmetz</surname><given-names>N.F.</given-names></name></person-group><article-title>COVID-19 vaccine frontrunners and their nanotechnology design</article-title><source>ACS Nano</source><volume>14</volume><year>2020</year><fpage>12522</fpage><lpage>12537</lpage><pub-id pub-id-type="pmid">33034449</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1021/acsnano.0c07197</pub-id></element-citation></ref><ref id="bb1385"><label>277</label><element-citation publication-type="journal" id="rf1385"><person-group person-group-type="author"><name name-style="western"><surname>Vijayan</surname><given-names>V.</given-names></name><name name-style="western"><surname>Mohapatra</surname><given-names>A.</given-names></name><name name-style="western"><surname>Uthaman</surname><given-names>S.</given-names></name><name name-style="western"><surname>Park</surname><given-names>I.K.</given-names></name></person-group><article-title>Recent advances in nanovaccines using biomimetic immunomodulatory materials</article-title><source>Pharmaceutics</source><volume>11</volume><year>2019</year><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/pharmaceutics11100534</pub-id><pub-id pub-id-type="pmcid">PMC6835828</pub-id><pub-id pub-id-type="pmid">31615112</pub-id></element-citation></ref><ref id="bb1390"><label>278</label><element-citation publication-type="journal" id="rf1390"><person-group person-group-type="author"><name name-style="western"><surname>Joshi</surname><given-names>V.B.</given-names></name><name name-style="western"><surname>Geary</surname><given-names>S.M.</given-names></name><name name-style="western"><surname>Salem</surname><given-names>A.K.</given-names></name></person-group><article-title>Biodegradable particles as vaccine delivery systems: size matters</article-title><source>AAPS J.</source><volume>15</volume><year>2013</year><fpage>85</fpage><lpage>94</lpage><pub-id pub-id-type="pmid">23054976</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1208/s12248-012-9418-6</pub-id><pub-id pub-id-type="pmcid">PMC3535111</pub-id></element-citation></ref><ref id="bb1395"><label>279</label><element-citation publication-type="journal" id="rf1395"><person-group person-group-type="author"><name name-style="western"><surname>Bishop</surname><given-names>C.J.</given-names></name><name name-style="western"><surname>Kozielski</surname><given-names>K.L.</given-names></name><name name-style="western"><surname>Green</surname><given-names>J.J.</given-names></name></person-group><article-title>Exploring the role of polymer structure on intracellular nucleic acid delivery via polymeric nanoparticles</article-title><source>J. Control. Release</source><volume>219</volume><year>2015</year><fpage>488</fpage><lpage>499</lpage><pub-id pub-id-type="pmid">26433125</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jconrel.2015.09.046</pub-id><pub-id pub-id-type="pmcid">PMC4745091</pub-id></element-citation></ref><ref id="bb1400"><label>280</label><element-citation publication-type="journal" id="rf1400"><person-group person-group-type="author"><name name-style="western"><surname>Walsh</surname><given-names>E.E.</given-names></name><name name-style="western"><surname>Frenck</surname><given-names>R.W.</given-names><suffix>Jr.</suffix></name><name name-style="western"><surname>Falsey</surname><given-names>A.R.</given-names></name><name name-style="western"><surname>Kitchin</surname><given-names>N.</given-names></name><name name-style="western"><surname>Absalon</surname><given-names>J.</given-names></name><etal/></person-group><article-title>Safety and immunogenicity of two RNA-based Covid-19 vaccine candidates</article-title><source>N. Engl. J. Med.</source><volume>383</volume><year>2020</year><fpage>2439</fpage><lpage>2450</lpage><pub-id pub-id-type="pmid">33053279</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1056/NEJMoa2027906</pub-id><pub-id pub-id-type="pmcid">PMC7583697</pub-id></element-citation></ref><ref id="bb1405"><label>281</label><element-citation publication-type="journal" id="rf1405"><person-group person-group-type="author"><name name-style="western"><surname>Krishnamachari</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Geary</surname><given-names>S.M.</given-names></name><name name-style="western"><surname>Lemke</surname><given-names>C.D.</given-names></name><name name-style="western"><surname>Salem</surname><given-names>A.K.</given-names></name></person-group><article-title>Nanoparticle delivery systems in cancer vaccines</article-title><source>Pharm. Res.</source><volume>28</volume><year>2011</year><fpage>215</fpage><lpage>236</lpage><pub-id pub-id-type="pmid">20721603</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s11095-010-0241-4</pub-id><pub-id pub-id-type="pmcid">PMC3559243</pub-id></element-citation></ref><ref id="bb1410"><label>282</label><element-citation publication-type="journal" id="rf1410"><person-group person-group-type="author"><name name-style="western"><surname>Zhou</surname><given-names>X.</given-names></name><name name-style="western"><surname>Jiang</surname><given-names>X.</given-names></name><name name-style="western"><surname>Qu</surname><given-names>M.</given-names></name><name name-style="western"><surname>Aninwene</surname><given-names>G.E.</given-names></name><name name-style="western"><surname>2nd</surname><given-names>V.</given-names></name><name name-style="western"><surname>Jucaud</surname><given-names>J.J.</given-names></name><name name-style="western"><surname>Moon</surname><given-names>Z. Gu</given-names></name><name name-style="western"><surname>Sun</surname><given-names>W.</given-names></name><name name-style="western"><surname>Khademhosseini</surname><given-names>A.</given-names></name></person-group><article-title>Engineering antiviral vaccines</article-title><source>ACS Nano</source><volume>14</volume><year>2020</year><fpage>12370</fpage><lpage>12389</lpage><pub-id pub-id-type="pmid">33001626</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1021/acsnano.0c06109</pub-id><pub-id pub-id-type="pmcid">PMC7534801</pub-id></element-citation></ref><ref id="bb1415"><label>283</label><element-citation publication-type="journal" id="rf1415"><person-group person-group-type="author"><name name-style="western"><surname>Itani</surname><given-names>R.</given-names></name><name name-style="western"><surname>Tobaiqy</surname><given-names>M.</given-names></name><name name-style="western"><surname>Al Faraj</surname><given-names>A.</given-names></name></person-group><article-title>Optimizing use of theranostic nanoparticles as a life-saving strategy for treating COVID-19 patients</article-title><source>Theranostics</source><volume>10</volume><year>2020</year><fpage>5932</fpage><lpage>5942</lpage><pub-id pub-id-type="pmid">32483428</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.7150/thno.46691</pub-id><pub-id pub-id-type="pmcid">PMC7254986</pub-id></element-citation></ref><ref id="bb1420"><label>284</label><element-citation publication-type="journal" id="rf1420"><person-group person-group-type="author"><name name-style="western"><surname>Wu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Wei</surname><given-names>W.</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>M.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>J.</given-names></name><name name-style="western"><surname>Ma</surname><given-names>G.</given-names></name><name name-style="western"><surname>Su</surname><given-names>Z.</given-names></name></person-group><article-title>Thermal-sensitive hydrogel as adjuvant-free vaccine delivery system for H5N1 intranasal immunization</article-title><source>Biomaterials</source><volume>33</volume><year>2012</year><fpage>2351</fpage><lpage>2360</lpage><pub-id pub-id-type="pmid">22192540</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.biomaterials.2011.11.068</pub-id></element-citation></ref><ref id="bb1425"><label>285</label><element-citation publication-type="journal" id="rf1425"><person-group person-group-type="author"><name name-style="western"><surname>Jackson</surname><given-names>N.A.C.</given-names></name><name name-style="western"><surname>Kester</surname><given-names>K.E.</given-names></name><name name-style="western"><surname>Casimiro</surname><given-names>D.</given-names></name><name name-style="western"><surname>Gurunathan</surname><given-names>S.</given-names></name><name name-style="western"><surname>DeRosa</surname><given-names>F.</given-names></name></person-group><article-title>The promise of mRNA vaccines: a biotech and industrial perspective</article-title><source>NPJ Vaccines</source><volume>5</volume><year>2020</year><fpage>11</fpage><pub-id pub-id-type="pmid">32047656</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41541-020-0159-8</pub-id><pub-id pub-id-type="pmcid">PMC7000814</pub-id></element-citation></ref><ref id="bb1430"><label>286</label><element-citation publication-type="journal" id="rf1430"><person-group person-group-type="author"><name name-style="western"><surname>Iavarone</surname><given-names>C.</given-names></name><name name-style="western"><surname>O&#8217;Hagan</surname><given-names>T.</given-names></name><name name-style="western"><surname>Yu</surname><given-names>D.</given-names></name><name name-style="western"><surname>Delahaye</surname><given-names>N.F.</given-names></name><name name-style="western"><surname>Ulmer</surname><given-names>J.B.</given-names></name></person-group><article-title>Mechanism of action of mRNA-based vaccines</article-title><source>Expert Rev. Vaccines</source><volume>16</volume><year>2017</year><fpage>871</fpage><lpage>881</lpage><pub-id pub-id-type="pmid">28701102</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1080/14760584.2017.1355245</pub-id></element-citation></ref><ref id="bb1435"><label>287</label><element-citation publication-type="journal" id="rf1435"><person-group person-group-type="author"><name name-style="western"><surname>Barba</surname><given-names>A.A.</given-names></name><name name-style="western"><surname>Bochicchio</surname><given-names>S.</given-names></name><name name-style="western"><surname>Dalmoro</surname><given-names>A.</given-names></name><name name-style="western"><surname>Lamberti</surname><given-names>G.</given-names></name></person-group><article-title>Lipid delivery systems for nucleic-acid-based-drugs: from production to clinical applications</article-title><source>Pharmaceutics</source><volume>11</volume><year>2019</year><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/pharmaceutics11080360</pub-id><pub-id pub-id-type="pmcid">PMC6723796</pub-id><pub-id pub-id-type="pmid">31344836</pub-id></element-citation></ref><ref id="bb1440"><label>288</label><element-citation publication-type="journal" id="rf1440"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>W.</given-names></name><name name-style="western"><surname>Szoka</surname><given-names>F.C.</given-names><suffix>Jr.</suffix></name></person-group><article-title>Lipid-based nanoparticles for nucleic acid delivery</article-title><source>Pharm. Res.</source><volume>24</volume><year>2007</year><fpage>438</fpage><lpage>449</lpage><pub-id pub-id-type="pmid">17252188</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s11095-006-9180-5</pub-id></element-citation></ref><ref id="bb1445"><label>289</label><element-citation publication-type="journal" id="rf1445"><person-group person-group-type="author"><name name-style="western"><surname>Sahay</surname><given-names>G.</given-names></name><name name-style="western"><surname>Querbes</surname><given-names>W.</given-names></name><name name-style="western"><surname>Alabi</surname><given-names>C.</given-names></name><name name-style="western"><surname>Eltoukhy</surname><given-names>A.</given-names></name><name name-style="western"><surname>Sarkar</surname><given-names>S.</given-names></name><etal/></person-group><article-title>Efficiency of siRNA delivery by lipid nanoparticles is limited by endocytic recycling</article-title><source>Nat. Biotechnol.</source><volume>31</volume><year>2013</year><fpage>653</fpage><lpage>658</lpage><pub-id pub-id-type="pmid">23792629</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/nbt.2614</pub-id><pub-id pub-id-type="pmcid">PMC3814166</pub-id></element-citation></ref><ref id="bb1450"><label>290</label><element-citation publication-type="journal" id="rf1450"><person-group person-group-type="author"><name name-style="western"><surname>Reichmuth</surname><given-names>A.M.</given-names></name><name name-style="western"><surname>Oberli</surname><given-names>M.A.</given-names></name><name name-style="western"><surname>Jaklenec</surname><given-names>A.</given-names></name><name name-style="western"><surname>Langer</surname><given-names>R.</given-names></name><name name-style="western"><surname>Blankschtein</surname><given-names>D.</given-names></name></person-group><article-title>mRNA vaccine delivery using lipid nanoparticles</article-title><source>Ther. Deliv.</source><volume>7</volume><year>2016</year><fpage>319</fpage><lpage>334</lpage><pub-id pub-id-type="pmid">27075952</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.4155/tde-2016-0006</pub-id><pub-id pub-id-type="pmcid">PMC5439223</pub-id></element-citation></ref><ref id="bb1455"><label>291</label><element-citation publication-type="other" id="rf1455"><person-group person-group-type="author"><name name-style="western"><surname>Moderna</surname></name></person-group><article-title>Moderna Ships mRNA Vaccine Against Novel Coronavirus (mRNA-1273) for Phase 1 Study</article-title><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://investors.modernatx.com/news-releases/news-release-details/moderna-ships-mrna-vaccine-against-novel-coronavirus-mrna-1273" id="ir0460">https://investors.modernatx.com/news-releases/news-release-details/moderna-ships-mrna-vaccine-against-novel-coronavirus-mrna-1273</ext-link><year>2020</year></element-citation></ref><ref id="bb1460"><label>292</label><element-citation publication-type="journal" id="rf1460"><person-group person-group-type="author"><name name-style="western"><surname>Jackson</surname><given-names>L.A.</given-names></name><name name-style="western"><surname>Anderson</surname><given-names>E.J.</given-names></name><name name-style="western"><surname>Rouphael</surname><given-names>N.G.</given-names></name><name name-style="western"><surname>Roberts</surname><given-names>P.C.</given-names></name><name name-style="western"><surname>Makhene</surname><given-names>M.</given-names></name><etal/></person-group><article-title>An mRNA vaccine against SARS-CoV-2 - preliminary report</article-title><source>N. Engl. J. Med.</source><volume>383</volume><year>2020</year><fpage>1920</fpage><lpage>1931</lpage><pub-id pub-id-type="pmid">32663912</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1056/NEJMoa2022483</pub-id><pub-id pub-id-type="pmcid">PMC7377258</pub-id></element-citation></ref><ref id="bb1465"><label>293</label><element-citation publication-type="journal" id="rf1465"><person-group person-group-type="author"><name name-style="western"><surname>Anderson</surname><given-names>E.J.</given-names></name><name name-style="western"><surname>Rouphael</surname><given-names>N.G.</given-names></name><name name-style="western"><surname>Widge</surname><given-names>A.T.</given-names></name><name name-style="western"><surname>Jackson</surname><given-names>L.A.</given-names></name><name name-style="western"><surname>Roberts</surname><given-names>P.C.</given-names></name><etal/></person-group><article-title>Safety and immunogenicity of SARS-CoV-2 mRNA-1273 vaccine in older adults</article-title><source>N. Engl. J. Med.</source><volume>383</volume><year>2020</year><fpage>2427</fpage><lpage>2438</lpage><pub-id pub-id-type="pmid">32991794</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1056/NEJMoa2028436</pub-id><pub-id pub-id-type="pmcid">PMC7556339</pub-id></element-citation></ref><ref id="bb1470"><label>294</label><element-citation publication-type="other" id="rf1470"><person-group person-group-type="author"><name name-style="western"><surname>National Institute of Health</surname></name></person-group><article-title>Promising Interim Results from Clinical Trial of NIH-Moderna COVID-19 Vaccine</article-title><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.nih.gov/news-events/news-releases/promising-interim-results-clinical-trial-nih-moderna-covid-19-vaccine" id="ir0465">https://www.nih.gov/news-events/news-releases/promising-interim-results-clinical-trial-nih-moderna-covid-19-vaccine</ext-link><year>2020</year></element-citation></ref><ref id="bb1475"><label>295</label><element-citation publication-type="other" id="rf1475"><person-group person-group-type="author"><name name-style="western"><surname>Moderna</surname></name></person-group><article-title>Moderna Announces Primary Efficacy Analysis in Phase 3 COVE Study for Its COVID-19 Vaccine Candidate and Filing Today with U.S. FDA for Emergency Use Authorization</article-title><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://investors.modernatx.com/news-releases/news-release-details/moderna-announces-primary-efficacy-analysis-phase-3-cove-study/" id="ir0470">https://investors.modernatx.com/news-releases/news-release-details/moderna-announces-primary-efficacy-analysis-phase-3-cove-study/</ext-link><year>2020</year></element-citation></ref><ref id="bb1480"><label>296</label><element-citation publication-type="book" id="rf1480"><person-group person-group-type="author"><name name-style="western"><surname>GlobeNewsWire</surname></name></person-group><part-title>BioNTech and Pfizer announce regulatory approval from German authority Paul-Ehrlich-Institut to commence first clinical trial of COVID-19 vaccine candidates</part-title><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.globenewswire.com/news-release/2020/04/22/2019785/0/en/BioNTech-and-Pfizer-announce-regulatory-approval-from-German-authority-Paul-Ehrlich-Institut-to-commence-first-clinical-trial-of-COVID-19-vaccine-candidates.html" id="ir0475">https://www.globenewswire.com/news-release/2020/04/22/2019785/0/en/BioNTech-and-Pfizer-announce-regulatory-approval-from-German-authority-Paul-Ehrlich-Institut-to-commence-first-clinical-trial-of-COVID-19-vaccine-candidates.html</ext-link><year>2020</year></element-citation></ref><ref id="bb1485"><label>297</label><element-citation publication-type="journal" id="rf1485"><person-group person-group-type="author"><name name-style="western"><surname>Mulligan</surname><given-names>M.J.</given-names></name><name name-style="western"><surname>Lyke</surname><given-names>K.E.</given-names></name><name name-style="western"><surname>Kitchin</surname><given-names>N.</given-names></name><name name-style="western"><surname>Absalon</surname><given-names>J.</given-names></name><name name-style="western"><surname>Gurtman</surname><given-names>A.</given-names></name><etal/></person-group><article-title>Phase 1/2 study to describe the safety and immunogenicity of a COVID-19 RNA vaccine candidate (BNT162b1) in adults 18 to 55&#160;years of age: interim report</article-title><source>medRxiv</source><year>2020</year><pub-id pub-id-type="doi">10.1101/2020.06.30.20142570</pub-id></element-citation></ref><ref id="bb1490"><label>298</label><element-citation publication-type="journal" id="rf1490"><person-group person-group-type="author"><name name-style="western"><surname>Sahin</surname><given-names>U.</given-names></name><name name-style="western"><surname>Muik</surname><given-names>A.</given-names></name><name name-style="western"><surname>Derhovanessian</surname><given-names>E.</given-names></name><name name-style="western"><surname>Vogler</surname><given-names>I.</given-names></name><name name-style="western"><surname>Kranz</surname><given-names>L.M.</given-names></name><etal/></person-group><article-title>COVID-19 vaccine BNT162b1 elicits human antibody and TH1 T cell responses</article-title><source>Nature</source><volume>586</volume><year>2020</year><fpage>594</fpage><lpage>599</lpage><pub-id pub-id-type="pmid">32998157</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41586-020-2814-7</pub-id></element-citation></ref><ref id="bb1495"><label>299</label><element-citation publication-type="other" id="rf1495"><person-group person-group-type="author"><name name-style="western"><surname>Pfizer</surname></name></person-group><article-title>Pfizer and Biontech Conclude Phase 3 Study of Covid-19 Vaccine Candidate, Meeting all Primary Efficacy Endpoints</article-title><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.pfizer.com/news/press-release/press-release-detail/pfizer-and-biontech-conclude-phase-3-study-covid-19-vaccine" id="ir0480">https://www.pfizer.com/news/press-release/press-release-detail/pfizer-and-biontech-conclude-phase-3-study-covid-19-vaccine</ext-link><year>2020</year></element-citation></ref><ref id="bb1500"><label>300</label><element-citation publication-type="other" id="rf1500"><person-group person-group-type="author"><name name-style="western"><surname>Pharmaceutical Technology</surname></name></person-group><article-title>UK authorises world's first Covid-19 vaccine, Pfizer/BioNTech's BNT162b2</article-title><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.pharmaceutical-technology.com/features/pfizer-covid-19-vaccine-approved-uk/" id="ir0485">https://www.pharmaceutical-technology.com/features/pfizer-covid-19-vaccine-approved-uk/</ext-link><year>2020</year></element-citation></ref><ref id="bb1505"><label>301</label><element-citation publication-type="other" id="rf1505"><person-group person-group-type="author"><name name-style="western"><surname>Pharmaceutical Business Review</surname></name></person-group><article-title>Canada has approved Pfizer and BioNTech's mRNA vaccine BNT162b2 for the prevention of Covid-19</article-title><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.pharmaceutical-business-review.com/news/canada-approves-bnt162b2-covid-19/" id="ir0490">https://www.pharmaceutical-business-review.com/news/canada-approves-bnt162b2-covid-19/</ext-link></element-citation></ref><ref id="bb1510"><label>302</label><element-citation publication-type="journal" id="rf1510"><person-group person-group-type="author"><name name-style="western"><surname>McKay</surname><given-names>P.F.</given-names></name><name name-style="western"><surname>Hu</surname><given-names>K.</given-names></name><name name-style="western"><surname>Blakney</surname><given-names>A.K.</given-names></name><name name-style="western"><surname>Samnuan</surname><given-names>K.</given-names></name><name name-style="western"><surname>Brown</surname><given-names>J.C.</given-names></name><etal/></person-group><article-title>Self-amplifying RNA SARS-CoV-2 lipid nanoparticle vaccine candidate induces high neutralizing antibody titers in mice</article-title><source>Nat. Commun.</source><volume>11</volume><year>2020</year><fpage>3523</fpage><pub-id pub-id-type="pmid">32647131</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41467-020-17409-9</pub-id><pub-id pub-id-type="pmcid">PMC7347890</pub-id></element-citation></ref><ref id="bb1515"><label>303</label><element-citation publication-type="journal" id="rf1515"><person-group person-group-type="author"><name name-style="western"><surname>Jocelyn</surname><given-names>K.</given-names></name></person-group><article-title>Temperature concerns could slow the rollout of new coronavirus vaccines</article-title><source>Science</source><year>2020</year></element-citation></ref><ref id="bb1520"><label>304</label><element-citation publication-type="journal" id="rf1520"><person-group person-group-type="author"><name name-style="western"><surname>Maurer</surname><given-names>N.</given-names></name><name name-style="western"><surname>Wong</surname><given-names>K.F.</given-names></name><name name-style="western"><surname>Stark</surname><given-names>H.</given-names></name><name name-style="western"><surname>Louie</surname><given-names>L.</given-names></name><name name-style="western"><surname>McIntosh</surname><given-names>D.</given-names></name><name name-style="western"><surname>Wong</surname><given-names>T.</given-names></name><name name-style="western"><surname>Scherrer</surname><given-names>P.</given-names></name><name name-style="western"><surname>Semple</surname><given-names>S.C.</given-names></name><name name-style="western"><surname>Cullis</surname><given-names>P.R.</given-names></name></person-group><article-title>Spontaneous entrapment of polynucleotides upon electrostatic interaction with ethanol-destabilized cationic liposomes</article-title><source>Biophys. J.</source><volume>80</volume><year>2001</year><fpage>2310</fpage><lpage>2326</lpage><pub-id pub-id-type="pmid">11325732</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S0006-3495(01)76202-9</pub-id><pub-id pub-id-type="pmcid">PMC1301421</pub-id></element-citation></ref><ref id="bb1525"><label>305</label><element-citation publication-type="journal" id="rf1525"><person-group person-group-type="author"><name name-style="western"><surname>Semple</surname><given-names>S.C.</given-names></name><name name-style="western"><surname>Akinc</surname><given-names>A.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>J.</given-names></name><name name-style="western"><surname>Sandhu</surname><given-names>A.P.</given-names></name><name name-style="western"><surname>Mui</surname><given-names>B.L.</given-names></name><etal/></person-group><article-title>Rational design of cationic lipids for siRNA delivery</article-title><source>Nat. Biotechnol.</source><volume>28</volume><year>2010</year><fpage>172</fpage><lpage>176</lpage><pub-id pub-id-type="pmid">20081866</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/nbt.1602</pub-id></element-citation></ref><ref id="bb1530"><label>306</label><element-citation publication-type="journal" id="rf1530"><person-group person-group-type="author"><name name-style="western"><surname>Lu</surname><given-names>X.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>L.</given-names></name><name name-style="western"><surname>Du</surname><given-names>H.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>J.</given-names></name><name name-style="western"><surname>Li</surname><given-names>Y.Y.</given-names></name><etal/></person-group><article-title>SARS-CoV-2 infection in children</article-title><source>N. Engl. J. Med.</source><volume>382</volume><year>2020</year><fpage>1663</fpage><lpage>1665</lpage><pub-id pub-id-type="pmid">32187458</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1056/NEJMc2005073</pub-id><pub-id pub-id-type="pmcid">PMC7121177</pub-id></element-citation></ref><ref id="bb1535"><label>307</label><element-citation publication-type="journal" id="rf1535"><person-group person-group-type="author"><name name-style="western"><surname>Rockx</surname><given-names>B.</given-names></name><name name-style="western"><surname>Kuiken</surname><given-names>T.</given-names></name><name name-style="western"><surname>Herfst</surname><given-names>S.</given-names></name><name name-style="western"><surname>Bestebroer</surname><given-names>T.</given-names></name><name name-style="western"><surname>Lamers</surname><given-names>M.M.</given-names></name><etal/></person-group><article-title>Comparative pathogenesis of COVID-19, MERS, and SARS in a nonhuman primate model</article-title><source>Science</source><volume>368</volume><year>2020</year><fpage>1012</fpage><lpage>1015</lpage><pub-id pub-id-type="pmid">32303590</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1126/science.abb7314</pub-id><pub-id pub-id-type="pmcid">PMC7164679</pub-id></element-citation></ref><ref id="bb1540"><label>308</label><element-citation publication-type="journal" id="rf1540"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>N.N.</given-names></name><name name-style="western"><surname>Li</surname><given-names>X.F.</given-names></name><name name-style="western"><surname>Deng</surname><given-names>Y.Q.</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>H.</given-names></name><name name-style="western"><surname>Huang</surname><given-names>Y.J.</given-names></name><etal/></person-group><article-title>A thermostable mRNA vaccine against COVID-19</article-title><source>Cell</source><volume>182</volume><year>2020</year><fpage>1271</fpage><lpage>1283</lpage><comment>(e1216)</comment><pub-id pub-id-type="pmid">32795413</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.cell.2020.07.024</pub-id><pub-id pub-id-type="pmcid">PMC7377714</pub-id></element-citation></ref><ref id="bb1545"><label>309</label><element-citation publication-type="journal" id="rf1545"><person-group person-group-type="author"><name name-style="western"><surname>Erasmus</surname><given-names>J.H.</given-names></name><name name-style="western"><surname>Khandhar</surname><given-names>A.P.</given-names></name><name name-style="western"><surname>O'Connor</surname><given-names>M.A.</given-names></name><name name-style="western"><surname>Walls</surname><given-names>A.C.</given-names></name><name name-style="western"><surname>Hemann</surname><given-names>E.A.</given-names></name><etal/></person-group><article-title>An Alphavirus-derived replicon RNA vaccine induces SARS-CoV-2 neutralizing antibody and T cell responses in mice and nonhuman primates</article-title><source>Sci. Transl. Med.</source><year>2020</year><fpage>12</fpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1126/scitranslmed.abc9396</pub-id><pub-id pub-id-type="pmcid">PMC7402629</pub-id><pub-id pub-id-type="pmid">32690628</pub-id></element-citation></ref><ref id="bb1550"><label>310</label><element-citation publication-type="other" id="rf1550"><person-group person-group-type="author"><name name-style="western"><surname>Drug Development and Delivery</surname></name></person-group><article-title>Novavax Advances Development of Novel COVID-19 Vaccine</article-title><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://drug-dev.com/novavax-advances-development-of-novel-covid-19-vaccine/" id="ir0495">https://drug-dev.com/novavax-advances-development-of-novel-covid-19-vaccine/</ext-link><year>2020</year></element-citation></ref><ref id="bb1555"><label>311</label><element-citation publication-type="other" id="rf1555"><person-group person-group-type="author"><name name-style="western"><surname>Novavax</surname></name></person-group><article-title>Novavax Initiates Phase 3 Efficacy Trial of COVID-19 Vaccine in the United Kingdom</article-title><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://ir.novavax.com/news-releases/news-release-details/novavax-initiates-phase-3-efficacy-trial-covid-19-vaccine-united" id="ir0500">https://ir.novavax.com/news-releases/news-release-details/novavax-initiates-phase-3-efficacy-trial-covid-19-vaccine-united</ext-link><year>2020</year></element-citation></ref><ref id="bb1560"><label>312</label><element-citation publication-type="other" id="rf1560"><person-group person-group-type="author"><name name-style="western"><surname>Takeda</surname></name></person-group><article-title>Novavax and Takeda Announce Collaboration for Novavax&#8217; COVID-19 Vaccine Candidate in Japan</article-title><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.takeda.com/newsroom/newsreleases/2020/novavax-and-takeda-announce-collaboration-for-novavax-covid-19-vaccine-candidate-in-japan/" id="ir0505">https://www.takeda.com/newsroom/newsreleases/2020/novavax-and-takeda-announce-collaboration-for-novavax-covid-19-vaccine-candidate-in-japan/</ext-link><year>2020</year></element-citation></ref><ref id="bb1565"><label>313</label><element-citation publication-type="journal" id="rf1565"><person-group person-group-type="author"><name name-style="western"><surname>Cyranoski</surname><given-names>D.</given-names></name></person-group><article-title>Profile of a killer: the complex biology powering the coronavirus pandemic</article-title><source>Nature</source><volume>581</volume><year>2020</year><fpage>22</fpage><lpage>26</lpage><pub-id pub-id-type="pmid">32367025</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/d41586-020-01315-7</pub-id></element-citation></ref><ref id="bb1570"><label>314</label><element-citation publication-type="journal" id="rf1570"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Honko</surname><given-names>A.</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>J.</given-names></name><name name-style="western"><surname>Gong</surname><given-names>H.</given-names></name><name name-style="western"><surname>Downs</surname><given-names>S.N.</given-names></name><name name-style="western"><surname>Vasquez</surname><given-names>J.H.</given-names></name><name name-style="western"><surname>Fang</surname><given-names>R.H.</given-names></name><name name-style="western"><surname>Gao</surname><given-names>W.</given-names></name><name name-style="western"><surname>Griffiths</surname><given-names>A.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>L.</given-names></name></person-group><article-title>Cellular nanosponges inhibit SARS-CoV-2 infectivity</article-title><source>Nano Lett.</source><volume>20</volume><year>2020</year><fpage>5570</fpage><lpage>5574</lpage><pub-id pub-id-type="pmid">32551679</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1021/acs.nanolett.0c02278</pub-id><pub-id pub-id-type="pmcid">PMC7301960</pub-id></element-citation></ref><ref id="bb1575"><label>315</label><element-citation publication-type="book" id="rf1575"><person-group person-group-type="author"><name name-style="western"><surname>Lixin</surname><given-names>L.</given-names></name><name name-style="western"><surname>Zhijia</surname><given-names>L.</given-names></name><name name-style="western"><surname>Haolin</surname><given-names>C.</given-names></name><name name-style="western"><surname>Hong</surname><given-names>L.</given-names></name><name name-style="western"><surname>Qiang</surname><given-names>G.</given-names></name><name name-style="western"><surname>Feng</surname><given-names>C.</given-names></name><name name-style="western"><surname>Guangxia</surname><given-names>G.</given-names></name><name name-style="western"><surname>Yongming</surname><given-names>C.</given-names></name></person-group><part-title>A Translatable Subunit Nanovaccine for COVID-19</part-title><year>2020</year></element-citation></ref><ref id="bb1580"><label>316</label><element-citation publication-type="other" id="rf1580"><person-group person-group-type="author"><name name-style="western"><surname>U.o.W. Institute for Protein Design</surname></name></person-group><article-title>De novo Nanoparticles as Vaccine Scaffolds</article-title><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.ipd.uw.edu/2020/08/de-novo-nanoparticles-vaccine-scaffolds/" id="ir0510">https://www.ipd.uw.edu/2020/08/de-novo-nanoparticles-vaccine-scaffolds/</ext-link><year>2020</year></element-citation></ref><ref id="bb1585"><label>317</label><element-citation publication-type="journal" id="rf1585"><person-group person-group-type="author"><name name-style="western"><surname>Martin</surname><given-names>J.T.</given-names></name><name name-style="western"><surname>Cottrell</surname><given-names>C.A.</given-names></name><name name-style="western"><surname>Antanasijevic</surname><given-names>A.</given-names></name><name name-style="western"><surname>Carnathan</surname><given-names>D.G.</given-names></name><name name-style="western"><surname>Cossette</surname><given-names>B.J.</given-names></name><etal/></person-group><article-title>Targeting HIV Env immunogens to B cell follicles in nonhuman primates through immune complex or protein nanoparticle formulations</article-title><source>NPJ Vaccines</source><volume>5</volume><year>2020</year><fpage>72</fpage><pub-id pub-id-type="pmid">32802411</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41541-020-00223-1</pub-id><pub-id pub-id-type="pmcid">PMC7406516</pub-id></element-citation></ref><ref id="bb1590"><label>318</label><element-citation publication-type="journal" id="rf1590"><person-group person-group-type="author"><name name-style="western"><surname>Roldao</surname><given-names>A.</given-names></name><name name-style="western"><surname>Mellado</surname><given-names>M.C.</given-names></name><name name-style="western"><surname>Castilho</surname><given-names>L.R.</given-names></name><name name-style="western"><surname>Carrondo</surname><given-names>M.J.</given-names></name><name name-style="western"><surname>Alves</surname><given-names>P.M.</given-names></name></person-group><article-title>Virus-like particles in vaccine development</article-title><source>Expert Rev. Vaccines</source><volume>9</volume><year>2010</year><fpage>1149</fpage><lpage>1176</lpage><pub-id pub-id-type="pmid">20923267</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1586/erv.10.115</pub-id></element-citation></ref><ref id="bb1595"><label>319</label><element-citation publication-type="journal" id="rf1595"><person-group person-group-type="author"><name name-style="western"><surname>Buonaguro</surname><given-names>L.</given-names></name><name name-style="western"><surname>Tornesello</surname><given-names>M.L.</given-names></name><name name-style="western"><surname>Buonaguro</surname><given-names>F.M.</given-names></name></person-group><article-title>Virus-like particles as particulate vaccines</article-title><source>Curr. HIV Res.</source><volume>8</volume><year>2010</year><fpage>299</fpage><lpage>309</lpage><pub-id pub-id-type="pmid">20353398</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2174/157016210791208659</pub-id></element-citation></ref><ref id="bb1600"><label>320</label><element-citation publication-type="journal" id="rf1600"><person-group person-group-type="author"><name name-style="western"><surname>Purcell</surname><given-names>A.W.</given-names></name><name name-style="western"><surname>McCluskey</surname><given-names>J.</given-names></name><name name-style="western"><surname>Rossjohn</surname><given-names>J.</given-names></name></person-group><article-title>More than one reason to rethink the use of peptides in vaccine design, Nat</article-title><source>Rev. Drug Discov</source><volume>6</volume><year>2007</year><fpage>404</fpage><lpage>414</lpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/nrd2224</pub-id><pub-id pub-id-type="pmid">17473845</pub-id></element-citation></ref><ref id="bb1605"><label>321</label><element-citation publication-type="journal" id="rf1605"><person-group person-group-type="author"><name name-style="western"><surname>Mateu</surname><given-names>M.G.</given-names></name></person-group><article-title>Virus engineering: functionalization and stabilization</article-title><source>Protein Eng. Des. Sel.</source><volume>24</volume><year>2011</year><fpage>53</fpage><lpage>63</lpage><pub-id pub-id-type="pmid">20923881</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/protein/gzq069</pub-id></element-citation></ref><ref id="bb1610"><label>322</label><element-citation publication-type="journal" id="rf1610"><person-group person-group-type="author"><name name-style="western"><surname>Zepeda-Cervantes</surname><given-names>J.</given-names></name><name name-style="western"><surname>Ramirez-Jarquin</surname><given-names>J.O.</given-names></name><name name-style="western"><surname>Vaca</surname><given-names>L.</given-names></name></person-group><article-title>Interaction between virus-like particles (VLPs) and pattern recognition receptors (PRRs) from dendritic cells (DCs): toward better engineering of VLPs</article-title><source>Front. Immunol.</source><volume>11</volume><year>2020</year><fpage>1100</fpage><pub-id pub-id-type="pmid">32582186</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fimmu.2020.01100</pub-id><pub-id pub-id-type="pmcid">PMC7297083</pub-id></element-citation></ref><ref id="bb1615"><label>323</label><element-citation publication-type="journal" id="rf1615"><person-group person-group-type="author"><name name-style="western"><surname>Qian</surname><given-names>C.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>X.</given-names></name><name name-style="western"><surname>Xu</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>J.</given-names></name><name name-style="western"><surname>Li</surname><given-names>T.</given-names></name><name name-style="western"><surname>Zheng</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Yu</surname><given-names>H.</given-names></name><name name-style="western"><surname>Gu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Li</surname><given-names>S.</given-names></name><name name-style="western"><surname>Xia</surname><given-names>N.</given-names></name></person-group><article-title>Recent progress on the versatility of virus-like particles</article-title><source>Vaccines (Basel)</source><volume>8</volume><year>2020</year><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/vaccines8010139</pub-id><pub-id pub-id-type="pmcid">PMC7157238</pub-id><pub-id pub-id-type="pmid">32244935</pub-id></element-citation></ref><ref id="bb1620"><label>324</label><element-citation publication-type="journal" id="rf1620"><person-group person-group-type="author"><name name-style="western"><surname>Kushnir</surname><given-names>N.</given-names></name><name name-style="western"><surname>Streatfield</surname><given-names>S.J.</given-names></name><name name-style="western"><surname>Yusibov</surname><given-names>V.</given-names></name></person-group><article-title>Virus-like particles as a highly efficient vaccine platform: diversity of targets and production systems and advances in clinical development</article-title><source>Vaccine</source><volume>31</volume><year>2012</year><fpage>58</fpage><lpage>83</lpage><pub-id pub-id-type="pmid">23142589</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.vaccine.2012.10.083</pub-id><pub-id pub-id-type="pmcid">PMC7115575</pub-id></element-citation></ref><ref id="bb1625"><label>325</label><element-citation publication-type="journal" id="rf1625"><person-group person-group-type="author"><name name-style="western"><surname>Chung</surname><given-names>Y.H.</given-names></name><name name-style="western"><surname>Cai</surname><given-names>H.</given-names></name><name name-style="western"><surname>Steinmetz</surname><given-names>N.F.</given-names></name></person-group><article-title>Viral nanoparticles for drug delivery, imaging, immunotherapy, and theranostic applications</article-title><source>Adv. Drug Deliv. Rev.</source><volume>156</volume><year>2020</year><fpage>214</fpage><lpage>235</lpage><pub-id pub-id-type="pmid">32603813</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.addr.2020.06.024</pub-id><pub-id pub-id-type="pmcid">PMC7320870</pub-id></element-citation></ref><ref id="bb1630"><label>326</label><element-citation publication-type="journal" id="rf1630"><person-group person-group-type="author"><name name-style="western"><surname>Mathieu</surname><given-names>C.</given-names></name><name name-style="western"><surname>Rioux</surname><given-names>G.</given-names></name><name name-style="western"><surname>Dumas</surname><given-names>M.C.</given-names></name><name name-style="western"><surname>Leclerc</surname><given-names>D.</given-names></name></person-group><article-title>Induction of innate immunity in lungs with virus-like nanoparticles leads to protection against influenza and <italic toggle="yes">Streptococcus pneumoniae</italic> challenge</article-title><source>Nanomedicine</source><volume>9</volume><year>2013</year><fpage>839</fpage><lpage>848</lpage><pub-id pub-id-type="pmid">23499666</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.nano.2013.02.009</pub-id></element-citation></ref><ref id="bb1635"><label>327</label><element-citation publication-type="journal" id="rf1635"><person-group person-group-type="author"><name name-style="western"><surname>Zeltins</surname><given-names>A.</given-names></name></person-group><article-title>Construction and characterization of virus-like particles: a review</article-title><source>Mol. Biotechnol.</source><volume>53</volume><year>2013</year><fpage>92</fpage><lpage>107</lpage><pub-id pub-id-type="pmid">23001867</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s12033-012-9598-4</pub-id><pub-id pub-id-type="pmcid">PMC7090963</pub-id></element-citation></ref><ref id="bb1640"><label>328</label><element-citation publication-type="journal" id="rf1640"><person-group person-group-type="author"><name name-style="western"><surname>Young</surname><given-names>K.R.</given-names></name><name name-style="western"><surname>McBurney</surname><given-names>S.P.</given-names></name><name name-style="western"><surname>Karkhanis</surname><given-names>L.U.</given-names></name><name name-style="western"><surname>Ross</surname><given-names>T.M.</given-names></name></person-group><article-title>Virus-like particles: designing an effective AIDS vaccine</article-title><source>Methods</source><volume>40</volume><year>2006</year><fpage>98</fpage><lpage>117</lpage><pub-id pub-id-type="pmid">16997718</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ymeth.2006.05.024</pub-id></element-citation></ref><ref id="bb1645"><label>329</label><element-citation publication-type="journal" id="rf1645"><person-group person-group-type="author"><name name-style="western"><surname>Thrane</surname><given-names>S.</given-names></name><name name-style="western"><surname>Janitzek</surname><given-names>C.M.</given-names></name><name name-style="western"><surname>Agerbaek</surname><given-names>M.O.</given-names></name><name name-style="western"><surname>Ditlev</surname><given-names>S.B.</given-names></name><name name-style="western"><surname>Resende</surname><given-names>M.</given-names></name><name name-style="western"><surname>Nielsen</surname><given-names>M.A.</given-names></name><name name-style="western"><surname>Theander</surname><given-names>T.G.</given-names></name><name name-style="western"><surname>Salanti</surname><given-names>A.</given-names></name><name name-style="western"><surname>Sander</surname><given-names>A.F.</given-names></name></person-group><article-title>A novel virus-like particle based vaccine platform displaying the placental malaria antigen VAR2CSA</article-title><source>PLoS One</source><volume>10</volume><year>2015</year><object-id pub-id-type="publisher-id">e0143071</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1371/journal.pone.0143071</pub-id><pub-id pub-id-type="pmcid">PMC4657905</pub-id><pub-id pub-id-type="pmid">26599509</pub-id></element-citation></ref><ref id="bb1650"><label>330</label><element-citation publication-type="journal" id="rf1650"><person-group person-group-type="author"><name name-style="western"><surname>Brune</surname><given-names>K.D.</given-names></name><name name-style="western"><surname>Leneghan</surname><given-names>D.B.</given-names></name><name name-style="western"><surname>Brian</surname><given-names>I.J.</given-names></name><name name-style="western"><surname>Ishizuka</surname><given-names>A.S.</given-names></name><name name-style="western"><surname>Bachmann</surname><given-names>M.F.</given-names></name><name name-style="western"><surname>Draper</surname><given-names>S.J.</given-names></name><name name-style="western"><surname>Biswas</surname><given-names>S.</given-names></name><name name-style="western"><surname>Howarth</surname><given-names>M.</given-names></name></person-group><article-title>Plug-and-Display: decoration of Virus-Like Particles via isopeptide bonds for modular immunization</article-title><source>Sci. Rep.</source><volume>6</volume><year>2016</year><fpage>19234</fpage><pub-id pub-id-type="pmid">26781591</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/srep19234</pub-id><pub-id pub-id-type="pmcid">PMC4725971</pub-id></element-citation></ref><ref id="bb1655"><label>331</label><element-citation publication-type="journal" id="rf1655"><person-group person-group-type="author"><name name-style="western"><surname>Chua</surname><given-names>A.J.</given-names></name><name name-style="western"><surname>Vituret</surname><given-names>C.</given-names></name><name name-style="western"><surname>Tan</surname><given-names>M.L.</given-names></name><name name-style="western"><surname>Gonzalez</surname><given-names>G.</given-names></name><name name-style="western"><surname>Boulanger</surname><given-names>P.</given-names></name><name name-style="western"><surname>Ng</surname><given-names>M.L.</given-names></name><name name-style="western"><surname>Hong</surname><given-names>S.S.</given-names></name></person-group><article-title>A novel platform for virus-like particle-display of flaviviral envelope domain III: induction of Dengue and West Nile virus neutralizing antibodies</article-title><source>Virol. J.</source><volume>10</volume><year>2013</year><fpage>129</fpage><pub-id pub-id-type="pmid">23617954</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/1743-422X-10-129</pub-id><pub-id pub-id-type="pmcid">PMC3668303</pub-id></element-citation></ref><ref id="bb1660"><label>332</label><element-citation publication-type="journal" id="rf1660"><person-group person-group-type="author"><name name-style="western"><surname>Pitoiset</surname><given-names>F.</given-names></name><name name-style="western"><surname>Vazquez</surname><given-names>T.</given-names></name><name name-style="western"><surname>Bellier</surname><given-names>B.</given-names></name></person-group><article-title>Enveloped virus-like particle platforms: vaccines of the future?</article-title><source>Expert Rev. Vaccines</source><volume>14</volume><year>2015</year><fpage>913</fpage><lpage>915</lpage><pub-id pub-id-type="pmid">25968245</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1586/14760584.2015.1046440</pub-id></element-citation></ref><ref id="bb1665"><label>333</label><element-citation publication-type="journal" id="rf1665"><person-group person-group-type="author"><name name-style="western"><surname>Jain</surname><given-names>N.K.</given-names></name><name name-style="western"><surname>Sahni</surname><given-names>N.</given-names></name><name name-style="western"><surname>Kumru</surname><given-names>O.S.</given-names></name><name name-style="western"><surname>Joshi</surname><given-names>S.B.</given-names></name><name name-style="western"><surname>Volkin</surname><given-names>D.B.</given-names></name><name name-style="western"><surname>Russell Middaugh</surname><given-names>C.</given-names></name></person-group><article-title>Formulation and stabilization of recombinant protein based virus-like particle vaccines</article-title><source>Adv. Drug Deliv. Rev.</source><volume>93</volume><year>2015</year><fpage>42</fpage><lpage>55</lpage><pub-id pub-id-type="pmid">25451136</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.addr.2014.10.023</pub-id></element-citation></ref><ref id="bb1670"><label>334</label><element-citation publication-type="journal" id="rf1670"><person-group person-group-type="author"><name name-style="western"><surname>Grgacic</surname><given-names>E.V.</given-names></name><name name-style="western"><surname>Anderson</surname><given-names>D.A.</given-names></name></person-group><article-title>Virus-like particles: passport to immune recognition</article-title><source>Methods</source><volume>40</volume><year>2006</year><fpage>60</fpage><lpage>65</lpage><pub-id pub-id-type="pmid">16997714</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ymeth.2006.07.018</pub-id><pub-id pub-id-type="pmcid">PMC7128828</pub-id></element-citation></ref><ref id="bb1675"><label>335</label><element-citation publication-type="journal" id="rf1675"><person-group person-group-type="author"><name name-style="western"><surname>Gerety</surname><given-names>R.J.</given-names></name><name name-style="western"><surname>Tabor</surname><given-names>E.</given-names></name></person-group><article-title>Newly licensed hepatitis B vaccine. Known safety and unknown risks</article-title><source>JAMA</source><volume>249</volume><year>1983</year><fpage>745</fpage><lpage>746</lpage><pub-id pub-id-type="pmid">6337271</pub-id></element-citation></ref><ref id="bb1680"><label>336</label><element-citation publication-type="journal" id="rf1680"><person-group person-group-type="author"><name name-style="western"><surname>Lacson</surname><given-names>E.</given-names></name><name name-style="western"><surname>Teng</surname><given-names>M.</given-names></name><name name-style="western"><surname>Ong</surname><given-names>J.</given-names></name><name name-style="western"><surname>Vienneau</surname><given-names>L.</given-names></name><name name-style="western"><surname>Ofsthun</surname><given-names>N.</given-names></name><name name-style="western"><surname>Lazarus</surname><given-names>J.M.</given-names></name></person-group><article-title>Antibody response to Engerix-B and Recombivax-HB hepatitis B vaccination in end-stage renal disease</article-title><source>Hemodial. Int.</source><volume>9</volume><year>2005</year><fpage>367</fpage><lpage>375</lpage><pub-id pub-id-type="pmid">16219057</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/j.1492-7535.2005.01155.x</pub-id></element-citation></ref><ref id="bb1685"><label>337</label><element-citation publication-type="journal" id="rf1685"><person-group person-group-type="author"><name name-style="western"><surname>McNeil</surname><given-names>C.</given-names></name></person-group><article-title>Who invented the VLP cervical cancer vaccines?</article-title><source>J. Natl. Cancer Inst.</source><volume>98</volume><year>2006</year><fpage>433</fpage><pub-id pub-id-type="pmid">16595773</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/jnci/djj144</pub-id></element-citation></ref><ref id="bb1690"><label>338</label><element-citation publication-type="journal" id="rf1690"><person-group person-group-type="author"><name name-style="western"><surname>Martelli</surname><given-names>P.</given-names></name><name name-style="western"><surname>Ferrari</surname><given-names>L.</given-names></name><name name-style="western"><surname>Morganti</surname><given-names>M.</given-names></name><name name-style="western"><surname>De Angelis</surname><given-names>E.</given-names></name><name name-style="western"><surname>Bonilauri</surname><given-names>P.</given-names></name><name name-style="western"><surname>Guazzetti</surname><given-names>S.</given-names></name><name name-style="western"><surname>Caleffi</surname><given-names>A.</given-names></name><name name-style="western"><surname>Borghetti</surname><given-names>P.</given-names></name></person-group><article-title>One dose of a porcine circovirus 2 subunit vaccine induces humoral and cell-mediated immunity and protects against porcine circovirus-associated disease under field conditions</article-title><source>Vet. Microbiol.</source><volume>149</volume><year>2011</year><fpage>339</fpage><lpage>351</lpage><pub-id pub-id-type="pmid">21216540</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.vetmic.2010.12.008</pub-id></element-citation></ref><ref id="bb1695"><label>339</label><element-citation publication-type="journal" id="rf1695"><person-group person-group-type="author"><name name-style="western"><surname>Charlton Hume</surname><given-names>H.K.</given-names></name><name name-style="western"><surname>Vidigal</surname><given-names>J.</given-names></name><name name-style="western"><surname>Carrondo</surname><given-names>M.J.T.</given-names></name><name name-style="western"><surname>Middelberg</surname><given-names>A.P.J.</given-names></name><name name-style="western"><surname>Roldao</surname><given-names>A.</given-names></name><name name-style="western"><surname>Lua</surname><given-names>L.H.L.</given-names></name></person-group><article-title>Synthetic biology for bioengineering virus-like particle vaccines</article-title><source>Biotechnol. Bioeng.</source><volume>116</volume><year>2019</year><fpage>919</fpage><lpage>935</lpage><pub-id pub-id-type="pmid">30597533</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/bit.26890</pub-id><pub-id pub-id-type="pmcid">PMC7161758</pub-id></element-citation></ref><ref id="bb1700"><label>340</label><element-citation publication-type="journal" id="rf1700"><person-group person-group-type="author"><name name-style="western"><surname>Shouval</surname><given-names>D.</given-names></name><name name-style="western"><surname>Roggendorf</surname><given-names>H.</given-names></name><name name-style="western"><surname>Roggendorf</surname><given-names>M.</given-names></name></person-group><article-title>Enhanced immune response to hepatitis B vaccination through immunization with a Pre-S1/Pre-S2/S vaccine</article-title><source>Med. Microbiol. Immunol.</source><volume>204</volume><year>2015</year><fpage>57</fpage><lpage>68</lpage><pub-id pub-id-type="pmid">25557605</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s00430-014-0374-x</pub-id><pub-id pub-id-type="pmcid">PMC4305084</pub-id></element-citation></ref><ref id="bb1705"><label>341</label><element-citation publication-type="journal" id="rf1705"><person-group person-group-type="author"><name name-style="western"><surname>Zhao</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Li</surname><given-names>S.</given-names></name><name name-style="western"><surname>Yu</surname><given-names>H.</given-names></name><name name-style="western"><surname>Xia</surname><given-names>N.</given-names></name><name name-style="western"><surname>Modis</surname><given-names>Y.</given-names></name></person-group><article-title>Virus-like particle-based human vaccines: quality assessment based on structural and functional properties</article-title><source>Trends Biotechnol.</source><volume>31</volume><year>2013</year><fpage>654</fpage><lpage>663</lpage><pub-id pub-id-type="pmid">24125746</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.tibtech.2013.09.002</pub-id></element-citation></ref><ref id="bb1710"><label>342</label><element-citation publication-type="journal" id="rf1710"><person-group person-group-type="author"><name name-style="western"><surname>Qiao</surname><given-names>Y.L.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>T.</given-names></name><name name-style="western"><surname>Li</surname><given-names>R.C.</given-names></name><name name-style="western"><surname>Hu</surname><given-names>Y.M.</given-names></name><name name-style="western"><surname>Wei</surname><given-names>L.H.</given-names></name><etal/></person-group><article-title>Efficacy, Safety, and immunogenicity of an <italic toggle="yes">Escherichia coli</italic>-produced bivalent human papillomavirus vaccine: an interim analysis of a randomized clinical trial</article-title><source>J. Natl. Cancer Inst.</source><volume>112</volume><year>2020</year><fpage>145</fpage><lpage>153</lpage><pub-id pub-id-type="pmid">31086947</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/jnci/djz074</pub-id><pub-id pub-id-type="pmcid">PMC7019098</pub-id></element-citation></ref><ref id="bb1715"><label>343</label><element-citation publication-type="journal" id="rf1715"><person-group person-group-type="author"><name name-style="western"><surname>Shinde</surname><given-names>V.</given-names></name><name name-style="western"><surname>Fries</surname><given-names>L.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Agrawal</surname><given-names>S.</given-names></name><name name-style="western"><surname>Cho</surname><given-names>I.</given-names></name><etal/></person-group><article-title>Improved titers against influenza drift variants with a nanoparticle vaccine</article-title><source>N. Engl. J. Med.</source><volume>378</volume><year>2018</year><fpage>2346</fpage><lpage>2348</lpage><pub-id pub-id-type="pmid">29897849</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1056/NEJMc1803554</pub-id></element-citation></ref><ref id="bb1720"><label>344</label><element-citation publication-type="journal" id="rf1720"><person-group person-group-type="author"><name name-style="western"><surname>Kato</surname><given-names>T.</given-names></name><name name-style="western"><surname>Takami</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Kumar Deo</surname><given-names>V.</given-names></name><name name-style="western"><surname>Park</surname><given-names>E.Y.</given-names></name></person-group><article-title>Preparation of virus-like particle mimetic nanovesicles displaying the S protein of Middle East respiratory syndrome coronavirus using insect cells</article-title><source>J. Biotechnol.</source><volume>306</volume><year>2019</year><fpage>177</fpage><lpage>184</lpage><pub-id pub-id-type="pmid">31614169</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jbiotec.2019.10.007</pub-id><pub-id pub-id-type="pmcid">PMC7114102</pub-id></element-citation></ref><ref id="bb1725"><label>345</label><element-citation publication-type="journal" id="rf1725"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>C.</given-names></name><name name-style="western"><surname>Zheng</surname><given-names>X.</given-names></name><name name-style="western"><surname>Gai</surname><given-names>W.</given-names></name><name name-style="western"><surname>Wong</surname><given-names>G.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>H.</given-names></name><etal/></person-group><article-title>Novel chimeric virus-like particles vaccine displaying MERS-CoV receptor-binding domain induce specific humoral and cellular immune response in mice</article-title><source>Antivir. Res.</source><volume>140</volume><year>2017</year><fpage>55</fpage><lpage>61</lpage><pub-id pub-id-type="pmid">28040513</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.antiviral.2016.12.019</pub-id><pub-id pub-id-type="pmcid">PMC7113847</pub-id></element-citation></ref><ref id="bb1730"><label>346</label><element-citation publication-type="journal" id="rf1730"><person-group person-group-type="author"><name name-style="western"><surname>Liu</surname><given-names>Y.V.</given-names></name><name name-style="western"><surname>Massare</surname><given-names>M.J.</given-names></name><name name-style="western"><surname>Barnard</surname><given-names>D.L.</given-names></name><name name-style="western"><surname>Kort</surname><given-names>T.</given-names></name><name name-style="western"><surname>Nathan</surname><given-names>M.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>L.</given-names></name><name name-style="western"><surname>Smith</surname><given-names>G.</given-names></name></person-group><article-title>Chimeric severe acute respiratory syndrome coronavirus (SARS-CoV) S glycoprotein and influenza matrix 1 efficiently form virus-like particles (VLPs) that protect mice against challenge with SARS-CoV</article-title><source>Vaccine</source><volume>29</volume><year>2011</year><fpage>6606</fpage><lpage>6613</lpage><pub-id pub-id-type="pmid">21762752</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.vaccine.2011.06.111</pub-id><pub-id pub-id-type="pmcid">PMC3165014</pub-id></element-citation></ref><ref id="bb1735"><label>347</label><element-citation publication-type="journal" id="rf1735"><person-group person-group-type="author"><name name-style="western"><surname>Lokugamage</surname><given-names>K.G.</given-names></name><name name-style="western"><surname>Yoshikawa-Iwata</surname><given-names>N.</given-names></name><name name-style="western"><surname>Ito</surname><given-names>N.</given-names></name><name name-style="western"><surname>Watts</surname><given-names>D.M.</given-names></name><name name-style="western"><surname>Wyde</surname><given-names>P.R.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>N.</given-names></name><name name-style="western"><surname>Newman</surname><given-names>P.</given-names></name><name name-style="western"><surname>Kent Tseng</surname><given-names>C.T.</given-names></name><name name-style="western"><surname>Peters</surname><given-names>C.J.</given-names></name><name name-style="western"><surname>Makino</surname><given-names>S.</given-names></name></person-group><article-title>Chimeric coronavirus-like particles carrying severe acute respiratory syndrome coronavirus (SCoV) S protein protect mice against challenge with SCoV</article-title><source>Vaccine</source><volume>26</volume><year>2008</year><fpage>797</fpage><lpage>808</lpage><pub-id pub-id-type="pmid">18191004</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.vaccine.2007.11.092</pub-id><pub-id pub-id-type="pmcid">PMC2267761</pub-id></element-citation></ref><ref id="bb1740"><label>348</label><element-citation publication-type="other" id="rf1740"><person-group person-group-type="author"><name name-style="western"><surname>Dynavax</surname></name></person-group><article-title>Dynavax Announces First Participants Dosed in Phase 1 Clinical Trial Evaluating Medicago's COVID-19 Vaccine Candidate with Dynavax's CpG 1018 Adjuvant</article-title><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://investors.dynavax.com/news-releases/news-release-details/dynavax-announces-first-participants-dosed-phase-1-clinical-0" id="ir0515">https://investors.dynavax.com/news-releases/news-release-details/dynavax-announces-first-participants-dosed-phase-1-clinical-0</ext-link><year>2020</year></element-citation></ref><ref id="bb1745"><label>349</label><element-citation publication-type="other" id="rf1745"><person-group person-group-type="author"><name name-style="western"><surname>Review</surname><given-names>E.P.</given-names></name></person-group><article-title>Plant-based COVID-19 Vaccine Enters Phase I Trials</article-title><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.europeanpharmaceuticalreview.com/news/124092/plant-based-covid-19-vaccine-enters-phase-i-trials/" id="ir0520">https://www.europeanpharmaceuticalreview.com/news/124092/plant-based-covid-19-vaccine-enters-phase-i-trials/</ext-link><year>2020</year></element-citation></ref><ref id="bb1750"><label>350</label><element-citation publication-type="journal" id="rf1750"><person-group person-group-type="author"><name name-style="western"><surname>Pillet</surname><given-names>S.</given-names></name><name name-style="western"><surname>Couillard</surname><given-names>J.</given-names></name><name name-style="western"><surname>Trepanier</surname><given-names>S.</given-names></name><name name-style="western"><surname>Poulin</surname><given-names>J.F.</given-names></name><name name-style="western"><surname>Yassine-Diab</surname><given-names>B.</given-names></name><name name-style="western"><surname>Guy</surname><given-names>B.</given-names></name><name name-style="western"><surname>Ward</surname><given-names>B.J.</given-names></name><name name-style="western"><surname>Landry</surname><given-names>N.</given-names></name></person-group><article-title>Immunogenicity and safety of a quadrivalent plant-derived virus like particle influenza vaccine candidate-Two randomized Phase II clinical trials in 18 to 49 and &gt;/=50&#160;years old adults</article-title><source>PLoS One</source><volume>14</volume><year>2019</year><object-id pub-id-type="publisher-id">e0216533</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1371/journal.pone.0216533</pub-id><pub-id pub-id-type="pmcid">PMC6550445</pub-id><pub-id pub-id-type="pmid">31166987</pub-id></element-citation></ref><ref id="bb1755"><label>351</label><element-citation publication-type="journal" id="rf1755"><person-group person-group-type="author"><name name-style="western"><surname>Lu</surname><given-names>J.</given-names></name><name name-style="western"><surname>Lu</surname><given-names>G.</given-names></name><name name-style="western"><surname>Tan</surname><given-names>S.</given-names></name><name name-style="western"><surname>Xia</surname><given-names>J.</given-names></name><name name-style="western"><surname>Xiong</surname><given-names>H.</given-names></name><name name-style="western"><surname>Yu</surname><given-names>X.</given-names></name><name name-style="western"><surname>Qi</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Yu</surname><given-names>X.</given-names></name><name name-style="western"><surname>Li</surname><given-names>L.</given-names></name><name name-style="western"><surname>Yu</surname><given-names>H.</given-names></name><name name-style="western"><surname>Xia</surname><given-names>N.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>T.</given-names></name><name name-style="western"><surname>Xu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Lin</surname><given-names>J.</given-names></name></person-group><article-title>A COVID-19 mRNA vaccine encoding SARS-CoV-2 virus-like particles induces a strong antiviral-like immune response in mice</article-title><source>Cell Res.</source><volume>30</volume><year>2020</year><fpage>936</fpage><lpage>939</lpage><pub-id pub-id-type="pmid">32801356</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41422-020-00392-7</pub-id><pub-id pub-id-type="pmcid">PMC7429369</pub-id></element-citation></ref><ref id="bb1760"><label>352</label><element-citation publication-type="journal" id="rf1760"><person-group person-group-type="author"><name name-style="western"><surname>Vragniau</surname><given-names>C.</given-names></name><name name-style="western"><surname>Bufton</surname><given-names>J.C.</given-names></name><name name-style="western"><surname>Garzoni</surname><given-names>F.</given-names></name><name name-style="western"><surname>Stermann</surname><given-names>E.</given-names></name><name name-style="western"><surname>Rabi</surname><given-names>F.</given-names></name><etal/></person-group><article-title>Synthetic self-assembling ADDomer platform for highly efficient vaccination by genetically encoded multiepitope display</article-title><source>Sci. Adv.</source><volume>5</volume><year>2019</year><object-id pub-id-type="publisher-id">eaaw2853</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1126/sciadv.aaw2853</pub-id><pub-id pub-id-type="pmcid">PMC6763337</pub-id><pub-id pub-id-type="pmid">31620562</pub-id></element-citation></ref><ref id="bb1765"><label>353</label><element-citation publication-type="other" id="rf1765"><person-group person-group-type="author"><name name-style="western"><surname>University of Bristol</surname></name></person-group><article-title>New Vaccine Platform Used to Develop COVID-19 Candidates</article-title><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.bristol.ac.uk/news/2020/april/covid-19-vaccine-platform.html" id="ir0525">http://www.bristol.ac.uk/news/2020/april/covid-19-vaccine-platform.html</ext-link><year>2020</year></element-citation></ref><ref id="bb1770"><label>354</label><element-citation publication-type="journal" id="rf1770"><person-group person-group-type="author"><name name-style="western"><surname>Kumar</surname><given-names>S.</given-names></name><name name-style="western"><surname>Zhi</surname><given-names>K.</given-names></name><name name-style="western"><surname>Mukherji</surname><given-names>A.</given-names></name><name name-style="western"><surname>Gerth</surname><given-names>K.</given-names></name></person-group><article-title>Repurposing antiviral protease inhibitors using extracellular vesicles for potential therapy of COVID-19</article-title><source>Viruses</source><volume>12</volume><year>2020</year><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/v12050486</pub-id><pub-id pub-id-type="pmcid">PMC7290948</pub-id><pub-id pub-id-type="pmid">32357553</pub-id></element-citation></ref><ref id="bb1775"><label>355</label><element-citation publication-type="journal" id="rf1775"><person-group person-group-type="author"><name name-style="western"><surname>Zhou</surname><given-names>X.</given-names></name><name name-style="western"><surname>Li</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Li</surname><given-names>T.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>W.</given-names></name></person-group><article-title>Follow-up of asymptomatic patients with SARS-CoV-2 infection</article-title><source>Clin. Microbiol. Infect.</source><volume>26</volume><year>2020</year><fpage>957</fpage><lpage>959</lpage><pub-id pub-id-type="pmid">32234453</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.cmi.2020.03.024</pub-id><pub-id pub-id-type="pmcid">PMC7271011</pub-id></element-citation></ref><ref id="bb1780"><label>356</label><element-citation publication-type="other" id="rf1780"><person-group person-group-type="author"><name name-style="western"><surname>Codiak</surname></name></person-group><article-title>Codiak BioSciences Collaborates with Ragon Institute to Evaluate the exoVACC&#8482; Vaccine Platform in SARS-CoV-2 and HIV</article-title><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.codiakbio.com/news/press-releases/codiak-biosciences-collaborates-with-ragon-institute-to-evaluate-the-exovacc-vaccine-platform-in-sars-cov-2-and-hiv" id="ir0530">https://www.codiakbio.com/news/press-releases/codiak-biosciences-collaborates-with-ragon-institute-to-evaluate-the-exovacc-vaccine-platform-in-sars-cov-2-and-hiv</ext-link><year>2020</year></element-citation></ref><ref id="bb1785"><label>357</label><element-citation publication-type="journal" id="rf1785"><person-group person-group-type="author"><name name-style="western"><surname>Mulligan</surname><given-names>M.J.</given-names></name><name name-style="western"><surname>Lyke</surname><given-names>K.E.</given-names></name><name name-style="western"><surname>Kitchin</surname><given-names>N.</given-names></name><name name-style="western"><surname>Absalon</surname><given-names>J.</given-names></name><name name-style="western"><surname>Gurtman</surname><given-names>A.</given-names></name><etal/></person-group><article-title>Phase 1/2 study of COVID-19 RNA vaccine BNT162b1 in adults</article-title><source>Nature</source><volume>586</volume><year>2020</year><fpage>589</fpage><lpage>593</lpage><pub-id pub-id-type="pmid">32785213</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41586-020-2639-4</pub-id></element-citation></ref></ref-list><ack id="ac0005"><sec id="s0115"><title>Acknowledgements</title><p id="p5345">We thank Doug Meigs, University of Nebraska Medical Center, for critical review of the manuscript. This work was supported by the <funding-source id="gts5000"><institution-wrap><institution-id institution-id-type="doi">10.13039/100000002</institution-id><institution>National Institutes of Health</institution></institution-wrap></funding-source>
R01 MH121402-01A1; R01 MH121402P01; R01 AG043540, R01 AG043530, P01 DA028555, P30 MH062261, R01 MH115860, R01 NS034249, R01 NS036126, the <funding-source id="gts6000">Carol Swartz Emerging Neuroscience Fund</funding-source> and the <funding-source id="gts7000">Margaret R. Larson Professorship</funding-source>.</p></sec></ack></back></article></pmc-articleset>